

US 20110097778A1

(19) United States (12) Patent Application Publication (10) Pub. No.: US 2011/0097778 A1

Power et al.

(54) CHIMERIC ALPHA-AMYLASE VARIANTS

- (76) Inventors: Scott D. Power, San Bruno, CA (US); Andrew Shaw, San Francisco, CA (US)
- 12/990,201 (21) Appl. No.:
- (22) PCT Filed: Apr. 23, 2009
- (86) PCT No.: PCT/US09/41498
 - § 371 (c)(1), (2), (4) Date: Dec. 16, 2010

Related U.S. Application Data

(60) Provisional application No. 61/126,066, filed on Apr. 30, 2008.

Publication Classification

(51) Int. Cl.

C12N 9/26	(2006.01)
C07H 21/00	(2006.01)
C12N 15/63	(2006.01)

Apr. 28, 2011 (43) **Pub. Date:**

C12N 1/21	(2006.01)
C12N 5/10	(2006.01)
C12S 9/00	(2006.01)
C12S 11/00	(2006.01)
C12P 7/02	(2006.01)
C12P 7/06	(2006.01)
C11D 3/386	(2006.01)
A23L 1/05	(2006.01)

(52) U.S. Cl. 435/161; 435/201; 536/23.2; 435/320.1; 435/252.3; 435/419; 435/252.31; 435/264; 435/263; 435/155; 510/392; 426/64; 426/48

(57)ABSTRACT

Chimeric alpha amylases having the characteristics of high thermostability and good performance in starch degradation, especially high-temperature liquefaction processes, are provided. The alpha-amylases are chimeras of AmyL and AmyS enzymes, and are useful in starch degradation processes. Methods of making the chimeric enzymes, and methods of using the chimeric alpha-amylases for liquefaction, cleaning starch residue from a surface, and treating woven material to remove coatings. Kits for practicing the methods are provided. Polynucleotides encoding the chimeric amylases, vectors, and expression hosts also are provided.








FIG. 1









Sequence ID "1" B. licheniformis AmyL

1 TNLNGTLMQY FEWYTPNDGQ HWKRLONDSA YLAEHGITAV WIPPAYKGTS 51 QADVGYGAYD LYDLGEFHOK GTVRTKYGTK GELQSAIKSL HSRDINVYGD 101 VVINHKGGAD ATEDVTAVEV DPADRNRVIS GEYLIKAWTH FHFPGRGSTY 151 SDFKWHWYHF DGTDWDESRK LNRIYKFQGK AWDWEVSSEN GNYDYLMYAD 201 IDYDHPDVVA EIKRWGTWYA NELQLDGFRL DAVKHIKFSF LRDWVNHVRE 251 KTGKEMFTVA EYWQNDLGAL ENYLNKTNFN HSVFDVPLHY QFHAASTQGG 301 GYDMRKLLNG TVVSKHPLKS VTFVDNHDTQ PGQSLESTVQ TWFKPLAYAF 351 ILTRESGYPQ VFYGDMYGTK GDSQREIPAL KHKIEPILKA RKQYAYGAQH 401 DYFDHHDIVG WTREGDSSVA NSGLAALITD GPGGAKRMYV GRQNAGETWH 451 DITGNRSEPV VINSEGWGEF HVNGGSVSIY VQR

Sequence ID "2" B. stearothermophilus AmyS

1 AAPFNGTMMQ YFEWYLPDDG TLWTKVANEA NNLSSLGITA LWLPPAYKGT 51 SRSDVGYGVY DLYDLGEFNQ KGTVRTKYGT KAQYLQAIQA AHAAGMQVYA 101 DVVFDHKGGA DGTEWVDAVE VNPSDRNQEI SGTYQIQAWT KFDFPGRGNT 151 YSSFKWRWYH FDGVDWDESR KLSRIYKFRG IGKAWDWEVD TENGNYDYLM 201 YADLDMDHPE VVTELKNWGK WYVNTTNIDG FRLDAVKHIK FSFFPDWLSY 251 VRSQTGKPLF TVGEYWSYDI NKLHNYITKT NGTMSLFDAP LHNKFYTASK 301 SGGAFDMRTL MTNTLMKDQP TLAVTFVDNH DTEPGQALQS WVDPWFKPLA 351 YAFILTROEG YPCVFYGDYY GIPQYNIPSL KSKIDPLLIA RRDYAYGTOH 401 DYLDHSDIIG WTREGVTEKP GSGLAALITD GPGGSKWMYV GKQHAGKVFY 451 DLTGNRSDTV TINSDGWGEF KVNGGSVSVW VPRKTT

"AmyS control." Note that this protein is the Sequence ID "3" mature form of a translation product that has been naturally processed to trim off the last 29 aa for the C-terminus. The precursor is encoded by SEQ ID NO: 20.

1 AAPFNGTMMQ YFEWYLPDDG TLWTKVANEA NNLSSLGITA LWLPPAYKGT 51 SRSDVGYGVY DLYDLGEFNQ KGTVRTKYGT KAQYLQAIQA AHAAGMQVYA 101 DVVFDHKGGA DGTEWVDAVE VNPSDRNQEI SGTYQIQAWT KFDFPGRGNT 151 YSSFKWRWYH FDGVDWDESR KLSRIYKFIG KAWDWEVDTE NGNYDYLMYA 201 DLDMDHPEVV TELKNWGKWY VNTTNIDGFR LDAVKHIKFS FFPDWLSYVR 251 SQTGKPLFTV GEYWSYDINK LHNYITKTNG TMSLFDAPLH NKFYTASKSG 301 GAFDMRTLMT NTLMKDQPTL AVTFVDNHDT EPGQALQSWV DPWFKPLAYA 351 FILTRQEGYP CVFYGDYYGI POYNIPSLKS KIDPLLIARR DYAYGTOHDY 401 LDHSDIIGWT REGVTEKPGS GLAALITDGP GGSKWMYVGK QHAGKVFYDL 451 TGNRSDTVTI NSDGWGEFKV NGGSVSVWVP RKTT

FIG. 7A

Sequence ID "4" 186

1	TNLNGTLMQY	FEWYTPNDGQ	HWKRLQNDSA	YLAEHGITAV	WIPPAYKGTS
51	QADVGYGAYD	LYDLGEFHQK	GTVRTKYGTK	GELQSAIKSL	HSRDINVYGD
101	VVINHKGGAD	ATEDVTAVEV	DPADRNRVIS	GEYLIKAWTH	FHFPGRGSTY
151	SDFKWHWYHF	DGTDWDESRK	LNRIYKFQGK	AWDWEV DTEN	GNYDYLMYAD
201	LDMDHPEVVT	ELKNWGKWYV	NTTNIDGFRL	DAVKHIKFSF	FPDWLSYVRS
251	QTGKPLFTVG	EYWSYDINKL	HNYITKTNGT	MSLFDAPLHN	KFYTASKSGG
251 301			HNYITKTNGT VTFVDNHDTE		
	AFDMRTLMTN	TLMKDQPTLA		PGQALQSWVD	PWFKPLAYAF
301	AFDMRTLMTN ILTRQEGYPC	TLMKDQPTLA VFYGDYYGIP	VTFVDNHDTE	PGQALQSWVD IDPLLIARRD	PWFKPLAYAF YAYGTQHDYL

Sequence ID "5" 187

1	TNLNGTLMQY	FEWYTPNDGQ	HWKRLQNDSA	YLAEHGITAV	WIPPAYKGTS
51	QADVGYGAYD	LYDLGEFHQK	GTVRTKYGTK	GELQSAIKSL	HSRDINVYGD
101	VVINHKGGAD	ATEDVTAVEV	DPADRNRVIS	GEYLIKAWTH	FHFPGRGSTY
151	SDFKWHWYHF	DGTDWDESRK	LNRIYKFQGK	AWDWEVSTEN	GNYDYLMYAD
201	LDMDHPEVVT	ELKNWGKWYV	NTTNIDGFRL	DAVKHIKFSF	FPDWLSYVRS
251	QTGKPLFTVG	EYWSYDINKL	HNYITKTNGT	MSLFDAPLHN	KFYTASKSGG
251 301			HNYITKTNGT VTFVDNHDTE		
	AFDMRTLMTN	TLMKDQPTLA		PGQALQSWVD	PWFKPLAYAF
301	AFDMRTLMTN ILTRQEGYPC	TLMKDQPTLA VFYGDYYGIP	VTFVDNHDTE	PGQALQSWVD IDPLLIARRD	PWFKPLAYAF YAYGTQHDYL

Sequence ID "6" 200

1	TNLNGTLMQY	FEWYTPNDGQ	HWKRLQNDSA	YLAEHGITAV	WIPPAYKGTS
51	QADVGYGAYD	LYDLGEFHQK	GTVRTKYGTK	GELQSAIKSL	HSRDINVYGD
101	VVINHKGGAD	ATEDVTAVEV	DPADRNRVIS	GEYLIKAWTH	FHFPGRGSTY
151	SDFKWHWYHF	DGTDWDESRK	LNRIYKFQGK	AWDWEVSSEN	GNYDYLMYAD
201	LDMDHPEVVT	ELKNWGKWYV	NTTNIDGFRL	DAVKHIKFSF	FPDWLSYVRS
251	QTGKPLFTVG	EYWSYDINKL	HNYITKTNGT	MSLFDAPLHN	KFYTASKSGG
301	AFDMRTLMTN	TLMKDQPTLA	VTFVDNHDTE	PGQALQSWVD	PWFKPLAYAF
351	ILTRQEGYPC	VFYGDYYGIP	QYNIPSLKSK	IDPLLIARRD	YAYGTQHDYL
401	DHSDIIGWTR	EGVTEKPGSG	LAALITDGPG	GSKWMYVGKQ	HAGKVFYDLT
451	GNRSDTVTIN	SDGWGEFKVN	GGSVSVWVPR	KTT	

Sequence ID "7" 200SB

1	TNLNGTLMQY	FEWYTPNDGQ	HWKRLQNDSA	YLAEHGITAV	WIPPAYKGTS
51	QADVGYGAYD	LYDLGEFHQK	GTVRTKYGTK	GELQSAIKSL	HSRDINVYGD
101	VVINHKGGAD	ATEDVTAVEV	DPADRNRVIS	GEYLIKAWTH	FHFPGRGSTY
151	SDFKWHWYHF	DGTDWDESRK	LNRIYKFQGK	AWDWEV <u>DT</u> EN	GNYDYLMYAD
201	LDMDHPEVVT	ELKNWGKWYV	NTTNIDGFRL	DAVKHIKFSF	FPDWLSYVRS
251	QTGKPLFTVG		HNYITKTNGT		
251 301	QTGKPLFTVG AFDMRTLMTN	TLMKDQPTLA	VTFVDNHDTE	PGQALQSWVD	PWFKPLAYAF
	QTGKPLFTVG AFDMRTLMTN	TLMKDQPTLA		PGQALQSWVD	PWFKPLAYAF
301	QTGKPLFTVG AFDMRTLMTN ILTRQEGYPC	TLMKDQPTLA VFYGDYYGIP	VTFVDNHDTE	PGQALQSWVD IDPLLIARRD	PWFKPLAYAF YAYGTQHDYL

FIG. 7B

Sequence	ID ``8″ 2	202			
1	TNLNGTLMQY	FEWYTPNDGQ	HWKRLQNDSA	YLAEHGITAV	WIPPAYKGTS
51	QADVGYGAYD	LYDLGEFHQK	GTVRTKYGTK	GELQSAIKSL	HSRDINVYGD
101	VVINHKGGAD	ATEDVTAVEV	DPADRNRVIS	GEYLIKAWTH	FHFPGRGSTY
151	SDFKWHWYHF	DGTDWDESRK	LNRIYKFQGK	AWDWEVSSEN	GNYDYLMYAD
201	I D MDHPEVVT	ELKNWGKWYV	NTTNIDGFRL	DAVKHIKFSF	FPDWLSYVRS
251	QTGKPLFTVG	EYWSYDINKL	HNYITKTNGT	MSLFDAPLHN	KFYTASKSGG
301	AFDMRTLMTN	TLMKDQPTLA	VTFVDNHDTE	PGQALQSWVD	PWFKPLAYAF
351	ILTRQEGYPC	VFYGDYYGIP	QYNIPSLKSK	IDPLLIARRD	YAYGTQHDYL
401	DHSDIIGWTR	EGVTEKPGSG	LAALITDGPG	GSKWMYVGKQ	HAGKVFYDLT
451	GNRSDTVTIN	SDGWGEFKVN	GGSVSVWVPR	KTT	

Sequence ID "9" 202SB

1	TNLNGTLMQY	FEWYTPNDGQ	HWKRLQNDSA	YLAEHGITAV	WIPPAYKGTS
51	QADVGYGAYD	LYDLGEFHQK	GTVRTKYGTK	GELQSAIKSL	HSRDINVYGD
101	VVINHKGGAD	ATEDVTAVEV	DPADRNRVIS	GEYLIKAWTH	FHFPGRGSTY
151	SDFKWHWYHF	DGTDWDESRK	LNRIYKFQGK	AWDWEV <u>DT</u> EN	GNYDYLMYAD
201	I DMDHPEVVT	ELKNWGKWYV	NTTNIDGFRL	DAVKHIKFSF	FPDWLSYVRS
251	QTGKPLFTVG	EYWSYDINKL	HNYITKTNGT	MSLFDAPLHN	KFYTASKSGG
251 301	-			MSLFDAPLHN PGQALQSWVD	
	AFDMRTLMTN ILTRQEGYPC	TLMKDQPTLA VFYGDYYGIP	VTFVDNHDTE QYNIPSLKSK	PGQALQSWVD IDPLLIARRD	PWFKPLAYAF YAYGTQHDYL
301	AFDMRTLMTN ILTRQEGYPC	TLMKDQPTLA VFYGDYYGIP	VTFVDNHDTE QYNIPSLKSK	PGQALQSWVD	PWFKPLAYAF YAYGTQHDYL

Sequence ID "10" 228

1	TNLNGTLMQY	FEWYTPNDGQ	HWKRLQNDSA	YLAEHGITAV	WIPPAYKGTS
51	QADVGYGAYD	LYDLGEFHQK	GTVRTKYGTK	GELQSAIKSL	HSRDINVYGD
101	VVINHKGGAD	ATEDVTAVEV	DPADRNRVIS	GEYLIKAWTH	FHFPGRGSTY
151			-	AWDWEVSSEN	
201	IDYDHPDVVA	EIKRWGTWYA	NELQLDGF RL	DAVKHIKFSF	FPDWLSYVRS
251	QTGKPLFTVG	EYWSYDINKL	HNYITKTNGT	MSLFDAPLHN	KFYTASKSGG
301		-		PGQALQSWVD	
351				IDPLLIARRD	
401	DHSDIIGWTR	EGVTEKPGSG	LAALITDGPG	GSKWMYVGKQ	HAGKVFYDLT
451	GNRSDTVTIN	SDGWGEFKVN	GGSVSVWVPR	KTT	

Sequence ID "11" 228SB

1	TNLNGTLMQY	FEWYTPNDGQ	HWKRLQNDSA	YLAEHGITAV	WIPPAYKGTS
51	QADVGYGAYD	LYDLGEFHQK	GTVRTKYGTK	GELQSAIKSL	HSRDINVYGD
101	VVINHKGGAD	ATEDVTAVEV	DPADRNRVIS	GEYLIKAWTH	FHFPGRGSTY
151	SDFKWHWYHF	DGTDWDESRK	LNRIYKFQGK	AWDWEV <u>DT</u> EN	GNYDYLMYAD
201	IDYDHPDVVA	EIKRWGTWYA	NELQLDGF RL	DAVKHIKFSF	FPDWLSYVRS
251	QTGKPLFTVG	EYWSYDINKL	HNYITKTNGT	MSLFDAPLHN	KFYTASKSGG
301	AFDMRTLMTN	TLMKDQPTLA	VTFVDNHDTE	PGQALQSWVD	PWFKPLAYAF
351	ILTRQEGYPC	VFYGDYYGIP	QYNIPSLKSK	IDPLLIARRD	YAYGTQHDYL
401	DHSDIIGWTR	EGVTEKPGSG	LAALITDGPG	GSKWMYVGKQ	HAGKVFYDLT
451	GNRSDTVTIN	SDGWGEFKVN	GGSVSVWVPR	KTT	

FIG. 7C

Sequence ID "12" 249

1	TNLNGTLMQY	FEWYTPNDGQ	HWKRLQNDSA	YLAEHGITAV	WIPPAYKGTS
51	QADVGYGAYD	LYDLGEFHQK	GTVRTKYGTK	GELQSAIKSL	HSRDINVYGD
101	VVINHKGGAD	ATEDVTAVEV	DPADRNRVIS	GEYLIKAWTH	FHFPGRGSTY
151	SDFKWHWYHF	DGTDWDESRK	LNRIYKFQGK	AWDWEVSSEN	GNYDYLMYAD
201	IDYDHPDVVA	EIKRWGTWYA	NELQLDGFRL	DAVKHIKFSF	LRDWVNHVR S
251	QTGKPLFTVG	EYWSYDINKL	HNYITKTNGT	MSLFDAPLHN	KFYTASKSGG
301	AFDMRTLMTN	TLMKDQPTLA	VTFVDNHDTE	PGQALQSWVD	PWFKPLAYAF
351	ILTRQEGYPC	VFYGDYYGIP	QYNIPSLKSK	IDPLLIARRD	YAYGTQHDYL
401	DHSDIIGWTR	EGVTEKPGSG	LAALITDGPG	GSKWMYVGKQ	HAGKVFYDLT
451	GNRSDTVTIN	SDGWGEFKVN	GGSVSVWVPR	KTT	

Sequence ID "13" 249SB

1	TNLNGTLMQY	FEWYTPNDGQ	HWKRLQNDSA	YLAEHGITAV	WIPPAYKGTS
51	QADVGYGAYD	LYDLGEFHQK	GTVRTKYGTK	GELQSAIKSL	HSRDINVYGD
101	VVINHKGGAD	ATEDVTAVEV	DPADRNRVIS	GEYLIKAWTH	FHFPGRGSTY
151	SDFKWHWYHF	DGTDWDESRK	LNRIYKFQGK	AWDWEV <u>DT</u> EN	GNYDYLMYAD
201	IDYDHPDVVA	EIKRWGTWYA	NELQLDGFRL	DAVKHIKFSF	LRDWVNHVR S
251	QTGKPLFTVG	EYWSYDINKL	HNYITKTNGT	MSLFDAPLHN	KFYTASKSGG
251 301			HNYITKTNGT VTFVDNHDTE		
	AFDMRTLMTN	TLMKDQPTLA		PGQALQSWVD	PWFKPLAYAF
301	AFDMRTLMTN ILTRQEGYPC	TLMKDQPTLA VFYGDYYGIP	VTFVDNHDTE	PGQALQSWVD IDPLLIARRD	PWFKPLAYAF YAYGTQHDYL

Sequence	ID	``14 ″	254	

1	TNLNGTLMQY	FEWYTPNDGQ	HWKRLQNDSA	YLAEHGITAV	WIPPAYKGTS
51	QADVGYGAYD	LYDLGEFHQK	GTVRTKYGTK	GELQSAIKSL	HSRDINVYGD
101	VVINHKGGAD	ATEDVTAVEV	DPADRNRVIS	GEYLIKAWTH	FHFPGRGSTY
151	SDFKWHWYHF	DGTDWDESRK	LNRIYKFQGK	AWDWEVSSEN	GNYDYLMYAD
201	IDYDHPDVVA	EIKRWGTWYA	NELQLDGFRL	DAVKHIKFSF	LRDWVNHVRE
251	KTGK PLFTVG	EYWSYDINKL	HNYITKTNGT	MSLFDAPLHN	KFYTASKSGG
301	AFDMRTLMTN	TLMKDQPTLA	VTFVDNHDTE	PGQALQSWVD	PWFKPLAYAF
351	ILTRQEGYPC	VFYGDYYGIP	QYNIPSLKSK	IDPLLIARRD	YAYGTQHDYL
401	DHSDIIGWTR	EGVTEKPGSG	LAALITDGPG	GSKWMYVGKQ	HAGKVFYDLT
451	GNRSDTVTIN	SDGWGEFKVN	GGSVSVWVPR	KTT	

Sequence ID "15" 254SB

1	TNLNGTLMQY	FEWYTPNDGQ	HWKRLQNDSA	YLAEHGITAV	WIPPAYKGTS
51	QADVGYGAYD	LYDLGEFHQK	GTVRTKYGTK	GELQSAIKSL	HSRDINVYGD
101	VVINHKGGAD	ATEDVTAVEV	DPADRNRVIS	GEYLIKAWTH	FHFPGRGSTY
151	SDFKWHWYHF	DGTDWDESRK	LNRIYKFQGK	AWDWEV <u>DT</u> EN	GNYDYLMYAD
201	IDYDHPDVVA	EIKRWGTWYA	NELQLDGFRL	DAVKHIKFSF	LRDWVNHVRE
251	KTGK PLFTVG	EYWSYDINKL	HNYITKTNGT	MSLFDAPLHN	KFYTASKSGG
301		~		PGQALQSWVD	
351	ILTRQEGYPC	VFYGDYYGIP	QYNIPSLKSK	IDPLLIARRD	YAYGTQHDYL
401	DHSDIIGWTR	EGVTEKPGSG	LAALITDGPG	GSKWMYVGKQ	HAGKVFYDLT
451	GNRSDTVTIN	SDGWGEFKVN	GGSVSVWVPR	KTT	

FIG. 7D

Sequence ID "16" 259

1	TNLNGTLMQY	FEWYTPNDGQ	HWKRLQNDSA	YLAEHGITAV	WIPPAYKGTS
51	QADVGYGAYD	LYDLGEFHQK	GTVRTKYGTK	GELQSAIKSL	HSRDINVYGD
101	VVINHKGGAD	ATEDVTAVEV	DPADRNRVIS	GEYLIKAWTH	FHFPGRGSTY
151	SDFKWHWYHF	DGTDWDESRK	LNRIYKFQGK	AWDWEVSSEN	GNYDYLMYAD
201	IDYDHPDVVA	EIKRWGTWYA	NELQLDGFRL	DAVKHIKFSF	LRDWVNHVRE
251	KTGKEMFTV G	EYWSYDINKL	HNYITKTNGT	MSLFDAPLHN	KFYTASKSGG
301	AFDMRTLMTN	TLMKDQPTLA	VTFVDNHDTE	PGQALQSWVD	PWFKPLAYAF
351	ILTRQEGYPC	VFYGDYYGIP	QYNIPSLKSK	IDPLLIARRD	YAYGTQHDYL
401	DHSDIIGWTR	EGVTEKPGSG	LAALITDGPG	GSKWMYVGKQ	HAGKVFYDLT
451	GNRSDTVTIN	SDGWGEFKVN	GGSVSVWVPR	KTT	

Sequence ID "17" 259SB

1	TNLNGTLMQY	FEWYTPNDGQ	HWKRLQNDSA	YLAEHGITAV	WIPPAYKGTS
51	QADVGYGAYD	LYDLGEFHQK	GTVRTKYGTK	GELQSAIKSL	HSRDINVYGD
101	VVINHKGGAD	ATEDVTAVEV	DPADRNRVIS	GEYLIKAWTH	FHFPGRGSTY
151	SDFKWHWYHF				
201	IDYDHPDVVA				
251				MSLFDAPLHN	
301				PGQALQSWVD	
351	_		-	IDPLLIARRD	
401	DHSDIIGWTR	EGVTEKPGSG	LAALITDGPG	GSKWMYVGKQ	HAGKVFYDLT
451	GNRSDTVTIN	SDGWGEFKVN	GGSVSVWVPR	KTT	

FIG. 7E

Sequence ID No.18 Nucleotide sequence of gene coding for B. licheniformis AmyL protein (SEQ ID NO: 1)

ACAAATCTTAATGGGACGCTGATGCAGTATTTTGAATGGTACACGCCCAATGACGGCCAACATTG GAAGCGTCTGCAAAACGACTCGGCATATTTGGCTGAACACGGTATTACTGCCGTCTGGATTCCCC CGGCATATAAGGGAACGAGCCAAGCGGATGTGGGCTACGGTGCTTACGACCTTTATGATTTAGGG GAGTTTCATCAAAAAGGGACGGTTCGGACAAAGTACGGCACAAAAGGAGAGCTGCAATCTGCGAT CAAAAGTCTTCATTCCCGCGACATTAACGTTTACGGGGATGTGGTCATCAACCACAAAGGCGGGG CTGATGCGACCGAAGATGTAACCGCGGTTGAAGTCGATCCCGCTGACCGCAACCGCGTAATTTCC GGAGAATACCTAATTAAAGCCTGGACACATTTTCATTTTCCGGGGCGCGGCAGCACATACAGCGA TTTTAAATGGCATTGGTACCATTTTGACGGAACCGATTGGGACGAGTCCCGAAAGCTGAACCGCA **TCTATAAGTTTCAAGGAAAGGCTTGGGATTGGGAAGTTTCCAGTGAAAACGGCAACTATGATTAT** TTGATGTATGCCGACATCGATTATGACCATCCTGATGTCGTAGCAGAAATTAAGAGATGGGGGCAC TTGGTATGCCAATGAGCTCCAATTGGACGGTTTCCGTCTTGATGCTGTCAAACACATTAAATTTT GAATATTGGCAGAATGACTTGGGCGCGCGGAAAACTATTTGAACAAAACAAATTTTAATCATTC AGTGTTTGACGTGCCGCTTCATTATCAGTTCCATGCTGCATCGACACAGGGAGGCGGCTATGATA TGAGGAAATTGCTGAACGGTACGGTCGTTTCCAAGCATCCGTTGAAATCGGTTACATTTGTCGAT AACCATGATACACAGCCGGGGCAGTCGCTTGAGTCGACTGTCCAAACATGGTTTAAGCCGCTTGC TTACGCTTTTATTCTCACAAGGGAATCTGGATACCCTCAGGTTTTCTACGGGGATATGTACGGGA CGAAAGGAGACTCCCAGCGCGAAATTCCTGCCTTGAAACACAAAATTGAACCGATCTTAAAAGCG AGAAAACAGTATGCGTACGGAGCACAGCATGATTATTTCGACCACCATGACATTGTCGGCTGGAC AAGGGAAGGCGACAGCTCGGTTGCAAATTCAGGTTTGGCGGCATTAATAACAGACGGACCCGGTG GGGCAAAGCGAATGTATGTCGGCCGGCAAAACGCCGGTGAGACATGGCATGACATTACCGGAAAC CGTTCGGAGCCGGTTGTCATCAATTCGGAAGGCTGGGGAGAGTTTCACGTAAACGGCGGGTCGGT TTCAATTTATGTTCAAAGA

Sequence ID No. 19 Nucleotide sequence of gene coding for В. stearothermophilus AmyS protein (SEQ ID NO: 2).

GCCGCACCGTTTAACGGTACCATGATGCAGTATTTTGAATGGTACTTGCCGGATGATGGCACGTT ATGGACCAAAGTGGCCAATGAAGCCAACAACTTATCCAGCCTTGGCATCACCGCTCTTTGGCTGC CGCCCGCTTACAAAGGAACAAGCCGCAGCGACGTAGGGTACGGAGTATACGACTTGTATGACCTC GGCGAATTCAATCAAAAAGGGACCGTCCGCACAAAATATGGAACAAAAGCTCAATATCTTCAAGC CATTCAAGCCGCCCACGCCGCTGGAATGCAAGTGTACGCCGATGTCGTGTTCGACCATAAAGGCG CAGCTTTAAGTGGCGCTGGTACCATTTTGACGGCGTTGATTGGGACGAAAGCCGAAAATTAAGCC GCATTTACAAATTCAGGGGCATCGGCAAAGCGTGGGATTGGGAAGTAGACACAGAAAACGGAAAC TATGACTACTTAATGTATGCCGACCTTGATATGGATCATCCCGAAGTCGTGACCGAGCTGAAAAA CTGGGGGAAATGGTATGTCAACAACGAACATTGATGGGTTCCGGCTTGATGCCGTCAAGCATA TTAAGTTCAGTTTTTTCCTGATTGGTTGTCGTATGTGCGTTCTCAGACTGGCAAGCCGCTATTT AACGATGTCTTTGTTTGATGCCCCGTTACACAACAAATTTTATACCGCTTCCAAATCAGGGGGGCG CATTTGATATGCGCACGTTAATGACCAATACTCTCATGAAAGATCAACCGACATTGGCCGTCACC TTCGTTGATAATCATGACACCGGACCCGGCCAAGCGCTTCAGTCATGGGTCGACCCATGGTTCAA ATTATGGCATTCCACAATATAACATTCCTTCGCTGAAAAGCAAAATCGATCCGCTCCTCATCGCG CGCAGGGATTATGCTTACGGAACGCAACATGATTATCTTGATCACTCCGACATCATCGGGTGGAC AAGGGAAGGGTCACTGAAAAACCAGGATCCGGGCTGGCCGCACTGATCACCGATGGGCCGGGAG GAAGCAAATGGATGTACGTTGGCAAACAACACGCTGGAAAAGTGTTCTATGACCTTACCGGCAAC CGGAGTGACACCGTCACCATCAACAGTGATGGATGGGGGGGAATTCAAAGTCAATGGCGGTTCGGT TTCGGTTTGGGTTCCTAGAAAAACGACC

FIG. 8A

Sequence ID no. 20 Nucleotide sequence of gene coding for precursor of AmyS control protein (precursor)

GCCGCACCGTTTAACGGTACCATGATGCAGTATTTTGAATGGTACTTGCCGGATGATGGCACGTT ATGGACCAAAGTGGCCAATGAAGCCAACAACTTATCCAGCCTTGGCATCACCGCTCTTTGGCTGC CGCCCGCTTACAAAGGAACAAGCCGCAGCGACGTAGGGTACGGAGTATACGACTTGTATGACCTC GGCGAATTCAATCAAAAAGGGACCGTCCGCACAAAATATGGAACAAAAGCTCAATATCTTCAAGC CATTCAAGCCGCCCACGCCGGCTGGAATGCAAGTGTACGCCGATGTCGTGTTCGACCATAAAGGCG CAGCTTTAAGTGGCGCTGGTACCATTTTGACGGCGTTGACTGGGACGAAAGCCGAAAATTAAGCC GCATTTACAAATTCATCGGCAAAGCGTGGGATTGGGAAGTAGACACAGAAAACGGAAACTATGAC TACTTAATGTATGCCGACCTTGATATGGATCATCCCGAAGTCGTGACCGAGCTGAAAAACTGGGG GAAATGGTATGTCAACACAACGAACATTGATGGGTTCCGGCTTGATGCCGTCAAGCATATTAAGT TCAGTTTTTTTCCTGATTGGTTGTCGTATGTGCGTTCTCAGACTGGCAAGCCGCTATTTACCGTC GTCTTTGTTTGATGCCCCGTTACACAACAAATTTTATACCGCTTCCAAATCAGGGGGGCGCATTTG ATATGCGCACGTTAATGACCAATACTCTCATGAAAGATCAACCGACATTGGCCGTCACCTTCGTT GATAATCATGACACCGAACCCGGCCAAGCGCTTCAGTCATGGGTCGACCCATGGTTCAAACCGTT GGCTTACGCCTTTATTCTAACTCGGCAGGAAGGATACCCGTGCGTCTTTTATGGTGACTATTATG GCATTCCACAATATAACATTCCTTCGCTGAAAAGCAAAATCGATCCGCTCCTCATCGCGCGCAGG GATTATGCTTACGGAACGCAACATGATTATCTTGATCACTCCGACATCATCGGGTGGACAAGGGA AGGGGTCACTGAAAAACCAGGATCCGGGCTGGCCGCACTGATCACCGATGGGCCGGGAGGAAGCA AATGGATGTACGTTGGCAAACAACACGCTGGAAAAGTGTTCTATGACCTTACCGGCAACCGGAGT GACACCGTCACCATCAACAGTGATGGATGGGGGGGAATTCAAAGTCAATGGCGGTTCGGTTTCGGT TTGGGTTCCTAGAAAAACGACCGTTTCTACCATCGCTCGGCCGATCACAACCCGACCGTGGACTG GTGAATTCGTCCGTTGGACCGAACCACGGTTGGTGGCATGGCCT

Sequence ID no. 21. Nucleotide sequence of gene coding hybrid 186 protein

ACAAATCTTAATGGGACGCTGATGCAGTATTTTGAATGGTACACGCCCAATGACGGCCAACATTG GAAGCGTCTGCAAAACGACTCGGCATATTTGGCTGAACACGGTATTACTGCCGTCTGGATTCCCC CGGCATATAAGGGAACGAGCCAAGCGGATGTGGGCTACGGTGCTTACGACCTTTATGATTTAGGG GAGTTTCATCAAAAAGGGACGGTTCGGACAAAGTACGGCACAAAAGGAGAGCTGCAATCTGCGAT CAAAAGTCTTCATTCCCGCGACATTAACGTTTACGGGGATGTGGTCATCAACCACAAAGGCGGCG CTGATGCGACCGAAGATGTAACCGCGGTTGAAGTCGATCCCGCTGACCGCAACCGCGTAATTTCC GGAGAATACCTAATTAAAGCCTGGACACATTTTCATTTTCCGGGGCGCGGCAGCACATACAGCGA TTTTAAATGGCATTGGTACCATTTTGACGGAACCGATTGGGACGAGTCCCGAAAGCTGAACCGCA TCTATAAGTTTCAAGGAAAGGCTTGGGATTGGGAAGTT**GACACAGAAAACGGAAACTATGACTAC** TTAATGTATGCCGACCTTGATATGGATCATCCCGAAGTCGTGACCGAGCTGAAAAACTGGGGGGAA **ATGGTATGTCAACAACGAACATTGATGGGTTCCGGCTTGATGCCGTCAAGCATATTAAGTTCA** GTTTTTTTCCTGATTGGTTGTCGTATGTGCGTTCTCAGACTGGCAAGCCGCTATTTACCGTCGGG TGCGCACGTTAATGACCAATACTCTCATGAAAGATCAACCGACATTGGCCGTCACCTTCGTTGAT AATCATGACACCGAGCCCGGCCAAGCGCTTCAGTCATGGGTCGACCCATGGTTCAAACCGTTGGC TTACGCCTTTATTCTAACTCGGCAGGAAGGATACCCGTGCGTCTTTTATGGTGACTATTATGGCA TATGCTTACGGAACGCAACATGATTATCTTGATCACTCCGACATCATCGGGTGGACAAGGGAAGG GGTCACTGAAAAACCAGGATCCGGGCTGGCCGCACTGATCACCGATGGGCCGGGAGGAAGCAAAT GGATGTACGTTGGCAAACAACACGCTGGAAAAGTGTTCTATGACCTTACCGGCAACCGGAGTGAC ACCGTCACCATCAACAGTGATGGATGGGGGGGAATTCAAAGTCAATGGCGGTTCGGTTTCGGTTTG GGTTCCTAGAAAAACGACC

Sequence ID No. 22. Nucleotide sequence of gene coding hybrid 187 protein

ACAAATCTTAATGGGACGCTGATGCAGTATTTTGAATGGTACACGCCCAATGACGGCCAACATTG GAAGCGTCTGCAAAACGACTCGGCATATTTGGCTGAACACGGTATTACTGCCGTCTGGATTCCCC CGGCATATAAGGGAACGAGCCAAGCGGATGTGGGCTACGGTGCTTACGACCTTTATGATTTAGGG GAGTTTCATCAAAAAGGGACGGTTCGGACAAAGTACGGCACAAAAGGAGAGCTGCAATCTGCGAT CAAAAGTCTTCATTCCCGCGACATTAACGTTTACGGGGATGTGGTCATCAACCACAAAGGCGGCG CTGATGCGACCGAAGATGTAACCGCGGTTGAAGTCGATCCCGCTGACCGCAACCGCGTAATTTCC TTTTAAATGGCATTGGTACCATTTTGACGGAACCGATTGGGACGAGTCCCGAAAGCTGAACCGCA TCTATAAGTTTCAAGGAAAGGCTTGGGAATTGGGAAGTTTCCACAGAAAACGGAAACTATGACTAC TTAATGTATGCCGACCTTGATATGGATCATCCCGAAGTCGTGACCGAGCTGAAAAACTGGGGGGAA **ATGGTATGTCAACAACGAACATTGATGGGTTCCGGCTTGATGCCGTCAAGCATATTAAGTTCA GTTTTTTTCCTGATTGGTTGTCGTATGTGCGTTCTCAGACTGGCAAGCCGCTATTTACCGTCGGG TTTGTTTGATGCCCCGTTACACAACAAATTTTATACCGCTTCCAAATCAGGGGGGCGCATTTGATA** TGCGCACGTTAATGACCAATACTCTCATGAAAGATCAACCGACATTGGCCGTCACCTTCGTTGAT AATCATGACACCGAGCCCGGCCAAGCGCTTCAGTCATGGGTCGACCCCATGGTTCAAACCGTTGGC TTACGCCTTTATTCTAACTCGGCAGGAAGGATACCCGTGCGTCTTTTATGGTGACTATTATGGCA TATGCTTACGGAACGCAACATGATTATCTTGATCACTCCGACATCATCGGGTGGACAAGGGAAGG **GGTCACTGAAAAAACCAGGATCCGGGCTGGCCGCACTGATCACCGATGGGCCGGGAGGAAGCAAAT** GGATGTACGTTGGCAAACAACACGCTGGAAAAGTGTTCTATGACCTTACCGGCAACCGGAGTGAC ACCGTCACCATCAACAGTGATGGATGGGGGGGGAATTCAAAGTCAATGGCGGTTCGGTTTCGGTTTG GGTTCCTAGAAAAACGACC

Sequence ID No. 23. Nucleotide sequence of gene coding hybrid 200 protein

ACAAATCTTAATGGGACGCTGATGCAGTATTTTGAATGGTACACGCCCAATGACGGCCAACATTG GAAGCGTCTGCAAAACGACTCGGCATATTTGGCTGAACACGGTATTACTGCCGTCTGGATTCCCC CGGCATATAAGGGAACGAGCCAAGCGGATGTGGGCTACGGTGCTTACGACCTTTATGATTTAGGG GAGTTTCATCAAAAAGGGACGGTTCGGACAAAGTACGGCACAAAAGGAGAGCTGCAATCTGCGAT CAAAAGTCTTCATTCCCGCGACATTAACGTTTACGGGGATGTGGTCATCAACCACAAAGGCGGCG CTGATGCGACCGAAGATGTAACCGCGGTTGAAGTCGATCCCGCTGACCGCAACCGCGTAATTTCC GGAGAATACCTAATTAAAGCCTGGACACATTTTCATTTTCCGGGGCGCGGCAGCACATACAGCGA **TTTTAAATGGCATTGGTACCATTTTGACGGAACCGATTGGGACGAGTCCCGAAAGCTGAACCGCA TCTATAAGTTTCAAGGAAAGGCTTGGGATTGGGAAGTTTCCAGTGAAAACGGCAACTATGATTAT** TTGATGTATGCCGACCTTGATATGGATCATCCCGAAGTCGTGACCGAGCTGAAAAACTGGGGGGAA **ATGGTATGTCAACAACGAACATTGATGGGTTCCGGCTTGATGCCGTCAAGCATATTAAGTTCA GTTTTTTTCCTGATTGGTTGTCGTATGTGCGTTCTCAGACTGGCAAGCCGCTATTTACCGTCGGG TTTGTTTGATGCCCCCGTTACACAACAAATTTTATACCGCTTCCAAATCAGGGGGGCGCATTTGATA** TGCGCACGTTAATGACCAATACTCTCATGAAAGATCAACCGACATTGGCCGTCACCTTCGTTGAT AATCATGACACCGAGCCCGGCCAAGCGCTTCAGTCATGGGTCGACCCATGGTTCAAACCGTTGGC TTACGCCTTTATTCTAACTCGGCAGGAAGGATACCCGTGCGTCTTTTATGGTGACTATTATGGCA TATGCTTACGGAACGCAACATGATTATCTTGATCACTCCGACATCATCGGGTGGACAAGGGAAGG **GGTCACTGAAAAACCAGGATCCGGGCTGGCCGCACTGATCACCGATGGGCCGGGAGGAAGCAAAT** GGATGTACGTTGGCAAACAACACGCTGGAAAAGTGTTCTATGACCTTACCGGCAACCGGAGTGAC ACCGTCACCATCAACAGTGATGGATGGGGGGGAATTCAAAGTCAATGGCGGTTCGGTTTCGGTTTG GGTTCCTAGAAAAACGACC

FIG. 8C

Sequence ID No. 24. Nucleotide sequence of gene coding hybrid 200SB protein

ACAAATCTTAATGGGACGCTGATGCAGTATTTTGAATGGTACACGCCCAATGACGGCCAACATTG GAAGCGTCTGCAAAACGACTCGGCATATTTGGCTGAACACGGTATTACTGCCGTCTGGATTCCCC CGGCATATAAGGGAACGAGCCAAGCGGATGTGGGCTACGGTGCTTACGACCTTTATGATTTAGGG GAGTTTCATCAAAAAGGGACGGTTCGGACAAAGTACGGCACAAAAGGAGAGCTGCAATCTGCGAT CAAAAGTCTTCATTCCCGCGACATTAACGTTTACGGGGATGTGGTCATCAACCACAAAGGCGGCG CTGATGCGACCGAAGATGTAACCGCGGTTGAAGTCGATCCCGCTGACCGCAACCGCGTAATTTCC GGAGAATACCTAATTAAAGCCTGGACACATTTTCATTTTCCGGGGCGCGCGGCAGCACATACAGCGA TTTTAAATGGCATTGGTACCATTTTGACGGAACCGATTGGGACGAGTCCCGAAAGCTGAACCGCA TCTATAAGTTTCAAGGAAAGGCTTGGGATTGGGAAGTT<u>GACACA</u>GAAAACGGCAACTATGATTAT TTGATGTATGCCGACCTTGATATGGATCATCCCGAAGTCGTGACCGAGCTGAAAAACTGGGGGAA **ATGGTATGTCAACACAACGAACATTGATGGGTTCCGGCTTGATGCCGTCAAGCATATTAAGTTCA** GTTTTTTTCCTGATTGGTTGTCGTATGTGCGTTCTCAGACTGGCAAGCCGCTATTTACCGTCGGG **TTTGTTTGATGCCCCGTTACACAACAAATTTTATACCGCTTCCAAATCAGGGGGCGCATTTGATA** TGCGCACGTTAATGACCAATACTCTCATGAAAGATCAACCGACATTGGCCGTCACCTTCGTTGAT AATCATGACACCGAGCCCGGCCAAGCGCTTCAGTCATGGGTCGACCCATGGTTCAAACCGTTGGC TTACGCCTTTATTCTAACTCGGCAGGAAGGATACCCGTGCGTCTTTTATGGTGACTATTATGGCA TTCCACAATATAACATTCCTTCGCTGAAAAGCAAAATCGATCCGCTCCTCATCGCGCGCAGGGAT TATGCTTACGGAACGCAACATGATTATCTTGATCACTCCGACATCATCGGGTGGACAAGGGAAGG GGTCACTGAAAAAACCAGGATCCGGGCTGGCCGCACTGATCACCGATGGGCCGGGAGGAAGCAAAT GGATGTACGTTGGCAAACAACACGCTGGAAAAGTGTTCTATGACCTTACCGGCAACCGGAGTGAC ACCGTCACCATCAACAGTGATGGATGGGGGGGAATTCAAAGTCAATGGCGGTTCGGTTTCGGTTTG GGTTCCTAGAAAAACGACC

Sequence ID No. 25. Nucleotide sequence of gene coding hybrid 202 protein.

ACAAATCTTAATGGGACGCTGATGCAGTATTTTGAATGGTACACGCCCAATGACGGCCAACATTG GAAGCGTCTGCAAAACGACTCGGCATATTTGGCTGAACACGGTATTACTGCCGTCTGGATTCCCC CGGCATATAAGGGAACGAGCCAAGCGGATGTGGGCTACGGTGCTTACGACCTTTATGATTTAGGG GAGTTTCATCAAAAAGGGACGGTTCGGACAAAGTACGGCACAAAAGGAGAGCTGCAATCTGCGAT CAAAAGTCTTCATTCCCGCGACATTAACGTTTACGGGGATGTGGTCATCAACCACAAAGGCGGCG CTGATGCGACCGAAGATGTAACCGCGGTTGAAGTCGATCCCGCTGACCGCAACCGCGTAATTTCC TTTTAAATGGCATTGGTACCATTTTGACGGAACCGATTGGGACGAGTCCCGAAAGCTGAACCGCA TCTATAAGTTTCAAGGAAAGGCTTGGGAATTGGGAAGTTTCCAGTGAAAACGGCAACTATGATTAT TTGATGTATGCCGACATCGATATGGATCATCCCGAAGTCGTGACCGAGCTGAAAAACTGGGGGGAA **ATGGTATGTCAACACAACGAACATTGATGGGTTCCGGCTTGATGCCGTCAAGCATATTAAGTTCA GTTTTTTTCCTGATTGGTTGTCGTATGTGCGTTCTCAGACTGGCAAGCCGCTATTTACCGTCGGG TTTGTTTGATGCCCCGTTACACAACAAATTTTATACCGCTTCCAAATCAGGGGGGCGCATTTGATA** TGCGCACGTTAATGACCAATACTCTCATGAAAGATCAACCGACATTGGCCGTCACCTTCGTTGAT AATCATGACACCGAGCCCGGCCAAGCGCTTCAGTCATGGGTCGACCCATGGTTCAAACCGTTGGC TTACGCCTTTATTCTAACTCGGCAGGAAGGATACCCGTGCGTCTTTTATGGTGACTATTATGGCA TATGCTTACGGAACGCAACATGATTATCTTGATCACTCCGACATCATCGGGTGGACAAGGGAAGG GGTCACTGAAAAAACCAGGATCCGGGCTGGCCGCACTGATCACCGATGGGCCGGGAGGAAGCAAAT GGATGTACGTTGGCAAACAACACGCTGGAAAAGTGTTCTATGACCTTACCGGCAACCGGAGTGAC ACCGTCACCATCAACAGTGATGGATGGGGGGGAATTCAAAGTCAATGGCGGTTCGGTTTCGGTTTG GGTTCCTAGAAAAACGACC

Sequence ID No. 26. Nucleotide sequence of gene coding hybrid 202SB protein.

ACAAATCTTAATGGGACGCTGATGCAGTATTTTGAATGGTACACGCCCAATGACGGCCAACATTG GAAGCGTCTGCAAAACGACTCGGCATATTTGGCTGAACACGGTATTACTGCCGTCTGGATTCCCC CGGCATATAAGGGAACGAGCCAAGCGGATGTGGGCTACGGTGCTTACGACCTTTATGATTTAGGG GAGTTTCATCAAAAAGGGACGGTTCGGACAAAGTACGGCACAAAAGGAGAGCTGCAATCTGCGAT CAAAAGTCTTCATTCCCGCGGCATTAACGTTTACGGGGATGTGGTCATCAACCACAAAGGCGGCG CTGATGCGACCGAAGATGTAACCGCGGTTGAAGTCGATCCCGCTGACCGCAACCGCGTAATTTCC GGAGAATACCTAATTAAAGCCTGGACACATTTTCATTTTCCGGGGCGCGGCAGCACATACAGCGA TTTTAAATGGCATTGGTACCATTTTGACGGAACCGATTGGGACGAGTCCCGAAAGCTGAACCGCA TCTATAAGTTTCAAGGAAAGGCTTGGGATTGGGAAGTT<u>GACACA</u>GAAAACGGCAACTATGATTAT TTGATGTATGCCGACATCGATATGGATCATCCCGAAGTCGTGACCGAGCTGAAAAACTGGGGGAA ATGGTATGTCAACAACGAACATTGATGGGTTCCGGCTTGATGCCGTCAAGCATATTAAGTTCA GTTTTTTTCCTGATTGGTTGTCGTATGTGCGTTCTCAGACTGGCAAGCCGCTATTTACCGTCGGG TTTGTTTGATGCCCCGTTACACAACAAATTTTATACCGCTTCCAAATCAGGGGGGGCGCATTTGATA TGCGCACGTTAATGACCAATACTCTCATGAAAGATCAACCGACATTGGCCGTCACCTTCGTTGAT AATCATGACACCGAGCCCGGCCAAGCGCTTCAGTCATGGGTCGACCCATGGTTCAAACCGTTGGC TTACGCCTTTATTCTAACTCGGCAGGAAGGATACCCGTGCGTCTTTTATGGTGACTATTATGGCA TTCCACAATATAACATTCCTTCGCTGAAAAGCAAAATCGATCCGCTCCTCATCGCGCGCAGGGAT TATGCTTACGGAACGCAACATGATTATCTTGATCACTCCGACATCATCGGGTGGACAAGGGAAGG GGTCACTGAAAAACCAGGATCCGGGCTGGCCGCACTGATCACCGATGGGCCGGGAGGAAGCAAAT GGATGTACGTTGGCAAACAACACGCTGGAAAAGTGTTCTATGACCTTACCGGCAACCGGAGTGAC ACCGTCACCATCAACAGTGATGGATGGGGGGGAATTCAAAGTCAATGGCGGTTCGGTTTCGGTTTG GGTTCCTAGAAAAACGACC

Sequence ID No. 27. Nucleotide sequence of gene coding hybrid 228 protein.

ACAAATCTTAATGGGACGCTGATGCAGTATTTTGAATGGTACACGCCCAATGACGGCCAACATTG GAAGCGTCTGCAAAACGACTCGGCATATTTGGCTGAACACGGTATTACTGCCGTCTGGATTCCCC CGGCATATAAGGGAACGAGCCAAGCGGATGTGGGCTACGGTGCTTACGACCTTTATGATTTAGGG GAGTTTCATCAAAAAGGGACGGTTCGGACAAAGTACGGCACAAAAGGAGAGCTGCAATCTGCGAT CAAAAGTCTTCATTCCCGCGGCATTAACGTTTACGGGGATGTGGTCATCAACCACAAAGGCGGCG CTGATGCGACCGAAGATGTAACCGCGGTTGAAGTCGATCCCGCTGACCGCAACCGCGTAATTTCC GGAGAATACCTAATTAAAGCCTGGACACATTTTCATTTTCCGGGGGCGCGCAGCACATACAGCGA TTTTAAATGGCATTGGTACCATTTTGACGGAACCGATTGGGACGAGTCCCGAAAGCTGAACCGCA TCTATAAGTTTCAAGGAAAGGCTTGGGAATTGGGAAGTTTCCAGTGAAAACGGCAACTATGATTAT TTGATGTATGCCGACATCGATTATGACCATCCTGATGTCGTAGCAGAAATTAAGAGATGGGGCAC TTGGTATGCCAATGAGCTCCAATTGGACGGTTTCCCGGCTTGATGCCGTCAAGCATATTAAGTTCA GTTTTTTTTCCTGATTGGTTGTCGTATGTGCGTTCTCAGACTGGCAAGCCGCTATTTACCGTCGGG TTTGTTTGATGCCCCGTTACACAAAATTTTATACCGCTTCCAAATCAGGGGGGCGCATTTGATA TGCGCACGTTAATGACCAATACTCTCATGAAAGATCAACCGACATTGGCCGTCACCTTCGTTGAT AATCATGACACCGAGCCCGGCCCAAGCGCCTTCAGTCATGGGTCGACCCATGGTTCAAACCGTTGGC TTACGCCTTTATTCTAACTCGGCAGGAAGGATACCCGTGCGTCTTTTATGGTGACTATTATGGCA TATGCTTACGGAACGCAACATGATTATCTTGATCACTCCGACATCATCGGGTGGACAAGGGAAGG GGTCACTGAAAAACCAGGATCCGGGCTGGCCGCACTGATCACCGATGGGCCGGGAGGAAGCAAAT GGATGTACGTTGGCAAACAACACGCTGGAAAAGTGTTCTATGACCTTACCGGCAACCGGAGTGAC ACCGTCACCATCAACAGTGATGGATGGGGGGGAATTCAAAGTCAATGGCGGTTCGGTTTCGGTTTG GGTTCCTAGAAAAACGACC



Sequence ID No. 28. Nucleotide sequence of gene coding hybrid 228SB protein.

GCGAATCTTAATGGGACGCTGATGCAGTATTTTGAATGGTACACGCCCAATGACGGCCAACATTG GAAGCGTCTGCAAAACGACTCGGCATATTTGGCTGAACACGGTATTACTGCCGTCTGGATTCCCC CGGCATATAAGGGAACGAGCCAAGCGGATGTGGGCTACGGTGCTTACGACCTTTATGATTTAGGG GAGTTTCATCAAAAAGGGACGGTTCGGACAAAGTACGGCACAAAAGGAGAGCTGCAATCTGCGAT CAAAAGTCTTCATTCCCGCGACATTAACGTTTACGGGGATGTGGTCATCAACCACAAAGGCGGCG CTGATGCGACCGAAGATGTAACCGCGGTTGAAGTCGATCCCGCTGACCGCAACCGCGTAATTTCC TTTTAAATGGCATTGGTACCATTTTGACGGAACCGATTGGGACGAGTCCCGAAAGCTGAACCGCA TCTATAAGTTTCAAGGAAAGGCTTGGGAATTGGGAAGTT<u>GACACA</u>GAAAACGGCAACTATGATTAT TTGATGTATGCCGACATCGATTATGACCATCCTGATGTCGTAGCAGAAATTAAGAGATGGGGGCAC TTGGTATGCCAATGAGCTCCAATTGGACGGTTTCCCGGCTTGATGCCGTCAAGCATATTAAGTTCA GTTTTTTTCCTGATTGGTTGTCGTATGTGCGTTCTCAGACTGGCAAGCCGCTATTTACCGTCGGG TGCGCACGTTAATGACCAATACTCTCATGAAAGATCAACCGACATTGGCCGTCACCTTCGTTGAT AATCATGACACCGAGCCCGGCCAAGCGCTTCAGTCATGGGTCGACCCATGGTTCAAACCGTTGGC TTACGCCTTTATTCTAACTCGGCAGGAAGGATACCCGTGCGTCTTTTATGGTGACTATTATGGCA TTCCACAATATAACATTCCTTCGCTGAAAAGCAAAATCGATCCGCTCCTCATCGCGCGCAGGGAT TATGCTTACGGAACGCAACATGATTATCTTGATCACTCCGACATCATCGGGTGGACAAGGGAAGG GGTCACTGAAAAACCAGGATCCGGGCTGGCCGCACTGATCACCGATGGGCCGGGAGGAAGCAAAT GGATGTACGTTGGCAAACAACACGCTGGAAAAGTGTTCTATGACCTTACCGGCAACCGGAGTGAC ACCGTCACCATCAACAGTGATGGATGGGGGGGGAATTCAAAGTCAATGGCGGTTCGGTTTCGGTTTG GGTTCCTAGAAAAACGACC

Sequence ID No. 29. Nucleotide sequence of gene coding hybrid 249 protein.

ACAAATCTTAATGGGACGCTGATGCAGTATTTTGAATGGTACACGCCCAATGACGGCCAACATTG GAAGCGTCTGCAAAACGACTCGGCATATTTGGCTGAACACGGTATTACTGCCGTCTGGATTCCCC CGGCATATAAGGGAACGAGCCAAGCGGATGTGGGCTACGGTGCTTACGACCTTTATGATTTAGGG GAGTTTCATCAAAAAGGGACGGTTCGGACAAAGTACGGCACAAAAGGAGAGCTGCAATCTGCGAT CAAAAGTCTTCATTCCCGCGACATTAACGTTTACGGGGGATGTGGTCATCAACCACAAAGGCGGCG CTGATGCGACCGAAGATGTAACCGCGGTTGAAGTCGATCCCGCTGACCGCAACCGCGTAATTTCC GGAGAATACCTAATTAAAGCCTGGACACATTTTCATTTTCCGGGGGCGCGGCAGCACATACAGCGA TTTTAAATGGCATTGGTACCATTTTGACGGAACCGATTGGGACGAGTCCCGAAAGCTGAACCGCA TCTATAAGTTTCAAGGAAAGGCTTGGGATTGGGAAGTTTCCAGTGAAAACGGCAACTATGATTAT TTGATGTATGCCGACATCGATTATGACCATCCTGATGTCGTAGCAGAAATTAAGAGATGGGGCAC TTGGTATGCCAATGAGCTCCAATTGGACGGTTTCCGTCTTGATGCTGTCAAACACATTAAATTTT CTTTTTTGCGGGATTGGGTTAATCATGTCAGG**TCTCAGACTGGCAAGCCGCTATTTACCGTCGGG** TGCGCACGTTAATGACCAATACTCTCATGAAAGATCAACCGACATTGGCCGTCACCTTCGTTGAT AATCATGACACCGAGCCCGGCCCAAGCGCTTCAGTCATGGGTCGACCCATGGTTCAAACCGTTGGC TTACGCCTTTATTCTAACTCGGCAGGAAGGATACCCGTGCGTCTTTTATGGTGACTATTATGGCA **TTCCACAATATAACATTCCTTCGCTGAAAAGCAAAATCGATCCGCTCCTCATCGCGCGCAGGGAT** TATGCTTACGGAACGCAACATGATTATCTTGATCACTCCGACATCATCGGGTGGACAAGGGAAGG GGTCACTGAAAAAACCAGGATCCGGGCTGGCCGCACTGATCACCGATGGGCCGGGAGGAAGCAAAT GGATGTACGTTGGCAAACAACACGCTGGAAAAGTGTTCTATGACCTTACCGGCAACCGGAGTGAC ACCGTCACCATCAACAGTGATGGATGGGGGGGGAATTCAAAGTCAATGGCGGTTCGGTTTCGGTTTG GGTTCCTAGAAAAACGACC

Sequence ID no. 30. Nucleotide sequence of gene coding hybrid 249SB protein.

ACAAATCTTAATGGGACGCTGATGCAGTATTTTGAATGGTACACGCCCAATGACGGCCAACATTG GAAGCGTCTGCAAAACGACTCGGCATATTTGGCTGAACACGGTATTACTGCCGTCTGGATTCCCC CGGCATATAAGGGAACGAGCCAAGCGGATGTGGGCTACGGTGCTTACGACCTTTATGATTTAGGG GAGTTTCATCAAAAAGGGACGGTTCGGACAAAGTACGGCACAAAAGGAGAGCTGCAATCTGCGAT CAAAAGTCTTCATTCCCGCGACATTAACGTTTACGGGGATGTGGTCATCAACCACAAAGGCGGCG CTGATGCGACCGAAGATGTAACCGCGGTTGAAGTCGATCCCGCTGACCGCAACCGCGTAATTTCC TTTTAAATGGCATTGGTACCATTTTGACGGAACCGATTGGGACGAGTCCCGAAAGCTGAACCGCA TCTATAAGTTTCAAGGAAAGGCTTGGGATTGGGAAGTT<u>GACACA</u>GAAAACGGCAACTATGATTAT TTGATGTATGCCGACATCGATTATGACCATCCTGATGTCGTAGCAGAAATTAAGAGATGGGGGCAC TTGGTATGCCAATGAGCTCCAATTGGACGGTTTCCGTCTTGATGCTGTCAAACACATTAAATTTT CTTTTTTGCGGGATTGGGTTAATCATGTCAGGTCTCAGACTGGCAAGCCGCTATTTACCGTCGGG TTTGTTTGATGCCCCGTTACACAACAAATTTTATACCGCTTCCAAATCAGGGGGGCGCATTTGATA TGCGCACGTTAATGACCAATACTCTCATGAAAGATCAACCGACATTGGCCGTCACCTTCGTTGAT AATCATGACACCGAGCCCGGCCCAAGCGCTTCAGTCATGGGTCGACCCATGGTTCAAACCGTTGGC TTACGCCTTTATTCTAACTCGGCAGGAAGGATACCCGTGCGTCTTTTATGGTGACTATTATGGCA TTCCACAATATAACATTCCTTCGCTGAAAAGCAAAATCGATCCGCTCCTCATCGCGCGCAGGGAT TATGCTTACGGAACGCAACATGATTATCTTGATCACTCCGACATCATCGGGTGGACAAGGGAAGG GGTCACTGAAAAAACCAGGATCCGGGCTGGCCGCACTGATCACCGATGGGCCGGGAGGAAGCAAAT GGATGTACGTTGGCAAACAACACGCTGGAAAAGTGTTCTATGACCTTACCGGCAACCGGAGTGAC ACCGTCACCATCAACAGTGATGGATGGGGGGGAATTCAAAGTCAATGGCGGTTCGGTTTCGGTTTG GGTTCCTAGAAAAACGACC

Sequence ID No. 31. Nucleotide sequence of gene coding hybrid 254 protein.

ACAAATCTTAATGGGACGCTGATGCAGTATTTTGAATGGTACACGCCCAATGACGGCCAACATTG GAAGCGTCTGCAAAACGACTCGGCATATTTGGCTGAACACGGTATTACTGCCGTCTGGATTCCCC CGGCATATAAGGGAACGAGCCAAGCGGATGTGGGCTACGGTGCTTACGACCTTTATGATTTAGGG GAGTTTCATCAAAAAGGGACGGTTCGGACAAAGTACGGCACAAAAGGAGAGCTGCAATCTGCGAT CAAAAGTCTTCATTCCCGCGACATTAACGTTTACGGGGATGTGGTCATCAACCACAAAGGCGGCG CTGATGCGACCGAAGATGTAACCGCGGTTGAAGTCGATCCCGCTGACCGCAACCGCGTAATTTCC GGAGAATACCTAATTAAAGCCTGGACACATTTTCATTTTCCGGGGGCGCGGCAGCACATACAGCGA TTTTAAATGGCATTGGTACCATTTTGACGGAACCGATTGGGACGAGTCCCGAAAGCTGAACCGCA TCTATAAGTTTCAAGGAAAGGCTTGGGATTGGGAAGTTTCCAGTGAAAACGGCAACTATGATTAT TTGATGTATGCCGACATCGATTATGACCATCCTGATGTCGTAGCAGAAATTAAGAGATGGGGCAC TTGGTATGCCAATGAGCTCCAATTGGACGGTTTCCGTCTTGATGCTGTCAAACACATTAAATTTT CTTTTTTGCGGGATTGGGTTAATCATGTCAGGGAAAAAACGGGGAAG**CCGCTATTTACCGTCGGG** TTTGTTTGATGCCCCGTTACACAACAAATTTTATACCGCTTCCAAATCAGGGGGGCGCATTTGATA TGCGCACGTTAATGACCAATACTCTCATGAAAGATCAACCGACATTGGCCGTCACCTTCGTTGAT AATCATGACACCGAGCCCGGCCAAGCGCTTCAGTCATGGGTCGACCCATGGTTCAAACCGTTGGC TTACGCCTTTATTCTAACTCGGCAGGAAGGATACCCGTGCGTCTTTTATGGTGACTATTATGGCA TTCCACAATATAACATTCCTTCGCTGAAAAGCAAAATCGATCCGCTCCTCATCGCCGCGCAGGGAT TATGCTTACGGAACGCAACATGATTATCTTGATCACTCCGACATCATCGGGTGGACAAGGGAAGG GGTCACTGAAAAACCAGGATCCGGGCTGGCCGCACTGATCACCGATGGGCCGGGAGGAAGCAAAT GGATGTACGTTGGCAAACAACACGCTGGAAAAGTGTTCTATGACCTTACCGGCAACCGGAGTGAC **ACCGTCACCATCAACAGTGATGGATGGGGGGGAATTCAAAGTCAATGGCGGTTCGGTTTCGGTTTG** GGTTCCTAGAAAAACGACC

Sequence ID No. 32. Nucleotide sequence of gene coding hybrid 254SB protein.

ACAAATCTTAATGGGACGCTGATGCAGTATTTTGAATGGTACACGCCCAATGACGGCCAACATTG GAAGCGTCTGCAAAACGACTCGGCATATTTGGCTGAACACGGTATTACTGCCGTCTGGATTCCCC CGGCATATAAGGGAACGAGCCAAGCGGATGTGGGCTACGGTGCTTACGACCTTTATGATTTAGGG GAGTTTCATCAAAAAGGGACGGTTCGGACAAAGTACGGCACAAAAGGAGAGCTGCAATCTGCGAT CAAAAGTCTTCATTCCCGCGACATTAACGTTTACGGGGATGTGGTCATCAACCACAAAGGCGGCG CTGATGCGACCGAAGATGTAACCGCGGTTGAAGTCGATCCCGCTGACCGCAACCGCGTAATTTCC GGAGAATACCTAATTAAAGCCTGGACACATTTTCATTTTCCGGGGGCGCGCAGCACATACAGCGA TTTTAAATGGCATTGGTACCATTTTGACGGAACCGATTGGGACGAGTCCCGAAAGCTGAACCGCA TCTATAAGTTTCAAGGAAAGGCTTGGGATTGGGAAGTT<u>GACACA</u>GAAAACGGCAACTATGATTAT TTGATGTATGCCGACATCGATTATGACCATCCTGATGTCGTAGCAGAAATTAAGAGATGGGGCAC TTGGTATGCCAATGAGCTCCAATTGGACGGTTTCCGTCTTGATGCTGTCAAACACATTAAATTTT CTTTTTTGCGGGATTGGGTTAATCATGTCAGGGAAAAAACGGGGAAG**CCGCTATTTACCGTCGGG** TTTGTTTGATGCCCCGTTACACAACAAATTTTATACCGCTTCCAAATCAGGGGGGCGCATTTGATA TGCGCACGTTAATGACCAATACTCTCATGAAAGATCAACCGACATTGGCCGTCACCTTCGTTGAT AATCATGACACCGAGCCCGGCCAAGCGCTTCAGTCATGGGTCGACCCATGGTTCAAACCGTTGGC TTACGCCTTTATTCTAACTCGGCAGGAAGGATACCCGTGCGTCTTTTATGGTGACTATTATGGCA TATGCTTACGGAACGCAACATGATTATCTTGATCACTCCGACATCATCGGGTGGACAAGGGAAGG GGTCACTGAAAAAACCAGGATCCGGGCTGGCCGCACTGATCACCGATGGGCCGGGAGGAAGCAAAT GGATGTACGTTGGCAAACAACACGCTGGAAAAGTGTTCTATGACCTTACCGGCAACCGGAGTGAC ACCGTCACCATCAACAGTGATGGATGGGGGGGAATTCAAAGTCAATGGCGGTTCGGTTTCGGTTTG GGTTCCTAGAAAAACGACC

Sequence ID No. 33. Nucleotide sequence of gene coding hybrid 259 protein.

ACAAATCTTAATGGGACGCTGATGCAGTATTTTGAATGGTACACGCCCAATGACGGCCAACATTG GAAGCGTCTGCAAAACGACTCGGCATATTTGGCTGAACACGGTATTACTGCCGTCTGGATTCCCC CGGCATATAAGGGAACGAGCCAAGCGGATGTGGGCTACGGTGCTTACGACCTTTATGATTTAGGG GAGTTTCATCAAAAAGGGACGGTTCGGACAAAGTACGGCACAAAAGGAGAGCTGCAATCTGCGAT CAAAAGTCTTCATTCCCGCGACATTAACGTTTACGGGGATGTGGTCATCAACCACAAAGGCGGCG CTGATGCGACCGAAGATGTAACCGCGGTTGAAGTCGATCCCGCTGACCGCAACCGCGTAATTTCC GGAGAATACCTAATTAAAGCCTGGACACATTTTCATTTTCCGGGGGCGCGCAGCACATACAGCGA TTTTAAATGGCATTGGTACCATTTTGACGGAACCGATTGGGACGAGTCCCGAAAGCTGAACCGCA TCTATAAGTTTCAAGGAAAGGCTTGGGATTGGGAAGTTTCCAGTGAAAACGGCAACTATGATTAT TTGATGTATGCCGACATCGATTATGACCATCCTGATGTCGTAGCAGAAATTAAGAGATGGGGCAC TTGGTATGCCAATGAGCTCCAATTGGACGGTTTCCGTCTTGATGCTGTCAAACACATTAAATTTT TTTGTTTGATGCCCCGTTACACAACAAATTTTATACCGCTTCCAAATCAGGGGGGCGCATTTGATA TGCGCACGTTAATGACCAATACTCTCATGAAAGATCAACCGACATTGGCCGTCACCTTCGTTGAT AATCATGACACCGAGCCCGGCCAAGCGCTTCAGTCATGGGTCGACCCATGGTTCAAACCGTTGGC TTACGCCTTTATTCTAACTCGGCAGGAAGGATACCCGTGCGTCTTTTATGGTGACTATTATGGCA TATGCTTACGGAACGCAACATGATTATCTTGATCACTCCGACATCATCGGGTGGACAAGGGAAGG GGTCACTGAAAAACCAGGATCCGGGCTGGCCGCACTGATCACCGATGGGCCGGGAGGAAGCAAAT GGATGTACGTTGGCAAACAACACGCTGGAAAAGTGTTCTATGACCTTACCGGCAACCGGAGTGAC **ACCGTCACCATCAACAGTGATGGATGGGGGGGAATTCAAAGTCAATGGCGGTTCGGTTTCGGTTTG** GGTTCCTAGAAAAACGACC

FIG. 8H

Sequence ID no. 34. Nucleotide sequence of gene coding hybrid 259SB protein.

ACAAATCTTAATGGGACGCTGATGCAGTATTTTGAATGGTACACGCCCAATGACGGCCAACATTG GAAGCGTCTGCAAAACGACTCGGCATATTTGGCTGAACACGGTATTACTGCCGTCTGGATTCCCC CGGCATATAAGGGAACGAGCCAAGCGGATGTGGGCTACGGTGCTTACGACCTTTATGATTTAGGG GAGTTTCATCAAAAAGGGACGGTTCGGACAAAGTACGGCACAAAAGGAGAGCTGCAATCTGCGAT CAAAAGTCTTCATTCCCGCGACATTAACGTTTACGGGGATGTGGTCATCAACCACAAAGGCGGCG CTGATGCGACCGAAGATGTAACCGCGGTTGAAGTCGATCCCGCTGACCGCAACCGCGTAATTTCC GGAGAATACCTAATTAAAGCCTGGACACATTTTCATTTTCCGGGGGCGCGGCAGCACATACAGCGA TTTTAAATGGCATTGGTACCATTTTGACGGAACCGATTGGGACGAGTCCCGAAAGCTGAACCGCA TCTATAAGTTTCAAGGAAAGGCTTGGGATTGGGAAGTTGACACAGAAAACGGCAACTATGATTAT TTGATGTATGCCGACATCGATTATGACCATCCTGATGTCGTAGCAGAAATTAAGAGATGGGGCAC TTGGTATGCCAATGAGCTCCAATTGGACGGTTTCCGTCTTGATGCTGTCAAACACATTAAATTTT **TTTGTTTGATGCCCCGTTACACAACAACTTTTATACCGCTTCCAAATCAGGGGGGCGCATTTGATA** TGCGCACGTTAATGACCAATACTCTCATGAAAGATCAACCGACATTGGCCGTCACCTTCGTTGAT AATCATGACACCGAGCCCGGCCAAGCGCTTCAGTCATGGGTCGACCCATGGTTCAAACCGTTGGC TTACGCCTTTATTCTAACTCGGCAGGAAGGATACCCGTGCGTCTTTTATGGTGACTATTATGGCA **TTCCACAATATAACATTCCTTCGCTGAAAAGCAAAATCGATCCGCTCCTCATCGCGCGCAGGGAT** TATGCTTACGGAACGCAACATGATTATCTTGATCACTCCGACATCATCGGGTGGACAAGGGAAGG GGTCACTGAAAAACCAGGATCCGGGCTGGCCGCACTGATCACCGATGGGCCGGGAGGAAGCAAAT GGATGTACGTTGGCAAACAACACGCTGGAAAAGTGTTCTATGACCTTACCGGCAACCGGAGTGAC **ACCGTCACCATCAACAGTGATGGATGGGGGGGAATTCAAAGTCAATGGCGGTTCGGTTTCGGTTTG** GGTTCCTAGAAAAACGACC

FIG. 81

CHIMERIC ALPHA-AMYLASE VARIANTS

CROSS-REFERENCE

[0001] This application claims priority to U.S. Patent Application Ser. No. 61/126,066, filed on Apr. 30, 2008 the contents of which are fully incorporated herein by reference.

FIELD OF THE INVENTION

[0002] This pertains generally to α -amylase enzymes for use in industrial processes, such as liquefaction, baking and cleaning applications. More specifically, it pertains to chimeric α -amylases with improved activity in high temperature applications, and/or that provide improved performance for starch degradation.

BACKGROUND

[0003] For many industrial processes that use starches, it is desirable to have amylolytic enzymes that can function under high temperature to rapidly breakdown starch to reduce viscosity. Examples of such enzymes are known in the art. For example, the α -amylases from *Bacillus licheniformis* or Bacillus stearothermophilus, AmyL and AmyS respectively, facilitate liquefaction of starches at high temperature. In the absence of added calcium, AmyL and variants of AmyL have higher thermostability than AmyS amylase, and thus are preferred for production of glucose and fructose (e.g., HFCS). AmyS and variants of AmyS are preferred in ethanol producing processes because they have higher specific activity on cornstarch at high temperature than does AmyL or its variants. Thus, AmyS has a faster initial rate of substrate viscosity reduction, which is a highly desirable attribute in starch liquefaction processes. However, AmyS has an undesirable characteristic in that its catalytic activity results in a higher final viscosity at the end of the process than that obtained with AmyL or its variants. The higher final viscosity is likely the result of the lower thermostability, i.e. AmyS is simply inactivated more quickly by the high temperature of the liquefaction process.

[0004] Methods of increasing the thermostability of enzymes have been studied. The thermostability of Amy Q (B. amyloliquefaciens amylase) was enhanced by the deletion of two amino acids, R176-Gly177, (numbering relative to amino acid sequence of AmyQ) as shown by Suzuki et al. (1989) (J. Biol. Chem. 264:18933), which are absent from the AmyL sequence. The thermostability of AmyS-type amylases can be increased by the deletion of two amino acid residues, R179-G180, (AmyS numbering) from a loop (F178 to A184) as shown by Igarashi et al. 1998 (Biochem. Biophys. Res. Comm. 248:772). However, a mutated AmyS enzyme with this deletion has a lower specific activity for corn starch hydrolysis at high-temperature than the parent enzyme, negating one of the principal advantages of AmyS amylases, as shown by Shiau et al. (2003) (Appl. Environ. Micro. 69:2383).

[0005] As discussed above, it is known in the art that, in the absence of added calcium, wild-type AmyL amylase is more thermostable than AmyS amylase. It is further known in the art that the AmyQ, an α -amylase from *Bacillus amyloliquefaciens* that is highly homologous to both AmyS and AmyL, is less thermostable than either AmyS or AmyL. Suzuki et al.

(1989) demonstrated that for AmyL-AmyQ-derived hybrids, the N-terminal portion of the AmyL enzymes was required to obtain high stability.

SUMMARY

[0006] Provided herein are chimeric polypeptides made preferably from AmyL and AmyS α -amylases. The novel chimeric amylases are useful in that a single enzyme provides the relatively higher thermostability seen in AmyL-type amylases, and the relatively higher specific activity seen in AmyS-type amylases.

[0007] Accordingly, provided herein are improved amylase enzymes that provide altered performance properties, for example in terms of their ability to reduce viscosity under high temperature conditions of liquefaction. The chimeric amylases display improved specific activity or the ability to provide a rapid reduction of the peak viscosity in starch liquefaction, as generally observed with AmyS-type amylases. In addition, the chimeric α -amylases have good thermostability, and thus, can provide a low final viscosity as typically seen with AmyL-type enzymes. Polypeptides with improved thermostability, thermostable amylases with increased specific activity, and compositions comprising the polypeptides and enzymes, as well as methods of using the novel enzymes or compositions are provided herein. Nucleic acids encoding the chimeric enzymes, including expression vectors, and host cells that express the chimeric amylases also are provided.

[0008] The chimeric α -amylases provide a benefit in that a single chimeric enzyme can provide many of the advantages provided in two separate enzymes. Production benefits for the manufacturer and economic benefits for both the end-user and the manufacturer may flow from the availability of the chimeric amylases described herein.

[0009] The chimeric α -amylases are particularly useful in ethanol production processes and other starch degradation processes at high temperature, such as liquefaction processes for syrup production or for fermentation, cleaning applications (e.g. washing, dishwashing), baking, or desizing of woven materials. The enzymes are relatively thermostable, and have good activity across a range of pH conditions, calcium ion concentrations, and redox conditions.

[0010] In one aspect, provided are chimeric polypeptides comprising an amino-terminal domain and a carboxy-terminal domain. The amino-terminal domain comprises about 180 or more contiguous amino acid residues of an AmyL amylase. Preferably, the amino-terminal portion comprises an N-terminal portion of the AmyL amylase. The carboxy-terminal domain of the chimeric polypeptides comprises a carboxyterminal portion of an AmyS amylase. The chimeric polypeptides have an overall length of about 480-515 amino acid residues. The chimeric polypeptides provided herein do not have the primary amino acid sequence of either the AmyL amylase or the AmyS amylase, nor of any other known polypeptide. The chimeric polypeptides have enhanced thermostability relative at least to the AmyS amylase. Thermostability that is equivalent to, or even better than, that of the AmyL is observed in some embodiments.

[0011] In another aspect, provided are thermostable chimeric α -amylases. The chimeric amylases comprise an N-terminal portion and a C-terminal portion; the N-terminal portion comprises a contiguous amino acid sequence from an N-terminal portion of an AmyL amylase. The C-terminal portion of the chimeric amylases comprises a contiguous

amino acid sequence from a C-terminal portion of an AmyS amylase. The chimeric α -amylases generally have a specific activity greater than that of AmyL amylase. The chimeric amylases also have greater thermostability at 95° C. than AmyS amylase. The primary amino acid sequence of the chimeric amylases is about 475-520 amino acid residues long.

[0012] Provided herein are compositions comprising one or more chimeric polypeptides or thermostable chimeric α -amylases as described above, or a combination thereof. The compositions can further comprise one or more additional polypeptides or enzymes. Also provided are food-grade lyophilized compositions comprising the compositions.

[0013] In another aspect, provided are polynucleotides that encode a chimeric polypeptide or thermostable α -amylase as provided above, vectors comprising the polynucleotides, and host cells comprising the vectors or polynucleotides. In one embodiment, the polynucleotide encodes a polypeptide having at least about 95% sequence identity to any of SEQ ID NOS: 1-17, but not having the precise sequence of SEQ ID NO: 1 or 2.

[0014] Provided as well are methods of making and using the chimeric polypeptides, thermostable α -amylases and the compositions disclosed herein. The methods of using provided herein contemplate the possibility of using one or more additional enzymes, including one or more additional amylases therewith. In one aspect, methods of producing a composition comprising a chimeric polypeptide or a thermostable α -amylase are provided. The methods comprise utilizing a host cell selected from the group consisting of Bacillus licheniformis, B. subtilis, and B. stearothermophilus, for a fermentation process wherein a protein is expressed, said protein comprising: (a) a chimeric polypeptide having a length of about 480-515 amino acid residues, and comprising an amino-terminal domain comprising about 180 or more contiguous amino acid residues of an N-terminal portion of an AmyL amylase, and a carboxy-terminal domain comprises a carboxy-terminal portion of an AmyS amylase; said chimeric polypeptide having enhanced thermostability relative at least to the AmyS amylase, or (b) a thermostable chimeric α -amylase about 475-520 amino acid residues long, and comprising an N-terminal portion comprising a contiguous amino acid sequence from an N-terminal portion of an AmyL amylase, and a C-terminal portion comprising a contiguous amino acid sequence from a C-terminal portion of an AmyS amylase, said chimeric α -amylase having a specific activity greater than the AmyL amylase and greater thermostability at 95° C. than the AmyS amylase. The methods entail at least partially purifying the expressed protein, to produce the composition.

[0015] A method is provided for liquefying a starch slurry comprising: making a slurry comprising a starch, heating the slurry to an acceptable temperature for liquefaction, adding to the slurry a composition comprising one or more of a chimeric polypeptide or thermostable chimeric α -amylase as provided herein, or a combination thereof. Incubating the slurry with the composition for a time and at a temperature sufficient to liquefy the starch slurry completes the method. The method can be used as part of process for producing fuel alcohol.

[0016] Also provided is a method of cleaning a surface to remove an unwanted or undesirable starch residue. The method comprises the steps of providing a surface that has starch residue to be removed, contacting the surface with a

composition comprising a chimeric polypeptide, thermostable chimeric α -amylase as disclosed herein, or a combination thereof, for a time and at a temperature sufficient to result in removal of the starch residue.

[0017] Provided also is a method of treating a woven material that has been previously subjected to contact with a coating comprising starch or a starch-derivative. The method comprises contacting the woven material with a liquid comprising a chimeric α -amylase as provided hereinabove, for a time and under conditions sufficient to substantially remove the coating from the woven material.

[0018] Kits for facilitating liquefaction of starch slurry, said kit comprising at least one of: (a) a chimeric polypeptide having a length of about 480-515 amino acid residues, and comprising an amino-terminal domain comprising about 180 or more contiguous amino acid residues of an N-terminal portion of an AmyL amylase, and a carboxy-terminal domain comprises a carboxy-terminal portion of an AmyS amylase; said chimeric polypeptide having enhanced thermostability relative at least to the AmyS control, or (b) a thermostable chimeric α -amylase about 475-520 amino acid residues long, and comprising an N-terminal portion comprising a contiguous amino acid sequence from an N-terminal portion of an AmyL amylase, and a C-terminal portion comprising a contiguous amino acid sequence from a C-terminal portion of an AmyS amylase, said chimeric α-amylase having a specific activity greater than the AmyL amylase and greater thermostability at 95° C. than the AmyS amylase. The kit also comprises instructions for use of the kit in the liquefaction of a starch slurry.

BRIEF DESCRIPTION OF THE DRAWINGS

[0019] FIG. **1** is a diagram of the plasmid used for the expression of the various hybrids and amylases. The plasmid elements are as follows: Bla, the beta lactamase gene which codes for ampicillin/carbenicillin resistance marker; AprE promoter region, promoter from *B. subtilis* AprE (alkaline protease) having a region of homology to the *Bacillus* hosts' chromosome that allows it to integrate into the host genome; AprE peptide, the *B. subtilis* AprE signal sequence; Hybrid 186; LAT Term, the native amylase LAT (licheniformis; CAT, the chloramphenicol acetyl transferase gene for chloramphenicol antibiotic resistance; ORI, the origin of replication for *E. coli*. Note that this plasmid lacks an origin of replication for *Bacillus*.

[0020] FIG. 2 shows the results of the performance of chimeric α -amylases in a thermostability screen at 95° C. in comparison to a control, AmyS control. The chimeric a-amylases comprised an amino terminal portion from AmyL and a carboxy-terminal portion from AmyS. The chimeras tested included 186, 187, 200, 202, 228, 249, 254, and 259. The three-digit number, where used in the name of a chimeric α -amylase herein, indicates the position of the last amino acid residue of the AmyL sequence, with the remainder of the chimera derived from the AmyS sequence. The control enzyme ("AmyS control") (SEQ ID NO: 3) used is a variant AmyS with a deletion of R179-G180 [described in WO2005/ 111203]. The enzymes were held at desired temperature (95° C.) and samples were removed at the time points indicated for assay. The assay conditions included pH 5.6 50 mM malate buffer, 2.6 mM CaCl₂, and 50 mM NaCl. The graph shows the relative catalytic activity remaining (as a percentage) on the

y-axis, over time (min) on the x-axis, using the MEGAZYME CERALPHA synthetic oligosaccharide substrate, as described herein. Detailed description of the incubation conditions and assays are provided in the methods section.

[0021] FIG. **3** shows the thermostability of additional chimeric α -amylases at 95° C. The graph, as in FIG. **2**, shows the amylase activity remaining (as a percentage) on the y-axis, over time (min) on the x-axis. The reaction conditions were the same as in FIG. **1**. The chimeras tested include 200SB, 202SB, and 228SB. "SB" as used herein, indicates that a stabilizing salt-bridge was created by introduction of S187D and S188T mutations. The control was the AmyS control (SEQ ID NO: 3).

[0022] FIG. **4** shows the thermostability of additional chimeric α -amylases at 95° C. The graph is as in FIGS. **2** and **3**. The reaction conditions were the same as in FIGS. **2** and **3**. The samples tested include the AmyS control, and chimeras 249SB, 254SB, and 259SB.

[0023] FIG. **5** shows the specific activity of several chimeric α -amylases at 75° C. The DNS reducing sugar detection assay, described below (see methods section for details), was used to determine the rate of reactions for chimeras 186, 228 and 228SB in comparison to the AmyL and the AmyS control enzyme. The specific activity is reported as mg glucose produced per second per mg enzyme in the reaction. All three chimeric enzymes tested showed greater specific activity than the AmyL enzyme at the elevated temperature, 75° C., tested.

[0024] FIG. **6** shows the changes in viscosity of corn flour substrate upon incubation with various hybrid amylases. Hybrids 186, 202SB, 228SB, and 228 were compared to the AmyS control for their ability to reduce viscosity as measured by EUROSTAR/IKA Labortechnik control-visc P7 electronic overhead stirrer with torque read output.

[0025] FIG. 7, panels A-E, shows the amino acid sequences of SEQ IDs 1 to 17. Amino sequence labels: For all hybrid amino acid sequences, Amy L sequence is shown in plain text, Amy S sequence region is shown in bold type, and Salt bridge sequence is shown underlined.

[0026] FIG. **8**, panels A-I, shows the nucleotide sequences of SEQ IDs 18 to 34. Nucleotide sequence labels: For all hybrid nucleotide sequences, Amy L sequence is shown in plain text, Amy S sequence region is shown in bold type, and Salt bridge sequence is shown underlined.

DETAILED DESCRIPTION

[0027] Chimeric α -amylases are provided having beneficial advantages over currently available α -amylases. The chimeric α -amylases comprise an N-terminal portion from an AmyL amylase and a C-terminal portion from an AmyS amylase. The chimeric a-amylases exhibit improved thermostability relative to the AmyS enzymes, and improved specific activity or ability to reduce peak viscosity relative to the AmyL enzymes. Thus, these properties allow the chimeric polypeptides and thermostable amylases to be used in hightemperature starch liquefaction, for example for production of fermentation products such as alcohol, and especially ethanol. They result in reduced peak viscosity relative to AmyL amylases used alone, and low final viscosities relative to AmyS amylases used alone. The chimeric enzymes provided herein also useful in the breakdown or removal of starch, amylase, amylopectin, or other substrates of a-amylase in other high-temperature processes such as baking, as well as in the treatment of woven materials to remove starch-based sizing agents, or cleaning/washing processes. The chimeric enzymes provided herein can also be used in conjunction with each and or in conjunction with one or more other enzymes, for example in a blend. Preferably, other enzymes used are active under the same or similar reaction conditions as those used for the chimeric α -amylases. This provides more flexibility to the end user, as well as certain economic and processing advantages. Processing conditions, such as pH, temperature, ionic strength, as well as the presence of required cofactors, can be established to permit activity of the α -amylases and any other enzymes present. Such processing conditions can facilitate the use of continuous or semi-continuous processes, rather than costly and time-consuming batch processes. Other features provided in certain embodiments of the chimeric α -amylases are increased specific activity, and the ability to reduce the peak viscosity or the final viscosity of a starch slurry, as well as or better than either of the AmyL and AmyS enzymes.

A. Definitions & Abbreviations

[0028] In accordance with this detailed description, the following abbreviations and definitions apply. It should be noted that as used herein, the singular forms "a," "an," and "the" include plural referents unless the context clearly dictates otherwise. Thus, for example, reference to "an enzyme" includes a plurality of such enzymes, and reference to "the formulation" includes reference to one or more formulations and equivalents thereof known to those skilled in the art, and so forth.

[0029] The term "about" with respect to a numerical value or range indicates that the numerical value can be 10% greater or less than the stated value. In other embodiments, "about" indicates that a numerical value can be 5% greater or less than the stated value. The skilled artisan will appreciate that term "about," when used in conjunction with a number or range of amino acid residues or base pairs, or the length of a polypeptide in amino acid residues, or the length of a polynucleotide in base pairs, encompasses only integer values.

[0030] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art. The following terms are provided below.

1.1. Definitions

[0031] "Amylase" means an enzyme that is, among other things, capable of catalyzing the degradation of starch, amylose, amylopectin, and the like. Generally, α -amylases (EC 3.2.1.1; α -D-(1 \rightarrow 4)-glucan glucanohydrolase) are defined as endo-acting enzymes cleaving α -D-(1 \rightarrow 4) O-glycosidic linkages in a polysaccharide containing three or more α -D- $(1\rightarrow 4)$ linked glucose units. The α -amylases release reducing groups in the α -configuration. They act on starch, glycogen and related poly- and oligosaccharides in a random manner. In contrast, the exo-acting amylolytic enzymes sequentially cleave the substrate molecule from the non-reducing end. The glucan 1,4- α -maltohydrolases (maltogenic α -amylases; EC 3.2.1.133) produce α -maltose as the end product, while β -amylases (EC 3.2.1.2) produce β -maltose. β -Amylases, α -glucosidases (EC 3.2.1.20; α -D-glucoside glucohydrolase), glucoamylase (EC 3.2.1.3; α -D-(1 \rightarrow 4)-glucan glucohydrolase), and product-specific amylases can produce malto-oligosaccharides of a specific length from their respective substrates. Glucoamylases release glucosyl residues

from the non-reducing ends of amylose and amylopectin molecules. Glucoamylases also catalyze the hydrolysis of α -1,6 and α -1,3 linkages, although at much slower rate than α -1,4 linkages.

[0032] A "chimeric polypeptide," or "chimera" means a protein containing sequences from more than one polypeptide. An chimeric polypeptide or α -amylase can be chimeric in the sense that it contains a portion, region, or domain from one molecule fused to one or more portions, regions, or domains from one or more other molecules. By way of example, a chimeric polypeptide or a chimeric α -amylase might comprise a sequence for a mature α -amylase protein linked to the sequence for the signal peptide of another α -amylase. The skilled artisan will appreciate that chimeric polypeptides and α -amylases need not consist of actual fusions of the protein sequences, but rather, polynucleotides with the corresponding encoding sequences can also be used to express chimeric polypeptides or a-amylases that comprise the same amino acid sequence as an actual or hypothetical fusion protein made from or ("derived from") other amylases. Thus, for example, a chimeric α -amylase or a chimeric polypeptide herein can comprise an amino-terminal portion of a first amylase and a carboxy-terminal portion of a second amylase, or the chimeric polypeptide or α -amylase could be expressed from a polynucleotide encoding a protein of the same sequence. In the case of a chimeric α -amylase, the catalytic activity of an α -amylase must be present in the resultant molecule. "Chimeric molecules" as used herein, can be either polynucleotides or polypeptides, and are not naturally occurring. A wild-type α -amylase occurs naturally. Chimeric amylases differ from a wild-type α -amylase in the amino acid residues of the mature protein, i.e., in the primary amino acid sequence of the active molecule without a signal sequence.

[0033] "Activity" with respect to enzymes means "catalytic activity" and encompasses any acceptable measure of enzyme activity, such as the rate of activity, the amount of activity, or the specific activity. Catalytic activity refers to the ability to catalyze a specific chemical reaction, such as the hydrolysis of a specific chemical bond. As the skilled artisan will appreciate, the catalytic activity of an enzyme only accelerates the rate of an otherwise slow chemical reaction. Because the enzyme only acts as a catalyst, it is neither produced nor consumed by the reaction itself. The skilled artisan will also appreciate that not all polypeptides have a catalytic activity. "Specific activity" is a measure of activity of an enzyme per unit of total protein or enzyme. Thus, specific activity may be expressed by unit weight (e.g. per gram, or per milligram) or unit volume (e.g. per ml) of enzyme. Further, specific activity may include a measure of purity of the enzyme, or can provide an indication of purity, for example, where a standard of activity is known, or available for comparison.

[0034] "Variants" refer to polypeptides and nucleic acids. The term "variant" may sometimes be used synonymously with the term "mutant." Variants include insertions, substitutions, deletions, transversions, truncations, and/or inversions at one or more locations in an amino acid or nucleotide sequence. Variant nucleic acids can include sequences that are complementary to sequences that are capable of hybridizing to the nucleotide sequences presented herein. For example, a variant sequence is complementary to sequences capable of hybridizing under stringent conditions, e.g., 50° C. and 0.2× SSC (1×SSC=0.15 M NaCl, 0.015 M sodium citrate, pH 7.0), to the nucleotide sequences presented herein. More particularly, the term variant encompasses sequences that are complementary to sequences that are capable of hybridizing under highly stringent conditions, e.g., 65° C. and $0.1 \times$ SSC, to the nucleotide sequences presented herein. In various embodiments, a variant is at least 60, 65, 70, 75, 80, 85, 90, 91, 92, 93, 94, 95, 96, 97, 98, or even 99% identical to a sequence expressly provided herein.

[0035] As used herein, the term "expression" refers to the process by which a polypeptide is produced based on the nucleic acid sequence of a gene or artificial sequence. The process includes both transcription and translation. "Expression product" refers generally to a protein made by translation, whether in vivo or in vitro. Similarly, if a gene is expressed, the gene product (usually protein, but sometimes RNA) is produced in a cell, such as a host cell comprising the gene.

[0036] "Microorganism" as used herein includes any bacterium, yeast, or fungus species.

[0037] "Isolated" with respect to protein, or nucleic acid sequences means that the sequence is at least substantially free from at least one other component that the sequence is naturally associated and found in nature. In the example of nucleic acid sequence, by isolated is meant isolated from genomic sequences.

[0038] "Purified" means that the material is in a relatively pure state, e.g., at least about 90% pure, at least about 95% pure, or at least about 98% pure. "Partially purified" encompasses lesser degrees of purity, provided that the protein or nucleic acid is "isolated" as used herein.

[0039] "Thermostable" means the enzyme retains measurable activity after exposure to elevated temperatures. One measure of the thermostability of an enzyme, such as an α -amylase, is its half-life (t_{1/2}), where half of the enzyme activity is lost by the half-life. The half-life value is calculated under defined conditions by measuring the residual amylase activity. In some embodiments, other measures of thermostability may be more useful or more practical, and may be measured and expressed, for example, as percent activity remaining after a specified exposure time at a temperature of interest. In another definition, thermostability is expressed as the melting temperature, or Tm, i.e. the midpoint of the transition from F<=>U in which F is folded protein and U is unfolded. Any mutation that causes an increase in Tm is said to be a stabilizing mutation. "Greater thermostability" or "enhanced thermostability" are used interchangeably herein. Any mutation that increases Tm or $t_{1/2}$ enhances thermostability of the associated polypeptide or enzyme. In some cases, rather than determine a Tm or $t_{1/2}$, other measures of stability are used. Tm cannot always be correctly determined because the transition from folded to unfolded may be irreversible. In such cases, stability can be defined as Tx, the temperature at which x percent protein remains functional after a specified time. If in a particular application it is known that an enzyme must remain active for about an hour, a useful comparison between enzymes may be a Tx for 60 minutes to ensure that an acceptable amount of activity remains after 60 minutes at a temperature at least that required in practice. Where irreversible denaturation is an issue, it is useful to assay under conditions similar to those in which the enzyme will be applied later, e.g. conditions of temperature, pH, or the presence of oxidants, detergents, or chelators must be considered.

[0040] Generally, after exposure of an enzyme to a temperature of interest for a desired time, the enzyme will be

assayed under standard assay conditions, including temperature. Thermostable enzymes may also be thermoactive enzymes, i.e. they can exhibit activity when assayed at high temperatures. As used herein, thermostable enzymes can be both resistant to heat denaturation and active at high temperatures.

[0041] "Thermostable chimeric α -amylases" are chimeric α -amylases as defined herein with enhanced thermostability relative to at least one amylase from which the chimera is derived. The thermostable chimeric amylases preferably have a thermostability that is greater than that of the less thermostable amylase from which the chimera is derived, and about that of the more thermostable amylase from which the chimera is derived.

[0042] "pH range" means the ability of the enzyme to exhibit catalytic activity from acidic to basic conditions. Common processes in which α -amylases are used may include pH conditions spanning 5 or more pH units. As used herein, "pH stable" relates to the ability of the enzyme to retain measurable activity over a wide range of pHs, for example, 1, 2, 3, 4, 5, or even more pH units. In addition to pH stability, the chimeric α -amylases described herein may also provide a pH optimum, wherein activity is maximal at a certain pH or pH range, under conditions of temperature, time, substrate concentration, and calcium ion concentration that are otherwise held constant.

[0043] As used herein, "amino acid sequence" is sometimes used synonymously with the term "polypeptide" and/or the term "protein." In some instances, the term "amino acid sequence" is synonymous with the term "peptide"; in some instances, the term "amino acid sequence" is synonymous with the term "enzyme." In other cases, which will be clear from the context, the "amino acid sequence" will refer to the actual sequence ("primary sequence") of amino acid side chains or "residues" in the backbone of a polypeptide. For example, the Sequence Listing provided herewith provides the amino acid sequences for several polypeptides or domains of polypeptides.

[0044] As used herein, "nucleotide sequence" or "nucleic acid sequence" refers to an oligonucleotide sequence or polynucleotide sequence ("polynucleotide") and variants, homologues, fragments and derivatives thereof. The nucleotide sequence may be of genomic, synthetic or recombinant origin and may be double-stranded or single-stranded, whether representing the sense or anti-sense strand. As used herein, the term "nucleotide sequence" includes genomic DNA, cDNA, synthetic DNA, and RNA. As with polypeptides, the term "nucleotide sequence" is also used at times in discussion of the actual sequence of nucleotides or bases along a polynucleotide backbone, i.e. the primary sequence.

[0045] "Homologue" means an entity having a certain degree of identity or "homology" with the subject amino acid sequences and the subject nucleotide sequences. Typically, homologues will comprise the same active site residues as the subject amino acid sequence. Homologues also retain α -amy-lase activity, although the homologue may have different enzymatic properties than the subject protein. A "homologous sequence" includes a polynucleotide or a polypeptide having a certain percent identity, e.g., at least about 80%, 85%, 90%, 95%, or 99%, with another sequence.

[0046] "Percent identity" or "percent sequence identity" means that a given percentage of bases or amino acid residues in a subject sequence or protein are exactly the same base or residue as present in a reference sequence or protein, for

example when comparing the two polypeptide sequences in an alignment. Amino acid sequences may be similar, but are not "identical" where an amino acid is substituted, deleted, or inserted in the subject sequence relative to the reference sequence. For proteins, the percent sequence identity is preferably measured between sequences that are in a similar state with respect to posttranslational modification. Typically, the "mature sequence" of the subject protein, i.e., that sequence which remains after processing to remove a signal sequence, is compared to a mature sequence of the reference protein. In other instances, a precursor sequence of a subject polypeptide sequence may be compared to the precursor of the reference sequence.

[0047] As used herein, "hybridization" includes the process by which a strand of nucleic acid joins with a complementary strand through base pairing, as well as the process of amplification as carried out in polymerase chain reaction (PCR) technologies. A nucleic acid encoding a chimeric α -amylase may exist as single- or double-stranded DNA or RNA, an RNA/DNA heteroduplex, or an RNA/DNA copolymer. As used herein, "copolymer" refers to a single nucleic acid strand that comprises both ribonucleotides and deoxyribonucleotides. The α -amylase encoding nucleic acid may be "optimized" to increase expression a specific organism by tailoring the nucleic acid to contain those codons which are preferentially utilized in translating native proteins in that organism.

[0048] As used herein, a "synthetic" compound is produced by chemical or enzymatic synthesis. Synthetic compounds include, but are not limited to, nucleic acids encoding chimeric α -amylases, preferably made with optimal codon usage for host organisms of choice for expression. A synthetic polypeptide or nucleic acid can also be prepared using in vitro techniques, such as in vitro transcription or translation, or PCR and the like.

[0049] As used herein, "transformed cell" includes cells, including both bacterial and fungal cells, that have been transformed by use of recombinant DNA techniques. Transformation typically occurs by insertion of one or more nucleotide sequences into a cell. The inserted nucleotide sequence may be a heterologous nucleotide sequence, i.e., is a sequence that is not naturally present in the cell that is to be transformed, such as a nucleic acid encoding a fusion protein or a chimeric polypeptide.

[0050] As used herein, "operably-linked" means that the described components are in a relationship permitting them to function in their intended manner. For example, a regulatory sequence can be "operably-linked" to a coding sequence in such a way that expression of the coding sequence is achieved under conditions compatible with the regulatory sequence.

[0051] As used herein, "biologically active" refers to a sequence having a similar structural, regulatory or biochemical function as the naturally occurring sequence, although not necessarily to the same degree. For example, a biologically active α -amylase is a polypeptide with measurable α -amylase activity.

[0052] "Genotoxic potential" as used herein refers to the potential for compounds, e.g. polypeptides, amylases or compositions comprising them, to be "genotoxic" in in vitro or in vivo studies. "Genotoxic" is a broad term that refers to any deleterious change in the genetic material regardless of the mechanism by which the change is induced. Genotoxic compounds, in the absence of other data, are generally presumed by regulatory bodies and researchers to be trans-species car-

cinogens, implying a hazard to humans. Accordingly, such compounds need not be subjected to long-term carcinogenicity studies. However, if such a compound is intended to be administered chronically to humans, a chronic toxicity study (up to 1 year) may be necessary to detect early tumorigenic effects. A test battery approach of in vitro and in vivo tests can be used to test for genotoxicity. The battery is preferably designed to reduce the risk of false negative results for compounds with genotoxic potential. Assessment of the genotoxic potential of a compound is preferably conducted as an independent, objective inquiry. Such an assessment preferably takes into account the totality of the findings and the intrinsic value and limitations of both the in vitro and in vivo tests. A single positive result in any assay for genotoxicity does not necessarily mean that the test compound poses a genotoxic hazard to humans. Genotoxic potential is preferably assessed in accordance with official guidelines, such as the "ICH Guideline on Specific Aspects of Regulatory Genotoxicity Tests". The guidance on genetic toxicity testing provided by FDA's Center for Food Safety and Applied Nutrition (58 FR 16536, Mar. 29, 1993) is also considered to be applicable for determination of genotoxic potential herein.

[0053] As used herein the term "starch" refers to any material comprised of the complex polysaccharide carbohydrates of plants. Starches generally comprise amylose and amylopectin with the formula $(C_6H_{10}O_5)_x$, wherein X can be any integer. The term "granular starch" refers to raw, i.e., uncooked starch, e.g., starch that has not been gelatinized. "Starch derivative" as used herein refers to any modified or derivatized starch, e.g. any starch altered by physical or chemical treatment to give altered properties for food processing or other use. Such changes can include altered gelling properties, flow properties of the dry starch or a slurry prepared therefrom, color, clarity, stability of a slurry or paste, and the like. For example, as used in confectionery products, acid-modified starch results from acid treatment that reduces the viscosity of a slurry or paste made therefrom. Chemical derivatives of starch, such as ethers and esters, show properties such as reduced gelatinization in hot water and greater stability to acids and alkalis ('inhibited' starch). Examples of starch derivatives include dextrin roasted starches, acidtreated starches, alkaline treated starches, bleached starch, oxidized starch, enzyme-treated starch, monostarch phosphate, distarch phosphate, phosphated distarch phosphate, acetylated distarch phosphate, starch acetate, acetylated distarch adipate, hydroxypropyl starch, hydroxypropyl distarch phosphate, and starch sodium octenylsuccinate, as well as various salts or esters, particularly fatty acid esters of the foregoing.

[0054] As used herein the term "saccharification" refers to enzymatic conversion of starch to glucose.

[0055] The term "liquefaction" refers to the stage in starch conversion in which gelatinized starch is hydrolyzed to give low molecular weight soluble dextrins. The term "degree of polymerization" (DP) refers to the number (n) of anhydro-glucopyranose units in a given saccharide. Examples of DP1 are the monosaccharides glucose and fructose. Examples of DP2 are the disaccharides maltose and sucrose. A "comparable liquefaction process" as used herein refers to a control processed for liquefaction. The liquefaction processes are conducted under controlled conditions, e.g. the liquefaction process comprises specified conditions of temperature, pH, calcium ion concentration, and substrate concentration. Comparable liquefaction processes provide a means to compare

different enzymes or enzyme blends in their ability to liquefy a starch by controlling for as much as possible except the differences in enzymes. As used herein "facilitating liquefaction" or "facilitating a liquefaction process" encompasses any degree of improvement in liquefaction of a starch slurry, such as making a liquefaction process more efficient, more effective, more economical, or easier (facile). The term includes reducing the number or amount of enzymes required, reducing the peak or final viscosity of the starch slurry, increasing the rate or extent of starch degradation, or the production of fragments of any particular DP, or of limit dextrins. Facilitating liquefaction also includes reducing the net energy requirements, improving the utilization of substrate, or improving other conditions such as the calcium ion concentration or tolerance of changes in calcium ion, ability to use different starch (i.e., substrate) sources, types, or concentrations, ability to operate at preferred pH levels or ranges, quantity and quality of the resultant product, and the like.

[0056] As used herein the term "dry solids content" (ds) refers to the total amount of solids in a slurry, on a dry weight basis. Dry solids content and dry weight basis are usually expressed as the weight of the subject material as a percentage of the weight of the total dry material. The term "slurry" refers to a mixture containing insoluble solids in a liquid, typically water or a similar solvent. Starch or flour is frequently suspended in a water-based solution to form a slurry for testing amylases, or for liquefaction processes.

[0057] The term "DE," or "dextrose equivalent," is defined as the percentage of reducing sugar as a fraction of total carbohydrate.

[0058] As used herein, the terms "fermentation" or "fermentation process" refer to the breakdown of organic substances and re-assembly into other substances, and as used here can encompass any process of "industrial fermentation," "biochemical fermentation," or "food fermentation." "Industrial fermentation" generally refers to highly oxygenated and aerobic growth conditions, whereas "biochemical fermentation" generally refers to a strictly anaerobic process. Carbohydrate substrates are required as a source of energy for the vast majority of industrial fermentation process to produce a variety of pharmaceuticals and precursors, as well as food ingredients. Where a fermentation is specified herein for use in the production of alcohol, e.g. ethanol, such as for fuel production, it is generally an oxygen-limited, oxygen-deprived, or even completely anaerobic process. Bio-fuels are fuels from renewable resources, for example ethanol derived from fermentation of a carbohydrate substrate. "Food fermentations" include fermentation processes to make alcoholic beverages (e.g. beer, wine), bread, and other fermented food products. Preferred food fermentations are those that result in the production of alcohol or food acids from carbohydrate substrates.

[0059] "Food processing aids" as used herein refers to substances used as manufacturing aids to enhance the appeal or utility of a food or food component, including clarifying agents, clouding agents, catalysts, flocculents, filter aids, and crystallization inhibitors, etc. Food processing aids are generally defined by regulatory bodies such as the Food and Drug Administration in the United States, Food Standards Australia New Zealand, or the Commission Regulation of the European Economic Community (EEC). See for example 21 C.F. R. §§170.3(o) "Definitions" describing the physical or technical functional effects for which direct human food ingredients may be added to foods in the United States. The definition provided therein, including those for "processing aids" are adopted from the National Academy of Sciences/National Research Council National Survey of Food Industries, reported to the Food and Drug Administration under the contract entitled "A Comprehensive Survey of Industry on the Use of Food Chemicals Generally Recognized as Safe" (September 1972), which is incorporated by reference in its entirety. Copies of that report are available from the National Technical Information Service (NTIS), 5285 Port Royal Rd., Springfield, Va. 22161, or at the National Archives and Records Administration (NARA).

[0060] As used herein, "stabilizing structures" refer to primary, secondary, tertiary, or quaternary structures that make a protein more stable, particularly more thermostable as defined hereinabove. Proteins are "stable" if under a given set of conditions they remain properly or adequately folded. Stabilizing structures in accordance herewith are formed by one or more stabilizing mutations. Some means of stabilizing proteins are not deemed "stabilizing structures" for purposes herein. Thus, basic ways of achieving improved stability are as diverse as using increased or decreased ion concentrations, inorganic solvents, using higher or lower protein concentrations, adding helper proteins, optimizing storage temperatures, or removing proteases from the medium. For example, calcium binding proteins and many enzymes that use calcium as a co-factor are normally more stable at higher calcium concentrations. For purposes herein, however, "stabilizing structures" do not encompass environmental factors and the like, but rather are chemical structures that lie within or result from the primary or higher order sequence, and alter the stability of the protein.

[0061] "Helix capping" is a stabilizing strategy that is known in the art and useful herein. "Helix-capping motifs" are stabilizing structures that comprise specific patterns of hydrogen bonding and hydrophobic interactions found at, or near, the ends of helices in proteins and peptides. The consensus sequence patterns of such motifs, together with results from simple molecular modeling, have been used to formulate useful rules of thumb for helix termination. See, e.g., Aurora and Rose, "Helix capping" Protein Science, 7(1):21-38 (1998, Cold Spring Harbor Laboratory Press). See also Presta and Rose, "Helix signals in proteins." Science, 240: 1632-1641 (1988)

[0062] "Salt bridge," as used herein, refers to hydrogen bonds between oppositely-charged amino acid residues (e.g. Asp-Arg) in the primary sequence of a polypeptide. Salt bridges contribute to the stability of a protein when the charges are 6-8 Angstroms or less away from each other. Thus, the charged residues may be widely separated in the primary amino acid sequence provided that, when folded, the charged residues come within the required proximity for interaction of the charges. Salt bridges typically work better when combined with other salt bridges. Thus, an array of charge residues, e.g. +, -, +, -, works better than one or two pairs of charged residues that are remote from each other in the structure. For example, extremophilic proteins, i.e. proteins from extremophiles, such as thermostable proteins, often have many salt bridges. An introduced salt bridge works better if the residues involved have only limited freedom in the folded protein.

B. Abbreviations

[0063] The following abbreviations apply unless indicated otherwise:

- [0064] AmyL Bacillus licheniformis α-amylase
- [0065] Amy Q Bacillus amyloliquefaciens α-amylase
- AmyS Bacillus stearothermophilus α -amylase [0066]
- [0067] AAU alpha amylase units
- ATCC American Type Culture Collection [0068]
- [0069] cDNA complementary DNA
- [0070] C.F.R. Code of Federal Regulations
- [0071] CFU colony forming units
- [0072]DE Dextrose Equivalent
- [0073] DEAE diethylaminoethanol
- [0074] DNA deoxyribonucleic acid
- [0075] DNS 3,5-dinitrosalicylic acid
- [0076] DPn degree of polymerization with n subunits
- [0077]ds dry solids
- [0078] EC Enzyme Commission for Enzyme Classification
- [0079] EEC European Economic Community
- [0080] EDTA ethylenediaminetetraacetic acid
- [0081] EGTA ethyleneglycoltetraacetic acid
- [0082] FDA Food & Drug Administration
- [0083] FAO Food and Agriculture Organization of the United Nations
- [0084] GLP Good Laboratory Practices
- GMP Good Manufacturing Practices [0085]
- [0086] GRAS Generally Recognized As Safe
- [0087] HFCS high fructose corn syrup
- [0088] HPLC High Performance Liquid Chromatography
- [0089] HS higher sugars (DPn, where n>3)
- [0090] JECFA Joint FAO/WHO Expert Committee on Food Additives
- [0091] kb kilobase
- [0092] kJ kiloJoule
- [0093] LAT B. licheniformis α -amylase
- [0094] LU liquefaction units
- [0095] mRNA messenger ribonucleic acid
- [0096] mg milligram
- [0097] mL milliliter
- [0098] mt metric ton (1000 kg)
- [0099] N Normal
- [0100] NTIS National Technical Information Service
- [0101] PCR polymerase chain reaction
- [0102] PEG polyethyleneglycol
- [0103] ppm parts per million
- [0104] RO Reverse osmosis
- [0105] RT-PCR reverse transcriptase polymerase chain reaction
- [0106] SB salt bridge
- [0107] SDS-PAGE sodium dodecyl sulfate-polyacrylamide gel electrophoresis
- [0108] SGA Superior Grain Amylase
- [0109] SKBU/g ds α -Amylase Unit per gram of dry solids. One α-Amylase Unit dextrinizes 1.0 g of limit dextrin substrate per hour under the conditions of the assay.
- [0110] 1× SSC 0.15 M NaCl, 0.015 M sodium citrate, pH 7.0
- [0111] WHO World Health Organization
- [0112]
- w/v weight/volume
- [0113] w/w weight/weight

[0114] μg microgram [0115] μL microliter

C. Chimeric α-Amylases

[0116] In a first of several aspects, chimeric polypeptides having a length of about 480-515 amino acid residues are provided. The chimeric polypeptides have an amino-terminal domain that comprises about 180 or more contiguous amino acid residues of an N-terminal portion of an AmyL amylase, and a carboxy-terminal domain comprises a carboxy-terminal portion of an AmyS amylase. The chimeric polypeptides do not have the primary amino acid sequence of either the AmyL amylase or the AmyS amylase, however, the chimeric polypeptides have enhanced thermostability relative at least to the AmyS amylase.

[0117] Known amylase sequences are not encompassed by the chimeric polypeptides or thermostable chimeric amylases described herein. For example the sequences disclosed in J. Biochem. Mol. Biol. 40: 315-324 (2006) by Sajedi et al. are specifically excluded. The α -amylase sequences provided in the public databases of the European Molecular Biology Laboratories (EMBL) or the National Center for Biotechnology Information (NCBI) more than one year prior to the filing date of this disclosure are also expressly excluded as sequences for the chimeric polypeptides and thermostable amylases provided herein. In one embodiment, the chimeric polypeptide or thermostable amylase does not have the sequence of any other known α -amylase, such as those disclosed in U.S. Pat. Nos. 6,939,703 by Van Der Laan and Aehle, 6,143,708 by Svendsen et al., or 5,830,837 by Bisgård-Frantzen et al.

[0118] The chimeric polypeptides generally comprise the catalytic activity of an α -amylase. In common usage, alphaamylase attacks the random alpha-1,4 linkages of a substrate such as amylose and/or amylopectin of starch, converting them to dextrins. In the process of doing so, the α -amylase reduces the viscosity and increases the dextrose equivalence (DE). The alpha-amylase enzyme is thus frequently used to liquefy and dextrinize starch, typically in slurries for the production of syrups or prior to fermentation of complex carbohydrates. They are also used for starch removal, e.g. cleaning processes, as well as in baking and other applications.

[0119] The chimeric polypeptides demonstrate altered performance characteristics relative to other α -amylases such as AmyL or AmyS. Such characteristics may include altered stability, pH range, oxidation stability, and thermostability. In particular, in various embodiments, the chimeric polypeptides provide better stability at high temperatures (i.e., 70-120° C.). They may also have advantageous properties in their requirement for calcium, resistance to changes in calcium ion concentration, and/or increased tolerance to pH extremes (i.e., pH 4.0 to 6.0, or pH 8.0 to 11.0) for activity. [0120] Many known thermostable amylases can degrade starch at temperatures of about 55° C. to about 80° C. or more. A chimeric polypeptide as provided herein may retain α -amylase activity after exposure to temperatures of up to about 95° C. or more. Thus, the chimeric polypeptides and thermostable chimeric amylases as provided herein are advantageous for use high temperature liquefaction, as well as in other processes that employ or require elevated temperatures, such as cooking, baking or the like.

[0121] In one embodiment, the chimeric polypeptides comprise at least one substituted amino acid residue in the N-ter-

minal domain, relative to the AmyL amylase, i.e. the portion of the chimera that corresponds to the contiguous amino acids of the chimera's N-terminal portion has a substitution relative to the sequence found in the AmyL amylase's N-terminal portion. Such a substitution preferably serves to provide a stabilizing structure, or at least a part of a stabilizing structure that enhances thermostability of the polypeptide. Various stabilizing structures may be known to those of skill in the art generally with respect to thermostability of proteins. Any such structures will suffice in various embodiments of the chimeric polypeptide. As defined above, "stabilizing structures" are primary, secondary, tertiary, or quaternary structures that make a protein more stable, particularly more thermostable as defined hereinabove.

[0122] Stabilizing structures in accordance herewith are formed by one or more stabilizing mutations that form chemical structures that lie within, or result from, the primary or higher order sequence, and alter the stability of the protein.

[0123] Proteins transition between folded and unfolded states. Stabilizing structures shift the equilibrium between folded and unfolded proteins towards the folded state (i.e., towards the left in the equilibrium: folded protein <-> unfolded protein). It is known in the art how to shift this equilibrium further to the left, i.e. to make a protein more stable. Modifications that destabilize the unfolded form and/ or stabilize the folded form are equally desirable as stabilizing structures. Methods for determining what structures will be stabilizing in a particular protein are known in the art. One approach to adding stabilizing structure include the use of amino acid residues that more stable members of the same protein family already use at that position. Thus, study of multiple sequence alignments of proteins from different origins is useful.

[0124] Helix capping, as defined above is one strategy for generating stabilizing structures that is known in the art and useful herein. Helix-capping motifs are stabilizing structures that comprise specific patterns of hydrogen bonding and hydrophobic interactions found at, or near, the ends of helices in proteins and peptides. Helix capping has been considered a bridge linking the conformation of secondary structure to super-secondary structure. In an α -helix, the first four >N—H groups and last four >C=O groups necessarily lack intrahelical hydrogen bonds. Instead, such groups are often capped by alternative hydrogen bond partners. Distinct capping motifs have been identified, some at the helix N-terminus and others at the C-terminus. The consensus sequence patterns of such motifs, together with results from simple molecular modeling, have been used to formulate useful rules of thumb for helix termination. See, e.g., Aurora and Rose, "Helix capping" Protein Science, 7(1):21-38 (1998, Cold Spring Harbor Laboratory Press). See also Presta and Rose, "Helix signals in proteins." Science, 240:1632-1641 (1988).

[0125] Increasing entropic stabilization (e.g. by substituting Gly -> X, or X -> Pro, where X is any amino acid residue) is another strategy for generating stabilizing structures. Other strategies include adding one or more disulphide bridges, filling cavities within the three-dimensional structure, especially when combined with entropic stabilization, e.g. Gly -> Ala, adding one or more salt bridges, particularly surface salt bridges, eliminating buried water molecules (e.g. substituting Ala -> Ser), improving hydrogen bonding, improving helix structure (e.g. "helix propensity") in helical portions or domains, improving strand structure (e.g. "strand propensity") in domains that form strands. Preferably, stabilizing

structures are introduced through substitution or mutation of one or more surface amino acid residues, however, substitution or mutation of amino acid residues buried within a higher level protein structure, or in the interior of a folded protein can also be useful for stabilizing. Stabilizing structures such as those described above and others known in the art can be incorporated rationally into known protein sequences using one or more stabilizing point mutations ("stabilizing mutations").

[0126] Stabilizing structures in general provide a decrease in the Gibbs free energy (Δ G) of the folded protein relative to the unfolded protein (thereby shifting the thermodynamic equilibrium between folded and unfolded protein towards the folded form). Stabilizing structures herein also provide energy to the structure, or require a certain amount of energy to break. For example, entropic stabilization requires about 2-5 kJ/M to disrupt, while helix capping requires a range of about 1-8 kJ/M (average of about 4 kJ/M). Hydrogen bonds provide 1-6 kJ/M, hydrophobic interaction provide a gain of about 100 J/M for each square Angstrom of such interaction. A salt bridge can provide up to 5 kJ/M, and a cysteine bridge (i.e. disulfide bridge) provides –10 to 10 kJ/M.

[0127] In one embodiment, the stabilizing structure is a salt bridge formed, at least in part, by the substituted amino acid residue. As defined herein, salt bridges comprise hydrogen bonds between oppositely-charged amino acid residues in the primary sequence of a polypeptide. Salt bridges with residue charges that are 6-8 Angstroms, or less, away from each other in a folded polypeptide, are preferred herein. Thus, the charged residues may be widely separated in the primary amino acid sequence provided that, when folded, the charged residues come within the required proximity for interaction of the charges. Salt bridges work better in combination with other salt bridges. Arrays of charged residue, e.g. +, -, +, -, work better than only one or two pairs of charged that are remote from each other in the structure. Preferably therefore, more than one salt bridge is introduced. Some polypeptides and amylases provided in accordance herewith have many salt bridges. In one embodiment the amino acid residues involved introduced salt bridge have only limited freedom in the folded protein.

[0128] The substituted amino acid residue corresponds to position 187 in the AmyL amylase, in one embodiment. In certain embodiments, an Asp and a Thr residue are substituted in the chimeric polypeptide for consecutive Ser residues (i.e., Ser Ser) in the AmyL amylase (Asp190 and Thr191 are the cognate positions in AmyS). Surprisingly, it was found that such substitutions, e.g. S187D-S188T, substantially increase the thermostability of the chimeric polypeptides in the context of the AmyL-AmyS hybrids or chimeras as provided herein. As discussed more fully in the working examples provided herewith, other researchers have previously reported that any S187D substitution in other contexts (e.g. in an AmyL-type sequence) results in a loss of, or decrease in, thermostability. Other substitutions, such as other acidic residues may be substituted in the chimera for other residues naturally present in a particular AmyL amylase. In one embodiment, the AmyL amylase on which the N-terminal contiguous amino acids are based has the amino acid sequence of SEQ ID NO: 1. The AmyS amylase has the amino acid sequence of SEQ ID NO: 2 in other embodiments. In presently preferred embodiments, the AmyL and AmyS have the sequences provided as SEQ ID NOs: 1 and 2, respectively. **[0129]** The chimeric polypeptides provided herein have, in various embodiments, at least about 95% sequence identity to any of SEQ ID NOS: 1-17. Notwithstanding the sequence identity, the skilled artisan will appreciate that the chimeric polypeptides provided in accordance herewith may not have the precise or exact amino acid sequence of SEQ ID NO: 1 or 2. In one embodiment, the chimeric polypeptide has at least about 95% sequence identity to one of SEQ ID NOs: 1-17, and specifically has an Asp residue substituted in the chimeric polypeptide for a Ser reside at position 187 in the AmyL amylase (numbering corresponding to amino acid sequence in AmyL).

[0130] As discussed above, the chimeric polypeptides provided herein preferably comprise the catalytic activity of an α -amylase. The amylase preferably retains at least about 50% of its activity after incubation at 95° C. for about 20, 30, 40, 50, or 60 or more minutes. In one embodiment, the chimeric polypeptide has an amylase activity that retains at least about 50%, 60%, 65%, 70%, 75%, 80%, 85% or more of its activity after incubation at 95° C. for about 60 minutes, or even at least about 80% of its activity after incubation at 95° C. for about 60, 65, or 70 minutes, or even about 75, 80, 85 or more minutes. In one embodiment, a decrease in activity, if any, is not greater than the corresponding decrease in an AmyL amylase from which the chimeric sequence was obtained in part, even after incubation for 90 or more minutes at 95° C. Thus, in some embodiments, there is no significant or measurable loss in activity for that time period.

[0131] In one embodiment, the chimeric polypeptides provided comprises a catalytic activity of an α -amylase that has greater specific activity than the AmyL amylase from which the amino-terminal portion was derived, at least in part.

[0132] In another aspect, provided herein are thermostable chimeric α -amylases. The chimeric amylases have many properties in common with the chimeric polypeptides provided above. The thermostable chimeric amylases have an N-terminal portion comprising a contiguous amino acid sequence from an N-terminal portion of an AmyL amylase, and a C-terminal portion comprising a contiguous amino acid sequence from a C-terminal portion of an AmyS amylase. The thermostable chimeric amylases have a specific activity greater than the AmyL amylase and greater thermostable amylases have a primary amino acid sequence that is about 475-520 residues long.

[0133] The thermostable chimeric amylases provide a number of applied benefits, or performance benefits. For example, in one embodiment, the thermostable amylases are characterized in that when used in a liquefaction process for a starch slurry, the chimeric amylases reduce peak viscosity of the starch slurry as well as the AmyS amylase does in a comparable liquefaction process. The thermostable chimeric amylases also reduce final viscosity of the starch slurry as well as the AmyL amylase does in a comparable liquefaction process. For purposes herein, a "comparable liquefaction process" means that the processes are conducted under controlled conditions, e.g., the liquefaction process comprises specified conditions of temperature, pH, calcium ion concentration, and substrate concentration.

[0134] The thermostability is frequently expressed herein as the amount time that the amylase retains activity after incubation at 95° C. In one embodiment, the chimeric amylase retains at least 50% of its activity after incubation at 95° C. for about 30, 40, 50 or even 60 or more minutes. In another,

it retains at least about 60, 70 or even 80% of its activity after incubation at 95° C. for about 60 or more minutes.

[0135] In one embodiment, the Amy L amylase has the sequence of SEQ ID NO: 1 and the AmyS amylase has the sequence of SEQ ID NO: 2. The chimeric amylase has at least about 95% sequence identity to any of SEQ ID NOS: 1-17, but is not the amylase of SEQ ID NO: 1 or 2, as described above for the chimeric polypeptides.

[0136] The chimeric amylases further comprise at least one substituted amino acid residue in the N-terminal domain, relative to the AmyL amylase, so as to provide at least a part of a stabilizing structure that enhances thermostability of the polypeptide. Stabilizing structures are discussed for chimeric polypeptides and that discussion applies equally to thermostable chimeric amylases. The stabilizing structure is preferably a salt bridge formed, at least in part, by the substituted amino acid residue, also as discussed above. As with the chimeric polypeptides, the substituted amino acid residues correspond to one or both of positions 187 and 188 in the AmyL or AmyS amylase, and more particularly comprise one Asp residue and/or one Thr residue substituted in the chimeric polypeptide for one Ser residue, or if both an Asp and a Thr residue, for two consecutive Ser residues in the AmyL amylase.

D. Compositions Comprising Chimeric a Amylases

[0137] Also provided are a variety of compositions comprises one or more chimeric polypeptides having the catalytic activity of an α -amylase, or thermostable chimeric amylases. The compositions include for example, enzyme concentrates, enzyme blends, purified enzymes, partially purified enzyme products, food additives, and cleaning products containing the chimeric α -amylase.

[0138] Such compositions have a variety of uses. The compositions can also provide more than one chimeric polypeptide or anylase, or other anylases, or a combination thereof. The compositions can be highly purified or only partially purified. They are standardized in terms of units of activity in certain embodiments. The compositions can be provided in a variety of physical forms including liquids of various concentrations and purity, gels, cakes, semisolids, or solids. The compositions are amenable to any physical form provided that measurable activity remains in the final composition. Thus, the compositions can be conveniently lyophilized, concentrated, frozen, spray-dried, or otherwise processed in a variety of known or useful manners. The compositions can be provided in standard sizes for certain commercial applications, or custom packaged.

[0139] In one embodiment, the composition includes a chimeric amylase as described or exemplified herein. Provided are particular compositions comprising one or more of:

[0140] (a) a chimeric polypeptide, such as that described above, having a length of about 480-515 amino acid residues, and having an amino-terminal domain comprising about 180 or more contiguous amino acid residues of an N-terminal portion of an AmyL amylase, and a carboxy-terminal domain comprising a carboxy-terminal portion of an AmyS amylase, the chimeric polypeptide having enhanced thermostability relative at least to the AmyS amylase,

[0141] (b) a thermostable chimeric α -amylase about 475-520 amino acid residues long, having an N-terminal portion comprising a contiguous amino acid sequence from an N-terminal portion of an AmyL amylase, and a C-terminal portion comprising a contiguous amino acid sequence from a C-terminal portion of an AmyS amylase, the chimeric α -amylase having a specific activity greater than the AmyL amylase and also having greater thermostability at 95° C. than the AmyS amylase; and

[0142] (c) any combination of (a) a chimeric polypeptide and (b) a thermostable chimeric amylase.

[0143] The compositions may further comprise one or more additional polypeptides. The skilled artisan will appreciate the one or more additional polypeptides can comprise any known enzyme activity. Thus, any of a variety of additional enzymes can be added to provide further utility or convenience to the compositions. In various embodiments, the additional enzyme can comprise one or more of bacterial β-amylases, e.g., BBA, fungal α-amylases, e.g., Clarase® L, or glucoamylase, isoamylases, isomerases, proteases, such as fungal and bacterial proteases, cellulases, lignases, hemicellulases, lipases, phospholipases, and cutinases. Compositions comprising one or more chimeric α -amylases as disclosed herein, together with a combination of any one or more of the foregoing, are contemplated for use herein. As disclosed above, fungal proteases include, for example, any proteindegrading enzyme activities obtained from Aspergillus spp., such as A. niger, A. awamori, A. oryzae; Mucor spp., e.g., M. *miehei; Rhizopus* spp., and the like. β -amylases (EC 3.2.1.2) are exo-acting maltogenic amylases, which catalyze the hydrolysis of 1,4- α -glucosidic linkages into amylopectin and related glucose polymers, thereby releasing maltose. β -amylases have been isolated from various plants and microorganisms. See Fogarty et al., in PROGRESS IN INDUSTRIAL MICRO-BIOLOGY, Vol. 15, pp. 112-115 (1979). These β -amylases have optimum temperatures in the range from 40° C. to 65° C. and optimum pH in the range from about 4.5 to about 7.0. Contemplated β -amylases include, but are not limited to, β-amylases from barley Spezyme® BBA 1500, Spezyme® DBA, OptimaltTM ME, OptimaltTM BBA (Genencor International, Inc.); and Novozym[™] WBA (Novozymes A/S).

[0144] The compositions in one embodiment are prepared or formulated for use as a food additive or as a processing aid suitable for use in food processes. A food-grade lyophilized composition comprising a chimeric polypeptide or thermostable chimeric amylase as disclosed herein is also provided. Such compositions are useful for cooking and baking applications, as well as any high-temperature applications where starch properties need to be altered, in terms of DP.

[0145] When prepared or formulated for use as a food additive or for use in food processes, the compositions must meet or exceed certain regulatory requirements. These requirements serve as a guide to the skilled artisan in preparing the compositions. Accordingly, the skilled artisan will appreciate that although the regulatory requirements may differ in various countries, generally the composition will be very low in heavy metal content, as well as low in lead and arsenic. Specifically, the total heavy metal content is preferably does not exceed about 40 ppm, and more preferably is less than about 30 ppm. The lead content of the compositions does not exceed about 10 ppm, and more preferably is less than about 5 or 3 ppm. The arsenic content of the composition is less than about 3 ppm. The compositions are also negative for mycotoxin and antibacterial content, when tested be standard methods.

[0146] The compositions are also clean with respect to their microbiological content, preferably being produced under GMP or GLP standards at a minimum when intended for food additive use or as food processing aids. In particular, the total viable count will not exceed about 5×10^4 CFU per gram of

composition. The compositions will preferably have a coliform count that does not exceed about 40 CFU per gram of composition. More preferably the count of coliforms will not exceed about 30 CFU per gram. Further, the compositions have no detectable *Salmonella* or *Shigella*, as measured by standard microbiological methods. Where the chimeric amylases are produced in host cell, the compositions will have less than 1 CFU of the organism per gram.

[0147] Further, the compositions possess a satisfactory standard of safety in terms of toxicity and the like. In one embodiment, the compositions show no genotoxic potential in suitable in vitro assays. The compositions also show no toxic effects in acute and/or sub-chronic dosing studies in animals.

[0148] For purposes of food additive or food processing aids, the production is preferably standard, as for many commercially used food enzymes. Thus, GMPs are used throughout the production process, meeting the requirements and specifications for food enzymes established for example, by the FDA, or international authorities, e.g., Food Chemicals Codex (4th Edition, 1996), the Joint FAO/WHO Expert Committee on Food Additives (JECFA) in the Compendium of Food Additives Specifications, Vol. 1, Annex 1 Addendum 9 (2001) (and earlier relevant Addenda). For example, the compositions comprising the chimeric α -amylase are produced using a process such as a fed-batch fermentation, e.g. a submerged fed-batch fermentation in an organism that is generally recognized as safe, or which has a long history of use for such purposes, for example for the production of food-grade enzyme preparations.

[0149] For some purposes herein, suitable organisms include Gram-positive bacteria from the genus *Bacillus* including, for example, *B. stearothermophilus*, *B. subtilis*, *B. licheniformis*, *B. brevis*, and *B. amyloliquefaciens*. Others including *B. coagulans*, *B. circulans*, *B. lautus*, *B. lentus*, *B. thuringiensis*, and *B. alkalophilus* may also be useful. Other Gram-positive bacteria that may be useful for production of some of the compositions described herein include *Strepto-myces lividans*, and *S. murinus*. Gram-negative bacteria, including *Escherichia coli* or a *Pseudomonas* species, may also be used to produce certain of the compositions provided herein.

[0150] Also provided herein are compositions comprising chimeric polypeptides and thermostable chimeric α -amylases that are useful to facilitate removal of a substrate for the enzyme (e.g. starch) from a variety of nonstarch (thus, nonsubstrate) materials, such as textiles, paper, glass, plastic, metal, canvas, porcelain, and the like. Because such materials are frequently removed during washing or cleaning processes, the compositions in one embodiment includes one or more soaps, detergents, cleaning agents, oxidants, or chelators. In one embodiment, the composition is a used a laundry detergent, in another it is a dishwashing detergent. The compositions, for these and other purposes described herein, may be formulated as gels. A variety of such gels are known in the art and provide certain advantages, for example, with respect to contact time and conditions for the enzyme to work on the substrate to be removed, in addition to an appealing and convenient usage form for consumers or users. The inclusion of standard cleaning agents, as well as detergents, soaps, oxidants, and/or chelators requires that the α -amylase activity be somewhat tolerant of the conditions found not only in the end-use, and preferably in the more concentrated or extreme conditions found in the product itself.

E. Characterization of the Chimeric Amylases

[0151] Proteins and enzymes such as the chimeric polypeptides and thermostable α -amylases provided herein can be characterized by a variety of methods and techniques known in the art. The nucleic acid and primary polypeptide sequences are useful means of comparing and analyzing the amylases provided herein. Three dimensional structural modeling, and/or physical crystallization are also useful. Determination of specific activity is frequently used characterize enzymes. Enzyme activity under a variety of conditions of substrate, temperature, pH, calcium concentration, and other factors can be assessed using standard assays known to the artisan skilled in this field, or by designing new assays based on known techniques of assaying amylases. Determining kinetic properties of the enzyme, including kinetic constants, such as V_{max} or K_m under specified conditions, is also useful for characterizing the chimeric amylases provided herein. Methods for determining the optimal pH for stability or for assay are known in the art, as are methods for determining the optimal calcium ion concentration for maximum activity and conditions for maximal stability during storage of the chimeric polypeptides and thermostable amylases.

[0152] Characterizing expression of the chimeric polypeptides and thermostable α -amylases in a host cell can be a useful characteristic, for example in determining the commercial potential of a process of making the chimeric proteins and enzymes. To evaluate the expression of the chimeric polypeptides and thermostable chimeric α -amylases in a host cell, one can measure the amount of expressed protein, the presence or amount of corresponding mRNA, or the enzyme activity (e.g., by monitoring conversion of a substrate to a product). Suitable assays include Northern and Southern blotting, RT-PCR (reverse transcriptase polymerase chain reaction), and in situ hybridization, using an appropriately labeled hybridizing probe. Measurements of the amount of expression of the chimeric polypeptides and thermostable chimeric α -amylases produced in a particular host cell, the rate of expression, or the maximal recovery are all examples of useful characteristics related to expression of the chimeric polypeptides and thermostable chimeric α -amylases provided herein.

[0153] Because the chimeric polypeptides and thermostable chimeric α -amylases have altered properties with respect to thermostability and specific activity, in certain embodiments they also have altered stability to oxidants, detergents, or chelators, in comparison to an α -amylase, such as an AmyL or AmyS enzyme. Thus, it may be useful to test the chimeric polypeptides and thermostable chimeric α -amylases that also provide such properties to find more useful α -amylases. For example, increased stability to oxidants, detergents, chelating agents, or even soaps, may be advantageous in compositions for cleaning processes, such as washing, dishwashing, textile desizing, or stain removal. The skilled artisan will appreciate that characterization of enzymes with respect to their stability or tolerance of cleaning agent, e.g. detergents, oxidants, chelators, or soaps, can be done by either exposing the polypeptide to the desired condition, including the cleaning agent, then assaying the activity under standard conditions, or by assaying the activity under the desired condition, including the cleaning agent. The former provides information about the stability of the

polypeptide to the harsh conditions. The latter provides information about the ability of the enzyme to have catalytic activity under the harsh conditions.

[0154] The chimeric polypeptides and thermostable chimeric α -amylases described herein can also exhibit extended half-life at a given temperature, relative to the AmyS or AmyL enzymes. In various embodiments, half-life can be increased by about 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, 200%, or more, particularly at elevated temperatures of about 55° C. to about 95° C. or more, particularly at about 80° C. or above. As described hereinabove, chimeric polypeptides and thermostable amylases with enhanced stability at 95° C. or above, relative to the α -amylases from which the chimera is derived, particularly the AmyS, are particularly useful.

[0155] In one embodiment, the chimeric polypeptides and thermostable chimeric α -amylases provided herein have the same pH stability as an amylase from which the chimera is derived, such as an AmyL-type or AmyS-type amylase. In another aspect, the chimeric polypeptides and thermostable amylases exhibit a greater range of stability to pH changes, or pH optimum or stable ranges are shifted to a desired area for the end commercial purpose of the enzyme. For example, in one embodiment, the chimeric polypeptides and thermostable amylases can degrade starch at about pH 4.5 to about pH 10.5. The chimeric polypeptides and thermostable amylases may have a longer half-life or higher activity (depending on the assay) relative to AmyL or AmyS under identical conditions. The chimeric α -amylase polypeptide also may have about 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, 200% or longer half-life under identical pH conditions. In another embodiment, the chimeric α -amylase may have higher specific activity, as compared to an AmyL or AmyS, under identical pH conditions. The chimeric polypeptides and α -amylases provided may have any combination of desirable characteristics listed herein.

F. Polynucleotides Encoding the Chimeric α-Amylases

[0156] In another of it several aspects, provided are polynucleotides that encode a chimeric polypeptide as described herein. Because the encoded polypeptides are not found in nature, the polypeptides must be made by the hand of man, e.g. synthesized or perhaps created through a directed mutagenesis and screening program. Specifically, the polynucleotides encode either of:

[0157] (a) a chimeric polypeptide having a length of about 480-515 amino acid residues, and having an amino-terminal domain comprising about 180 or more contiguous amino acid residues of an N-terminal portion of an AmyL amylase, and a carboxy-terminal domain comprising a carboxy-terminal portion of an AmyS amylase; the chimeric polypeptide having enhanced thermostability relative at least to the AmyS amylase, or

[0158] (b) a thermostable chimeric α -amylase about 475-520 amino acid residues long, and having an N-terminal portion comprising a contiguous amino acid sequence from an N-terminal portion of an AmyL amylase, and a C-terminal portion comprising a contiguous amino acid sequence from a C-terminal portion of an AmyS amylase, said chimeric α -amylase having a specific activity greater than the AmyL amylase, and greater thermostability at 95° C. than the AmyS amylase. **[0159]** In one embodiment, the polynucleotide encodes a polypeptide having at least about 95% sequence identity to any of SEQ ID NOS: 1-17. In various embodiments, the encoded polypeptide has at least about 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% sequence identity to any of SEQ ID NOS: 1-17; however, the polypeptide does not have the exact sequence of SEQ ID NOS: 1 or 2.

[0160] Presently preferred polynucleotides are exemplified in the sequence listing as SEQ ID NOS: 18-34, encoding, respectively, the polypeptides having amino acid sequences of SEQ ID NOS: 1-17. As the skilled artisan will appreciate, considerable variation among polynucleotides is possible without significant changes to an encoded amino acid sequence. In particular, substantial codon variation is possible because of redundancy in the genetic code (e.g. "wobble"), and because of codon usage preferences among different organisms. Accordingly, in various embodiments, the polynucleotides useful herein have sequences that are 60% or more identical to the polynucleotides of SEQ ID NOS: 18-34. More preferred are polynucleotides having sequences with 65, 70, 75, or 80% sequence identity to SEQ ID NOS: 18-34. Polynucleotides with greater than 80% identity, for example, 85, or 90% identity are also preferred for use herein. Similarly, polynucleotides with at least about 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% sequence identity to any of SEQ ID NOS: 18-34 are also useful herein. The foregoing discussion for all of the polynucleotides is subject to the proviso that in no case should an encoded polypeptide have the exact sequence of SEQ ID NOS: 1 or 2, nor should the polynucleotide have 100% sequence identity with either of SEQ ID NO: 18 or 19. The skilled artisan will appreciate that for use in the construction or making of the novel chimeric amylases, polynucleotides having sequences 100% identical to SEQ ID NO: 18 and 19 may be useful, as may polynucleotides encoding an amino acid sequence that is SEQ ID NO: 1 or 2, however, these polynucleotides do not encoded a novel chimeric amylase for purposes herein.

[0161] In one embodiment, the polynucleotide is a genomic DNA, while in another embodiment, the polynucleotide is a cDNA. Due to the degeneracy of the genetic code, there are multiple polynucleotides provided in accordance with this disclosure that can encode the same polypeptide. Polynucleotides also include mRNAs that encode a chimeric polypeptide or thermostable α -amylase as provided herein.

[0162] In one presently preferred embodiment, the polynucleotide encoding the chimeric polypeptide or α -amylase is optimized for expression of the chimeric polypeptide in a host cell from a microorganism or a plant by adapting the polynucleotide compositions to favor the those codons used preferentially in the host cell. Techniques for optimizing codon usage are known in the art. Codon usage tables for various organisms are available in standard resources such as texts or practice manuals for biotechnology.

[0163] Also provided are vectors comprising the polynucleotides encoding the chimeric polypeptides and α -amylases. Any vector for maintaining a polynucleotide, producing quantities of a polynucleotide, manipulating a polynucleotide sequence, or for expressing a polynucleotide in vitro or in a host cell is contemplated for use herein. Examples of suitable vectors are provided in standard biotechnology manuals and texts, e.g., Sambrook et al., MOLECULAR CLONING: A LABORATORY MANUAL, 3rd ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. (2001).

[0164] In one embodiment, preferred vectors are useful for expression of the encoded polypeptide in a host cell, especially in a microbial cell, such as a bacterial cell, or in a plant cell. Expression vectors may be adapted for transient expression of the chimeric α -amylases, for example, to confirm catalytic and other properties prior to scaling up. Expression vectors for long-term use, and large-scale production are preferably adapted for stable expression, for example by integration into the host cell chromosome, or by stable incorporation of a self-replicating polynucleotide sequence. In one embodiment, the vector, a DNA construct is transferred to a host cell by an expression vector that comprises regulatory sequences operably-linked to a coding sequence for the chimeric polypeptide or chimeric a amylase.

[0165] Presently preferred vectors include pBR322, and pUC vectors, such as pUC18, and particularly modifications and derivatives thereof. Such vectors are generally well-known vectors adapted for use in microbial systems. In one embodiment, the vector is a pJH101t, a pBR322 derivative that is adapted for integrating into *B. subtilis*, and which contains the multicloning site from pUC18, and several use-ful *Bacillus* sequences. See e.g. Ferrari et al., *J. Bacteriology*, 154:1513-1515, incorporated herein by reference for all purposes. Use of the pJH101t vector in construction of hybrids expressing the chimeric amylases is exemplified herein (see Methods, under Examples, below). Modification of the vector backbone can be used to facilitate site-directed mutagenesis, for example to produce chimeras featuring salt bridges or the like.

[0166] Provided also are microbial cells, including yeast, fungi, or bacterial cells, comprising the vector comprising the polynucleotide that encodes the chimeric polypeptides or α -amylases. In one embodiment, the vector is an expression vector suitable for expression of the encoded polypeptide in the host cell. In another embodiment, a plant cell is provided, said cell comprising a plant expression vector. Vectors for expression in various host cells are known in the art and such vectors, it will be appreciated contain required regulatory sequences, such as promoters and the like, to facilitate expression of the encoded polynucleotide. Exemplary promoters for use in Bacillus include the promoters from the amylase genes in AmyL, AmyQ, AmyM, or AmyS, as well as the promoters from xylA and xylB genes in *B. subtilis*. In one embodiment, the expression vector contains one or more strong promoters, either constitutive or inducible for expressing or over-expressing the encoded polypeptide. In another embodiment, the polynucleotide includes sequences for post-translational modification of the peptide, such as transporting the expressed polypeptide out of the cell, or to a specific compartment within the host cell, to facilitate production, isolation, or purification of the polypeptide from the host cell. For example, the polynucleotides can include one or more sequences such that the chimeric polypeptide or α -amylase is initially produced with a heterologous polypeptide attached to one end, such as a signal peptide from B. licheniformis to promote secretion of the expressed protein from a bacterial host cell. The polynucleotide may also include sequences such that the chimeric amylase is initially produced with a "purification sequence," i.e., a sequence to facilitate purification of the expressed protein, wherein the "purification sequence" is cleaved or removed during purification.

[0167] Where the host cell is a plant, it is contemplated that in one embodiment the plant is a crop plant that is used for starch production. The chimeric polypeptides or α -amylases

can be overproduced in the plant. The chimeric polypeptide or amylase can be overproduced and compartmentalized with that part of the plant used for starch storage, e.g., the seed. Thus, the plant can be harvested, the starch can be isolated and the chimeric α -amylase activity will be co-purified with the starch. This embodiment is particularly useful where the plant is used for alcohol fermentation, especially for fuel ethanol.

[0168] In one embodiment, the host cell is from an organism acceptable for the production of food processing aids or food additives. Presently, host cells that are from *Bacillus licheniformis, Bacillus subtilis*, or *Bacillus stearothermophilus* are preferred. Suitable plasmids for use in bacterial cells including vectors for self-replication in *Bacillus* are known in the art. In one embodiment exemplified herein, the host cell is a *B. subtilis* SC6.1 comprising a xylose-inducible promoter controlling a competency gene. Accordingly, the cells, in the presence of xylose, are competent to bind or take up DNA, such as the polynucleotides, vectors, and other constructs provided herein.

[0169] Methods of Making and Using the Chimeric Polypeptides and α -Amylases

[0170] All methods of making and/or using the chimeric polypeptides and thermostable chimeric α -amylases may be in conjunction with one or more other enzymes of any classification, or type, or activity, as described above in the context of chimeric polypeptides, thermostable amylases, and the compositions provided herein. Provided in accordance with another aspect of the disclosure herein are methods of producing the chimeric amylase polypeptides. In one embodiment, the method provided produces at least one chimeric polypeptide or a thermostable α -amylase as described hereinabove. The method utilizes a host cell selected from the group consisting of *Bacillus licheniformis, B. subtilis*, and *B. stearothermophilus*, for a fermentation process wherein a protein is expressed. The protein comprises:

[0171] a chimeric polypeptide having a length of about 480-515 amino acid residues, and having an amino-terminal domain comprising about 180 or more contiguous amino acid residues of an N-terminal portion of an AmyL amylase, and a carboxy-terminal domain comprising a carboxy-terminal portion of an AmyS amylase; said chimeric polypeptide having enhanced thermostability relative at least to the AmyS amylase, or

[0172] a thermostable chimeric α -amylase about 475-520 amino acid residues long, having an N-terminal portion comprising a contiguous amino acid sequence from an N-terminal portion of an AmyL amylase, and a C-terminal portion comprising a contiguous amino acid sequence from a C-terminal portion of an AmyS amylase, said chimeric α -amylase having a specific activity greater than the AmyL amylase, and greater thermostability at 95° C. than the AmyS amylase. After the protein is expressed, the method provides a step of at least partially purifying the expressed polypeptide, thereby producing the composition.

[0173] The fermentation process can be of any type, although fed-batch fermentation processes, such as submerged fed-batch fermentation, are useful herein. The methods provided further comprise the step of further purifying the chimeric polypeptide in certain embodiments, to make a purified composition showing no evidence of genotoxic potential in in vitro assays; and no evidence of toxic effects in acute and sub-chronic dosing studies in animals. Such compositions are useful as food processing aids, or in some cases, as direct food additives.

[0174] The method produces a purified or partially purified composition that comprises not more than 40 ppm total heavy metals, not more than 5 ppm arsenic, not more than 10 ppm lead, not more than 5×10^4 total viable organisms (CFU/g), not more than 30 coliforms (CFU/g), and no detectable *Salmonella*, mycotoxins or antibacterial activity by standard tests.

[0175] In various embodiments, the methods are also useful for making partially purified or purified compositions that comprise more than one α -amylase activity, and in some embodiments further comprise at least one other enzyme activity.

[0176] Also provided are methods using the compositions comprising the chimeric α -amylases. Methods of liquefying a complex carbohydrate are specifically provided. A method of liquefying a starch slurry comprising: making a slurry comprising a starch, heating the slurry to an acceptable temperature for liquefaction, adding to the slurry a composition comprising one or more of: (a) a chimeric polypeptide having a length of about 480-515 amino acid residues, having an amino-terminal domain comprising about 180 or more contiguous amino acid residues of an N-terminal portion of an AmyL amylase, and a carboxy-terminal domain comprising a carboxy-terminal portion of an AmyS amylase; said chimeric polypeptide having enhanced thermostability relative at least to the AmyS amylase, (b) a thermostable chimeric α -amylase about 475-520 amino acid residues long, having an N-terminal portion comprising a contiguous amino acid sequence from an N-terminal portion of an AmyL amylase, and a C-terminal portion comprising a contiguous amino acid sequence from a C-terminal portion of an AmyS amylase, said chimeric α -amylase having a specific activity greater than the AmyL amylase, and greater thermostability at 95° C. than the AmyS amylase, or (c) a combination thereof, and incubating the slurry with the composition for a time and at a temperature sufficient to liquefy the starch slurry.

[0177] As used herein "liquefy" does not mean that every available substrate linkage is cleaved, rather it means that the complex carbohydrate is at least partially hydrolyzed, as evidenced by a measurable reduction in final viscosity, an increase in the DE of the slurry, or another measure of an increase in reducing groups, dextrins, or α -maltose units.

[0178] In one embodiment of the method of claim, the substrate is a starch, or a carbohydrate comprising amylose, or amylopectin. The method preferably utilizes a slurry that comprises about 15-40% starch on a dry-weight basis. The slurry comprises about 20-40% starch on a dry-weight basis in one embodiment, in another, the slurry comprises between about 30 to about 36 or 37.5% starch. Lower amounts of starch can be used, but may limiting in terms of economic considerations. Maximum viscosity and related factors, such as required power inputs for mixing may limit the maximum amount of starch to be used in the slurry. The skilled artisan will appreciate the practical considerations in making the starch slurry.

[0179] In one embodiment, the addition of the composition reduces the peak viscosity of the slurry as much as the addition of an AmyS amylase used in a comparable liquefaction, and reduces the final viscosity of the slurry as much as the addition of a AmyL amylase used in a comparable liquefaction.

[0180] The temperature of the liquefaction method can range from room temperature to over 100° C., but more preferably is about 50° C. to about 95° C. In one embodiment, the temperature is at least about 80° C. to about 100° C. The liquefaction can entail a complex temperature curve over time, for example, the reaction may start at a low temperature and be increased by methods known in the art to the desired end temperature. The temperature may also be reduced after a specific amount of time, or after a desired end-point in reached in terms of viscosity, DE value, or another measure of liquefaction. The skilled artisan will thus appreciate that the method need not entail a specific temperature for a particular duration, provided that the amylase activity can function at the temperature and under the conditions provided. Other conditions that can impact the activity include the pH and the calcium ion concentration, in addition to the presence or absence of one or more of detergents, oxidants, or chelators. [0181] In one embodiment, the liquefaction is part of fermentation. Fermentation is used to produce a food product, a food additive, a fuel, or a fuel additive in some embodiments. In preferred embodiments, fermentation is for a fuel or fuel additive that is an alcohol, preferably ethanol or another lower alcohol (e.g. less than about C_6 - C_8).

[0182] In another embodiment, the maximal (or peak) viscosity of the slurry is reduced to at least that produced by the AmyS used alone. In various embodiments, the final viscosity is at least that achieved by the AmyL used alone, and is 2-, 3-, 5-, 10-, 15-, 18-, 20-, 21-, 22-, 24-, 25-, 26-, 27-, 28-, 29-, or even 30-fold lower than the maximum viscosity during the process. The skilled artisan will appreciate the more the viscosity is reduced, the further the starch is liquefied, the greater the production of dextrins (or the higher the DE of the resultant liquefied starch).

[0183] Another aspect contemplates the use of additional enzymes with the chimeric polypeptides, amylases and compositions provided herein for liquefaction and subsequent processing of the slurry. Thus, two or more α -amylases can be used alone or in combination with other enzymes discussed herein. For example, a third enzyme may be another α -amylase, e.g., a yeast α -amylase, or another α -amylase, either *Bacillus* α -amylases or non-*Bacillus* α -amylases. Improved liquefaction via enhanced hydrolysis activity during the liquefaction process increases the efficiency subsequent processing steps (see e.g. WO 98/22613). For example, a result may be decreased requirement for glucoamylase during the saccharification step.

[0184] Additional enzymes, such as β -amylases, can be used with or in the polypeptides, amylases or compositions. β -amylases suitable for use herein include, but are not limited to, β -amylases from barley Spezyme® BBA 1500, Spezyme® DBA, OptimaltTM ME, OptimaltTM BBA (Genencor International, Inc.), and NovozymTM WBA (Novozymes A/S).

[0185] Another enzyme contemplated for use in the composition is a glucoamylase (EC 3.2.1.3). Glucoamylases are derived from a microorganism or a plant. For example, glucoamylases can be of fungal or bacterial origin. Exemplary bacterial glucoamylases are *Aspergillus* glucoamylases, in particular *A. niger* G1 or G2 glucoamylase (Boel et al. (1984), *EMBO J.* 3(5): 1097-1102), or variants thereof, such as disclosed in WO 92/00381 and WO 00/04136; *A. awamori* glucoamylase (WO 84/02921); *A. oryzae* glucoamylase (*Agric. Biol. Chem.* (1991), 55(4): 941-949), or variants or fragments thereof. The glucoamylase advantageously is present in an

amount of no more than, or even less than, 0.5 glucoamylase activity unit (AGU)/g DS (i.e., glucoamylase activity units per gram of dry solids). The glucoamylase is derived from an *Aspergillus* sp., *Talaromyces* sp., *Pachykytospora* sp., or *Trametes* sp., with exemplary examples being *Aspergillus* niger, *Talaromyces emersonii*, *Trametes cingulata*, or *Pachykytospora papyracea*. In one embodiment, the process also comprises the use of a carbohydrate-binding domain of the type disclosed in, for example, WO 98/22613.

[0186] Other contemplated Aspergillus glucoamylase variants include variants to enhance the thermal stability: G137A and G139A (Chen et al. (1996), Prot. Eng. 9: 499-505); D257E and D293E/Q (Chen et al. (1995), Prot. Eng. 8: 575-582); N182 (Chen et al. (1994), Biochem. J. 301: 275-281); disulphide bonds, A246C (Fierobe et al. (1996), Biochemistry, 35: 8698-8704); and introduction of Pro residues in positions A435 and S436 (Li et al. (1997) Protein Eng. 10: 1199-1204). Other contemplated glucoamylases include Talaromyces glucoamylases, in particular derived from T. emersonii (WO 99/28448), T. leycettanus (U.S. Pat. No. RE 32,153), T. duponti, or T. thermophilus (U.S. Pat. No. 4,587, 215). Contemplated bacterial glucoamylases include glucoamylases from the genus Clostridium, in particular C. thermoamylolyticum (EP 135138) and C. thermohydrosulfuricum (WO 86/01831). Suitable glucoamylases include the glucoamylases derived from Aspergillus oryzae, such as a glucoamylase having 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, or even 90% homology to the amino acid sequence shown in SEQ ID NO: 2 in WO 00/04136. Also suitable are commercial glucoamylases, such as AMG 200L; AMG 300 L; SANTM SUPER and AMGTM E (Novozymes); OPTI-DEX® 300 (Genencor International, Inc.); AMIGASETM and AMIGASE™ PLUS (from DSM); G-ZYME® G900 (Enzyme Bio-Systems); and G-ZYME® G990 ZR (A. niger glucoamylase and low protease content). Glucoamylases may be added in an amount of 0.02-2.0 AGU/g DS or 0.1-1.0 AGU/g DS, e.g., 0.2 AGU/g DS.

[0187] Another enzyme that can optionally be added is a debranching enzyme, such as an isoamylase (EC 3.2.1.68) or a pullulanases (EC 3.2.1.41). Isoamylase hydrolyses α -1,6-D-glucosidic branch linkages in amylopectin and β -limit dextrins and can be distinguished from pullulanases by the inability of isoamylase to attack pullulan and by the limited action of isoamylase on α -limit dextrins. Debranching enzymes may be added in effective amounts well known to the person skilled in the art.

[0188] The polypeptides, amylases, and compositions provided herein can be used in baking processes, They can be added alone or in a combination with other enzymes for any of a variety of purposes. They can be added with other amylases, e.g. an anti-staling amylase to prevent or retard staling, i.e., crumb firming of baked products. The amount of antistaling amylase will typically be in the range of 0.01-10 mg of enzyme protein per kg of flour, e.g., 0.5 mg/kg ds. Additional anti-staling amylases that can be used in combination with the chimeric polypeptides, amylases, and compositions provided herein include an endo-amylase, e.g., a bacterial endo-amylase from Bacillus. The additional amylase is a maltogenic α-amylase (EC 3.2.1.133), e.g., from Bacillus in one embodiment. Novamyl[®] is an exemplary maltogenic α -amylase from B. stearothermophilus strain NCIB 11837 and is described in Christophersen et al., Starch 50: 39-45 (1997). Other examples of anti-staling endo-amylases include bacterial α-amylases derived from Bacillus, such as B. licheniformis or B. amyloliquefaciens. The anti-staling amylase may be an exo-amylase, such as β -amylase, e.g., from plant sources, such as soybean, or from microbial sources, such as Bacillus. [0189] Phospholipases are also be used together with the chimeric polypeptides, amylases, and compositions disclosed herein in certain embodiments for baking applications. The phospholipase may have A_1 or A_2 activity to remove fatty acid from the phospholipids, forming a lysophospholipid. It may or may not have lipase activity, i.e., activity on triglyceride substrates. The phospholipase typically has a temperature optimum in the range of 30-90° C., e.g., 30-70° C. The added phospholipases can be of animal origin, for example, from pancreas, e.g., bovine or porcine pancreas, snake venom or bee venom. Alternatively, the phospholipase may be of microbial origin, e.g., from filamentous fungi, yeast or bacteria, such as the genus or species. Exemplary sources of phospholipases include Aspergillus, A. niger; Dictyostelium, D. discoideum; Mucor, M. javanicus, M. mucedo, M. subtilissimus; Neurospora, N. crassa; Rhizomucor, R. pusillus; Rhizopus, R. arrhizus, R. japonicus, R. stolonifer; Sclerotinia, S. libertiana; Trichophyton, T. rubrum; Whetzelinia, W. sclerotiorum; Bacillus, B. megaterium, B. subtilis; Citrobacter, C. freundii; Enterobacter, E. aerogenes, E. cloacae; Edwardsiella, E. tarda; Etwinia, E. herbicola; Escherichia, E. coli; Klebsiella, K. pneumoniae; Proteus, P. vulgaris; Providencia, P. stuartii; Salmonella, S. typhimurium; Serratia, S. liquefasciens, S. marcescens; Shigella, S. flexneri; Streptomyces, S. violeceoruber; Yersinia, Y. enterocolitica; Fusarium, F. oxysporum, (strain DSM 2672 for example).

[0190] The phospholipase is added in an amount that improves the softness of the bread during the initial period after baking, particularly the first 24 hours. The amount of phospholipase will typically be in the range of about 0.01-10 mg of enzyme protein per kg of flour, e.g., 0.1-5 mg/kg. Phospholipase activity generally will be in the range of about 20-1000 Lipase Unit (LU)/kg of flour, where a Lipase Unit is defined as the amount of enzyme required to release 1 µmol butyric acid per minute at 30° C., pH 7.0, with gum arabic as emulsifier and tributyrin as substrate.

[0191] Optionally, an additional enzyme may be used together with the anti-staling amylase and the phospholipase. The additional enzyme may be a second amylase, such as an amyloglucosidase, a β-amylase, a cyclodextrin glucanotransferase, or the additional enzyme may be a peptidase, in particular an exopeptidase, a transglutaminase, a lipase, a cellulase, a hemicellulase, in particular a pentosanase, such as xylanase, a protease, a protein disulfide isomerase, e.g., a protein disulfide isomerase as disclosed in WO 95/00636, for example, a glycosyltransferase, a branching enzyme (1,4- α glucan branching enzyme), a 4-a-glucanotransferase (dextrin glycosyltransferase) or an oxidoreductase, e.g., a peroxidase, a laccase, a glucose oxidase, a pyranose oxidase, a lipooxygenase, an L-amino acid oxidase, or a carbohydrate oxidase. The additional enzyme(s) may be of any origin, including mammalian and plant, and particularly of microbial (bacterial, yeast or fungal) origin and may be obtained by techniques conventionally used in the art.

[0192] The xylanase is typically of microbial origin, e.g., derived from a bacterium or fungus, such as a strain of *Aspergillus*, in particular of *A. aculeatus*, *A. niger* (cf. WO 91/19782), *A. awamori* (e.g., WO 91/18977), or *A. tubigensis* (e.g., WO 92/01793); from a strain of *Trichoderma*, e.g., *T. reesei*, or from a strain of *Humicola*, e.g., *H. insolens* (e.g., WO 92/17573). Pentopan® and Novozym 384® are commer-

cially available xylanase preparations produced from Trichoderma reesei. The amyloglucosidase may be an A. niger amyloglucosidase (such as AMG®). Other useful amylase products include Grindamyl® A 1000 or A 5000 (available from Grindsted Products, Denmark) and Amylase® H or Amylase® P (available from Gist-Brocades, The Netherlands). The glucose oxidase may be a fungal glucose oxidase, in particular an Aspergillus niger glucose oxidase (such as Gluzyme®). An exemplary protease is Neutrase®. An exemplary lipase can be derived from strains of Thermomyces (Humicola), Rhizomucor, Candida, Aspergillus, Rhizopus, or Pseudomonas, in particular from Thermomyces lanuginosus (Humicola lanuginosa), Rhizomucor miehei, Candida antarctica, Aspergillus niger, Rhizopus delemar or Rhizopus arrhizus, or Pseudomonas cepacia. In specific embodiments, the lipase may be Lipase A or Lipase B derived from Candida antarctica as described in WO 88/02775, for example, or the lipase may be derived from Rhizomucor miehei as described in EP 238,023, for example, or Humicola lanuginosa, described in EP 305,216, for example, or Pseudomonas cepacia as described in EP 214,761 and WO 89/01032, for example.

[0193] Provided herein are methods of cleaning a surface to remove an unwanted or undesired starch residue. The methods comprise the steps of providing a surface that has a starch residue to be removed, contacting the surface with a composition that comprises one or more chimeric polypeptides or α -amylases, for a time and at a temperature sufficient, and under conditions permissive to result in removal of the starch residue. The surface can be on any material; for example, it can be on a dish, plate, glass, etc, or it can be on clothing or fabric. It can also be for example a counter-top or work surface, or a commercial vessel of any type that must be periodically or regularly cleaned.

[0194] In one embodiment, the composition comprises at least one other enzyme, for example one or more of a protease, a lipase, an additional amylase, or a combination thereof. In another embodiment, a step of rinsing or bulk removal of residue is implemented prior to the contacting step. Such a step removes bulk starch from the cleaning process to enable the enzyme to work on the remaining, and more difficult to remove, substrate. The method of cleaning can be conducted at any temperature, but preferably the temperature during the contacting step reaches at least 50-100° C. In one embodiment, the method comprises a step of sterilizing the surface, or steam treating the surface after the residue is removed. The composition further comprises at least one detergent, oxidant, chelator, or a combination thereof in several embodiments.

[0195] In embodiments wherein the composition comprises one or more additional enzymes, while the composition can comprise any useful enzyme activity, the following embodiments may offer particular advantages.

[0196] The composition can comprise 2,6- β -D-fructan hydrolase, one or more α -amylases, and one or more other cleaning enzymes, such as a protease, a lipase, a cutinase, a carbohydrase, a cellulase, a pectinase, a mannanase, an arabinase, a galactanase, a xylanase, an oxidase, a laccase, and/ or a peroxidase, and/or combinations thereof. In general the properties of the chosen enzyme(s) preferably are compatible with the selected detergent, (e.g., pH-optimum, compatibility with other enzymatic and non-enzymatic ingredients, etc.), and the enzyme(s) are preferably provided in effective amounts.

[0197] Proteases from any source are suited for use herein including those of animal, vegetable or microbial origin. Chemically-modified or engineered enzymes are also suitable. The protease can have any type of activity or active site known, e.g. exo- or endo-proteolytic activities of the serine, metallo- or alkaline- or acid-type protease, depending on the conditions of use. Alkaline proteases are preferred in certain embodiments, as are trypsin-like proteases. Examples of alkaline proteases are subtilisins, especially those derived from Bacillus spp., e.g., subtilisin Novo, subtilisin Carlsberg, subtilisin 309 (see, e.g., U.S. Pat. No. 6,287,841), subtilisin 147, and subtilisin 168 (see, e.g., WO 89/06279). Examples of trypsin-like proteases are trypsin (e.g., of porcine or bovine origin), and Fusarium proteases (see, e.g., WO 89/06270 and WO 94/25583). Examples of useful proteases also include, but are not limited to, the variants described in WO 92/19729 and WO 98/20115. Suitable commercially available protease enzymes include Alcalase®, Savinase®, Primase™, DuralaseTM, Esperase[®], and KannaseTM (Novo Nordisk A/S); Maxapem[™], Maxatase[®], MaxacalTM, Properase[™]. Purafect®, Purafect OxPTM, FN2TM, and FN3TM (Genencor International, Inc.).

[0198] Lipases of any type may be used in conjunction with the compositions provided herein. Exemplary lipases include those of bacterial or fungal origin. Chemically-modified and engineered enzymes are also useful herein. Examples of useful lipases include, but are not limited to, lipases from Humicola (synonym Thermomyces), e.g. H. lanuginosa (T. lanuginosus) (see, e.g., EP 258068 and EP 305216) and H. insolens (see, e.g., WO 96/13580); a Pseudomonas lipase (e.g., from P. alcaligenes or P. pseudoalcaligenes; see, e.g., EP 218 272), P. cepacia (see, e.g., EP 331 376), P. stutzeri (see, e.g., GB 1,372,034), P. fluorescens, Pseudomonas sp. strain SD 705 (see, e.g., WO 95/06720 and WO 96/27002), P. wisconsinensis (see, e.g., WO 96/12012); a Bacillus lipase (e.g., from B. subtilis; see, e.g., Dartois et al. Biochemica Biophysica Acta, 1131: 253-360 (1993)), B. stearothermophilus (see, e.g., JP 64/744992), or B. pumilus (see, e.g., WO 91/16422). Additional lipase variants contemplated for use in the formulations include those described, for example, in: WO 92/05249, WO 94/01541, WO 95/35381, WO 96/00292, WO 95/30744, WO 94/25578, WO 95/14783, WO 95/22615, WO 97/04079, WO 97/07202, EP 407225, and EP 260105. Some commerciallyavailable lipase enzymes include Lipolase® and Lipolase® Ultra (Novo Nordisk A/S).

[0199] Polyesterases useful herein include, but are not limited to, those described in WO 01/34899 (Genencor International, Inc.) and WO 01/14629 (Genencor International, Inc.), and can be included in any combination with other enzymes discussed herein.

[0200] The compositions can also be combined with other α -amylases including commercially available amylases, such as, but not limited to Duramyl®, TermamylTM, Fungamyl® and BANTM (Novo Nordisk A/S), as well as Rapidase®, and Purastar® (Genencor International, Inc.).

[0201] Cellulases of any type or origin, such as those of bacterial or fungal origin can be added to, or used with, the compositions, as can chemically-modified or engineered enzymes. Suitable cellulases include cellulases from the genera *Bacillus, Pseudomonas, Humicola, Fusarium, Thielavia,* and *Acremonium*. For example, the fungal cellulases produced from *Humicola insolens, Myceliophthora thermophila* and *Fusarium oxysporum* disclosed in U.S. Pat. Nos. 4,435, 307; 5,648,263; 5,691,178; 5,776,757; and WO 89/09259.

Exemplary cellulases have benefit for the color care of textiles. Examples of such cellulases are described in EP 0495257; EP 531 372; WO 99/25846 (Genencor International, Inc.), WO 96/34108 (Genencor International, Inc.), WO 96/11262; WO 96/29397; and WO 98/08940, for example. Other examples are cellulase variants, such as those described in WO 94/07998; WO 98/12307; WO 95/24471; PCT/DK98/00299; EP 531 315; U.S. Pat. Nos. 5,457,046; 5,686,593; and 5,763,254. Commercially available cellulases include Celluzyme® and Carezyme® (Novo Nordisk A/S); ClazinaseTM and Puradax® HA (Genencor International, Inc.); and KAC-500(B)TM (Kao Corporation).

[0202] Peroxidases and oxidases are also suitable for use in or with the compositions provided herein, include enzymes of plant, bacterial or fungal origin. Chemically-modified and engineered enzymes are also well-suited for use herein. Examples of useful peroxidases include peroxidases from *Coprinus*, e.g., from *C. cinereus*, and variants thereof as those described in WO 93/24618, WO 95/10602, and WO 98/15257. Commercially available peroxidases include GuardzymeTM (Novo Nordisk A/S), for example.

[0203] Also provided herein are methods of treating a woven material using the chimeric α -amylases described herein. Methods of treating woven materials, such as fabrics, with amylases are known in the art. The methods provided can improve the feel and/or appearance of a woven material, such as a textile or a fabric. The methods comprise contacting the woven material with a liquid comprising chimeric polypeptides or thermostable α -amylases. In one embodiment, the woven material is a fabric or textile. In another embodiment, the woven material is treated with the liquid under pressure. The liquid is generally an aqueous solution.

[0204] The methods are typically applied during or after a weaving process, e.g., the weaving of a fabric or textile. Alternatively, the method can be used during a desizing stage, or during one or more additional steps further processing the woven material. The methods are useful because during the weaving process for many materials, such as fabrics and textiles, the material (e.g. threads to be woven) is exposed to considerable mechanical strain. Prior to the weaving process, particularly on commercial looms, the materials to be woven are often coated with a "sizing" comprising starch or starch derivatives, to increase their tensile strength and to prevent breaking. The chimeric polypeptides and thermostable amylases provided herein can be applied during or after weaving to remove such sizing starch or starch derivatives.

[0205] The chimeric polypeptides and chimeric α -amylases provided herein can be used alone or with other desizing chemical reagents, such as detergents and/or desizing enzymes to desize woven materials such as fabrics, including cotton and cotton-containing fabrics.

[0206] The chimeric polypeptides and α -amylases provided herein also have application for enzymatic finishing methods have been developed for clothing, for example, in the manufacture of denim jeans. The action of amylolytic enzymes can provide softness to the fabric and make the cotton more accessible to the subsequent enzymatic finishing steps (e.g., to achieve a stone-washed appearance).

[0207] Kits for practicing the foregoing methods of liquefying a starch slurry, cleaning a starch residue from a surface, and for treating a woven material to remove a coating comprising starch or a starch derivative are also provided herein. The kits include at least one chimeric polypeptide or chimeric α -amylase as provided herein, or one composition provided herein, along with instructions for practicing the corresponding methods.

[0208] All references cited herein are incorporated by reference in their entirety herein for all purposes. The working examples provided below are provided to further describe and illustrate certain aspects of the chimeric α -amylases, and thus should not be construed to be limiting.

EXAMPLES

Methods

Hybrid Strain Construction

[0209] All chimeric nucleotide sequences were ordered as full-length synthetic genes from DNA 2.0 (Menlo Park, Calif.). All plasmids were digested with EcoRI and BamHI restriction endonucleases. The gene fragments were gel extracted using the Qiagen Gel Extraction kit, according to the manufacturer's protocol. Similarly, the integrating B. subtilis vector, pJH101t, was digested with EcoRI and BamHI restriction endonucleases. Following agarose gel separation, the ~5 kb plasmid backbone band was gel extracted and cleaned up with the Qiagen Gel Extraction kit. The plasmid pJH101t is a derivative of the plasmid pBR322, originally isolated from E. coli, with the EcoRI/HindIII fragment replaced by the pUC18 multicloning site EcoRI/HindIII fragment, and the HindIII/BamHI fragment replaced by the Bacillus amyloliquefaciens alkaline protease (apr) gene terminator sequence, and containing also the HpaII/Sau3a fragment of the natural Bacillus plasmid pC 194 carrying the chloramphenicol acetyl transferase (CAT) gene (blunted) in the PvuII site. (Ferrari, FA, Nguyen A, Lang D, and Hoch JA (1983) Construction and Properties of an Integrable Plasmid for Bacillus subtilis J. Bacteriology, 154:1513-1515).

[0210] All chimeric genes were ligated into pJH101t at the EcoRI-HindIII sites using DNA Ligation Kit, Mighty Mix from Takara (Madison, Wis.). $5 \Box L$ of the ligation mixture were transformed into Invitrogen Oneshot Top10 *E. coli* chemical competent cells according to the manufacturer's protocol. LA+50 ppm carbenicillin plates were used for selection of transformants.

[0211] Transformants were screened to determine if the chimeric gene was present by extracting plasmid DNA from the clones using the Qiagen Miniprep kit. The plasmid was then digested with EcoRI-BamHI to see if a ~2.2 kb band is present indicating that the vector contains the hybrid gene. For final verification, the miniprep DNA was extracted and sequenced by Sequetech (Mountain View, Calif.) using the following sequencing primers:

m	-	-7	-	-	\sim	-	

Fred550-F 5' aaccgcggttgaagtcgatccc	3'	(SEQ	ID	NO :	35)
Fred610-R 5' cccggaaaatgaaaatgtgtcc	3'	(SEQ	ID	NO :	36)
Ethyl 1130-F 5' cgcacgttaatgaccaatactc	3'	(SEQ	ID	NO :	37)
Ethyl 1190-R 5' gcttggccgggctcggtgtcat	3'	(SEQ	ID	NO :	38)

[0212] The constructs were named pJH101-AprFr186Et, pJH101-AprFr187Et, etc (see FIG. 1) to refer to the chimeric amylase encoded therein. Plasmid DNA containing the chi-

meric construct was transformed into frozen *B. subtilis* SC6.1 competent cells (also called BG3594comK, genotype: DaprE, DnprE, degUHy32, oppA, DspoIIE3501, amyE::xy-IRPxylAcomK-phleo)) by adding 5-10 μ L of plasmid to 200 μ L of competent cells followed by 37° C. incubation at 250 rpm for 1 hour. The SC6.1 *B. subtilis* cells have a competency gene (comK) which is placed under a xylose inducible pro-

moter, so xylose was used to induce competency for DNA binding and uptake. The transformation reaction was plated on LA+5 ppm chloramphenicol+1% insoluble starch and incubated at 37° C., overnight.

[0213] Transformants showing a clearing (or halo) in the agar around the colony were selected and amplified by streaking on LA+25 ppm chloramphenicol+1% insoluble starch. The formation of a halo in the agar around the colony reflects the ability of the transformed cells to produce an amylase enzyme that degrades the insoluble starch in the agar medium. The plates were incubated at 37° C., overnight. Colonies with a larger halo were selected to grow in shake flasks. For the purpose of protein expression, a fresh single colony was inoculated into 5 mL LB+25 ppm chloramphenicol and incubate at 37° C., 250 rpm, for 6 to 8 hours. 30 µL of this pre-culture was added into a 250 mL flask filled with 30 mL of cultivation media (described below) supplemented with 25 ppm chloramphenicol and 5 mM CaCl₂. The shake flasks were incubated for 60-65 hours at 37° C., with mixing at 250 rpm. Cultures were harvested by centrifugation at 5000 rpm for 20 minutes in conical tubes. The culture supernatants, enriched in recombinant amylase, were used for assays.

[0214] The cultivation media was an enriched semi-defined media based on MOPs buffer, with urea as major nitrogen source, glucose as the main carbon source, and supplemented with 1% soytone for robust cell growth.

[0215] For construction of chimeras with a salt bridge mutation, the original backbone vector, pJH101-AprFr200Et (and 202, 228, 249, 254, 259), was used as a template for a site directed mutagenesis reaction using the Stratagene QuikChange Site-Directed Mutagenesis kit. 50 ng of template DNA was used for PCR along with the following primers:

SS187DT-200etc fwd

(SEQ ID NO: 39) 5'-gcttgggattgggaagttgacacagaaaacggcaactatg-3'

SS187DT-200etc rev

(SEQ ID NO: 40) 5'-catagttgccgttttctgtgtcaacttcccaatcccaagc-3'

[0216] Thermocycler conditions were 1× at 95° C. for 1 min, 18× at 95° C. for 50 sec, 60° C. for 50 sec, 68° C. for 8.5 min, followed by 1× at 68° C. for 7 min and hold at 4° C. Following PCR, all reactions were incubated at 37° C., overnight after addition of 1 μ L of DpnI. 1.54 of the digested reaction was transformed into Invitrogen Oneshot Top10 *E. coli* chemical competent cells following the manufacturer's protocols. The reactions were plated on LA+50 ppm carbenicillin. To extract plasmid DNA for sequencing, transformants were cultured in 5 mL LA+50 ppm carbenicillin, 37° C., 250 rpm, overnight. Plasmid DNA was extracted using the Qiagen Miniprep Kit following the manufacturer's protocol. Plasmid DNA was sequenced by Sequetech (Mountain View, Calif.) using the sequencing primers listed below:

Fred550-F

5' aaccgcggttgaagtcgatccc	3'	(SEQ	ID	NO:	35)
Fred610-R 5' cccggaaaatgaaaatgtgtcc	3'	(SEQ	ID	NO :	36)
Ethyl 1130-F 5' cgcacgttaatgaccaatactc	3'	(SEQ	ID	NO :	37)
Ethyl 1190-R 5' gcttggccgggctcggtgtcat	3'	(SEQ	ID	NO :	38)

[0217] After determining which isolates had the correct sequence, $10 \ \mu\text{L}$ of plasmid DNA was transformed into $100 \ \mu\text{L}$ of frozen *B. subtilis* SC6.1 competent cells. Transformants were grown as described above.

[0218] Enzymatic Thermostability Assay

[0219] In this assay, the thermostability of the amylases was determined using a PCR thermocycler. Residual activity of the amylases was measured after incubation at a set temperature such as 95° C. following sampling over a standard time interval such as 60 minutes to obtain the inactivation curve at that temperature. For each time point, 110 µl sample were placed in a thin-walled PCR tube and held at 25° C. for 4 minutes in the thermocycler after the tubes were sealed. The temperature was ramped to e.g. 95° C. Timing was initiated when the target temperature was reached. Over appropriate time intervals, tubes were removed and placed on ice. The samples were assayed for residual endo alpha amylase activity using the Megazyme Ceralpha assay as described below. [0220] Megazyme Ceralpha Assay: This assay is a modification of the published protocols for Megazyme endo alphaamylase Kit K-CERA 08/05 (AOAC Method 2002.01) (Megazyme International, Ireland). Reagent vials contain the substrate, which is non-reducing end-blocked p-nitrophenyl maltoheptaoside (BPNPG7, 54.5 mg) and thermostable alpha glucosidase (125 U at pH 6.0). For each assay, the entire contents of one vial was dissolved in 10.0 mL of distilled water. 30 mL assay buffer (50 mM Na malate, 2.6 mM CaCl₂, 50 mM NaCl, 0.002% Triton X-100, pH 6.7) was added to the vial solution and 10 mL aliquots of this were frozen for further use. 0.79 mL substrate solution in buffer was added to a (preferably masked) cuvette. The cuvette was placed in the holder and a blank reading was obtained. Ten μL enzyme samples were then added to the cuvette to start the assay. Absorbance per minute was measured at 400 nm or 410 nm and the values corrected for dilution and protein concentration. The % activity remaining is reported for each chimeric enzyme after normalizing to 100% for the AmyS control.

[0221] Specific Activity Determination by DNS Reducing Sugar Assay

[0222] In this assay, the relative specific activity of the chimeric enzymes with respect to non-chimeric enzymes was determined by measuring the release of glucose from potato starch substrate using the DNS reducing sugar detection method described below.

[0223] Reagents used:

[0224] Buffer: 200 mM sodium acetate+2.5 mM $\rm CaCl_2$ and 0.002% Tween 20

[0225] DNS solution: 8 g NaOH were dissolved in 300 mL water and 5 g 3-5 Dinitro Salicylic acid was added to this solution and dissolved, with heating if necessary. 150 g sodium potassium tartarate was then added to this solution and the total volume made up to 500 mL.

[0226] Substrate: 4% potato starch solution (5.33 g potato starch dissolved to 100 mL of water). For a working substrate solution, 1 part buffer was added to 3 parts starch solution. Substrate solution was made fresh each day.

[0227] Procedure: An aliquot of 110 µL of substrate was added to $200\,\mu\text{L}$ PCR tubes. The tubes were placed in the PCR thermocycler. The program was started by first keeping the tubes at 4° C. for a few minutes. During this time, 10 µL of enzyme, appropriately diluted with buffer containing 0.002% Tween 20, was added to the tubes. The tubes were quickly mixed and as soon as the thermocycler reached the desired reaction temperature of 95° C., the 0 timepoint reaction was stopped by the addition of 10 µL 1% NaOH. At each time point, one reaction tube was removed and quenched with 10 µL 1% NaOH. When all reactions were completed, 32.5 µL of each reaction mixture was placed in another 200 µL PCR tube containing 75 µL of water. 100 µL DNS solution was added to each tube and the contents mixed thoroughly. The tubes were incubated at 99° C. for 5 minutes in the PCR thermocycler. Following incubation, the tubes were cooled, $150 \,\mu\text{L}$ of each reaction mixture was placed in a microtiter plate well, and the absorbance measured at 543 nm. Glucose was used as a standard. The specific activity values are expressed as mg glucose/sec per mg enzyme.

[0228] 4) Viscosity Measurement Assay (Glass Cooker/ Viscometer Procedure)

[0229] In this assay, viscosity reduction of corn starch substrate solution at pH 5.8. by amylases was measured in a glass cooker/viscometer. The corn starch substrate slurry was made up fresh in batch mode with 36% corn flour dry solids in distilled water and adjusted to pH 5.8 using sulfuric acid. The slurry was pre-incubated for 1 hour at 60° C. in a large plastic beaker. For viscosity measuring, the reaction vessel was heated to 110° C. with an oil bath with a thermal coat around reaction vessel while it was heating to temperature. The slurry was poured into the reaction vessel with stirring at a rotation speed of 100 rpm. Diluted alpha amylase enzyme samples were added directly into the reaction vessel to dose the slurry with 1.33 U/g DS. The thermal coat was removed from the reaction vessel and the vessel maintained at 85° C. for the duration of the experiment. The internal temperature and viscosity was measured using a EUROSTAR/IKA Labortechnik control-visc P7 electronic overhead stirrer with torque read output every 30 seconds for the first 10 minutes, then every 4 minutes for a total of 62 minutes.

Example 1

Creation of Novel Chimeric Amylases from AmyL and AmyS Sequences

[0230] An effort was undertaken to make chimeras of AmyL and AmyS to combine the preferred attributes of AmyL-type enzymes (AmyL and variants thereof) with those of AmyS-type enzymes (AmyS and variants thereof) into individual enzymes. Ideally, resultant chimeric enzymes would have the best properties of each enzyme—e.g., thermostability similar to that of AmyL-type enzymes, combined with the high specific activity of AmyS-type enzymes for starch substrates at high temperature. Such enzymes would be useful in starch liquefaction, such as for ethanol production, as the catalytic activity obtained from them would ideally lead to a fast initial rate of viscosity reduction and low final viscosity.

[0231] A series of chimeric molecules were constructed from AmyL and AmyS (SEQ ID NOs: 4-17). The chimeras comprised an N-terminal portion derived from AmyL (SEQ ID NO: 1), and a C-terminal portion derived from AmyS (SEQ ID NO: 2). The N-terminal portion of the chimeras comprised a minimum of 186 amino acid residues from the N-terminal end of the mature polypeptide sequence of AmyL (SEQ ID NO: 1) and a maximum of about 260 such amino acid residues. The remainder of the chimera (i.e. the C-terminal portion) comprised amino acid residues from the C-terminal portion of the mature polypeptide sequence of AmyS (SEQ ID NO: 2). A maximum of 297-326 amino acid residues from the C-terminal region of AmyS (SEQ ID NO: 2), and a minimum of 224-253 such amino acid residues. The C-terminal portion of the chimeras all included the amino acid residues K-T-T corresponding to positions 484-486 of the mature AmyS sequence (SEQ ID NO: 2). The chimeras are generally named for the last residue of the AmyL-derived sequence. See Hybrid Strain Construction, under "Methods", above, and FIG. 1, for description of cloning process.

[0232] The following chimeric α -amylases were constructed for use herein in the working examples:

[0233] First Generation Chimeras included: 186, 187, 200, 202, 228, 249, 254, and 259.

[0234] Second Generation Chimeras included: 200SB, 202SB, and 228SB.

[0235] Third Generation Chimeras included: 249SB, 254SB, and 259SB.

Example 2

$\begin{array}{l} \mbox{Thermostability Screening of First Generation Chi-}\\ \mbox{meric } \alpha\mbox{-}\mbox{Amylases Derived from AmyL and AmyS}\\ \mbox{Enzymes} \end{array}$

[0236] The first generation chimeras consisted of single cross-over mutants wherein the N-terminal portion of the chimeric amylase derived from AmyL and the C-terminal portion derived from AmyS as described above. The chimeric amylases screened for thermostability were 186, 187, 200, 202, 228, 249, 254, and 259. The chimeric amylases were assayed at 95° C. throughout the time course. Samples were removed at the indicated time points and activity was measured. For each chimera, the percent activity is plotted versus the number of minutes the enzyme was held at 95° C., in 50 mM malate buffer, pH 5.6 with 2.6 mM CaCl₂ and 50 mM NaCl. Assay conditions were as described in the Methods section above. For each enzyme, the remaining activity was calculated as a percentage of the activity of for the enzyme that had not been incubated at 95° C. The control enzyme was AmyS control (SEQ ID NO: 3).

[0237] Results and Discussion. Results are shown in FIG. **2**. Based on what was previously known or believed about the thermostability of Amy L and AmyS, in the single cross-over chimeras expectations were that the greater the number of amino acid residues from AmyL, the greater the thermostability of the chimera. However, as can be seen from FIG. **2**, it was unexpectedly discovered that the chimeric α -amylase with the fewest number of AmyL-derived amino acid residues was the most thermostable. Interestingly, the chimeric amylase containing the first 187 residues derived from AmyL was

not highly thermostable, despite the difference of only a single amino acid residue—that at position 187.

Example 3

Thermostability Screening of Second Generation Chimeric α-Amylases Derived from AmyL and AmyS Enzymes: Incorporation of Stabilizing Structures

[0238] The stability data from Example 2 showed that among the chimeric α -amylases tested, the chimera containing only the first 186 amino acid residues of the AmyL sequence had high thermostability, while the other chimeric α -amylases, containing more of the AmyL sequence, were not thermostable, including the 187 chimera, which differed from the 186 chimera at only position 187. The data suggested that the replacement of the Asp residue with a Ser residue at position 187 was directly related to the lack of thermostability of the 187 chimera, and possibly related to the lack of thermostability of each of the chimeric amylases containing more than 186 amino acid residues from AmyL.

[0239] This is highly surprising given that other work has reported that the mutation S187D in AmyL-derived amylases reduces thermostability of the amylase. For example, U.S. Pat. No. 6,939,703 to Van Der Laan and Aehle discloses that, although S187D mutants had a higher specific activity under certain assay conditions, the S187D amylase had a substantially shorter half-life at 93° C. than the *B. licheniformis* wild-type amylase at all calcium ion concentrations tested. U.S. Pat. No. 6,143,708 to Svendson et al. also discloses that S187D mutants of *B. licheniformis* amylase had increased specific activity, however they also report substantially reduced thermostability at 70° C. at either pH 4.5 or 6.2 across a range of calcium ion concentrations.

[0240] In the context of the chimeric amylases that are the subject of this disclosure it was thus completely unexpected that the alteration of Ser to Asp at position 187 would increase thermostability. To test this hypothesis, the mutations S187D and S188T were introduced into a number of the chimeric α -amylases that were not highly thermostable in the screen of the first generation chimeras. The chimeric α -amylases tested included 200SB, 202SB, and 228SB. As in Example 2, the thermostability of each chimeric enzyme at 95° C. was compared to that of the AmyS control. The assays and calculation of activity remaining were as in Example 2.

[0241] Results and Discussion. The results of the thermostability screen are shown in FIG. 3 for the first set of chimeric molecules. Surprisingly, the alteration of two amino acid residues was indeed found to improve the stability of the chimeras. Without being limited a particular theory of operation, it was considered that the S187D and S188T mutations may help form a salt bridge that stabilizes the active site, or the overall tertiary structure of the enzyme, thereby enhancing thermostability. While the S187D mutation in the context of an otherwise AmyL amino acid sequence is destabilizing with respect to thermal challenges, in the context of the chimeric amylases here, it is evident that the Asp residue present in the S187D mutants interacts with one or more amino acid residues from the AmyS portion of the molecule to result in enhanced stability. Thus, e.g. the chimeric amylases with 200, 202, and even 228 residues from the AmyL sequence had good thermostability provided that a salt-bridge or other stabilizing structure was included.

Example 4

Thermostability Screening of Third Generation Chimeric α-Amylases Derived from AmyL and AmyS Enzymes. Incorporation of Salt Bridges Stabilizing Chimeras with Longer AmyL Sequences

[0242] Based on the observations from Examples 2 and 3 on the first and second generation chimeras, it was believed that chimeras with longer portions of AmyL, and concomitantly less AmyS sequence could be produced. Chimeras were produced with up to 259 amino acid residues at the N-terminal portion derived from an AmyL, to determine whether chimeric amylases could be produced with both enhanced thermostability and high specific activity.

[0243] The chimeric α -amylases tested included 249SB, 254SB, and 259SB. The thermostability of each chimeric enzyme was tested at 95° C., and compared to that of the AmyS control, as in the preceding Examples. The assays and calculation of activity remaining were also performed as in the preceding Examples.

[0244] Results and Discussion. The results of the thermostability screen for the second set of chimeric amylases are shown in FIG. 4. As can be seen, each of the chimeric amylases show excellent thermostability under the conditions tested. These third-generation chimeric enzymes had 30-40% more AmyL sequence than the first-generation enzymes, which did not demonstrate good thermostability, showing that the rational incorporation of strategically-placed stabilizing structures, particularly salt bridges enabled chimeric α -amylases with the beneficial properties of both AmyL and AmyS to be made. These enzymes will thus be useful for all applications where thermostable amylases are currently used, such as starch degradation, HFCS production, desizing, and cleaning. Due to their increased specific activity and high thermostability, they will be particularly useful in starch liquefaction processes as they provide reduced peak viscosity, as well as low final viscosity of the starch slurry.

Example 5

Specific Activity of Chimeric α-Amylases Derived From AmyL and AmyS Enzymes

[0245] The chimeric α -amylases tested for specific activity were 186, 228 and 228SB. The evaluation included the AmyL protein (SEQ ID NO: 1) as well as the AmyS control (SEQ ID NO: 3). The specific activity of the five enzymes was determined at 75° C. using potato starch as the substrate and DNS reducing sugar assay to measure the relative reaction rates. **[0246]** Results and Discussion. The specific activity comparison results are shown in FIG. **5** as mg/mL glucose produced per second per mg/mL of enzyme. All three chimeric amylases showed significantly higher specific activity towards the substrate as compared to the AmyL amylase at this elevated temperature.

Example 6

Viscosity Changes with Hybrid Amylases

[0247] In this example, experiments were conducted to measure viscosity reduction in a viscometer for several chimeric amylases: 186, 228, 202SB and 228 SB, and for the

AmyS control (SEQ ID NO: 3), at pH 5.8 using viscosity measurement assay as described, using a EUROSTAR/IKA Labortechnik Control-Visc P7 electronic overhead stirrer with torque read output.

[0248] Results and Discussion. FIG. **6** shows that viscosity reduction for whole corn substrate is observed for several of the amylase chimeras tested. Consistent with results observed for protein stability (FIG. **2**), hybrid 186 performed comparably to the AmyS control in final viscosity. Chimera 228 had no effect on viscosity reduction under these conditions, consistent with its poor stability at high temperature (FIG. **2**).

Salt-bridged chimeras 202SB and 228 SB both showed reduction of viscosity in this assay. In the case of salt-bridged chimera 228SB, peak viscosity was the same as for the AmyS control, and final viscosity was lower than that observed for the AmyS control (FIG. **6**), clearly showing a benefit in performance.

[0249] It will be apparent to those skilled in the art that the chimeric α -amylases and the methods of making and using those chimeric amylases can be varied or modified without departing from the scope or spirit or of this disclosure. Thus, such variations and modifications are included within the scope of the appended claims.

SEQUENCE LISTING

<160> NUMBER OF SEQ ID NOS: 40 <210> SEO ID NO 1 <211> LENGTH: 483 <212> TYPE: PRT <213> ORGANISM: Bacillus licheniformis <400> SEOUENCE: 1 Thr Asn Leu Asn Gly Thr Leu Met Gln Tyr Phe Glu Trp Tyr Thr Pro 10 1 5 15 Asn Asp Gly Gln His Trp Lys Arg Leu Gln Asn Asp Ser Ala Tyr Leu 25 Ala Glu His Gly Ile Thr Ala Val Trp Ile Pro Pro Ala Tyr Lys Gly 40 Thr Ser Gln Ala Asp Val Gly Tyr Gly Ala Tyr Asp Leu Tyr Asp Leu 55 50 Gly Glu Phe His Gln Lys Gly Thr Val Arg Thr Lys Tyr Gly Thr Lys 65 70 75 80 Gly Glu Leu Gln Ser Ala Ile Lys Ser Leu His Ser Arg Asp Ile Asn 90 85 Val Tyr Gly Asp Val Val Ile Asn His Lys Gly Gly Ala Asp Ala Thr 100 105 Glu Asp Val Thr Ala Val Glu Val Asp Pro Ala Asp Arg Asn Arg Val 115 120 125 Ile Ser Gly Glu Tyr Leu Ile Lys Ala Trp Thr His Phe His Phe Pro 135 140 130
 Gly Arg Gly Ser Thr Tyr Ser Asp Phe Lys
 Trp His Trp Tyr His Phe

 145
 150
 155
 160
 Asp Gly Thr Asp Trp Asp Glu Ser Arg Lys Leu Asn Arg Ile Tyr Lys 165 170 175 Phe Gln Gly Lys Ala Trp Asp Trp Glu Val Ser Ser Glu Asn Gly Asn 185 180 190 Tyr Asp Tyr Leu Met Tyr Ala Asp Ile Asp Tyr Asp His Pro Asp Val 200 205 Val Ala Glu Ile Lys Arg Trp Gly Thr Trp Tyr Ala Asn Glu Leu Gln 215 220 210 Leu Asp Gly Phe Arg Leu Asp Ala Val Lys His Ile Lys Phe Ser Phe 230 225 235 240 Leu Arg Asp Trp Val Asn His Val Arg Glu Lys Thr Gly Lys Glu Met 245 250 255

-continued

												0011	CIII	ucu	
Phe	Thr	Val	Ala 260	Glu	Tyr	Trp	Gln	Asn 265	Asp	Leu	Gly	Ala	Leu 270	Glu	Asn
Tyr	Leu	Asn 275	Lys	Thr	Asn	Phe	Asn 280		Ser	Val	Phe	Asp 285	Val	Pro	Leu
His	Tyr 290	Gln	Phe	His	Ala	Ala 295		Thr	Gln	Gly	Gly 300	Gly	Tyr	Asp	Met
Arg 305		Leu	Leu	Asn	Gly 310	Thr	Val	Val	Ser	Lys 315	His	Pro	Leu	Lys	Ser 320
Val	Thr	Phe	Val	Asp 325	Asn	His	Asp	Thr	Gln 330	Pro	Gly	Gln	Ser	Leu 335	Glu
Ser	Thr	Val	Gln 340	Thr	Trp	Phe	Lys	Pro 345	Leu	Ala	Tyr	Ala	Phe 350	Ile	Leu
Thr	Arg	Glu 355	Ser	Gly	Tyr	Pro	Gln 360		Phe	Tyr	Gly	Asp 365	Met	Tyr	Gly
Thr	Lys 370	Gly	Asp	Ser	Gln	Arg 375		Ile	Pro	Ala	Leu 380	Lys	His	Lys	Ile
Glu 385	Pro	Ile	Leu	Lys	Ala 390	Arg	Lys	Gln	Tyr	Ala 395	Tyr	Gly	Ala	Gln	His 400
Asp	Tyr	Phe	Asp	His 405	His	Asp	Ile	Val	Gly 410	Trp	Thr	Arg	Glu	Gly 415	Asp
Ser	Ser	Val	Ala 420	Asn	Ser	Gly	Leu	Ala 425	Ala	Leu	Ile	Thr	Asp 430	Gly	Pro
Gly	Gly	Ala 435	Гла	Arg	Met	Tyr	Val 440	-	Arg	Gln	Asn	Ala 445	Gly	Glu	Thr
Trp	His 450	Asp	Ile	Thr	Gly	Asn 455	Arg	Ser	Glu	Pro	Val 460	Val	Ile	Asn	Ser
Glu 465	Gly	Trp	Gly	Glu	Phe 470	His	Val	Asn	Gly	Gly 475		Val	Ser	Ile	Tyr 480
	Gln	Arg													
<21()> SH	EO II	D NO	2											
<211	L> LH 2> TY	ENGTI	H: 4	86											
					illu	s st	earo	ther	moph	ilus					
<400)> SH	EQUEI	NCE :	2											
Ala 1	Ala	Pro	Phe	Asn 5	Gly	Thr	Met	Met	Gln 10	Tyr	Phe	Glu	Trp	Tyr 15	Leu
Pro	Asp	Asp	Gly 20	Thr	Leu	Trp	Thr	Lys 25	Val	Ala	Asn	Glu	Ala 30	Asn	Asn
Leu	Ser	Ser 35	Leu	Gly	Ile	Thr	Ala 40	Leu	Trp	Leu	Pro	Pro 45	Ala	Tyr	Lys
Gly	Thr 50	Ser	Arg	Ser	Asp	Val 55	Gly	Tyr	Gly	Val	Tyr 60	Asp	Leu	Tyr	Asp
Leu 65	Gly	Glu	Phe	Asn	Gln 70	Lys	Gly	Thr	Val	Arg 75	Thr	Lys	Tyr	Gly	Thr 80
ГÀа	Ala	Gln	Tyr	Leu 85	Gln	Ala	Ile	Gln	Ala 90	Ala	His	Ala	Ala	Gly 95	Met
Gln	Val	Tyr	Ala 100	Asp	Val	Val	Phe	Asp 105	His	ГЛа	Gly	Gly	Ala 110	Asp	Gly
Thr	Glu	Trp 115	Val	Asp	Ala	Val	Glu 120	Val	Asn	Pro	Ser	Asp 125	Arg	Asn	Gln

Gu Lie Ser Gly Thr Tyr Gin Lie Gin Ala Try The Jup Phe Asp Phe 100 101 102 105 105 105 105 105 105 105 105 105 105												-	con	tin	ued					 	 _
145150155155160Phe App Gly Val AppTrp App Glu Ser Arg Lyg Leu Ser Arg IleTrpLyg Phe Arg Cly Ile Gly Lyg Ala Tep App Trp Glu Val App Thr GluAnn Gly Ann Tyr App Tyr Leu Mee Tyr Ala App Leu App Met App His205Pro Glu Val Val Thr Glu Leu Lyg Ann Trp Gly Lyg Trp Tyr Val Ann210211Thr Thr Ann Ile App Gly Phe Arg Leu App Ala Val Lyg His Ile Lyg225226Phe Ser Phe Phe Pro App Trp Leu Ser Tyr Val Arg Ser Gln Thr Gly206Phe Ser Phe Phe Pro App Trp Leu Ser Tyr Nap Ile Ann Lyg207208Phe Ser Phe Phe Pro Pap Thr Ann Thr Leu Met Ser Lup Ser Gly Gly Nal209209201200201201201202203203204205205206206207208208209209201201201202203203204205205206206207208208209209209201201201202203203204205205205206206207208208209209 <t< td=""><td>Glu</td><td></td><td>Ser</td><td>Gly</td><td>Thr</td><td>Tyr</td><td></td><td>Ile</td><td>Gln</td><td>Ala</td><td>Trp</td><td></td><td>Lys</td><td>Phe</td><td>Asp</td><td>Phe</td><td></td><td></td><td></td><td> </td><td></td></t<>	Glu		Ser	Gly	Thr	Tyr		Ile	Gln	Ala	Trp		Lys	Phe	Asp	Phe				 	
Lye Phe Arg Giy Lie Giy Lye Ala Trp Aep Trp Glu Val Aep Thr GluAen Gly Aen Tyr Aep Tyr Leu Met Tyr Ala Aep Leu Aep Met Aep His195Pro Glu Val Val Thr Glu Leu Lye Ann Trp Gly Lye Trp Tyr Val Aen210210Pro Glu Val Val Thr Glu Leu Lye Ann Trp Gly Lye Trp Tyr Val Aen210211Pro Glu Val Val Thr Glu Leu Lye Aen Trp Gly Lye Trp Tyr Val Aen212213Pro Glu Val Val Thr Glu Gly Glu Tyr Trp Ser Tyr Aep Tle Aen Lye225Lye Pro Leu Phe Thr Val Gly Glu Tyr Trp Ser Tyr Aep Tle Aen Lye260Leu His Aen Tyr Ile Thr Lye Thr Aen Gly Thr Met See Leu Phe Aep260Phe Aep Met Arg Thr Leu Met Thr Aen Thr Leu Met Lye Aep Gln Pro260261Phe Aep Met Arg Thr Leu Met Thr Aen Thr Leu Met Lye Aep Gln Pro265266276276276276276277278287288298299290290291291292292293293294294295295296296297298298298299299299290290291292292293294295295295296296<		-	Arg	Gly	Asn		Tyr	Ser	Ser	Phe	-	Trp	Arg	Trp	Tyr						
180 185 190 Aen Gly Am Tyr Am Tyr Leu Met Tyr Ala Am Leu Am Met Am His 200 210 Yan Tyr Am Tyr Leu Met Tyr Ala Am Leu Am Met Am His 200 210 Val Val Thr Glu Leu Lys Am Trp Gly Lys Trp Tyr Val Am 211 Thr Glu Leu Lys Am Trp Gly Lys Trp Tyr Val Am 225 Thr Am Iie Am Gly Phe Arg Leu Am Ala Val Lye His Iie Lys 226 Phe Phe Pro Am Trp Gly Glu Tyr Trp Ser Tyr Am Jie Am Lys 226 Phe Phe Pro Am Tyr Lie U Ser Tyr Val Arg Ser Glu Thr Gly 226 Phe Jon Leu His Am Lys Thr Ala Ser Lys Ser Gly Gly Gly Ala 2260 Thr Luu His Am Lys Thr Ala Ser Lys Ser Gly Gly Gly Ala 2260 Thr Leu His Am Lys Thr Ala Ser Lys Ser Gly Gly Gla Si 2260 Thr Leu His Am Lys Thr Ala Ser Lys Ser Gly Gly Gla Ala 2260 Thr Leu His Am Lys Thr Ala Ser Lys Ser Gly Gly Gla Ala 2260 Thr Leu His Am Lys Thr Ala Ser Lys Ser Gly Gly Gla Si 310 Thr Fire Law Thr Am Thr Leu Met Thr Am Thr Leu Net Lys Asp Gln Pro 325 310 Thr Pro Cay Trp Pro Cys Val Pro Tyr Gly Gla Si 311 Thr Glu So Trp Val Am The Pro Ser Leu Lys Ser Lys The Si 312 Thr Glu So Trp Val Am The Pro Ser Leu Lys Ser Lys The Sis Si 313 Thr Glu	Phe	Asp	Gly	Val	_	Trp	Asp	Glu	Ser		Lya	Leu	Ser	Arg		Tyr					
195196200205Pro Glu Val Val Thr Glu Leu Lye Aan Trr Gly Lye Trp Tyr Val Aan 210200205Thr Thr Aan He Aap Gly Phe Arg Leu Aap Ala Val Lye HJe He Lye 235240Phe Ser Phe Phe Pro Aap Trp Leu Ser Tyr Val Arg Ser Gln Thr Gly 245245Lye Pro Leu Phe Thr Val Gly Glu Tyr Trp Ser Tyr Aap He Aan Lye 275Leu HJe Aan Tyr He Thr Lye Thr Aan Gly Thr Met Ser Leu Phe Aap 275Ala Pro Leu Hie Aan Lye Phe Tyr Thr Ala Ser Lye Ser Gly Gly Ala 280Phe Aap Ket Arg Thr Leu Met Thr Aan Thr Leu Met Lye Aap Gln Pro 310305Thr Leu Ala Val Thr Fw Val Aap Aan Hie Aap Thr Glu Pro Gly Gly Gli 345Ala Leu Gln Ser Trp Val Aap Aon Hie Aap Tyr Ala Tyr Ala 346306Phe He Leu Thr Arg Gln Glu Gly Tyr Pro Cye Val Phe Tyr Gly Aap 355307308Phe He Leu He Ala Arg Arg Ap Tyr Ala Tyr Gly Thr Gly Aap 366309Asp Pro Leu Leu He Ala Arg Arg Ap Tyr Ala Tyr Gly Thr Glu Fro 306309309300300301302303304305305305306307307308309309309300300301301302303304305305305306307307308309309309300300 </td <td>Lys</td> <td>Phe</td> <td>Arg</td> <td></td> <td></td> <td>Gly</td> <td>Lys</td> <td>Ala</td> <td></td> <td>Asp</td> <td>Trp</td> <td>Glu</td> <td>Val</td> <td></td> <td>Thr</td> <td>Glu</td> <td></td> <td></td> <td></td> <td></td> <td></td>	Lys	Phe	Arg			Gly	Lys	Ala		Asp	Trp	Glu	Val		Thr	Glu					
210 215 215 220 Thr Thr Aon Ile Aop Gly Phe Arg Leu Aop Ala Val Lyo His Ile Lys 240 Phe Ser Phe Phe Pro Aop Trp Leu Ser Tyr Val Arg Ser Gln Thr Gly 245 Lys Pro Leu Phe Thr Val Gly Glu Tyr Trp Ser Tyr Aop Ile Aon Lys 275 Leu His Aon Tyr Ile Thr Lyo Thr Aon Gly Thr Met Ser Leu Phe Asp 275 Ala Pro Leu His Aon Lys Phe Tyr Thr Ala Ser Lys Ser Gly Gly Ala 200 Phe Arg Met Arg Thr Leu Met Thr Aon Thr Leu Met Lys Acp Gln Pro 315 Sof Aop Met Arg Thr Val Gl Glu Gly Tyr Pro Cys Val Phe Tyr Gly Gln 335 Ala Leu Gln Ser Try Val Asp Pro Trp Phe Lys Pro Leu Ala Tyr Ala 350 Phe Ile Leu Thr Arg Gln Glu Gly Tyr Pro Cys Val Phe Tyr Gly Asp 365 Tyr Tyr Gly Ile Pro Gln Tyr Asn Ile Pro Ser Leu Lys Ser Lys Ile 380 Aop Tyr Leu Asp Karg Arg Apg Tyr Ala Tyr Gly Thr Gln His 390 Apg Tyr Leu Asp His Ser Asp Ile Ile Gly Trp Thr Arg Glu Gly Val 415 Apg Tyr Leu Asp His Ser Asp Ile Ile Gly Trp Thr Arg Glu Gly Val 415 Apg Tyr Leu Asp His Ser Asp Ile Ile Gly Trp Thr Arg Glu Gly Val 415 Apg Tyr Leu Asp His Reg Ser Asp Thr Val Thr Ile Asn Ser Lys Val 445 Apg Tyr Leu Asp His Reg Ser Asp Thr Val Thr Ile Asp Ser Val 540 Apg Tyr Leu Asp His Reg Ser Asp Thr Val Thr Ile Asp Ser Val 540 Apg Tyr Leu Asp His Reg Ser Asp Thr Val Thr Ile Asp Ser Val 540 Apg Tyr Leu Asp His Reg Ser Asp Thr Val Thr Ile Asp Ser 450 Apg Gl	Asn	Gly			Asp	Tyr	Leu		-	Ala	Asp	Leu		Met	Asp	His					
225230230235240Phe Ser Phe Phe Pro Amp Try Leu Ser Tyr Val Arg Ser Gin Thr Gly 245250250250Lyg Pro Leu Phe Thr Val Gly Glu Tyr Try Ser Tyr Amp Tile Am Lyg 260260777Amp Tile Am Lyg 270Leu His Am Tyr Ile Thr Lyg Thr Am Cly Thr Met Ser Leu Phe Amp 290285Gly Gly Ala 300Phe Amp Met Arg Thr Lau Net Thr Am Thr Leu Ser Lyg Ser Gly Gly Ala 290780780Phe Amp Met Arg Thr Phe Val Amp Am His Amp Thr Glu Pro 315791791Ala Leu Gln Ser Try Val Amp Pro Try Phe Lyg Pro Leu Ala Tyr Ala 340791791Phe Leu Thr Ang Gln Glu Gly Tyr Pro Cyg Val Phe Tyr Gly Amp 355797791Tyr Tyr Gly Ile Pro Gln Tyr Am Ile Pro Ser Leu Lyg Ser Lyg Ile 370795791Amp Tyr Leu Amp His Ser Amp Ile Ile Gly Trp Thr Ang Glu Gly Val 445792Amp Tyr Leu Amp His Ser Amp Ile Ile Gly Trp Thr Ang Glu Gly Val 445792Gly Gly Ser Lyg Trp Met Tyr Val Gly Lyg Gln His Ala Gly Lyg Val 445Amp Cury Amp Leu Thr Gly Am Ang Ser Amp Thr Val Gly Lyg Val 445Amp Gly Trp Gly Glu Phe Lyg Val Amp Gly Cury 475Amp Gly Trp Gly Glu Phe Lyg Val Amp Gly Cury 475Amp Gly Trp Gly Glu Phe Lyg Val Amp Gly Cury 475Amp Cury Amp Leu Thr ThrAmp Cury Try Amp	Pro		Val	Val	Thr	Glu		Lys	Asn	Trp	Gly	-	Trp	Tyr	Val	Asn					
245250255Lya Pro Leu Phe Thr Val Gly Glu Tyr Trp Ser Tyr Am 1e Am Lya 255266Leu His Am Tyr Ile Thr Lya Thr Am Gly Thr Met Ser Leu Phe Am 275Ala Pro Leu Hie Am Lya Phe Tyr Thr Ala Ser Lya Ser Gly Gly Gly Ala 290Phe Am Met Arg Thr Leu Met Thr Am Thr Leu Met Lya Am Gly Gln Pro 310Ana Leu Gln Ser Trp Val Am Pro Trp Phe Lya Pro Leu Ala Tyr Ala 340Phe Ile Leu Thr Arg Gln Glu Gly Tyr Pro Cya Val Phe 310Phe Ile Leu Thr Arg Gln Glu Gly Tyr Pro Cya Val Phe 346Phe Ile Leu Thr Am Gln Glu Gly Tyr Pro Cya Val Phe 346Phe Ile Leu Thr Am Gln Glu Gly Tyr Pro Cya Val Phe 346Phe Tle Leu Am Val Thr Met Ser Am 440Am Glu Ser Trp Val Am Am Am Am Am Tyr Gly Gly Thr Gln His 346Am Tyr Tyr Gly Gly Ser Gly Leu Ala Ala Leu Ile Thr Am Gly Lya Gly Pro 440Am Tyr Leu Am His Ser Am Thr Leu Am Gly Cly am Thr Am Gly Lya Gly Pro 440Am Gly Ser Lya Trp Met Tyr Yal Gly Lya Gly Thr Mat Gly Lya Val 445Am Tyr Gly Gly Ser Gly Leu Ala Ala La Leu Ile Thr Am Ser 440Am Gly Ser Lya Thr Gly Am Arg Ser Am Thr Val Thr Ile Am Ser 440Am Tyr Am Leu Thr Gly Am Arg Ser Am Thr Val Thr Ile Am Ser 440Am Tyr Am Leu Thr Gly Am Arg Ser Am Thr Val Thr Ile Am Ser 450Am Tyr Am Leu Thr Gly Gly Thr Gly Am Arg Ser Am Thr Val Thr Ile Am Ser 450Am Tyr Am Leu Thr Gly Am Arg Ser Am Thr Val Thr Ile Am Ser 450Am Tyr Am Leu Thr Gly Am Arg Ser Am Thr Val Thr Ile Am Ser 450Am Tyr Am Leu Thr Gly Am Arg Ser Am Thr Val Thr Ile Am Ser 450Am Tyr Am Leu Thr Gly Gly Thr Gly Gly Ser Val Ser Val Trp 465Am Tyr Am Leu Thr Gly Gly Thr Thr 4			Asn	Ile	Asp	-	Phe	Arg	Leu	Asp		Val	Lys	His	Ile	-					
Lew Hie Aen Tyr Ile Thr Lyr Thr Aen Gly Thr Met Ser Lew Phe Aep 275 Ala Pro Lew Hie Aen Lyr Phe Tyr Thr Ala Ser Lyr Ser Gly Gly Ala 290 Phe Asp Met Arg Thr Lew Met Thr Aen Thr Lew Met Lyr Aep Gln Pro 310 310 Thr Lew Ala Val Thr Phe Val Aep Aen Hie Aep Thr Glu Pro Gly Gln 330 Ala Lew Gln Ser Trp Val Aep Pro Trp Phe Lyr Pro Lew Ala Tyr Ala 340 Phe Ile Lew Thr Arg Gln Glu Gly Tyr Pro Cyr Val Phe Tyr Gly Aep 345 Tyr Tyr Gly Ile Pro Gln Tyr Aen Ile Pro Ser Lew Lyr Ser Lyr Ile 370 Arg Tyr Lew Aep His Ser Aep Ile Ile Gly Trp Thr Arg Glu Gly Val 405 Aep Tyr Lew Aep His Ser Aep Ile Ile Gly Trp Thr Arg Glu Gly Val 410 Thr Glu Lyr Pro Gly Ser Gly Lew Ala Ala Lew Ile Thr Aep Gly Pro 420 Gly Gly Ser Lyr Gly Aen Try Val App Net Tyr Val Arg Gln His Ala Gly Lyr Val 445 Aeg Gly Trp Gly Gly Den Tyr Val Ang Gly Gly Ser Val Ser Val 445 Aeg Gly Trp Gly Gly Den Tyr Val Ang Gly Gly Ser Val Ser Val 445 Val Pro Arg Lyr Gly Thr Thr 445 Val Pro Arg Lyr Thr Mar 445 Val Pro Arg Lyr Thr Chy Map	Phe	Ser	Phe	Phe		Asp	Trp	Leu	Ser		Val	Arg	Ser	Gln		Gly					
275 280 285 Ala Pro Leu His Asn Lys Phe Tyr Thr Ala Ser Lys Ser Gly Gly Ala Phe Asp Met Arg Thr Leu Mathematication Mathematication Thr Asp Thr Asp Asp Thr Leu Mathematication Thr Asp Asp Thr Leu Asp Thr Pro Try Tyr Tyr <td>Lys</td> <td>Pro</td> <td>Leu</td> <td></td> <td>Thr</td> <td>Val</td> <td>Gly</td> <td>Glu</td> <td>-</td> <td>Trp</td> <td>Ser</td> <td>Tyr</td> <td>Asp</td> <td></td> <td>Asn</td> <td>Lys</td> <td></td> <td></td> <td></td> <td></td> <td></td>	Lys	Pro	Leu		Thr	Val	Gly	Glu	-	Trp	Ser	Tyr	Asp		Asn	Lys					
290295300PheAspMetArgThrLeuMetThrAsnThrLeuMetLysAspGln320ThrLeuAlaValThrPheValAspAsnThrBaspThrGluProGlyGln310320310310MathThrPheValAspAspThrGluProGlyGly3111ThrPheValAspAspAspPheLysProGlyGlyGly312ThrValAspProTrpPheLysProLysAspThrAsp325ThrGlyGlyThrAspThrAspProCysValPheTyrGlyAsp7yrTyrGlyGlyThrAspThrAspTyrProSerLysSerLysIle355TyrGlyGlyThrGlnTyrAspTyrAspSerLysSerLysIle355TyrGlyGlySerLysSerLysSerLysIleAsp7yrGlyGlyFerGlyTyrFroSerLysSerLysSerLysIle355TyrGlyGlyGlyTyrAspFroSerGlyHisHisAsp <td>Leu</td> <td>His</td> <td></td> <td>Tyr</td> <td>Ile</td> <td>Thr</td> <td>Lys</td> <td></td> <td>Asn</td> <td>Gly</td> <td>Thr</td> <td>Met</td> <td></td> <td>Leu</td> <td>Phe</td> <td>Asp</td> <td></td> <td></td> <td></td> <td></td> <td></td>	Leu	His		Tyr	Ile	Thr	Lys		Asn	Gly	Thr	Met		Leu	Phe	Asp					
305 310 315 320 Thr Leu Ala Val Thr Phe Val Asp Asn His Asp Thr Glu Pno Gly Gln 335 Glu Clu Ser Try Val Asp Pro Trp Phe Lys Pro Leu Ala Tyr Ala 350 Ala Leu Glu Ser Try Val Asp Clu Cly Tyr Pro Cys Val Phe Tyr Gly Asp 355 Tyr Ala 350 Tyr Tyr Gly Ile Pro Gln Tyr Asn Ile Pro Ser Leu Lys Ser Lys Ile 380 Thr Glu Lue Asp His Ser Asp Tle Ile Gly Tyr Thr Arg Glu Gly Val 415 Asp Pro Leu Leu Ile Ala Arg Arg Asp Tyr Ala Tyr Ala 380 Thr Arg Glu Gly Leu Ala Ala Leu Ile Thr Asp Gly Val 415 Gly Gly Ser Lys Trp Met Tyr Val Gly Lys Gln His Ala Gly Lys Val 415 Thr Add 415 Fhe Tyr Asp Leu Thr Gly Asn Arg Ser Asp Thr Val Asp 416 Thr Add 415 Asp Pro Leu Leu Thr Gly Asn Arg Ser Asp Thr Val 425 Thr Add 415 Cly Ser Lys Trp Met Tyr Val Gly Lys Gln His Ala Gly Lys Val 445 Asp Gly Trp Gly Glu Phe Lys Val Asn Gly Gly Ser Val Ser Val Trp 480 Asp Gly Trp Gly Glu Phe Lys Val Asn Gly Gly Ser Val Ser Val Trp 480 Val Pro Arg Lys Thr Thr 484 Vall Pro Arg Lys Thr Thr 484 Vall Pro Kry EPR PRT Vall Pro Reg Lys ORD DN 3 Vall Pro Reg Lys Thr PRE PRT Vall Pro Arg Lys Thr Thr 484 Vall Pro Kry EPR PRT Vall Pro RPR PRT Ser Club Sec Lys PRT Vall Pro RPR PRT Vall Pro Arg Lys Thr Thr 485 </td <td>Ala</td> <td></td> <td>Leu</td> <td>His</td> <td>Asn</td> <td>Lys</td> <td></td> <td>Tyr</td> <td>Thr</td> <td>Ala</td> <td>Ser</td> <td>-</td> <td>Ser</td> <td>Gly</td> <td>Gly</td> <td>Ala</td> <td></td> <td></td> <td></td> <td></td> <td></td>	Ala		Leu	His	Asn	Lys		Tyr	Thr	Ala	Ser	-	Ser	Gly	Gly	Ala					
325 330 335 Ala Leu Gln Ser Try Val Asp Try Try Sing Gln Try Val Asp Try Try Sing Gln Glu Gly Try Pro Cry Val Asp Sing Try Sing Gln Gln Gly Try Pro Cry Val Asp Sing Try Try Gly IIe Tro Sing Try Sing Gln Gln Try Asn IIe Pro Ser Leu Lry Sing Cry			Met	Arg	Thr		Met	Thr	Asn	Thr		Met	Lys	Asp	Gln						
340 345 350 Phe Ile Leu Thr Arg Glu Gly Tyr Pro Cys Val Phe Tyr Gly Asp Tyr Tyr Gly Glu Ile Tyr Asn Ile Pro Cys Val Phe Tyr Gly Asp Tyr Tyr Gly Ile Pro Gln Tyr Asn Ile Pro Ser Lue Ile Asp Pro Leu Ile Ala Arg Asp Tyr Gly Thr Gln Gly Asp Tyr Asp Asp Tyr Asp Asp Tyr Asp Asp Asp Asp Ile Asp Asp Ile A	Thr	Leu	Ala	Val		Phe	Val	Asp	Asn		Asp	Thr	Glu	Pro		Gln					
355360365TyrGlyIleProGlnTyrAsnIleProSerLeuLysSerLysIleAspProLeuIleAlaArgArgArgAspTyrGlyThrGlnHis385ProLeuIleAlaArgArgArgArgTyrAlaTyrGlyThrGlnHis385ProLeuAlaArgArgArgArgTyrAlaTyrGlyThrGlyAlaAspTyrLeuAspHisSerAspIleGlyTyrThrArgGluGlyValAspTyrLeuAspHisSerAspIleIleGlyTyrGluGlyValAspTyrLeuAspHisAspClyTyrAlaGlyValAspGlyPro420SerLysTyrValAspGlyGlyLeuAlaAlaLeuIleAspGlyPro410YarValAspFirValAspFirAspAspFirAsp </td <td>Ala</td> <td>Leu</td> <td>Gln</td> <td></td> <td>Trp</td> <td>Val</td> <td>Asp</td> <td>Pro</td> <td></td> <td>Phe</td> <td>Гла</td> <td>Pro</td> <td>Leu</td> <td></td> <td>Tyr</td> <td>Ala</td> <td></td> <td></td> <td></td> <td></td> <td></td>	Ala	Leu	Gln		Trp	Val	Asp	Pro		Phe	Гла	Pro	Leu		Tyr	Ala					
370375380AspProLeuIleAlaArgArgAspTyrAlaTyrGlyThrGlnHis385ProLeuLeuIleAlaArgArgAspTyrAlaTyrGlyThrGlnHisAspTyrLeuAspHisSerAspIleIleGlyThrArgGluGlyValAspTyrLeuAspHisSerAspIleIleGlyThrArgGlyValGlyGlySerLysTrpMetTyrValGlyLysGlyValAspGlySerLysTrpMetTyrValGlyLysValAspGlySerLysTrpMetTyrValGlyLysValAspGlyTrpGlyAspForMashGlySerValAshAspGlyTrpGlyGluPheLysValAshGlySerValSerValAspGlyTrpGlyGluPheLysValAshGlySerValSerValYas465GlySerThrHaSerValSerValSerValYas<210>SEQIDN0SSerSerSerSerSerSerSer<	Phe	Ile		Thr	Arg	Gln	Glu		Tyr	Pro	Cys	Val		Tyr	Gly	Asp					
385 390 395 400 Asp Tyr Leu Asp His Ser Asp Ile Ile Gly Trp Thr Arg Glu Gly Val 415 Thr Glu Lys Pro Gly Ser Gly Leu Ala Ala Leu Ile Thr Asp Gly Pro 420 Gly Gly Ser Lys Trp Met Tyr Val Gly Lys Gln His Ala Gly Lys Val 445 Phe Tyr Asp Leu Thr Gly Asn Arg Ser Asp Thr Val Thr Ile Asn Ser 460 Asp Gly Trp Gly Glu Phe Lys Val Asn Gly Gly Ser Val Ser Val Ser Val 774 Val Pro Arg Lys Thr Thr 485 <210> SEQ ID NO 3 <211> LENGTH: 484 <212> TYPE: PRT <213> ORGANISM: Bacillus stearothermophilus	Tyr	-	-	Ile	Pro	Gln		Asn	Ile	Pro	Ser		Lys	Ser	Lys	Ile					
405 410 415 Thr Glu Lys Pro Gly Ser Gly Leu Ala Ala Ileu Ile Thr Aga Gly Pro Glu Lys Pro Gly Ser Gly Ser Ala Ala Ala Ileu Ile Thr Aga Gly Pro Glu Gly Ser Lys Ring Gly Ser Aga Ser Aga Ser Aga Aga Ser Aga <	~		Leu	Leu	Ile		Arg	Arg	Asp	Tyr		Tyr	Gly	Thr	Gln						
420 425 430 Gly Gly Ser Lys Trp Met Tyr Val Gly Lys Gly Lys Val Phe Tyr Asp Leu Thr Gly Asr Arg Ser Asp Trp Gly Mash Arg Ser Asn Gly Gly Ser Val	Asp	Tyr	Leu	Asp		Ser	Asp	Ile	Ile		Trp	Thr	Arg	Glu		Val					
435 440 445 Phe Tyr Asp Leu Thr Gly Asn Arg Ser Asp Thr Val Thr Ile Asn Ser 450 Asp Gly Trp Gly Glu Phe Lys Val Asn Gly Gly Ser Val Ser Val Trp 465 Val Pro Arg Lys Thr Thr 485 <210> SEQ ID NO 3 <211> LENGTH: 484 <212> TYPE: PRT <213> ORGANISM: Bacillus stearothermophilus	Thr	Glu	Lys			Ser	Gly	Leu		Ala	Leu	Ile	Thr			Pro					
450 455 460 Asp Gly Trp Gly Glu Phe Lys Val Asn Gly Gly Ser Val Ser Val Trp 465 470 475 480 Val Pro Arg Lys Thr Thr 485 <210> SEQ ID NO 3 <211> LENGTH: 484 <212> TYPE: PRT <213> ORGANISM: Bacillus stearothermophilus	Gly	Gly		-	Trp	Met				Lys	Gln	His		Gly	Lys	Val					
465 470 475 480 Val Pro Arg Lys Thr Thr 485 <210> SEQ ID NO 3 <211> LENGTH: 484 <212> TYPE: PRT <213> ORGANISM: Bacillus stearothermophilus	Phe			Leu	Thr	Gly		Arg	Ser	Asp			Thr	Ile	Asn	Ser					
485 <210> SEQ ID NO 3 <211> LENGTH: 484 <212> TYPE: PRT <213> ORGANISM: Bacillus stearothermophilus			Trp	Gly	Glu		ГЛЗ	Val	Asn			Ser	Val	Ser	Val	-					
<211> LENGTH: 484 <212> TYPE: PRT <213> ORGANISM: Bacillus stearothermophilus	Val	Pro	Arg	Lys		Thr															
	<21 <21 <21	1> L] 2> T 3> O]	ENGTI YPE : RGANI	H: 4 PRT ISM:	84 Bac:	illu:	s ste	earo	therr	noph:	ilus										

Ala	Ala	Pro	Phe	Asn	Glv	Thr	Met	Met	Gln	Tvr	Phe	Glu	Trn	Tvr	Leu
1	TIL G		1110	5	017		mee		10	- / -	1110	oru		15	Dea
Pro	Asp	Asp	Gly 20	Thr	Leu	Trp	Thr	Lys 25	Val	Ala	Asn	Glu	Ala 30	Asn	Asn
Leu	Ser	Ser 35	Leu	Gly	Ile	Thr	Ala 40	Leu	Trp	Leu	Pro	Pro 45	Ala	Tyr	Гла
Gly	Thr 50	Ser	Arg	Ser	Asp	Val 55	Gly	Tyr	Gly	Val	Tyr 60	Asp	Leu	Tyr	Asp
Leu 65	Gly	Glu	Phe	Asn	Gln 70	Lys	Gly	Thr	Val	Arg 75	Thr	Lys	Tyr	Gly	Thr 80
Lys	Ala	Gln	Tyr	Leu 85	Gln	Ala	Ile	Gln	Ala 90	Ala	His	Ala	Ala	Gly 95	Met
Gln	Val	Tyr	Ala 100	Asp	Val	Val	Phe	Asp 105	His	Lys	Gly	Gly	Ala 110	Asp	Gly
Thr	Glu	Trp 115	Val	Asp	Ala	Val	Glu 120	Val	Asn	Pro	Ser	Asp 125	Arg	Asn	Gln
Glu	Ile 130	Ser	Gly	Thr	Tyr	Gln 135	Ile	Gln	Ala	Trp	Thr 140	Lys	Phe	Asp	Phe
Pro 145	Gly	Arg	Gly	Asn	Thr 150	Tyr	Ser	Ser	Phe	Lys 155	Trp	Arg	Trp	Tyr	His 160
Phe	Asp	Gly	Val	Asp 165	Trp	Asp	Glu	Ser	Arg 170	Lys	Leu	Ser	Arg	Ile 175	Tyr
ГÀа	Phe	Ile	Gly 180	ГЛа	Ala	Trp	Asp	Trp 185	Glu	Val	Asp	Thr	Glu 190	Asn	Gly
Asn	Tyr	Asp 195	Tyr	Leu	Met	Tyr	Ala 200	Asp	Leu	Asp	Met	Asp 205	His	Pro	Glu
Val	Val 210	Thr	Glu	Leu	Lys	Asn 215	Trp	Gly	Lys	Trp	Tyr 220	Val	Asn	Thr	Thr
Asn 225	Ile	Asp	Gly	Phe	Arg 230	Leu	Asp	Ala	Val	Lys 235	His	Ile	Lys	Phe	Ser 240
Phe	Phe	Pro	Asp	Trp 245	Leu	Ser	Tyr	Val	Arg 250	Ser	Gln	Thr	Gly	Lys 255	Pro
Leu	Phe	Thr	Val 260	Gly	Glu	Tyr	Trp	Ser 265	Tyr	Asp	Ile	Asn	Lys 270	Leu	His
Asn	Tyr	Ile 275	Thr	Lys	Thr	Asn	Gly 280	Thr	Met	Ser	Leu	Phe 285	Asp	Ala	Pro
Leu	His 290	Asn	Lys	Phe	Tyr	Thr 295	Ala	Ser	Lys	Ser	Gly 300	Gly	Ala	Phe	Asp
Met 305	Arg	Thr	Leu	Met	Thr 310	Asn	Thr	Leu	Met	Lys 315	Asp	Gln	Pro	Thr	Leu 320
Ala	Val	Thr	Phe	Val 325	Asp	Asn	His	Aab	Thr 330	Glu	Pro	Gly	Gln	Ala 335	Leu
Gln	Ser	Trp	Val 340	Asp	Pro	Trp	Phe	Lys 345	Pro	Leu	Ala	Tyr	Ala 350	Phe	Ile
Leu	Thr	Arg 355	Gln	Glu	Gly	Tyr	Pro 360	Суз	Val	Phe	Tyr	Gly 365	Asp	Tyr	Tyr
Gly	Ile 370	Pro	Gln	Tyr	Asn	Ile 375	Pro	Ser	Leu	Lys	Ser 380	Lys	Ile	Asp	Pro
Leu 385	Leu	Ile	Ala	Arg	Arg 390	Asp	Tyr	Ala	Tyr	Gly 395	Thr	Gln	His	Asp	Tyr 400

Leu Asp His Ser Asp Ile Ile Gly Trp Thr Arg Glu Gly Val Thr Glu Lys Pro Gly Ser Gly Leu Ala Ala Leu Ile Thr Asp Gly Pro Gly Gly Ser Lys Trp Met Tyr Val Gly Lys Gln His Ala Gly Lys Val Phe Tyr Asp Leu Thr Gly Asn Arg Ser Asp Thr Val Thr Ile Asn Ser Asp Gly Trp Gly Glu Phe Lys Val Asn Gly Gly Ser Val Ser Val Trp Val Pro Arg Lys Thr Thr <210> SEQ ID NO 4 <211> LENGTH: 483 <212> TYPE: PRT <213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: Hybrid comprising N-terminal portion of AmyL through position 186, and C-terminal portion from AmyS <400> SEQUENCE: 4 Thr Asn Leu Asn Gly Thr Leu Met Gln Tyr Phe Glu Trp Tyr Thr Pro Asn Asp Gly Gln His Trp Lys Arg Leu Gln Asn Asp Ser Ala Tyr Leu Ala Glu His Gly Ile Thr Ala Val Trp Ile Pro Pro Ala Tyr Lys Gly Thr Ser Gln Ala Asp Val Gly Tyr Gly Ala Tyr Asp Leu Tyr Asp Leu Gly Glu Phe His Gln Lys Gly Thr Val Arg Thr Lys Tyr Gly Thr Lys 65 70 75 80 Gly Glu Leu Gln Ser Ala Ile Lys Ser Leu His Ser Arg Asp Ile Asn Val Tyr Gly Asp Val Val Ile Asn His Lys Gly Gly Ala Asp Ala Thr Glu Asp Val Thr Ala Val Glu Val Asp Pro Ala Asp Arg Asn Arg Val Ile Ser Gly Glu Tyr Leu Ile Lys Ala Trp Thr His Phe His Phe Pro Gly Arg Gly Ser Thr Tyr Ser Asp Phe Lys Trp His Trp Tyr His Phe Asp Gly Thr Asp Trp Asp Glu Ser Arg Lys Leu Asn Arg Ile Tyr Lys Phe Gl
n Gly Lys Ala Tr
p Asp Tr
p Glu Val Asp Thr Glu As
n Gly Asn Tyr Asp Tyr Leu Met Tyr Ala Asp Leu Asp Met Asp His Pro Glu Val Val Thr Glu Leu Lys Asn Trp Gly Lys Trp Tyr Val Asn Thr Thr Asn Ile Asp Gly Phe Arg Leu Asp Ala Val Lys His Ile Lys Phe Ser Phe Phe Pro Asp Trp Leu Ser Tyr Val Arg Ser Gln Thr Gly Lys Pro Leu

-continued

											-	con	tin	ued		
Phe	Thr	Val	Gly 260	Glu	Tyr	Trp	Ser	Tyr 265	Asp	Ile	Asn	Lys	Leu 270	His	Asn	
Tyr	Ile	Thr 275	Lys	Thr	Asn	Gly	Thr 280	Met	Ser	Leu	Phe	Asp 285	Ala	Pro	Leu	
His	Asn 290	Lys	Phe	Tyr	Thr	Ala 295	Ser	Lys	Ser	Gly	Gly 300	Ala	Phe	Asp	Met	
Arg 305	Thr	Leu	Met	Thr	Asn 310	Thr	Leu	Met	Lys	Asp 315	Gln	Pro	Thr	Leu	Ala 320	
Val	Thr	Phe	Val	Asp 325	Asn	His	Asp	Thr	Glu 330	Pro	Gly	Gln	Ala	Leu 335	Gln	
Ser	Trp	Val	Asp 340	Pro	Trp	Phe	Lys	Pro 345	Leu	Ala	Tyr	Ala	Phe 350	Ile	Leu	
Thr	Arg	Gln 355	Glu	Gly	Tyr	Pro	Cys 360	Val	Phe	Tyr	Gly	Asp 365	Tyr	Tyr	Gly	
Ile	Pro 370	Gln	Tyr	Asn	Ile	Pro 375	Ser	Leu	Lys	Ser	Lys 380	Ile	Asp	Pro	Leu	
Leu 385	Ile	Ala	Arg	Arg	Asp 390	Tyr	Ala	Tyr	Gly	Thr 395	Gln	His	Asp	Tyr	Leu 400	
Asp	His	Ser	Asp	Ile 405	Ile	Gly	Trp	Thr	Arg 410	Glu	Gly	Val	Thr	Glu 415	Lys	
Pro	Gly	Ser	Gly 420	Leu	Ala	Ala	Leu	Ile 425	Thr	Asp	Gly	Pro	Gly 430	Gly	Ser	
Lys	Trp	Met 435	Tyr	Val	Gly	Гла	Gln 440	His	Ala	Gly	Lys	Val 445	Phe	Tyr	Asp	
Leu	Thr 450	Gly	Asn	Arg	Ser	Asp 455	Thr	Val	Thr	Ile	Asn 460	Ser	Asp	Gly	Trp	
Gly 465	Glu	Phe	Lys	Val	Asn 470	Gly	Gly	Ser	Val	Ser 475	Val	Trp	Val	Pro	Arg 480	
ГЛа	Thr	Thr														
<211 <212 <213 <220	> LE > T\ > OF > FE > O	ENGTH YPE : RGAN EATUH THER	ISM: RE: INF(33 Art: DRMA	rion	: Hyl		-		-				rtior Amys		AmyL
<400)> SH	EQUEI	NCE :	5												
Thr 1	Asn	Leu	Asn	Gly 5	Thr	Leu	Met	Gln	Tyr 10	Phe	Glu	Trp	Tyr	Thr 15	Pro	
Asn	Asp	Gly	Gln 20	His	Trp	ГАЗ	Arg	Leu 25	Gln	Asn	Asp	Ser	Ala 30	Tyr	Leu	
Ala	Glu	His 35	Gly	Ile	Thr	Ala	Val 40	Trp	Ile	Pro	Pro	Ala 45	Tyr	Lys	Gly	
Thr	Ser 50	Gln	Ala	Asp	Val	Gly 55	Tyr	Gly	Ala	Tyr	Asp 60	Leu	Tyr	Asp	Leu	
Gly 65	Glu	Phe	His	Gln	Lys 70	Gly	Thr	Val	Arg	Thr 75	ГЛа	Tyr	Gly	Thr	Lуз 80	
00			Gln	Ser	<u> </u>	TIA	Lvs	Ser	Leu	His	Ser	Arg	Asp	Ile	Asn	
	Glu	Leu	GIII	85	лта	110	2,5		90					95		

-cont	٦r	າມຄ	C

														ued	
Glu	Asp	Val 115	Thr	Ala	Val	Glu	Val 120	Asp	Pro	Ala	Asp	Arg 125	Asn	Arg	Val
Ile	Ser 130	Gly	Glu	Tyr	Leu	Ile 135	ГЛа	Ala	Trp	Thr	His 140	Phe	His	Phe	Pro
Gly 145	Arg	Gly	Ser	Thr	Tyr 150	Ser	Asp	Phe	ГЛа	Trp 155	His	Trp	Tyr	His	Phe 160
Asp	Gly	Thr	Asp	Trp 165	Asp	Glu	Ser	Arg	Lys 170	Leu	Asn	Arg	Ile	Tyr 175	Lys
Phe	Gln	Gly	Lys 180	Ala	Trp	Asp	Trp	Glu 185	Val	Ser	Thr	Glu	Asn 190	Gly	Asn
Tyr	Aap	Tyr 195	Leu	Met	Tyr	Ala	Asp 200	Leu	Asp	Met	Aap	His 205	Pro	Glu	Val
Val	Thr 210	Glu	Leu	Lys	Asn	Trp 215	Gly	Lys	Trp	Tyr	Val 220	Asn	Thr	Thr	Asn
Ile 225	Asp	Gly	Phe	Arg	Leu 230	Asp	Ala	Val	Lys	His 235	Ile	Lys	Phe	Ser	Phe 240
Phe	Pro	Asp	Trp	Leu 245	Ser	Tyr	Val	Arg	Ser 250	Gln	Thr	Gly	Lys	Pro 255	Leu
Phe	Thr	Val	Gly 260	Glu	Tyr	Trp	Ser	Tyr 265	Asp	Ile	Asn	Гла	Leu 270	His	Asn
Tyr	Ile	Thr 275	Lys	Thr	Asn	Gly	Thr 280	Met	Ser	Leu	Phe	Asp 285	Ala	Pro	Leu
His	Asn 290	Lys	Phe	Tyr	Thr	Ala 295	Ser	Lys	Ser	Gly	Gly 300	Ala	Phe	Asp	Met
Arg 305	Thr	Leu	Met	Thr	Asn 310	Thr	Leu	Met	Lys	Asp 315	Gln	Pro	Thr	Leu	Ala 320
	Thr	Phe	Val	Asp 325	Asn	His	Asp	Thr	Glu 330		Gly	Gln	Ala	Leu 335	Gln
Ser	Trp	Val	Asp 340		Trp	Phe	Lys	Pro 345		Ala	Tyr	Ala	Phe 350		Leu
Thr	Arg	Gln 355		Gly	Tyr	Pro	Сув 360		Phe	Tyr	Gly	Asp 365		Tyr	Gly
Ile	Pro 370		Tyr	Asn	Ile	Pro 375		Leu	Lys	Ser	Lys 380		Asp	Pro	Leu
		Ala	Arg	Arg	Asp	Tyr	Ala	Tyr	Gly			His	Asp	Tyr	
385 Asp	His	Ser	Asp		390 Ile			Thr	Arg	395 Glu	Gly	Val	Thr		400 Lys
Pro	Gly	Ser	_	405 Leu	Ala	Ala	Leu		410 Thr	Asp	Gly	Pro	-	415 Gly	Ser
Lys	Trp		420 Tyr	Val	Gly	Гла		425 His	Ala	Gly	Гла		430 Phe	Tyr	Asp
Leu		435 Gly	Asn	Arg	Ser		440 Thr	Val	Thr	Ile		445 Ser	Asp	Gly	Trp
-	450 Glu	Phe	Гла	Val	Asn	455 Gly	Gly	Ser	Val		460 Val	Trp	Val	Pro	-
465	Thr	Thr			470					475					480

<212> TYPE: PRT <213> ORGANISM: Artificial

		THER	INF	ORMA											n of AmyL	
< 40	0> SI	EQUEI	NCE :	6						-				-		
Thr 1	Asn	Leu	Asn	Gly 5	Thr	Leu	Met	Gln	Tyr 10	Phe	Glu	Trp	Tyr	Thr 15	Pro	
Asn	Asp	Gly	Gln 20	His	Trp	Lys	Arg	Leu 25	Gln	Asn	Aap	Ser	Ala 30	Tyr	Leu	
Ala	Glu	His 35	Gly	Ile	Thr	Ala	Val 40	Trp	Ile	Pro	Pro	Ala 45	Tyr	Lys	Gly	
Thr	Ser 50	Gln	Ala	Asp	Val	Gly 55	Tyr	Gly	Ala	Tyr	Asp 60	Leu	Tyr	Asp	Leu	
Gly 65	Glu	Phe	His	Gln	Lys 70	Gly	Thr	Val	Arg	Thr 75	Гла	Tyr	Gly	Thr	Lys 80	
Gly	Glu	Leu	Gln	Ser 85	Ala	Ile	ГЛЗ	Ser	Leu 90	His	Ser	Arg	Asp	Ile 95	Asn	
Val	Tyr	Gly	Asp 100	Val	Val	Ile	Asn	His 105	Lys	Gly	Gly	Ala	Asp 110	Ala	Thr	
Glu	Asp	Val 115	Thr	Ala	Val	Glu	Val 120	Asp	Pro	Ala	Asp	Arg 125	Asn	Arg	Val	
Ile	Ser 130	Gly	Glu	Tyr	Leu	Ile 135	Lys	Ala	Trp	Thr	His 140	Phe	His	Phe	Pro	
Gly 145	Arg	Gly	Ser	Thr	Tyr 150	Ser	Asp	Phe	Lys	Trp 155	His	Trp	Tyr	His	Phe 160	
Asp	Gly	Thr	Asp	Trp 165	Asp	Glu	Ser	Arg	Lys 170	Leu	Asn	Arg	Ile	Tyr 175	Lys	
Phe	Gln	Gly	Lys 180	Ala	Trp	Asp	Trp	Glu 185	Val	Ser	Ser	Glu	Asn 190	Gly	Asn	
Tyr	Asp	Tyr 195	Leu	Met	Tyr	Ala	Asp 200	Leu	Asp	Met	Aap	His 205	Pro	Glu	Val	
	210			Гла		215					220					
225	-	-		Arg	230				-	235		-			240	
				Leu 245					250					255		
			260					265					270			
-		275	-	Thr		-	280					285				
	290	-		Tyr		295		-		-	300			_		
305				Thr	310					315					320	
				Asp 325					330					335		
			340	Pro				345					350			
		355		Gly			360					365				
Ile	Pro	Gln	Tyr	Asn	Ile	Pro	Ser	Leu	Lys	Ser	Lys	Ile	Asp	Pro	Leu	

-continued

											-	con	tin	ued	
	370					375					380				
Leu 385	Ile	Ala	Arg	Arg	Asp 390		Ala	Tyr	Gly	Thr 395	Gln	His	Asp	Tyr	Leu 400
Asp	His	Ser	Asp	Ile 405	Ile	Gly	Trp	Thr	Arg 410	Glu	Gly	Val	Thr	Glu 415	Lys
Pro	Gly	Ser	Gly 420	Leu	Ala	Ala	Leu	Ile 425	Thr	Asp	Gly	Pro	Gly 430	Gly	Ser
Lys	Trp	Met 435	Tyr	Val	Gly	Lys	Gln 440	His	Ala	Gly	Lya	Val 445	Phe	Tyr	Asp
Leu	Thr 450	Gly	Asn	Arg	Ser	Asp 455		Val	Thr	Ile	Asn 460	Ser	Asp	Gly	Trp
Gly 465	Glu	Phe	Lys	Val	Asn 470	Gly	Gly	Ser	Val	Ser 475	Val	Trp	Val	Pro	Arg 480
Lys	Thr	Thr													
<213 <213 <213 <220 <223	1> L] 2> T 3> O] 0> F] 3> O t]		I: 4: PRT ISM: RE: INFO gh po	B3 Art: ORMA osit:	TION	: Hyl		-	-		-teri port		-		
	Asn	Leu	Asn		Thr	Leu	Met	Gln	Tyr 10	Phe	Glu	Trp	Tyr		Pro
1 Asn	Asp	Gly	Gln 20	5 His	Trp	ГЛа	Arg	Leu 25		Asn	Aap	Ser	Ala 30	15 Tyr	Leu
Ala	Glu	His 35		Ile	Thr	Ala	Val 40		Ile	Pro	Pro	Ala 45		Lys	Gly
Thr	Ser 50		Ala	Asp	Val	Gly 55		Gly	Ala	Tyr	Asp 60		Tyr	Asp	Leu
Gly 65		Phe	His	Gln	Lys 70		Thr	Val	Arg	Thr 75	Lys	Tyr	Gly	Thr	Lys 80
	Glu	Leu	Gln	Ser 85		Ile	Lys	Ser	Leu 90		Ser	Arg	Asp	Ile 95	
Val	Tyr	Gly	Asp 100		Val	Ile	Asn	His 105		Gly	Gly	Ala	Asp 110		Thr
Glu	Asp	Val 115		Ala	Val	Glu	Val 120		Pro	Ala	Aap	Arg 125		Arg	Val
Ile	Ser 130		Glu	Tyr	Leu	Ile 135	Lys	Ala	Trp	Thr	His 140		His	Phe	Pro
Gly 145		Gly	Ser	Thr	Tyr 150			Phe	Lys	Trp 155	His	Trp	Tyr	His	Phe 160
	Gly	Thr	Asp	Trp 165		Glu	Ser	Arg	Lys 170		Asn	Arg	Ile	Tyr 175	
Phe	Gln	Gly	Lys 180		Trp	Asp	Trp	Glu 185		Asp	Thr	Glu	Asn 190		Asn
Tyr	Asp	Tyr 195		Met	Tyr	Ala	Asp 200		Asp	Met	Asp	His 205		Glu	Val
Val	Thr 210		Leu	Lys	Asn	Trp 215		Lys	Trp	Tyr	Val 220		Thr	Thr	Asn
Ile		Gly	Phe	Arg	Leu		Ala	Val	Lys	His	Ile	Lys	Phe	Ser	Phe

-continued

											-	con	tin	ued	
225					230					235					240
Phe	Pro	Asp	Trp	Leu 245	Ser	Tyr	Val	Arg	Ser 250	Gln	Thr	Gly	Lys	Pro 255	Leu
Phe	Thr	Val	Gly 260	Glu	Tyr	Trp	Ser	Tyr 265	Asp	Ile	Asn	Lys	Leu 270	His	Asn
Tyr	Ile	Thr 275	Lys	Thr	Asn	Gly	Thr 280	Met	Ser	Leu	Phe	Asp 285	Ala	Pro	Leu
His	Asn 290	Lys	Phe	Tyr	Thr	Ala 295	Ser	Lys	Ser	Gly	Gly 300	Ala	Phe	Asp	Met
Arg 305	Thr	Leu	Met	Thr	Asn 310	Thr	Leu	Met	Lys	Asp 315	Gln	Pro	Thr	Leu	Ala 320
Val	Thr	Phe	Val	Asp 325	Asn	His	Asp	Thr	Glu 330	Pro	Gly	Gln	Ala	Leu 335	Gln
Ser	Trp	Val	Asp 340	Pro	Trp	Phe	Lys	Pro 345	Leu	Ala	Tyr	Ala	Phe 350	Ile	Leu
Thr	Arg	Gln 355	Glu	Gly	Tyr	Pro	Cys 360	Val	Phe	Tyr	Gly	Asp 365	Tyr	Tyr	Gly
Ile	Pro 370		Tyr	Asn	Ile	Pro 375		Leu	Lys	Ser	Lys 380	Ile	Asp	Pro	Leu
Leu 385		Ala	Arg	Arg	Asp 390		Ala	Tyr	Gly	Thr 395		His	Asp	Tyr	Leu 400
	His	Ser	Asp	Ile 405	Ile	Gly	Trp	Thr	Arg 410		Gly	Val	Thr	Glu 415	
Pro	Gly	Ser	Gly 420		Ala	Ala	Leu	Ile 425		Asp	Gly	Pro	Gly 430		Ser
ГЛа	Trp			Val	Gly	ГЛа			Ala	Gly	Гла			Tyr	Asp
Leu		435 Gly	Asn	Arg	Ser	_	440 Thr	Val	Thr	Ile		445 Ser	Asp	Gly	Trp
-	450 Glu	Phe	Lys	Val	Asn	455 Gly	Gly	Ser	Val		460 Val	Trp	Val	Pro	-
465 Lys	Thr	Thr			470					475					480
<211 <212 <213 <220 <223	L> LH 2> T 3> OH 0> FH 3> OT t}	EATUI FHER	H: 4 PRT ISM: RE: INF gh p	83 Art ORMA osit	ific TION ion :	: Hyl									n of S
					Thr	Leu	Met	Gln	Tyr 10	Phe	Glu	Trp	Tyr	Thr 15	Pro
	Asp	Gly	Gln 20		Trp	Lys	Arg	Leu 25		Asn	Asp	Ser	Ala 30		Leu
Ala	Glu	His 35		Ile	Thr	Ala	Val 40		Ile	Pro	Pro	Ala 45		Lys	Gly
Thr	Ser 50		Ala	Aap	Val	Gly 55		Gly	Ala	Tyr	Asp 60		Tyr	Asp	Leu
Gly 65		Phe	His	Gln	Lys 70		Thr	Val	Arg	Thr 75		Tyr	Gly	Thr	Lys 80
	Glu	Leu	Gln	Ser	Ala	Ile	Lys	Ser	Leu		Ser	Arg	Asp	Ile	

-continued

											-	con	tin	ued						
				85					90					95						
Val	Tyr	Gly	Asp 100	Val	Val	Ile	Asn	His 105	Lys	Gly	Gly	Ala	Asp 110	Ala	Thr					
Glu	Asp	Val 115	Thr	Ala	Val	Glu	Val 120	Asp	Pro	Ala	Asp	Arg 125	Asn	Arg	Val					
Ile	Ser 130	Gly	Glu	Tyr	Leu	Ile 135	Lys	Ala	Trp	Thr	His 140	Phe	His	Phe	Pro					
Gly 145	Arg	Gly	Ser	Thr	Tyr 150	Ser	Asp	Phe	Lys	Trp 155	His	Trp	Tyr	His	Phe 160					
Asp	Gly	Thr	Asp	Trp 165	Asp	Glu	Ser	Arg	Lys 170	Leu	Asn	Arg	Ile	Tyr 175	Lys					
Phe	Gln	Gly	Lys 180	Ala	Trp	Asp	Trp	Glu 185	Val	Ser	Ser	Glu	Asn 190	Gly	Asn					
Tyr	Asp	Tyr 195	Leu	Met	Tyr	Ala	Asp 200	Ile	Asb	Met	Asp	His 205	Pro	Glu	Val					
Val	Thr 210	Glu	Leu	ГЛЗ	Asn	Trp 215	Gly	Lys	Trp	Tyr	Val 220	Asn	Thr	Thr	Asn					
Ile 225	Asp	Gly	Phe	Arg	Leu 230	Asp	Ala	Val	Lys	His 235	Ile	Lys	Phe	Ser	Phe 240					
Phe	Pro	Asp	Trp	Leu 245	Ser	Tyr	Val	Arg	Ser 250	Gln	Thr	Gly	ГЛа	Pro 255	Leu					
Phe	Thr	Val	Gly 260	Glu	Tyr	Trp	Ser	Tyr 265	Asp	Ile	Asn	Lys	Leu 270	His	Asn					
Tyr	Ile	Thr 275	ГЛа	Thr	Asn	Gly	Thr 280	Met	Ser	Leu	Phe	Asp 285	Ala	Pro	Leu					
	Asn 290	-		-		295		-		-	300			-						
305	Thr				310					315					320					
	Thr			325			-		330		-			335						
	Trp		340		-			345					350							
	Arg	355		-	-		360			-	-	365	-	-	-					
	Pro 370 Ile		-			375			-		380		_							
385	His		-	-	390	-		-	-	395			_	-	400					
-	Gly		-	405		-	-		410		-			415	-					
	Trp		420					425		-	-		430	-						
-	Thr	435	-		-	-	440			-	-	445		-	-					
	450 Glu					455					460									
465			-		470					475		-			480					
-15																				

```
-continued
```

<210> SEO ID NO 9 <211> LENGTH: 483 <212> TYPE: PRT <213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: Hybrid comprising N-terminal portion of AmyL through position 202, and C-terminal portion from AmyS <400> SEOUENCE: 9 Thr Asn Leu Asn Gly Thr Leu Met Gln Tyr Phe Glu Trp Tyr Thr Pro Asn Asp Gly Gln His Trp Lys Arg Leu Gln Asn Asp Ser Ala Tyr Leu Ala Glu His Gly Ile Thr Ala Val Trp Ile Pro Pro Ala Tyr Lys Gly Thr Ser Gln Ala Asp Val Gly Tyr Gly Ala Tyr Asp Leu Tyr Asp Leu Gly Glu Phe His Gln Lys Gly Thr Val Arg Thr Lys Tyr Gly Thr Lys Gly Glu Leu Gln Ser Ala Ile Lys Ser Leu His Ser Arg Asp Ile Asn Val Tyr Gly Asp Val Val Ile Asn His Lys Gly Gly Ala Asp Ala Thr Glu Asp Val Thr Ala Val Glu Val Asp Pro Ala Asp Arg Asn Arg Val 115 120 125 Ile Ser Gly Glu Tyr Leu Ile Lys Ala Trp Thr His Phe His Phe Pro Gly Arg Gly Ser Thr Tyr Ser Asp Phe Lys Trp His Trp Tyr His Phe Asp Gly Thr Asp Trp Asp Glu Ser Arg Lys Leu Asn Arg Ile Tyr Lys 165 170 175 Phe Gln Gly Lys Ala Trp Asp Trp Glu Val Asp Thr Glu Asn Gly Asn Tyr Asp Tyr Leu Met Tyr Ala Asp Ile Asp Met Asp His Pro Glu Val Val Thr Glu Leu Lys Asn Trp Gly Lys Trp Tyr Val Asn Thr Thr Asn Ile Asp Gly Phe Arg Leu Asp Ala Val Lys His Ile Lys Phe Ser Phe Phe Pro Asp Trp Leu Ser Tyr Val Arg Ser Gln Thr Gly Lys Pro Leu Phe Thr Val Gly Glu Tyr Trp Ser Tyr Asp Ile Asn Lys Leu His Asn Tyr Ile Thr Lys Thr Asn Gly Thr Met Ser Leu Phe Asp Ala Pro Leu His Asn Lys Phe Tyr Thr Ala Ser Lys Ser Gly Gly Ala Phe Asp Met Arg Thr Leu Met Thr Asn Thr Leu Met Lys Asp Gln Pro Thr Leu Ala Val Thr Phe Val Asp Asn His Asp Thr Glu Pro Gly Gln Ala Leu Gln Ser Tr
p Val Asp Pro Tr
p Phe Lys Pro Leu Ala Tyr Ala Phe Ile Leu - 345

```
-continued
```

Thr Arg Gln Glu Gly Tyr Pro Cys Val Phe Tyr Gly Asp Tyr Tyr Gly Ile Pro Gln Tyr Asn Ile Pro Ser Leu Lys Ser Lys Ile Asp Pro Leu Leu Ile Ala Arg Arg Asp Tyr Ala Tyr Gly Thr Gln His Asp Tyr Leu Asp His Ser Asp Ile Ile Gly Trp Thr Arg Glu Gly Val Thr Glu Lys Pro Gly Ser Gly Leu Ala Ala Leu Ile Thr Asp Gly Pro Gly Gly Ser Lys Trp Met Tyr Val Gly Lys Gln His Ala Gly Lys Val Phe Tyr Asp Leu Thr Gly Asn Arg Ser Asp Thr Val Thr Ile Asn Ser Asp Gly Trp Gly Glu Phe Lys Val Asn Gly Gly Ser Val Ser Val Trp Val Pro Arg Lys Thr Thr <210> SEQ ID NO 10 <211> LENGTH: 483 <212> TYPE: PRT <213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: Hybrid comprising N-terminal portion of AmyL through position 228, and C-terminal portion from AmyS <400> SEQUENCE: 10 Thr Asn Leu Asn Gly Thr Leu Met Gln Tyr Phe Glu Trp Tyr Thr Pro Asn Asp Gly Gln His Trp Lys Arg Leu Gln Asn Asp Ser Ala Tyr Leu Ala Glu His Gly Ile Thr Ala Val Trp Ile Pro Pro Ala Tyr Lys Gly 35 40 45 Thr Ser Gln Ala Asp Val Gly Tyr Gly Ala Tyr Asp Leu Tyr Asp Leu Gly Glu Phe His Gln Lys Gly Thr Val Arg Thr Lys Tyr Gly Thr Lys Gly Glu Leu Gln Ser Ala Ile Lys Ser Leu His Ser Arg Asp Ile Asn Val Tyr Gly Asp Val Val Ile Asn His Lys Gly Gly Ala Asp Ala Thr Glu Asp Val Thr Ala Val Glu Val Asp Pro Ala Asp Arg Asn Arg Val Ile Ser Gly Glu Tyr Leu Ile Lys Ala Trp Thr His Phe His Phe Pro Gly Arg Gly Ser Thr Tyr Ser Asp Phe Lys Trp His Trp Tyr His Phe Asp Gly Thr Asp Trp Asp Glu Ser Arg Lys Leu Asn Arg Ile Tyr Lys Phe Gln Gly Lys Ala Trp Asp Trp Glu Val Ser Ser Glu Asn Gly Asn Tyr Asp Tyr Leu Met Tyr Ala Asp Ile Asp Tyr Asp His Pro Asp Val 195 200 205

Val	Ala 210	Glu	Ile	Lys	Arg	Trp 215	Gly	Thr	Trp	Tyr	Ala 220	Asn	Glu	Leu	Gln	
Leu 225	Asp	Gly	Phe	Arg	Leu 230	Asp	Ala	Val	Lys	His 235	Ile	ГЛа	Phe	Ser	Phe 240	
Phe	Pro	Asp	Trp	Leu 245	Ser	Tyr	Val	Arg	Ser 250	Gln	Thr	Gly	Гла	Pro 255	Leu	
Phe	Thr	Val	Gly 260	Glu	Tyr	Trp	Ser	Tyr 265	Asp	Ile	Asn	Гла	Leu 270	His	Asn	
Tyr	Ile	Thr 275	Lys	Thr	Asn	Gly	Thr 280	Met	Ser	Leu	Phe	Asp 285	Ala	Pro	Leu	
His	Asn 290		Phe	Tyr	Thr	Ala 295	Ser	Lys	Ser	Gly	Gly 300	Ala	Phe	Asp	Met	
Arg 305	Thr	Leu	Met	Thr	Asn 310	Thr	Leu	Met	Lys	Asp 315	Gln	Pro	Thr	Leu	Ala 320	
/al	Thr	Phe	Val	Asp 325	Asn	His	Asp	Thr	Glu 330	Pro	Gly	Gln	Ala	Leu 335	Gln	
Ser	Trp	Val	Asp 340	Pro	Trp	Phe	Гла	Pro 345	Leu	Ala	Tyr	Ala	Phe 350	Ile	Leu	
Γhr	Arg	Gln 355	Glu	Gly	Tyr	Pro	Суз 360	Val	Phe	Tyr	Gly	Asp 365	Tyr	Tyr	Gly	
Ile	Pro 370	Gln	Tyr	Asn	Ile	Pro 375	Ser	Leu	Lys	Ser	Lys 380	Ile	Asp	Pro	Leu	
Leu 385	Ile	Ala	Arg	Arg	Asp 390		Ala	Tyr	Gly	Thr 395	Gln	His	Asp	Tyr	Leu 400	
Asp	His	Ser	Asp	Ile 405	Ile	Gly	Trp	Thr	Arg 410	Glu	Gly	Val	Thr	Glu 415	Lys	
?ro	Gly	Ser	Gly 420	Leu	Ala	Ala	Leu	Ile 425	Thr	Asp	Gly	Pro	Gly 430	Gly	Ser	
Lys	Trp	Met 435	Tyr	Val	Gly	Lys	Gln 440	His	Ala	Gly	Lys	Val 445	Phe	Tyr	Asp	
Leu	Thr 450	Gly	Asn	Arg	Ser	Asp 455	Thr	Val	Thr	Ile	Asn 460	Ser	Asp	Gly	Trp	
Gly 465	Glu	Phe	Lys	Val	Asn 470	Gly	Gly	Ser	Val	Ser 475	Val	Trp	Val	Pro	Arg 480	
Lys	Thr	Thr														
<211 <212 <213 <220	L> LH 2> TY 3> OH 0> FH 3> OY	EATUR FHER	H: 48 PRT ISM: RE: INFO	33 Art: DRMA	ific: TION ion 2	: Hyl										AmyL
<400)> SI	EQUEI	ICE :	11												
Thr 1	Asn	Leu	Asn	Gly 5	Thr	Leu	Met	Gln	Tyr 10	Phe	Glu	Trp	Tyr	Thr 15	Pro	
Asn	Asp	Gly	Gln 20	His	Trp	Lys	Arg	Leu 25	Gln	Asn	Asp	Ser	Ala 30	Tyr	Leu	
Ala	Glu	His 35	Gly	Ile	Thr	Ala	Val 40	Trp	Ile	Pro	Pro	Ala 45	Tyr	Lys	Gly	
Thr	Ser 50	Gln	Ala	Asp	Val	Gly 55	Tyr	Gly	Ala	Tyr	Asp 60	Leu	Tyr	Asp	Leu	

Gly	Glu	Phe	His	Gln	Lys	Gly	Thr	Val	Arg	Thr	Lys	Tyr	Gly	Thr	Lys
65					70	-			0	75			-		80
Gly	Glu	Leu	Gln	Ser 85	Ala	Ile	Lys	Ser	Leu 90	His	Ser	Arg	Asp	Ile 95	Asn
Val	Tyr	Gly	Asp 100	Val	Val	Ile	Asn	His 105	Lys	Gly	Gly	Ala	Asp 110	Ala	Thr
Glu	Asp	Val 115	Thr	Ala	Val	Glu	Val 120	Asb	Pro	Ala	Asp	Arg 125	Asn	Arg	Val
Ile	Ser 130	Gly	Glu	Tyr	Leu	Ile 135	Lys	Ala	Trp	Thr	His 140	Phe	His	Phe	Pro
Gly 145	Arg	Gly	Ser	Thr	Tyr 150	Ser	Asp	Phe	Lys	Trp 155	His	Trp	Tyr	His	Phe 160
Asp	Gly	Thr	Asp	Trp 165	Asp	Glu	Ser	Arg	Lys 170	Leu	Asn	Arg	Ile	Tyr 175	Lys
Phe	Gln	Gly	Lys 180	Ala	Trp	Asp	Trp	Glu 185	Val	Asp	Thr	Glu	Asn 190	Gly	Asn
Tyr	Asp	Tyr 195	Leu	Met	Tyr	Ala	Asp 200	Ile	Aab	Tyr	Asp	His 205	Pro	Asp	Val
Val	Ala 210	Glu	Ile	Lys	Arg	Trp 215	Gly	Thr	Trp	Tyr	Ala 220	Asn	Glu	Leu	Gln
Leu 225	Asp	Gly	Phe	Arg	Leu 230	Asp	Ala	Val	Lys	His 235	Ile	Lys	Phe	Ser	Phe 240
Phe	Pro	Aab	Trp	Leu 245	Ser	Tyr	Val	Arg	Ser 250	Gln	Thr	Gly	Lys	Pro 255	Leu
Phe	Thr	Val	Gly 260	Glu	Tyr	Trp	Ser	Tyr 265	Asp	Ile	Asn	Lys	Leu 270	His	Asn
Tyr	Ile	Thr 275	Lys	Thr	Asn	Gly	Thr 280	Met	Ser	Leu	Phe	Asp 285	Ala	Pro	Leu
His	Asn 290	Lys	Phe	Tyr	Thr	Ala 295	Ser	Lys	Ser	Gly	Gly 300	Ala	Phe	Asp	Met
Arg 305	Thr	Leu	Met	Thr	Asn 310	Thr	Leu	Met	Lys	Asp 315	Gln	Pro	Thr	Leu	Ala 320
Val	Thr	Phe	Val	Asp 325	Asn	His	Asp	Thr	Glu 330	Pro	Gly	Gln	Ala	Leu 335	Gln
Ser	Trp	Val	Asp 340	Pro	Trp	Phe	Lys	Pro 345	Leu	Ala	Tyr	Ala	Phe 350	Ile	Leu
Thr	Arg	Gln 355	Glu	Gly	Tyr	Pro	Сув 360	Val	Phe	Tyr	Gly	Asp 365	Tyr	Tyr	Gly
Ile	Pro 370	Gln	Tyr	Asn	Ile	Pro 375	Ser	Leu	Lys	Ser	Lys 380	Ile	Asp	Pro	Leu
Leu 385	Ile	Ala	Arg	Arg	Asp 390	Tyr	Ala	Tyr	Gly	Thr 395	Gln	His	Asp	Tyr	Leu 400
Asp	His	Ser	Asp	Ile 405	Ile	Gly	Trp	Thr	Arg 410	Glu	Gly	Val	Thr	Glu 415	Lys
Pro	Gly	Ser	Gly 420	Leu	Ala	Ala	Leu	Ile 425	Thr	Asp	Gly	Pro	Gly 430	Gly	Ser
ГЛа	Trp	Met 435	Tyr	Val	Gly	ГЛа	Gln 440	His	Ala	Gly	ГЛа	Val 445	Phe	Tyr	Asp
Leu	Thr 450	Gly	Asn	Arg	Ser	Asp 455	Thr	Val	Thr	Ile	Asn 460	Ser	Asp	Gly	Trp

Gly Glu Phe Lys Val Asn Gly Gly Ser Val Ser Val Trp Val Pro Arg Lys Thr Thr <210> SEQ ID NO 12 <211> LENGTH: 483 <212> TYPE: PRT <213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: Hybrid comprising N-terminal portion of AmyL through position 249, and C-terminal portion from AmyS <400> SEQUENCE: 12 Thr Asn Leu Asn Gly Thr Leu Met Gln Tyr Phe Glu Trp Tyr Thr Pro Asn Asp Gly Gln His Trp Lys Arg Leu Gln Asn Asp Ser Ala Tyr Leu Ala Glu His Gly Ile Thr Ala Val Trp Ile Pro Pro Ala Tyr Lys Gly Thr Ser Gln Ala Asp Val Gly Tyr Gly Ala Tyr Asp Leu Tyr Asp Leu Gly Glu Phe His Gln Lys Gly Thr Val Arg Thr Lys Tyr Gly Thr Lys 65 70 75 80 Gly Glu Leu Gln Ser Ala Ile Lys Ser Leu His Ser Arg Asp Ile Asn Val Tyr Gly Asp Val Val Ile Asn His Lys Gly Gly Ala Asp Ala Thr Glu Asp Val Thr Ala Val Glu Val Asp Pro Ala Asp Arg Asn Arg Val Ile Ser Gly Glu Tyr Leu Ile Lys Ala Trp Thr His Phe His Phe Pro Gly Arg Gly Ser Thr Tyr Ser Asp Phe Lys Trp His Trp Tyr His Phe Asp Gly Thr Asp Trp Asp Glu Ser Arg Lys Leu Asn Arg Ile Tyr Lys Phe Gln Gly Lys Ala Trp Asp Trp Glu Val Ser Ser Glu Asn Gly Asn Tyr Asp Tyr Leu Met Tyr Ala Asp Ile Asp Tyr Asp His Pro Asp Val Val Ala Glu Ile Lys Arg Trp Gly Thr Trp Tyr Ala Asn Glu Leu Gln Leu Asp Gly Phe Arg Leu Asp Ala Val Lys His Ile Lys Phe Ser Phe Leu Arg Asp Trp Val Asn His Val Arg Ser Gln Thr Gly Lys Pro Leu Phe Thr Val Gly Glu Tyr Trp Ser Tyr Asp Ile Asn Lys Leu His Asn Tyr Ile Thr Lys Thr Asn Gly Thr Met Ser Leu Phe Asp Ala Pro Leu His Asn Lys Phe Tyr Thr Ala Ser Lys Ser Gly Gly Ala Phe Asp Met Arg Thr Leu Met Thr Asn Thr Leu Met Lys Asp Gln Pro Thr Leu Ala 305 310 315 320

											-	con	tin	ued	
Val	Thr	Phe	Val	Asp 325	Asn	His	Asp	Thr	Glu 330	Pro	Gly	Gln	Ala	Leu 335	Gln
Ser	Trp	Val	Asp 340	Pro	Trp	Phe	Lys	Pro 345	Leu	Ala	Tyr	Ala	Phe 350	Ile	Leu
Thr	Arg	Gln 355	Glu	Gly	Tyr	Pro	Сув 360	Val	Phe	Tyr	Gly	Asp 365	Tyr	Tyr	Gly
Ile	Pro 370	Gln	Tyr	Asn	Ile	Pro 375	Ser	Leu	Lys	Ser	LYa 380	Ile	Asp	Pro	Leu
Leu 385	Ile	Ala	Arg	Arg	Asp 390	Tyr	Ala	Tyr	Gly	Thr 395	Gln	His	Asp	Tyr	Leu 400
Asp	His	Ser	Asp	Ile 405	Ile	Gly	Trp	Thr	Arg 410	Glu	Gly	Val	Thr	Glu 415	Lys
Pro	Gly	Ser	Gly 420	Leu	Ala	Ala	Leu	Ile 425	Thr	Asp	Gly	Pro	Gly 430	Gly	Ser
Гла	Trp	Met 435	Tyr	Val	Gly	Гла	Gln 440	His	Ala	Gly	Lys	Val 445	Phe	Tyr	Asp
Leu	Thr 450	Gly	Asn	Arg	Ser	Asp 455	Thr	Val	Thr	Ile	Asn 460	Ser	Asp	Gly	Trp
Gly 465	Glu	Phe	Lys	Val	Asn 470	Gly	Gly	Ser	Val	Ser 475	Val	Trp	Val	Pro	Arg 480
Lys	Thr	Thr													
<223	3> 0. tl		INF(h p	osit:			orid and								n of S
Thr 1	Asn	Leu	Asn	Gly 5	Thr	Leu	Met	Gln	m						
Asn	Asp	Gly							19r 10	Phe	Glu	Trp	Tyr	Thr 15	Pro
Ala			Gln 20	His	Trp	Lys	Arg		10			-	-	15	
	Glu	His 35	20		-	-	Arg Val 40	Leu 25	10 Gln	Asn	Asp	Ser	Ala 30	15 Tyr	Leu
Thr		35	20 Gly	Ile	Thr	Ala	Val	Leu 25 Trp	10 Gln Ile	Asn Pro	Asp Pro	Ser Ala 45	Ala 30 Tyr	15 Tyr Lys	Leu Gly
	Ser 50	35 Gln	20 Gly Ala	Ile Asp	Thr Val	Ala Gly 55	Val 40	Leu 25 Trp Gly	10 Gln Ile Ala	Asn Pro Tyr	Asp Pro Asp 60	Ser Ala 45 Leu	Ala 30 Tyr Tyr	15 Tyr Lys Asp	Leu Gly Leu
Gly 65	Ser 50 Glu	35 Gln Phe	20 Gly Ala His	Ile Asp Gln	Thr Val Lys 70	Ala Gly 55 Gly	Val 40 Tyr	Leu 25 Trp Gly Val	10 Gln Ile Ala Arg	Asn Pro Tyr Thr 75	Asp Pro Asp 60 Lys	Ser Ala 45 Leu Tyr	Ala 30 Tyr Tyr Gly	15 Tyr Lys Asp Thr	Leu Gly Leu Lys 80
Gly 65 Gly	Ser 50 Glu Glu	35 Gln Phe Leu	20 Gly Ala His Gln	Ile Asp Gln Ser 85	Thr Val Lys 70 Ala	Ala Gly 55 Gly Ile	Val 40 Tyr Thr	Leu 25 Trp Gly Val Ser	10 Gln Ile Ala Arg Leu 90	Asn Pro Tyr Thr 75 His	Asp Pro Asp 60 Lys Ser	Ser Ala 45 Leu Tyr Arg	Ala 30 Tyr Tyr Gly Asp	15 Tyr Lys Asp Thr Ile 95	Leu Gly Leu Lys 80 Asn
Gly 65 Gly Val	Ser 50 Glu Glu Tyr	35 Gln Phe Leu Gly	20 Gly Ala His Gln Asp 100	Ile Asp Gln Ser 85 Val	Thr Val Lys 70 Ala Val	Ala Gly 55 Gly Ile Ile	Val 40 Tyr Thr Lys	Leu 25 Trp Gly Val Ser His 105	10 Gln Ile Ala Arg Leu 90 Lys	Asn Pro Tyr Thr 75 His Gly	Asp Pro Asp 60 Lys Ser Gly	Ser Ala 45 Leu Tyr Arg Ala	Ala 30 Tyr Tyr Gly Asp 110	15 Tyr Lys Asp Thr Ile 95 Ala	Leu Gly Leu Lys 80 Asn Thr
Gly 65 Gly Val Glu	Ser 50 Glu Glu Tyr Asp	35 Gln Phe Leu Gly Val 115	20 Gly Ala His Gln Asp 100 Thr	Ile Asp Gln Ser 85 Val Ala	Thr Val Lys 70 Ala Val Val	Ala Gly 55 Gly Ile Ile Glu	Val 40 Tyr Thr Lys Asn Val	Leu 25 Trp Gly Val Ser His 105 Asp	10 Gln Ile Ala Arg Leu 90 Lys Pro	Asn Pro Tyr Thr 75 His Gly Ala	Aap Pro Aap 60 Lys Ser Gly Aap	Ser Ala 45 Leu Tyr Arg Ala Arg 125	Ala 30 Tyr Tyr Gly Asp 110 Asn	15 Tyr Lys Asp Thr Ile 95 Ala Arg	Leu Gly Leu Lys 80 Asn Thr Val
Gly 65 Gly Val Glu Ile	Ser 50 Glu Glu Tyr Asp Ser 130	35 Gln Phe Leu Gly Val 115 Gly	20 Gly Ala His Gln Asp 100 Thr Glu	Ile Asp Gln Ser 85 Val Ala Tyr	Thr Val Lys 70 Ala Val Val Leu	Ala Gly 55 Gly Ile Glu Ile 135	Val 40 Tyr Thr Lys Asn Val 120	Leu 25 Trp Gly Val Ser His 105 Asp Ala	10 Gln Ile Ala Arg Leu 90 Lys Pro Trp	Asn Pro Tyr Thr 75 Gly Ala Thr	Asp Pro Asp 60 Lys Ser Gly Asp His 140	Ser Ala 45 Leu Tyr Arg Ala Arg 125 Phe	Ala 30 Tyr Tyr Gly Asp 110 Asn His	15 Tyr Lys Asp Thr Ile 95 Ala Arg Phe	Leu Gly Leu Lys 80 Asn Thr Val Pro

-continued

											-	con	tin	ued							
Phe	Gln	Gly	Lys 180	Ala	Trp	Asp	Trp	Glu 185	Val	Asp	Thr	Glu	Asn 190	Gly	Asn						
Tyr	Asp	Tyr 195	Leu	Met	Tyr	Ala	Asp 200	Ile	Asp	Tyr	Asp	His 205	Pro	Asp	Val						
Val	Ala 210	Glu	Ile	Lys	Arg	Trp 215	Gly	Thr	Trp	Tyr	Ala 220	Asn	Glu	Leu	Gln						
Leu 225	Asp	Gly	Phe	Arg	Leu 230	Asp	Ala	Val	Lys	His 235	Ile	ГЛа	Phe	Ser	Phe 240						
Leu	. Arg	Asp	Trp	Val 245	Asn	His	Val	Arg	Ser 250	Gln	Thr	Gly	Гла	Pro 255	Leu						
Phe	Thr	Val	Gly 260	Glu	Tyr	Trp	Ser	Tyr 265	Aab	Ile	Asn	ГЛа	Leu 270	His	Asn						
Tyr	Ile	Thr 275	Lys	Thr	Asn	Gly	Thr 280	Met	Ser	Leu	Phe	Asp 285	Ala	Pro	Leu						
His	Asn 290		Phe	Tyr	Thr	Ala 295	Ser	Lys	Ser	Gly	Gly 300	Ala	Phe	Asp	Met						
Arg 305	Thr	Leu	Met	Thr	Asn 310	Thr	Leu	Met	Lys	Asp 315	Gln	Pro	Thr	Leu	Ala 320						
Val	Thr	Phe	Val	Asp 325	Asn	His	Asp	Thr	Glu 330	Pro	Gly	Gln	Ala	Leu 335	Gln						
Ser	Trp	Val	Asp 340	Pro	Trp	Phe	Lys	Pro 345	Leu	Ala	Tyr	Ala	Phe 350	Ile	Leu						
Thr	Arg	Gln 355	Glu	Gly	Tyr	Pro	Суя 360	Val	Phe	Tyr	Gly	Asp 365	Tyr	Tyr	Gly						
Ile	Pro 370		Tyr	Asn	Ile	Pro 375	Ser	Leu	Lys	Ser	LYa 380	Ile	Asp	Pro	Leu						
Leu 385	Ile	Ala	Arg	Arg	Asp 390		Ala	Tyr	Gly	Thr 395	Gln	His	Asp	Tyr	Leu 400						
Asp	His	Ser	Asp	Ile 405	Ile	Gly	Trp	Thr	Arg 410	Glu	Gly	Val	Thr	Glu 415	Lys						
Prc	Gly	Ser	Gly 420	Leu	Ala	Ala	Leu	Ile 425	Thr	Asp	Gly	Pro	Gly 430	-	Ser						
Гуз	Trp	Met 435	Tyr	Val	Gly	Lys	Gln 440	His	Ala	Gly	Lys	Val 445	Phe	Tyr	Asp						
Leu	. Thr 450	Gly	Asn	Arg	Ser	Asp 455	Thr	Val	Thr	Ile	Asn 460	Ser	Asp	Gly	Trp						
Gly 465	Glu	Phe	Lys	Val	Asn 470	Gly	Gly	Ser	Val	Ser 475	Val	Trp	Val	Pro	Arg 480						
Lys	Thr	Thr																			
<21 <21 <21 <22		ENGTI YPE : RGANI EATUI	H: 4 PRT ISM: RE: INF	33 Art: DRMA	FION	: Hyl		-					-			AmyL					
<40	0> SI													1							
Thr 1	Asn	Leu	Asn	Gly 5	Thr	Leu	Met	Gln	Tyr 10	Phe	Glu	Trp	Tyr	Thr 15	Pro						
Asr	Asp	Gly	Gln 20	His	Trp	ГЛа	Arg	Leu 25	Gln	Asn	Asp	Ser	Ala 30	Tyr	Leu						

											-	con	ιm	uea		 	
Ala	Glu	His 35	Gly	Ile	Thr	Ala	Val 40	Trp	Ile	Pro	Pro	Ala 45	Tyr	Lys	Gly		
Thr	Ser 50	Gln	Ala	Asp	Val	Gly 55	Tyr	Gly	Ala	Tyr	Asp 60	Leu	Tyr	Asp	Leu		
Gly 65	Glu	Phe	His	Gln	Lys 70	Gly	Thr	Val	Arg	Thr 75	Гла	Tyr	Gly	Thr	Lys 80		
Gly	Glu	Leu	Gln	Ser 85	Ala	Ile	Lys	Ser	Leu 90	His	Ser	Arg	Asp	Ile 95	Asn		
Val	Tyr	Gly	Asp 100	Val	Val	Ile	Asn	His 105	Lys	Gly	Gly	Ala	Asp 110	Ala	Thr		
Glu	Asp	Val 115	Thr	Ala	Val	Glu	Val 120	Asp	Pro	Ala	Asp	Arg 125	Asn	Arg	Val		
Ile	Ser 130	Gly	Glu	Tyr	Leu	Ile 135	Lys	Ala	Trp	Thr	His 140	Phe	His	Phe	Pro		
Gly 145		Gly	Ser	Thr	Tyr 150	Ser	Asp	Phe	Lys	Trp 155	His	Trp	Tyr	His	Phe 160		
	Gly	Thr	Asp	Trp 165		Glu	Ser	Arg	Lys 170		Asn	Arg	Ile	Tyr 175			
Phe	Gln	Gly	Lys 180		Trp	Asp	Trp	Glu 185		Ser	Ser	Glu	Asn 190		Asn		
Tyr	Asp	Tyr 195		Met	Tyr	Ala	Asp 200		Asp	Tyr	Aap	His 205		Asp	Val		
Val	Ala 210		Ile	Lys	Arg	Trp 215		Thr	Trp	Tyr	Ala 220		Glu	Leu	Gln		
Leu 225		Gly	Phe	Arg	Leu 230	Asp	Ala	Val	Lys	His 235		Lys	Phe	Ser	Phe 240		
	Arg	Asp	Trp	Val 245		His	Val	Arg	Glu 250		Thr	Gly	Lys	Pro 255			
Phe	Thr	Val	Gly 260		Tyr	Trp	Ser	Tyr 265		Ile	Asn	Гла	Leu 270		Asn		
Tyr	Ile			Thr	Asn	Gly			Ser	Leu	Phe	_		Pro	Leu		
His		275 Lys	Phe	Tyr	Thr	Ala	280 Ser	Lys	Ser	Gly		285 Ala	Phe	Asp	Met		
	290 Thr	Leu	Met	Thr		295 Thr	Leu	Met	Lys	-	300 Gln	Pro	Thr	Leu			
305 Val	Thr	Phe	Val		310 Asn	His	Asp	Thr		315 Pro	Gly	Gln	Ala	Leu	320 Gln		
Ser	Trp	Val			Trp	Phe	Lys		330 Leu	Ala	Tyr	Ala		335 Ile	Leu		
Thr	Arg		340 Glu		Tyr	Pro		345 Val	Phe	Tyr	Gly		350 Tyr	Tyr	Gly		
Ile		355 Gln	Tyr	Asn	Ile	Pro	360 Ser	Leu	Гла	Ser		365 Ile	Asp	Pro	Leu		
	370 Ile	Ala	Arg	Arg		375 Tyr	Ala	Tyr	Gly		380 Gln	His	Asp	Tyr			
385 Asp	His	Ser	Asp	Ile	390 Ile	Gly	Trp	Thr	Arg	395 Glu	Gly	Val	Thr	Glu	400 Lys		
-			-	405		Ala	-		410		-			415	-		
	-		420			Lys		425		_	-		430	-			
-10	P		- 1 -	* 4 1	0±9	-75	0111		a	0±9	-10		10	- Y -	••••F		

Leu Thr Gly As
n Arg Ser Asp Thr Val Thr Ile As
n Ser Asp Gly Tr
p $% \left({{\mathbb{F}}_{{\mathbb{F}}}} \right)$ Gly Glu Phe Lys Val Asn Gly Gly Ser Val Ser Val Trp Val Pro Arg Lys Thr Thr <210> SEQ ID NO 15 <211> LENGTH: 483 <212> TYPE: PRT <213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: Hybrid comprising N-terminal portion of AmyL through position 254, and C-terminal portion from AmyS <400> SEQUENCE: 15 Thr Asn Leu Asn Gly Thr Leu Met Gln Tyr Phe Glu Trp Tyr Thr Pro Asn Asp Gly Gln His Trp Lys Arg Leu Gln Asn Asp Ser Ala Tyr Leu 20 25 30 Ala Glu His Gly Ile Thr Ala Val Trp Ile Pro Pro Ala Tyr Lys Gly 35 40 45 Thr Ser Gln Ala Asp Val Gly Tyr Gly Ala Tyr Asp Leu Tyr Asp Leu Gly Glu Phe His Gln Lys Gly Thr Val Arg Thr Lys Tyr Gly Thr Lys65707580 Gly Glu Leu Gln Ser Ala Ile Lys Ser Leu His Ser Arg Asp Ile Asn 85 90 95 Val Tyr Gly Asp Val Val Ile Asn His Lys Gly Gly Ala Asp Ala Thr Glu Asp Val Thr Ala Val Glu Val Asp Pro Ala Asp Arg Asn Arg Val Ile Ser Gly Glu Tyr Leu Ile Lys Ala Trp Thr His Phe His Phe Pro Gly Arg Gly Ser Thr Tyr Ser Asp Phe Lys Trp His Trp Tyr His Phe Asp Gly Thr Asp Trp Asp Glu Ser Arg Lys Leu Asn Arg Ile Tyr Lys Phe Gln Gly Lys Ala Trp Asp Trp Glu Val Asp Thr Glu Asn Gly Asn Tyr Asp Tyr Leu Met Tyr Ala Asp Ile Asp Tyr Asp His Pro Asp Val Val Ala Glu Ile Lys Arg Trp Gly Thr Trp Tyr Ala Asn Glu Leu Gln Leu Asp Gly Phe Arg Leu Asp Ala Val Lys His Ile Lys Phe Ser Phe Leu Arg Asp Trp Val Asn His Val Arg Glu Lys Thr Gly Lys Pro Leu Phe Thr Val Gly Glu Tyr Trp Ser Tyr Asp Ile Asn Lys Leu His Asn 260 265 270 Tyr Ile Thr Lys Thr Asn Gly Thr Met Ser Leu Phe Asp Ala Pro Leu His Asn Lys Phe Tyr Thr Ala Ser Lys Ser Gly Gly Ala Phe Asp Met

-continued

												con	tin	ued			
	290					295					300						
Arg 305	Thr	Leu	Met	Thr	Asn 310	Thr	Leu	Met	Lys	Asp 315	Gln	Pro	Thr	Leu	Ala 320		
Val	Thr	Phe	Val	Asp 325	Asn	His	Asp	Thr	Glu 330	Pro	Gly	Gln	Ala	Leu 335	Gln		
Ser	Trp	Val	Asp 340	Pro	Trp	Phe	Lys	Pro 345	Leu	Ala	Tyr	Ala	Phe 350	Ile	Leu		
Thr	Arg	Gln 355	Glu	Gly	Tyr	Pro	Сув 360	Val	Phe	Tyr	Gly	Asp 365	Tyr	Tyr	Gly		
Ile	Pro 370	Gln	Tyr	Asn	Ile	Pro 375	Ser	Leu	Lys	Ser	Lys 380	Ile	Asp	Pro	Leu		
Leu 385	Ile	Ala	Arg	Arg	Asp 390	Tyr	Ala	Tyr	Gly	Thr 395	Gln	His	Asp	Tyr	Leu 400		
Asp	His	Ser	Asp	Ile 405	Ile	Gly	Trp	Thr	Arg 410	Glu	Gly	Val	Thr	Glu 415	Lys		
Pro	Gly	Ser	Gly 420	Leu	Ala	Ala	Leu	Ile 425	Thr	Asp	Gly	Pro	Gly 430	Gly	Ser		
ГЛа	Trp	Met 435	Tyr	Val	Gly	ГЛЗ	Gln 440	His	Ala	Gly	Lys	Val 445	Phe	Tyr	Asp		
Leu	Thr 450	Gly	Asn	Arg	Ser	Asp 455	Thr	Val	Thr	Ile	Asn 460	Ser	Asp	Gly	Trp		
Gly 465	Glu	Phe	ГÀа	Val	Asn 470	Gly	Gly	Ser	Val	Ser 475	Val	Trp	Val	Pro	Arg 480		
Lys	Thr	Thr															
<21 <21 <21 <22		ENGTI YPE : RGANI EATUI FHER	H: 4 PRT ISM: RE: INF(B3 Art: ORMA	TION											AmyL	
<40	0> S1	EQUEI	ICE :	16													
Thr 1	Asn	Leu	Asn	Gly 5	Thr	Leu	Met	Gln	Tyr 10	Phe	Glu	Trp	Tyr	Thr 15	Pro		
Asn	Asp	Gly	Gln 20	His	Trp	ГЛа	Arg	Leu 25	Gln	Asn	Asp	Ser	Ala 30	Tyr	Leu		
Ala	Glu	His 35	Gly	Ile	Thr	Ala	Val 40	Trp	Ile	Pro	Pro	Ala 45	Tyr	ГЛа	Gly		
Thr	Ser 50	Gln	Ala	Asp	Val	Gly 55	Tyr	Gly	Ala	Tyr	Asp 60	Leu	Tyr	Asp	Leu		
Gly 65	Glu	Phe	His	Gln	Lys 70	Gly	Thr	Val	Arg	Thr 75	Lys	Tyr	Gly	Thr	Lys 80		
Gly	Glu	Leu	Gln	Ser 85	Ala	Ile	Lys	Ser	Leu 90	His	Ser	Arg	Asp	Ile 95	Asn		
Val	Tyr	Gly	Asp 100	Val	Val	Ile	Asn	His 105	Lys	Gly	Gly	Ala	Asp 110	Ala	Thr		
Glu	Asp	Val 115	Thr	Ala	Val	Glu	Val 120	Asp	Pro	Ala	Asp	Arg 125	Asn	Arg	Val		
Ile	Ser 130	Gly	Glu	Tyr	Leu	Ile 135	Гла	Ala	Trp	Thr	His 140	Phe	His	Phe	Pro		
Gly	Arg	Gly	Ser	Thr	Tyr	Ser	Aab	Phe	Lys	Trp	His	Trp	Tyr	His	Phe		

-continued

										-	con	tin	ued	
145				150					155					160
Aap Gly	Thr	Asp	Trp 165		Glu	Ser	Arg	Lys 170	Leu	Asn	Arg	Ile	Tyr 175	Lys
Phe Gln	Gly	Lys 180		Trp	Asp	Trp	Glu 185	Val	Ser	Ser	Glu	Asn 190	Gly	Asn
Tyr Asp	Tyr 195	Leu	Met	Tyr	Ala	Asp 200	Ile	Asp	Tyr	Asp	His 205	Pro	Asp	Val
Val Ala 210		Ile	ГЛа	Arg	Trp 215	Gly	Thr	Trp	Tyr	Ala 220	Asn	Glu	Leu	Gln
Leu Asp 225	Gly	Phe	Arg	Leu 230	Asp	Ala	Val	Lys	His 235	Ile	Lys	Phe	Ser	Phe 240
Leu Arg	Asp	Trp	Val 245		His	Val	Arg	Glu 250	Lys	Thr	Gly	Lys	Glu 255	Met
Phe Thr	Val	Gly 260	Glu		Trp	Ser	Tyr 265	Asp	Ile	Asn	Lys	Leu 270	His	Asn
Tyr Ile	Thr 275			Asn	Gly	Thr 280		Ser	Leu	Phe	Asp 285		Pro	Leu
His Asn 290	Lys	Phe	Tyr	Thr	Ala 295		Lys	Ser	Gly	Gly 300		Phe	Asp	Met
Arg Thr 305		Met	Thr	Asn 310		Leu	Met	ГЛа	Asp 315		Pro	Thr	Leu	Ala 320
Val Thr	Phe	Val	_	Asn	His	Asp	Thr			Gly	Gln	Ala		
Ser Trp	Val	_			Phe	Гуз		330 Leu	Ala	Tyr	Ala		335 Ile	Leu
Thr Arg		340 Glu		Tyr	Pro		345 Val	Phe	Tyr	Gly		350 Tyr	Tyr	Gly
Ile Pro	355 Gln	Tyr	Asn	Ile	Pro	360 Ser	Leu	Lys	Ser	Lys	365 Ile	Asp	Pro	Leu
370 Leu Ile		Arg	Arg	Asp	375 Tyr	Ala	Tyr	Gly	Thr	380 Gln	His	Asp	Tyr	Leu
385 Asp His		-	-	390	-		-	-	395			_	-	400
-		-	405		-	-		410		-			415	-
Pro Gly		420					425		-	-		430	-	
Lys Trp	435	-		-	-	440			-	-	445		-	-
Leu Thr 450		Asn	Arg	Ser	Asp 455	Thr	Val	Thr	Ile	Asn 460	Ser	Asp	Gly	Trp
Gly Glu 465	Phe	Lys	Val	Asn 470	Gly	Gly	Ser	Val	Ser 475	Val	Trp	Val	Pro	Arg 480
Lys Thr	Thr													
<210> S <211> L <212> T <213> O <220> F	ENGTI YPE : RGAN	H: 4 PRT ISM:	83	ific	ial									
<223> 0	THER	INF		TION ion										
<400> S	EQUE	NCE :	17											
Thr Asn	Leu	Asn	Gly	Thr	Leu	Met	Gln	Tyr	Phe	Glu	Trp	Tyr	Thr	Pro

-continued

											-	con	tin	ued	
1				5					10					15	
Asn	Asp	Gly	Gln 20	His	Trp	ГЛа	Arg	Leu 25	Gln	Asn	Aap	Ser	Ala 30	Tyr	Leu
Ala	Glu	His 35	Gly	Ile	Thr	Ala	Val 40	Trp	Ile	Pro	Pro	Ala 45	Tyr	Lys	Gly
Thr	Ser 50	Gln	Ala	Asp	Val	Gly 55	Tyr	Gly	Ala	Tyr	Asp 60	Leu	Tyr	Asp	Leu
Gly 65	Glu	Phe	His	Gln	Lys 70	Gly	Thr	Val	Arg	Thr 75	Lya	Tyr	Gly	Thr	Lуз 80
Gly	Glu	Leu	Gln	Ser 85	Ala	Ile	Lys	Ser	Leu 90	His	Ser	Arg	Asp	Ile 95	Asn
Val	Tyr	Gly	Asp 100	Val	Val	Ile	Asn	His 105	Lys	Gly	Gly	Ala	Asp 110	Ala	Thr
Glu	Asp	Val 115	Thr	Ala	Val	Glu	Val 120	Asp	Pro	Ala	Asp	Arg 125	Asn	Arg	Val
Ile	Ser 130	Gly	Glu	Tyr	Leu	Ile 135	Lys	Ala	Trp	Thr	His 140	Phe	His	Phe	Pro
Gly 145	Arg	Gly	Ser	Thr	Tyr 150	Ser	Asp	Phe	Lys	Trp 155	His	Trp	Tyr	His	Phe 160
Asp	Gly	Thr	Asp	Trp 165	Asp	Glu	Ser	Arg	Lys 170	Leu	Asn	Arg	Ile	Tyr 175	Lys
Phe	Gln	Gly	Lys 180	Ala	Trp	Asp	Trp	Glu 185	Val	Asp	Thr	Glu	Asn 190	Gly	Asn
Tyr	Asp	Tyr 195	Leu	Met	Tyr	Ala	Asp 200	Ile	Asp	Tyr	Asp	His 205	Pro	Asp	Val
Val	Ala 210	Glu	Ile	ГЛа	Arg	Trp 215	Gly	Thr	Trp	Tyr	Ala 220	Asn	Glu	Leu	Gln
Leu 225	Asp	Gly	Phe	Arg	Leu 230	Asp	Ala	Val	Lys	His 235	Ile	Гла	Phe	Ser	Phe 240
Leu	Arg	Asp	Trp	Val 245	Asn	His	Val	Arg	Glu 250	Lys	Thr	Gly	Гла	Glu 255	Met
Phe	Thr	Val	Gly 260	Glu	Tyr	Trp	Ser	Tyr 265	Asp	Ile	Asn	Lys	Leu 270	His	Asn
Tyr	Ile	Thr 275		Thr	Asn	Gly	Thr 280		Ser	Leu	Phe	Asp 285		Pro	Leu
His	Asn 290		Phe	Tyr	Thr	Ala 295		Lys	Ser	Gly	Gly 300		Phe	Asp	Met
Arg 305	Thr	Leu	Met	Thr	Asn 310	Thr	Leu	Met	Lys	Asp 315	Gln	Pro	Thr	Leu	Ala 320
		Phe	Val	Asp 325	Asn	His	Asp	Thr	Glu 330			Gln	Ala	Leu 335	
Ser	Trp	Val	Asp 340	Pro		Phe	Lys	Pro 345	Leu	Ala	Tyr	Ala	Phe 350		Leu
Thr	Arg	Gln 355	Glu		Tyr	Pro	Суз 360	Val		Tyr	Gly			Tyr	Gly
Ile				Asn	Ile	Pro	Ser		Lys	Ser		365 Ile	Asp	Pro	Leu
		Ala	Arg	Arg		375 Tyr		Tyr	Gly		380 Gln	His	Asp	Tyr	
385 Asp		Ser	Asp		390 Ile	Gly	Trp	Thr		395 Glu	Gly	Val	Thr		400 Lys
				405					410					415	

Pro Gly Ser Gly Leu Ala Ala Leu Ile Thr Asp Gly Pro Gly Gly Ser 425 420 430 Lys Trp Met Tyr Val Gly Lys Gln His Ala Gly Lys Val Phe Tyr Asp 435 440 445 Leu Thr Gly Asn Arg Ser Asp Thr Val Thr Ile Asn Ser Asp Gly Trp 450 455 460 Gly Glu Phe Lys Val Asn Gly Gly Ser Val Ser Val Trp Val Pro Arg 465 470 475 480 Lys Thr Thr <210> SEQ ID NO 18 <211> LENGTH: 1449 <212> TYPE: DNA <213> ORGANISM: Bacillus licheniformis <400> SEQUENCE: 18 acaaatetta atgggaeget gatgeagtat tttgaatggt acaegeecaa tgaeggeeaa 60 cattggaagc gtctgcaaaa cgactcggca tatttggctg aacacggtat tactgccgtc 120 tggattcccc cggcatataa gggaacgagc caagcggatg tgggctacgg tgcttacgac 180 ctttatgatt taggggagtt tcatcaaaaa gggacggttc ggacaaagta cggcacaaaa 240 300 qqaqaqctqc aatctqcqat caaaaqtctt cattcccqcq acattaacqt ttacqqqqat 360 gtgqtcatca accacaaaqq cqqcqctqat qcqaccqaaq atqtaaccqc qqttqaaqtc 420 gatecegetg acegeaaceg egtaatttee ggagaataee taattaaage etggacaeat tttcattttc cggggcgcgg cagcacatac agcgatttta aatggcattg gtaccatttt 480 qacqqaaccq attqqqacqa qtcccqaaaq ctqaaccqca tctataaqtt tcaaqqaaaq 540 gcttgggatt gggaagtttc cagtgaaaac ggcaactatg attatttgat gtatgccgac 600 atcgattatg accatectga tgtegtagea gaaattaaga gatggggeae ttggtatgee 660 720 aatgagetee aattggaegg ttteegtett gatgetgtea aacacattaa attteettt ttgcgggatt gggttaatca tgtcagggaa aaaacgggga aggaaatgtt tacggtagct 780 gaatattggc agaatgactt gggcgcgctg gaaaactatt tgaacaaaac aaattttaat 840 cattcagtgt ttgacgtgcc gcttcattat cagttccatg ctgcatcgac acagggaggc 900 ggctatgata tgaggaaatt gctgaacggt acggtcgttt ccaagcatcc gttgaaatcg 960 gttacatttg tcgataacca tgatacacag ccggggcagt cgcttgagtc gactgtccaa 1020 acatggttta agccgcttgc ttacgctttt attctcacaa gggaatctgg ataccctcag 1080 gttttctacg gggatatgta cgggacgaaa ggagactccc agcgcgaaat tcctgccttg 1140 aaacacaaaa ttgaaccgat cttaaaagcg agaaaacagt atgcgtacgg agcacagcat 1200 gattatttcg accaccatga cattgtcggc tggacaaggg aaggcgacag ctcggttgca 1260 aattcaggtt tggcggcatt aataacagac ggacccggtg gggcaaagcg aatgtatgtc 1320 ggccggcaaa acgccggtga gacatggcat gacattaccg gaaaccgttc ggagccggtt 1380 gtcatcaatt cggaaggctg gggagagttt cacgtaaacg gcgggtcggt ttcaatttat 1440 gttcaaaga 1449

<210> SEQ ID NO 19 <211> LENGTH: 1458

Add> SEQUENCE 19 cocccacc thranged a category and seque a category graded graded a category a category accessory acces	<212> TYPE: DNA <213> ORGANISM: Bacillus stearothermophilus	
acgtatágja cinangsági canagaági akutak cingerítég atakasét 120 cittiggetge egecegítt canaggaaca ageograegi negtaggit eggaatgaa 240 anageteat atetteange extenange gecegarge teogenean atatiggaaca 240 gatgteigt tegecedian aggoggeget geogenegi angtgaagga egecigagaa 340 geotateogi eogeoogia canagaaate tegggeneet atenanteen ageotgggene 240 ateggeneigt tegecedian aggoggeneet atenanteen ageotgggene 240 ateggeneigt tegecegitg gagageneet atenantee geotggeneet atenanteen ageotgggene 240 titgneegiget tigateggg gagaeneet atenantee geotggeneet atenanteen ageotgggene 240 titgneegiget gagageneet atenantee geotgeneen ageotggeneet atenanteen ageotgeneet atenanteen ageotggeneet atenanteen ageotggeneet atenateen ageotggeneet atenateen ageotggeneet atenateen ageotggeneet atenanteen ageotgeneet atenanteen ageotgeneet atenateen ageotgeneet atenateen ageotgeneet atenanteen ageotgeneet atenateen atenateen ageotgeneet atenateen ageotgeneet atenateen ageotgeneet atenateen ageotgeneet atenateen ageotgeneet atenatee	<400> SEQUENCE: 19	
<pre>cttggttg: cgcccgctt: caacgaaca agccgcagcg agtaggtd: cggagtata 180 gacttgatg acctgggga attcaatcaa aasgggacg toogcacaa atatggaaca 240 aasgctcaat atcttcaagc cattcaagc goccacgcg toggastgca agtgtacgc 300 gatgtogtt togaccata agcoggogt gacggacag atggggtag cgccgctgaa 340 gacattgat toccgggg ggggacacac tactcaagt taagtgggg toggacaaa 440 ttggacggc togatgggg ggaagtaga aastaagc gaattaagt agcagaaag 440 tagcggaca togggggt ggaagtaga aastaagc gaattaagt caggtgga 440 tagcggacag ctgggggt ggaagtaga aastaagc gaattaagt attcaaggg 440 tagcggaca togggggt ggaagtaga aastaagc gaattaagt cagggaaa 440 ttgacggc ttgatgggg cgaagtaga aastaagc gaattaag cagtggaa 440 tagcggaca togggggt ggaagtaga aastaagc gaagtaga agtagaaa 170 ttocgttt toctgatg gttoggt ggagtaga acaagaacg gaagtaga gocggaa 470 tagcggg tattggg totggogta ggogocgt agccgacaa acttaat 170 aaaggaga ggtettgt tgatgocg taacaaaa acttgat ggacgaaaa taggacaaa togstogg toccdatog gocggggg aggggaa agcgaaaa tagataat gaccogg cgcagggg aggggga aggggata tagacaaa tagtagcg tacttatgg gggggatt aggctaag aggggatg tagacgaaca into into into into into into into into</pre>	geogeacogt ttaacggtac catgatgcag tattttgaat ggtacttgee ggatgatgge	60
gattigtatų actogorga atacata angogarog togosana ataiggana 240 anagotonai atotionago satuonagos gocongoso diggatigo agiginagos 300 gatgiogigi togososana agigogogot gaoginaega atgigigi agosotopa 360 gisantogi togosogina congananto togogonos atonantoch agosiggang 420 anattigat ticoogigog gigonacaeo tactonago titagigog otogitacat 480 tituarogog tigattigig gigaigaesae tactonago gocitanaa attagigog 540 atogosana opigogatig gigaigaesae caganaao ganactaiga catataing 600 tatgosana opigogatig gigaigaesae caganaao ganactaiga catataing 600 tatgosana opigogatig gigaigaga canagaesa gicogiaaca digaigaga attagae 120 ticogitti ticoligatig gitogitogi gicogotig aigosoga gocitana 780 acogotogi atatigaga catagaigg ticogotig aigosofaa gocitata 780 acogotogi attigaig gitogoti gicogotig aigosofaa gocitata 780 acogotogig attigaig gitogoti agosogaa coggotaa agotiganae 1900 toaggiggo dattigaig gitogoti tacacaaca attitae ogoticonaa 900 toaggiggo cattigata gocicagit atgaecaata otocicagaa gaostata 180 acatigorog toacotigi tigataatai gacacagae coggocaage goticagita 1020 taggigatoga catagita a cagitigat taggeotita atgatiga agasonaaca 1020 gattatotig atcoactogi tigataatai gacacagae coggocaage gatigaaacae 1200 gattatotig atcoactogi catagaegi gigasaagga agagigaaa gaggaaaca 1200 gattatotig atcoactogi attaacogi gigasonagga gaagaaagi gatagaeci 1300 accataaa aogutgaa agutitat gaccatae gocigagaga gaagaaatig 1120 gacaacaaca aogutgaaa agutitata gacataga gocigatat 1200 silli tikonni. 1539 silli TUPE NMA silli OKONINNI MITICOL. EKS Encoding precursor form of AnyS control silli TUPONMATION. EKS Encoding precursor form of AnyS control silli tacogiga catagaiga catagaega agutgaiga gagitagaiga gi gacitagat catagitago catagago aacaatta cogotiga catagaegi 120 colligatiga cocaagiggo catagaago aacaatta cogotogi catagaegi 120 colligatiga cocaagiggo catagaago aacaatta cogotiga catagaegi 120 colligatiga cocaagiggo catagaago aacaatta cogotiga catagaegi 120 colligatiga cocagitiga catagagoa aacaatta cogotiga catagaegi 120 colligatig cocogita catagagoa aacaatat cogotiga	acgttatgga ccaaagtggc caatgaagcc aacaacttat ccagccttgg catcaccgct	120
aaagetcaa attitaaage attitaage geccaegeeg etggaatgea agtgtagee 300 gatgtegtgt tegaccata aggeegeget gaeggecaege attgggtgg egecgeegea 360 gteaateeg tigatggge egaageega aattagee geattaeaa atteagggge 420 aaattigatt tteeeggge gggeaaeae teeggeaeet ateaaatee ageatggaeg 420 aaattggtt tigatggge egaageega aaattagee geattaeaa atteagggge 540 ateggeaaag egtgggatg ggaagtage acagaaaeg gaaaetatg etaettaatg 600 tatgeegaee tigatagga etaeegaag geeggaeeg agetgaaaa etagggggaa 660 tggtatgtea acaaegaa eatgatggg teeggettg atgeegteaa geeggaaae etagggggaaa 660 tggtatgtea acaaegaa eatgatggg teeggettg atgeegteaa geeggaaeae 400 aaegegaaega tgeettggttg gtggeeg agetgaaea ageegaaeae 400 aaegegaaega tgeettggt tggtgeeg tggeegea geegaaaeae 400 aeegteggg attitegatg etageeegt taegegetee agaetgaaae 400 aeegteggg etattgata geegeegt aageegaaee eegeeaaeae 900 teaggegge cattgata geegeegt aageegaae eegeeaaeae 900 teaggegge cattgata geegeegt aegeegeae eegeeaaeae 900 teaggeggeg eattgata geegeegt aegeegaee eegeeaaeae 900 teaggeggeg eattgata geegeegt aageegaae eegeeaaaeae 900 teaggeggeg cattgata geegeegt ageegaae eegeeaaeae 900 teaggeggeg cattgata geegeegg taegeegae eegeeaaeae 900 teaggeggeg eattgata geegeegg taegeegae eegeegae 900 teaggeggeg eattgata geegeegg egageegae eegeegaeg 900 taegegeage teeeetteg tgataatea gaeeegae eegeegaeg 900 taecegtegg tetttatgg tgacatta geeegeeg eegeegae geegaaagga 1000 taecegtegg tetttatg tgacattat geeette teegeetta 1000 gattaettg ateacetee daeege geeggag gaacaaeg gatgaeeaat 1200 geaaeaaea tegateegae daeteega geegegag ageeaaeg gatgaeegee 120 geegaaeeat aegetggaa agtgtetet geeteege 120 eegeaeest tument: 1539 eegeeaest tument: 1539 eegeeaest tument: 1550 eegeeaest tument: 1550 eegeeaest tument: 1550 eegeeaest tument: 1550 eegeeaest taeeggea eatgaege agtaggea eegaggage 60 aesttgga eeaagtege eatgaege aaestatat eegeetgg eegeagee 120 eettggetge eeeegetta eaaggaaea ageegeage geegaggate eggatgaee 120 eettggetge eeeegetta eaaggaeea ageegeage geegaggate eggagatae 120 eettggetge eeeegetta eaaggaee ageegaege geegaggate eggagtaea 240 aaage	ctttggctgc cgcccgctta caaaggaaca agccgcagcg acgtagggta cggagtatac	180
<pre>gdgtcgtgt t cgaccata aggcggcgt jacgggcgcg aktgggtgg cgcgtgtga 360 ggtgtcgtgt t cgaccatca aggcggaat c tggggcact atcaaatca agcatggacg 420 aatttgat ttcccgggg gggaaaca tatcacggt ttaggtgg ctggtacat 480 tttgacggcg ttgattggg cgaaagceg aattagg ggaactatga ctattaag 100 tatgccgace ttgattgg tatccceaa gecggaaca gactgaaaa ctgggggaaa 660 tggtatgtca acacaacgaa catgatggg ttccggetg agctgaaaa ctgggggaaa 660 tggtatgtca acacaacga catgatggg ttccggetg agctgaaaa ctgggggaaa 660 taggeraacg tggtgggt ggtgggaat ggeggtaca aaattaa tacaggggaa 660 taggeraagg tggtgggt ggtgggaat ggeggtac aaattaga gactgaaaa ctgggggaaa 660 taggeraagg tggtggg taggegaaca aattgagg taccggetga gacgaata ag 770 ttcagtttt ttcctgatg gttgtgtat ggegetctc agactggaa gccggtatt 780 accggegggg aatatggg ctatggact acagaaca aatttaat tacgaaaca 940 aacggacgg tgctttgt tgatgcogt a agaccaac acattaat tacgaaaca 940 caagggggg cattggad taggccgt aagaccaac accggcaac ggetcaatga 900 tcagggggg cattggat ggacgatg taggccgaac cgggaacag gettgatga 100 tacgggggg cattggat ggacaggg tagccaacg gettagga 100 tacgggtggac catggtcaa accgtggg tggaccaag gacggaagga 100 gattacttg tacacceg accaccgg ggagggaa taggaggaaat ggaggaacat 1200 ggtcaacaa tggatcoget ccccacogg ggaggga agggggtaa tggaggaaca 1200 ggatacaaa togatcoget ccccacogg ggaggga gaggaaatg gatgtacgt 1320 ggcaacaaa acgtggaa agtgtttat gacctacg gcaacogga tgaccacce 1380 accatacaa gfgatggatg gggggaatt aaagtcaatg goggttagt ttgggt 140 gttcotagaa aacgac 1458 *223> OTHER INFORMITON IN INS INSE Incoding precursor form of AmyS control *400> SEQUINCH 105 gccgaccogt ttacaggac aagtaga tatgtatg cg ataccggt 100 cttrggt c cgcccgtt caaaggaaca agccgcacg gatgagga cgaagtag cg actatgg caaagtgg caaagagga agcgaaca 120 cttrggtgg cccaagtggc caagaggac agccacgg gatgagga cg actatgg accaacgtgg caagaggac agcaagtg cg actatgg accaacgtgg caagaggg caagaagca agcgagga cg acgtatgg accaagtgg caagagga tatttgaa ggracgaaga 120 acgttatgg accaaggg caagaggac agccacgg gatgagga caaccg t 120 cttrggtgg ccgccgt tacaaggaaca agccgcacg gatgagga cgaggataa 120 aaagtcaa attttatcaag cattaaagc gccaccgg gatgagga</pre>	gacttgtatg acctcggcga attcaatcaa aaagggaccg tccgcacaaa atatggaaca	240
<pre>creat.cog: cogacogae ccaagaatc toggcact atcaatca agcatgaeg 420 aaatttgat tteeeggee gggcaaaee tacteeaget taagtgeeg etggtaeca 480 tttgaeggee ttgattggg eggaaaeeg aaattagee geattaea atteagggee 420 ateggeaeg etggatg gggaagtage acagaaaeeg gaactage etaetaag 600 taggeaege etggegaatg gggaagtage acagaaaeeg gaactage etaetaag 720 tteagtttt teeetgatg gtgteget ggegeaege ageegaaae etggeggeae 660 teggeaegg atattggg etggeeget ggegeaete ageegeaege geegeatta 780 acegteggg ga atattgg gtgteget ggegeegt ageegaae ageegeaeae 900 teeggggge eattggae etggeeget ageegeae ageegeae geegeaeae 900 teegggggeg eattggae etggeeget ageecegae eeggeeaege geeleaete 170 acegtegg teeettg tgaeget ageecegae eeggeeaege geeleaete 170 acegtegge teetttg tgaegeegt tageeceae aattaet tacgaaaae 900 teegggggee eattggee etgeeege ttggeedett atgeeeae agetggaaeg 960 acettggeeg teeetteg gegeaegt ageecegae eeggeeaege geteagtea 1000 gattaettg atgeeeget tggeeetta tageeege eeggeaegg 1000 taceeggegge geeetta gegeetta taeegetta teegettegee 1140 aaaageaaa tegateege teetetegg eggeagga gaagaagg aggeeaaat 1200 ggeaaeaae eegetggaaa agtteat geeeteae aattaat teetteegt 1140 geteedaaa acgetggaa agtteat geeeteae aattaae teeteegt 1380 aceetaaea gigatggaa agtteat geeeteae aggeggae tggeeget 1320 ggeaaeaae aegetggaaa agttetat gaeeteae form of Amys control <400> SEQUENCE: 20 geoeeeegt ttaaeggee taeteaeae aagetgeeg eggeaggae eggaagaa 66 aegttagga ceaagageg eateaaea geeegeeg agtegged atggeegee 120 ecttgget geeeetta eaagteege ageegeg egeegegae eggeagaaeae 120 geceeeegt ttaeegee ateageege ageegeeg egeegegae form of Amys control <400> SEQUENCE: 20 geceeeegt ttaeegee ateateae ageegege eggeggae eggaggae eggagaeaea 120 geceeeegt ttaeegee ateageege ageegeeg egeegege eggeggae eggagaeaea 120 ecttgget geceette eaagteege ageegeg egeegegee eggagaeaea 120 geceeeegt ttaeegeet ateageege form of Amys control <400> SEQUENCE: 20 geceeeegt ttaeegeet ateageege gegeggae eggaggae eggagaeaea 120 ecttgget egeeeget ateaaeea ageegeege eggeggae eggagaeae 120 ecttggee egeegeet acaagageege ageegegae eggagaeaea</pre>	aaageteaat atetteaage catteaagee geeeacgeeg etggaatgea agtgtaegee	300
aatttgat tteceggeg ggeaacaee taeteeage taagageg etggaeet 480 tttgaeggeg ttgatggga egaageega aattaagee geattaaa atteaggge 540 ateggeag etggggattg ggagtagae eegaaaaeg gaaetatge etaetaaa atteagggee 540 ttgeegeee ttgatatgga teateeega gtegtgaeeg geetgaaaa etgggggaa 660 tggtatgtea eeeaaaega eattgaegg tteeggettg atgeegteaa geegetatt 780 acegteegggg aatattgga etatgaeg etaegaaeae aeutteatae etgeegaa geegetatt 780 acegteegggg aatattgga etageeeg ttaeeaaea aattteate egeeteeaa 900 teagggggeg eattgata geegeegta atgeeegaa eeegeeaa geegetaat 1780 acegteegggg eattgata geeeegat atgeeega eeegeeage gettagtea 1020 teagggggeg eattgata gegeeegtt aegeetta tteeaaea gaateaeeg 960 acattgeeeg teaeettag tgaeatat geeeegae eeggeeaae eeggeeaaeg 1020 tgggtegee eatggtea aeeegtege taegeetta tteetaeeg geaggaaga 1080 taeeegtegg teatettag tgaeatata geeeegae eeggeeaaeg gettagtea 1020 ggateeegge tggeeegee eegeegeegeegeeggg gaaggagg aaggegaagg 1080 taeeegtegg tetttatg tgaeatata geeetgae eeggeeaagg attgaeaee 1200 ggateeegge tggeeegeet gaeeegaa gegeegggg gaageaaatg gaageaeat 1200 ggataeeegaa aeegtege egeegggag gageaaagg gaageaaatg 1200 ggateeegge tggeeegee geegggg gageaaagg gaggaaaee 1260 ggateeegge tggeegeeg geegggg gageaaagg gaggaaate 1320 geeaaeaa eegetggaa agtgtteta gaeetae eagteeag geegggg taeeegee 1380 aceeteaea gegetggaa agtgtteta gaeetaeg geegggg gaageaaatg gagtaeegt 1320 getteetagaa aaeegee 1468 *210 - SSO ID NO 20 *211 - LBMNEH: h319 *212 - TFFF: DNA *213 - DNA MINH: hrifeial *220 - FFFFUEE *213 - DNA MINH: hrifeial *220 - FFFFUEE *213 - DNA MINH: hrifeial *220 - FFFFUEE *214 - LBMNEH herebaallee. BSE Encoding preeuror form of AmS control *400 - SEQUENCE: 20 geegeaeegt ttaeeggae aateaeegae ageegeag aegegata eggagtate 180 gaettgata eeesgeege atteatae aagggaeeg teegeegaa atatggaee 180 gaettgata eeesgeega atteataea aagggaeeg teegeegaa atatggaea 180 gaettgata eeesgeega atteataea aagggaeeg teegeegaa 180 gaettgata eeesgeega atteataea aagggaeeg teegeegaa 180 aaggteega teefeega atteataea aagggaeeg teegeaega 180 seesgeega	gatgtcgtgt tcgaccataa aggcggcgct gacggcacgg aatgggtgga cgccgtcgaa	360
ttlgacggog ttgatagga cgaaagooga aaattagoo gotttaa ta accggacaag ogtgggattg ggaagtaga cacgaaaaog gaactatga ctacttaatg 600 tatgoogaca (ttgatatgga toatooogaa gtogtgacog agotgaaaa ctggggggaa 660 tggtatgtca acacaaoga cattgatggg ttcoggottg atgoogtcaa gotattaag 720 ttcagtttt ttcotgattg gtugtogtat gtgggttca agactggaa googtatt 780 accgtogggg aatatggag otatgacaa cacaaoga cattgatgg tcoggottg atgoogtcaa gotattaag 720 ttcagtttt ttcotgattg gtugtogtat gtgogttca agactggaa googtatt 780 accgtogggg aatatggag otatgacaa acaagtga acaaagtga agoogtatt 780 accgtogggg cattgata gogcoogt aatgaccaaca aatttaac coottcaaga agatcaacog 960 acattgoog tcacottog tgataataa gocacaata ctotcatgaa agatcaacog 960 acattgoog tcacottog tgatatat gogcatgat tagoctaat ttoetacg gaaggaaga 1080 taccogtog totttatg tgatatta gocacaga coggocaacg gottagta 1020 tgggtogac catggtcaa acogtggot tagocaata ctotcatga agatcaacog 1260 ggatcoggot tggoogact gactacagg ggogggg gaaggaaatg gaagaaat 1200 ggatactgg tggoogac gacacacgg ggogggg gaaggaaag gaggagaaat 1200 ggatacaga atogatooga catcatogg ggoogggg gaagcaaatg gaagtaagt 1320 ggaaacaaa togatogga tggoogac gacacaga ggooggg gaagcaaatg gatgtacgt 1380 accatcaaca ggotggag gggggaatt agaccaad googgtcgg ttcoggttgg 1440 gttcotaga aaacgac 1458 <2100 SEQ ID NO 20 <2110 LENNEN: 1339 <2120 TYPE: DNA <2120 SEQUENCE: 20 googcaccgt ttaacggac atgatgaag tattttgat ggatattgc gagtgatg 60 acgttatgg coasagtgg caaggaga tatttgaat ggacatta coggottgg caccocgt 120 ctttggotg coccocgt t caaaggaac aacgotgag agtgatgg cagaggta 210 acgttatgg coasagtgo caagagaa aacgocg acgatggg caccocgt 120 ctttggotg coccocgt tacaaaggaaca agoogaag agtgaggta cggagtaa 210 agactgatag caasgtgc attoaacaa agoogaag acgataggg cagaggata 210 acgttatga coasagtgo caagagaa agogcag gotgaggga cggaggata 210 aaagtcaat attotcaag cattacaaga agoogaa gatgaggt cggagtaa 210 aaagtcaat attotcaag cattacaaga agoogac gotgagga cagaggata 210 aaagtcaat attotcaag cattacaaga agoogac gotgagga cagaggata 210	gtcaatccgt ccgaccgcaa ccaagaaatc tcgggcacct atcaaatcca agcatggacg	420
ateggeaaag egigggatig ggaagtage acagaaaeg gaaactafga etattata tatgeegaee tigatagig teatecegaa gtegigaeeg ageigaaaa eigggggaaa teggetagiea acaeaegaa catigaiggg tteeggetig atgeegiea geatataag 720 titagittit teetigatig gitgjeegta gigegittee agaetggeaa geegetatti 780 acceptegggg atattigg etaigaeet acaeagitge acaataeat taegaaaaea 840 aaeggaaega tigtettigt tigageeeg taacaeaa aattitatae egeteeaa 900 teaggggeg eattigat geegeegita atgeeeaa acteeta taegaaaaea 940 acatiggeeg teaeettigt tigataetea gaeeagae eeggeeaage geteagaa 1020 tigggteggee eattigat gegeaegita atgeeeaae eeggeeaage geteagaa 1020 tigggteggee eatgeteea acegitgge taegeetta teaeeagae geteagaaga 1080 taecegiggg teattigat gegeaegita aggeettea aataaeat teeteegig 1140 aaaageaaaa tegateege eeceata ggeeaeggag gaageaaatg gaageaaeae 1260 ggateegge tiggeegeaet gateeegg gegegggag gaageaaatg gaageaeaea 1260 ggateegge tiggeegeaet gateeegg egeagggag gaageaaatg gatgaeegt 1320 geeaaaeaa aegetggaa agtgetea gaeetaeg geeaegga gaageaatg gatgaeegt 1380 acceateaaea gigaiggaig gggggaate agaeteag geeggtegg tidgeeege 1380 acceateaaea gigaiggaig gggggaate aaagteaatg geegteegt teeggetig 1440 gitteetagaa aaaegeee 1458 <210> SSO ID NO 20 <211> tisseffi: hsso <220> F2MINF: <220> F2MINF: <220	aaatttgatt ttcccgggcg gggcaacacc tactccagct ttaagtggcg ctggtaccat	480
tatgscgacc ttgatatgga teateccgaa gtegtgaceg agetgaaaaa ofgggggaaa 660 tggtatgtea acacaacga cattgatggg tteeggette ageetggacaa geegetattaag 720 tteagttitt tteetgatig gitgegitat gigegittee agaetggeaa geegetatt 780 accepteggg aatattggag etatgacate acacagtig acaattaet taegaaaaca 840 aaeggaaega tgiettigit igatgeeeg taaeacaae aattatat eegeteeaa 900 teagggggeg eattgati geegeegita agaecaata eteteadee 960 acattggeeg teaeettegi igataateai gaeaeegaa eeggeeaage getteagtea 1020 tigggitegaee eatggiteaa acegitigee taegeetta tietaaeteg geaggaagga 1080 taeeegigeg teattigit gataateai gaeaeegaa eeggeeaage geiteagtea 1020 tigggitegaee eatggiteaa acegitigee taegeetta tietaaeteg geaggaagga 1080 taeeegigeg tettitatig tigateateai ggeeaegga agaggageae tigaaaaeea 1200 gattatettig ateaeeegi eecaateggi eggagggai aggegaaaatig gatgaaeegi 1300 gattatettig ateaeeegi agteeegi eecaateggg gaggegaaatig gatgaaeegi 1300 ggataeaeaa aegetggaaa agigteetai gaeetaeegi geeaeegga gaageaaatig gatgaeegi 1380 aceateaaea gigatggai giggegaate agaetaag geegiteggi tieggittigg 1440 gitteetagaa aaaegaee 1458 <210> SEQ ID NO 20 <211> tEMROH: 1539 <220> FEMION: <220> FEMION:	tttgacggcg ttgattggga cgaaagccga aaattaagcc gcatttacaa attcaggggc	540
tggtatgtca acacacaga cattgatggg ttccggcttg atgccgca gcatattag 720 ttcagtttt ttcctgattg gttgcgtat gtgcgttc agactgcga gccgctatt 780 accgtcgggg atattggag ctatgaca acagtgc acaattacat tacgaaaaaca 840 accggggg attgtcttt tgatgcccg ttacacaaca aatttatac cgcttcaaa 900 tcagggggc cattgatat gcgcacgta atgaccaaa ctctcatgaa agatcaacg 960 acattggccg tcaccttcg tgataatcat gacacagac ccggccaagc gctcagtca 1020 tgggtcgac catggttcaa accgtgggt tacggcatt attctaatcg gcaggaagga 1080 taccogggg tctttagg tgatattag ggacaggg taggcatag gacagaaga 1280 gattacttg atcactccg ctcacacgg ggagaggg tagggaca tgaaaaca 1200 ggatcaggg tggccaca gatcacagg gggcgggg gaaggaaatg gatgtacgt 1320 ggatcaggg tggccaca gatcacaga gggcgggg gaagcaaatg gatgacgt 1320 ggatcaggg tggccgaa agtgttct gactatca gaccaggg gaagcaaatg gatgtacgt 1320 ggatcagaa acggtggaa agtgttct gactatcag gcaggggg taggcaagg tgacacgtc 1380 accataca gtgatggatg gggggaatt agactaacg gcggtggg tgacacgga tgacgcacg 1440 gttcctagaa aacgacc 1459 c210 > SEQ ID NO 20 c211 > LENGTH: 153 c220 > FENTHER c220 > FENTHER c2	atcggcaaag cgtgggattg ggaagtagac acagaaaacg gaaactatga ctacttaatg	600
ttoagtitti titoetgatig gitgeograf giogittoe agaetgoda googetatti 780 accigtoggg atatiggag etatgacet aacagitge acaattade taegaaaaca 840 aacggaega tgetettigt tigatgoeceg ttaecaaca aattitate egetteeaa 900 teagggigge eattgatat gegeaegita atgaecaaa eteteaaga agateaaceg 960 acattggeeg teaeettegi tgataateai gaecaegaa eeggeeaage getteagtea 1020 tigggitegaee eatggiteaa acegitigget taegeetta teteaaetig geaggagagg 1080 taecegigeg tettitaigg tgaetatta ggeeaegia atgaecaea eatataeae teeteegi 1140 aaaageaaaa tegateegi eeteaagi ggeeagggi aagggaeaet gaaaaeae 1260 ggateegige tiggeegeaet gateaeegi ggeegiggi gaaegeaaat gaatgaeaet 1280 ggateegige tiggeegeaet gateaeegi ggeegiggi gaageaaatg gaageaaatg 1280 ggateegige tiggeegeaet gateaeegi ggeegiggi gaageaaatg gaageaeti 1320 ggeeaaeaa aegetgagaa agtgeteta gaeetaeegi geegitegi teegittig 1440 gteedaaa aagaae 1458 <210> SEQ ID NO 20 <211> temerin: 153 <220> FeXINTE: NAA 213> OREANISM: Artificial <220> FEXINTE: >222> OTHER INFORMATION: EBS2 Encoding precursor form of AmyS control <400> SEQUENCE: 20 geecaecgi taaeggae caagaagea agegaeatig ggatgaegi ei 120 cttiggete eeceeci eatagaae aagegee aacaattat eegeettig eataeeci 120 cttiggete eeceeci eatagaae aacgee aacaattat eegeettig eataeeci 120 cttiggete eeceeci eatagaae aagegee aacaattat eegeettig eataeeci 120 cttiggete eeceeci eatagage aagegae aegaaggae aegagatae 120 cttiggete eeceeci eatagaae aagegee geegeegi eegaaeaa eatagaeae 120 gaettatig aceecigei eatagaaea agegeegi eegaaeaa eatagaeae 120 cttiggete eeceeci eatagaaea ageeci eeceeci eeceeci eeceeci eegaaeaea 120 aagetteat ateeteage etteaage eeceeci eeceeci eeceeci eegaaaeae 120 aagetteat ateeteage eeteeci eeceeci eeceeci eegaaaeae 120	tatgccgacc ttgatatgga tcatcccgaa gtcgtgaccg agctgaaaaa ctgggggaaa	660
accgtgggg atattggag ctatgacatc accaqgtg c acattacat tacgaaaca 840 aacgggggg c atttgat gogcacgt atgacacaa atttatac cgcttcaaa 900 tcagggggg c atttgat gogcacgt agacacgaa ccggcaag gottagta 1020 tgggtogac catggttaa acgttgget tacgactta ttetaactg goaggagga 1080 taccgggg tetttatg tgacatta gocacgaa caggacgag attetata 1200 gattatettg atcaetecga cateategg tgacaagg aggggtaa tgetagga aggagaaa 1220 ggatacggg tggeegaa aggtgteta goeegagg agggggtaa tgetaaaaaca 1260 ggatceggg tggeegaa gatcaeteg ggeegggg gaagaaatg gatgtaegt 1320 ggaaacaaa acgetggaa aggtgteta aggeetgge gaacegga taggetaet 1200 gattatettg atcaeteega gaeegagg gaageaaatg gatgtaegt 1320 ggaaacaaa acgetggaa aggtgteta aggeegggag gaageaaatg gatgtaegt 1320 ggeaaacaac acgetggaaa agtgtteta gaeetaeg geggtegg tteggttegg	tggtatgtca acacaacgaa cattgatggg ttccggcttg atgccgtcaa gcatattaag	720
aacggaacga tgtottgtt tgatgoccog ttacacaaca aatttatac ogottocaaa 900 toagggggg cattgatat gogcacgtta atgaccaata ototoatgaa agatcaacog 960 acattggcog teacettegt tgataateat gacacegaae oeggecaage getteagtea 1020 tgggtegaee eatggtteaa acegttgget taegeetta ttetaaeteg geaggaagga 1080 taecogtgeg tetttatgg tgaetattat ggeatteeae aatataaeat teettegetg 1140 aaaageaaaa tegateeget eeteategg egaggggt aagggggteae tgaaaaacea 1260 ggateeggge tggeegeaet gateacegat gggeegggag gaaggaggteae tgaaaaacea 1260 ggateeggge tggeegeaet gateacegat gggeegggag gaageaaatg gatgtaegtt 1320 ggeaaacaae acgeetggaaa agtgteetat gaeettaeeg geaaegggg tgaeeegg 1140 ateetaaeae atgeetggaaa agtgteeta gaeettaeeg geaaegggg teeggateegg 1440 gtteetagaa aaaegaee 1458 <210> SEQ ID NO 20 <211> LENOTH: 1539 <212> TYPE: DNA <213> ORGANISM: Artificial <220> FEATURE: <223> OTHEN INFORMATION: EBS2 Encoding precursor form of AmyS control <400> SEQUENCE: 20 geegeaeegt ttaaeggtae catgatgedg tatttgaat ggtaettge ggatgatgge 60 acgttatgga ceaaaggtge Caatgaagee aacaacttat ceageetgg eateaceget 120 etttggetge egeeegtta caaaggaaea agegegaeg agtagggta eggagtatea 180 gaettgag eeeeegga atteaateaa aagggaeeg teegeaeaa atatggaae 240 aageeteat atetteaage eateaceg egeeegeet etggaatgea agtgtaeeg 300	ttcagttttt ttcctgattg gttgtcgtat gtgcgttctc agactggcaa gccgctattt	780
tcagggggg catttgatat gegeacgtta atgaccata eteteateg agateaaceg 960 acattggeeg teaeetteg tgataateat gacacegaae eeggeeagge getteagtea 1020 tgggtegace eatggtteaa acegttgget taegeetta ttetaaeteg geaggaagga 1080 taecegtgeg tetttatgg tgaetattat ggeatteeae aatataaeat teettegetg 1140 aaaageaaaa tegateeget eeteategg tggaeaaggg aaggggteae tgaaaaaeea 1260 ggateeggge tggeegeaet gateacegat gggeegggag gaageaaatg gatgtaegtt 1320 ggeaaacaae acgetggaaa agtgttetat gaeettaeeg geaeggag tgaeacegte 1380 accateaaea gtgatggatg gggggaatte aaagteaatg geggteeggt tteggttegg	accgtcgggg aatattggag ctatgacatc aacaagttgc acaattacat tacgaaaaca	840
acattggcog teaecttegt tgataateat gaeaeegaae eeggeeaage getteagtea 1020 tgggtegaee eatggteaa acegttgget taegeettea ttetaaeteg geaggaagga 1080 taeeegtgeg tetttatgg tgaetattat ggeatteea aatataaet teettegetg 1140 aaaageaaaa tegateeget eetetatgg gegeggggat atgetaegg aaegeaaeat 1200 gattaetteg ateaeteega eateaeegg gegegggag aagggggteae tgaaaaaeea 1260 ggateeggge tggeegeaet gateaeegat gggeegggag gaageaaatg gatgtaegtt 1320 ggeaaaeaae aegetggaaa agtgttetat gaeettaeeg geaaeegga tgaeaeegte 1380 aceateaaea ggegggaatte aaagteaatg geggteegg tgaeaeegte 1380 aceateaaea gtgatggatg gggggaatte aaagteaatg geggtteggt teeggttegg 1440 gtteetagaa aaaegaee 1458 <210> SEQ ID NO 20 <211> LENGTH: 1539 <212> TYPE: DNA 213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: EBS2 Encoding precursor form of AmyS control <400> SEQUENCE: 20 geegeaeegt ttaaeggtae catgaagee gaecaetta ceageettge cateaeegt 120 etttggetge egeeegtta eaaagtaaa agegeeaeg aegtagggta eggagtatee 180 gaectgtagg aceaagtgge catgaagaea agegeegeg teegaaea atatggaaea 240 aageteaat ateteaage eateaaeae agegeege teggaaggae agtgaaeae 240	aacggaacga tgtctttgtt tgatgccccg ttacacaaca aattttatac cgcttccaaa	900
tgggtegaee eatggteaa acgttgget taegeetta ttetaacteg geaggaagga 1080 taecegtgeg tetttatgg tgaetatat ggeatteea aatataacat teettegetg 1140 aaaageaaaa tegateeget eeteatagg eggaggat atgetteegg aaegeaacat 1200 gattatettg ateacteega eateateggg tggaeaaggg aaggggteee tgaaaaacea 1260 ggateeggge tggeegeaet gateacegat gggeegggag gaageaaatg gatgtaegtt 1320 ggeaaacaae acgetggaaa agtgttetat gaeettaeeg geaaeeggag tggaeaeegt 1380 aceateaaea gtgatggatg gggggaatte aaagteaatg geggteegt tteggtttgg 1440 gtteetagaa aaaegaee 1458 <210> SEQ ID NO 20 <211> LENGTH: 1539 <212> TYPE: DNA <213> OREANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: EBS2 Encoding precursor form of AmyS control <400> SEQUENCE: 20 geegeaeegt ttaaeggte catgaagee aaeaetta ceageettgg cateaeeget 120 etttggetge egeeegetta eaaaggaea ageggaegg acgtaggta eggagtatae 180 gaettgtagg aceaagtgge categaage geeedegg teegeaeaa atatggaaea 240 aaegeteaat atetteaage eatteaage geeedegge etggaatgea agtgtaegee 300	tcaggggggg catttgatat gcgcacgtta atgaccaata ctctcatgaa agatcaaccg	960
taccegtgeg tetttatgg tgaetattat ggeatteea aatataacat teettegetg 1140 aaaageaaaa tegateeget eeteategeg egeagggat atgettaegg aaegeaacat 1200 gattatettg ateaeteega cateateggg tggaeaaggg aagggggeae tgaaaaaeea 1260 ggateeggge tggeegeaet gateaeegat gggeegggag gaageaaatg gatgtaegtt 1320 ggeaaaeaae aegetggaaa agtgttetat gaeettaeeg geaaeeggag tgaeaeegt 1380 aceateaaea gtgatggatg gggggaatte aaagteaatg geggteggt teeggttegg 1440 gtteetagaa aaaegaee 1458 <210> SEQ ID NO 20 <211> LENGTH: 1539 <212> TYPE: DNA <213> ORANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: EBS2 Encoding precursor form of AmyS control <400> SEQUENCE: 20 geegeaeegt ttaaeggtae catgatgeag tattttgaat ggtaettgee ggatgatge 60 aegttatgga eceaagtgge caatgaagee aaeaaettat ceageettgg cateaeegt 120 cettggetge egeeegta ateaateaa aagggaeeg aegtagggta eggatatae 180 gaettgtatg aceteggega atteaateaa aaagggaeeg teegeaeaa atatggaeea 240 aageteaat atetteaage catteaagee geeegege etggaatgea agtgtaegee 300	acattggeeg teacettegt tgataateat gacaeegaae eeggeeaage getteagtea	1020
aaaagcaaaa tegateeget eeteateegg egeagggatt atgettaegg aacgeaacat 1200 gattatettg ateaeteegg eateateegg tggacaaggg aaggeggtee tgaaaaacea 1260 ggateeggge tggeegeaet gateaeegg gggeegggag gaageaaatg gatgtaegtt 1320 ggeaaacaae aegetggaaa agtgttetat gaeettaeeg geaaeeggag tgaeaeegte 1380 accateaaea gtgatggatg gggggaatte aaagteaatg geggtteggt tteggtttgg 1440 gtteetagaa aaaegaee 1458 <2110 > SEQ ID NO 20 <2110 > SEQ ID NO 20 <2112 > EUROTH: 1539 <2122 > TYPE: DNA <2133 > ORGANISM: Artificial <2205 > FEATURE: <2223 > OTHER INFORMATION: EBS2 Encoding precursor form of AmyS control <400> SEQUENCE: 20 geegeaeegt ttaaeegtae eatgatgeag tatttgaat ggtaettgee ggatgatgge 60 acgttatgga eceaagtgge caatgaagee aacaaetta ceageettge eatecaeegt 120 etttggetge egeeegtta eaaaggaaea ageegaegg acgtagggta eggagtatae 180 gaettgtatg aceteggega atteaatea aaagggaeeg teegeaeaa atatggaaea 240 aaageteaat actteeagee geeeaegeeg etggaatgea agtgtaegee 300	tgggtcgacc catggttcaa accgttggct tacgccttta ttctaactcg gcaggaagga	1080
gattatettg ateaeteegg eateaeeggg tggacaaggg aaggggteae tgaaaaacea 1260 ggateeggge tggeegeaet gateaeegga gggeegggag gaageaaatg gatgtaegtt 1320 ggeaaaeaae aegetggaaa agtgttetat gaeettaeeg geaaeeggag tgaeeeegte 1380 accateaaea gtgatggatg gggggaatte aaagteaatg geegtteggt tteggtttgg 1440 gtteetagaa aaaegaee 1458 <210> SEQ ID NO 20 <211> LENOTH: 1539 <212> TYPE: DNA <213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: EBS2 Encoding precursor form of AmyS control <400> SEQUENCE: 20 geegeaeegt ttaaeggtae eatgatgeag tattttgaat ggtaettgee ggatgatgge 60 aegttatgga ceaaagtgge eaatgaagee aacaaetta ceageettgg eateaeegte 120 etttggetge egeeegetta eaaaggaaea ageegeaegg acgtaggtga eggagtatae 180 gaettgtatg aeeteggega atteaateaa aaagggaeeg teegeaeaaa atatggaaea 240 aaageteaat atetteaage eatteaaee geeeaegeeg etggaatgea agtgtaeegee 300	taccegtgeg tettttatgg tgactattat ggeatteeae aatataaeat teettegetg	1140
<pre>ggatccgggc tggccgcact gatcaccgat gggccgggag gaagcaaatg gatgtacgtt 1320 ggcaaacaac acgctggaaa agtgttetat gacettaccg geaaccggag tgacaccgte 1380 accateaaca gtgatggatg gggggaatte aaagteaatg geggtteggt tteggtttgg 1440 gtteetagaa aaacgaee 1458 <210> SEQ ID NO 20 <211> LENGTH: 1539 2212> TYPE: DNA 2123> OFHER INFORMATION: EBS2 Encoding precursor form of AmyS control <400> SEQUENCE: 20 gccgcaccgt ttaacggtae catgatgeag tatttgaat ggtacttgee ggatgatgge 60 acgttatgga ceaaagtgge caatgaagee aacaacttat ceageettgg cateacceget 120 ctttggetge egeeegetta caaaggaaca ageegeageg acgtagggta eggagtatee 180 gacttgtatg accteggega atteaateaa aaagggaeeg tegeaccaaa atatggaaca 240 aaageteaat atetteaage catteaagee geeegeeg etggaatgea agtgtacgee 300</pre>	aaaagcaaaa tcgatccgct cctcatcgcg cgcagggatt atgcttacgg aacgcaacat	1200
ggcaaacaac acgctggaaa agtgttctat gaccttaccg gcaaccggag tgacaccgtc 1380 accatcaaca gtgatggatg gggggaattc aaagtcaatg gcggttcggt ttcggtttgg 1440 gttcctagaa aaacgacc 1458 <211> LENGTH: 1539 <212> TYPE: DNA <213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: EBS2 Encoding precursor form of AmyS control <400> SEQUENCE: 20 gccgcaccgt ttaacggtac catgatgcag tattttgaat ggtacttgcc ggatgatggc 60 acgttatgga ccaaagtggc caatgaagcc aacaacttat ccagccttgg catcaccgct 120 ctttggctgc cgcccgctta caaaggaaca agccgcagcg acgtagggta cggagtatac 180 gacttgtatg acctcggcga attcaatcaa aaagggaccg tccgcacaaa atatggaaca 240 aaagctcaat atcttcaagc cattcaagcc gcccacgccg ctggaatgca agtgtaccgc 300	gattatettg ateacteega cateateggg tggacaaggg aagggggteae tgaaaaaeea	1260
accatcaaca gtgatggatg gggggaatte aaagteaatg geggtteggt tteggttteg 1440 gtteetagaa aaaegaee 1458 <210> SEQ ID NO 20 <211> LENGTH: 1539 <212> TTPE: DNA <213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: EBS2 Encoding precursor form of AmyS control <400> SEQUENCE: 20 geegeacegt ttaaeggtae catgatgeag tatttgaat ggtaettgee ggatgatgge 60 acgttatgga ceaaagtgge caatgaagee aacaacttat ceageettgg cateaceget 120 etttggetge egeeegetta eaaaggaaca ageegeageg acgtagggta eggagtatae 180 gaettgtatg aceteggega atteaateaa aaagggaeeg teegeaaaa atatggaaca 240 aaageteaat atetteaage catteaagee geeeaegeeg etggaatgea agtgtaegee 300	ggateeggge tggeegeact gateacegat gggeegggag gaageaaatg gatgtaegtt	1320
gttcctagaa aaacgacc 1458 <210> SEQ ID NO 20 <211> LENGTH: 1539 <212> TYPE: DNA <213> ORGANISM: Artificial <220> FEATURE: <222> OTHER INFORMATION: EBS2 Encoding precursor form of AmyS control <400> SEQUENCE: 20 gccgcaccgt ttaacggtac catgatgcag tatttgaat ggtacttgcc ggatgatggc 60 acgttatgga ccaaagtggc caatgaagcc aacaacttat ccagccttgg catcaccgct 120 ctttggctgc cgcccgctta caaaggaaca agccgcagcg acgtagggta cggagtatac 180 gacttgtatg acctcggcga attcaatcaa aaagggaccg tccgcacaaa atatggaaca 240 aaagctcaat atcttcaagc cattcaagcc gcccacgccg ctggaatgca agtgtacgcc 300	ggcaaacaac acgctggaaa agtgttctat gaccttaccg gcaaccggag tgacaccgtc	1380
<pre><pre><pre><pre><pre><pre><210> SEQ ID NO 20 <211> LENGTH: 1539 <212> TYPE: DNA <213> ORGANISM: Artificial <220> FEATURE: <2223> OTHER INFORMATION: EBS2 Encoding precursor form of AmyS control <400> SEQUENCE: 20 gccgcaccgt ttaacggtac catgatgcag tattttgaat ggtacttgcc ggatgatggc 60 acgttatgga ccaaagtggc caatgaagcc aacaacttat ccagccttgg catcaccgct 120 ctttggctgc cgcccgctta caaaggaaca agccgcagcg acgtagggta cggagtatac 180 gacttgtatg acctcggcga attcaatcaa aaagggaccg tccgcacaaa atatggaaca 240 aaagctcaat atcttcaagc cattcaagcc gcccacgccg ctggaatgca agtgtacgcc 300</pre></pre></pre></pre></pre></pre>	accatcaaca gtgatggatg gggggaattc aaagtcaatg gcggttcggt ttcggtttgg	1440
<pre><211> LENGTH: 1539 <212> TYPE: DNA <213> ORGANISM: Artificial <220> FEATURE: <2223> OTHER INFORMATION: EBS2 Encoding precursor form of AmyS control <400> SEQUENCE: 20 gccgcaccgt ttaacggtac catgatgcag tattttgaat ggtacttgcc ggatgatggc 60 acgttatgga ccaaagtggc caatgaagcc aacaacttat ccagccttgg catcaccgct 120 ctttggctgc cgcccgctta caaaggaaca agccgcagcg acgtagggta cggagtatac 180 gacttgtatg acctcggcga attcaatcaa aaagggaccg tccgcacaaa atatggaaca 240 aaagctcaat atcttcaagc cattcaagcc gcccacgccg ctggaatgca agtgtacgcc 300</pre>	gttcctagaa aaacgacc	1458
gccgcaccgt ttaacggtac catgatgcag tattttgaat ggtacttgcc ggatgatggc60acgttatgga ccaaagtggc caatgaagcc aacaacttat ccagccttgg catcaccgct120ctttggctgc cgcccgctta caaaggaaca agccgcagcg acgtagggta cggagtatac180gacttgtatg acctcggcga attcaatcaa aaagggaccg tccgcacaaa atatggaaca240aaagctcaat atcttcaagc cattcaagcc gcccacgccg ctggaatgca agtgtacgcc300	<211> LENGTH: 1539 <212> TYPE: DNA <213> ORGANISM: Artificial <220> FEATURE:	rol
acgttatgga ccaaagtggc caatgaagcc aacaacttat ccagccttgg catcaccgct 120 ctttggctgc cgcccgctta caaaggaaca agccgcagcg acgtagggta cggagtatac 180 gacttgtatg acctcggcga attcaatcaa aaagggaccg tccgcacaaa atatggaaca 240 aaagctcaat atcttcaagc cattcaagcc gcccacgccg ctggaatgca agtgtacgcc 300	<400> SEQUENCE: 20	
ctttggctgc cgcccgctta caaaggaaca agccgcagcg acgtagggta cggagtatac 180 gacttgtatg acctcggcga attcaatcaa aaagggaccg tccgcacaaa atatggaaca 240 aaagctcaat atcttcaagc cattcaagcc gcccacgccg ctggaatgca agtgtacgcc 300	geegeaeegt ttaaeggtae catgatgeag tattttgaat ggtaettgee ggatgatgge	60
gacttgtatg acctcggcga attcaatcaa aaagggaccg tccgcacaaa atatggaaca 240 aaagctcaat atcttcaagc cattcaagcc gcccacgccg ctggaatgca agtgtacgcc 300	acgttatgga ccaaagtggc caatgaagcc aacaacttat ccagccttgg catcaccgct	120
aaageteaat atetteaage catteaagee geeeaegeeg etggaatgea agtgtaegee 300	ctttggctgc cgcccgctta caaaggaaca agccgcagcg acgtagggta cggagtatac	180
	gacttgtatg acctcggcga attcaatcaa aaagggaccg tccgcacaaa atatggaaca	240
gatgtcgtgt tcgaccataa aggcggcgct gacggcacgg aatgggtgga cgccgtcgaa 360	aaagctcaat atcttcaagc cattcaagcc gcccacgccg ctggaatgca agtgtacgcc	300
	gatgtcgtgt tcgaccataa aggcggcgct gacggcacgg aatgggtgga cgccgtcgaa	360

46

gtcaatccgt ccgaccgcaa ccaagaaatc tcgggcacct atcaaatcca agcatggacg	420
aaatttgatt ttcccgggcg gggcaacacc tactccagct ttaagtggcg ctggtaccat	480
tttgacggcg ttgactggga cgaaagccga aaattaagcc gcatttacaa attcatcggc	540
aaagcgtggg attgggaagt agacacagaa aacggaaact atgactactt aatgtatgcc	600
gacettgata tggateatee egaagtegtg acegagetga aaaaetgggg gaaatggtat	660
gtcaacacaa cgaacattga tgggttccgg cttgatgccg tcaagcatat taagttcagt	720
ttttttcctg attggttgtc gtatgtgcgt tctcagactg gcaagccgct atttaccgtc	780
ggggaatatt ggagctatga catcaacaag ttgcacaatt acattacgaa aacaaacgga	840
acgatgtett tgtttgatge ecegttaeae aacaaatttt ataeegette caaateaggg	900
ggcgcatttg atatgcgcac gttaatgacc aatactctca tgaaagatca accgacattg	960
gccgtcacct tcgttgataa tcatgacacc gaacccggcc aagcgcttca gtcatgggtc	1020
gacccatggt tcaaaccgtt ggcttacgcc tttattctaa ctcggcagga aggatacccg	1080
tgcgtctttt atggtgacta ttatggcatt ccacaatata acattccttc gctgaaaagc	1140
aaaatcgatc cgctcctcat cgcgcgcagg gattatgctt acggaacgca acatgattat	1200
cttgatcact ccgacatcat cgggtggaca agggaagggg tcactgaaaa accaggatcc	1260
gggetggeeg caetgateae egatgggeeg ggaggaagea aatggatgta egttggeaaa	1320
caacacgctg gaaaagtgtt ctatgacctt accggcaacc ggagtgacac cgtcaccatc	1380
aacagtgatg gatggggggga attcaaagtc aatggcggtt cggtttcggt ttgggttcct	1440
	1500
agaaaaacga ccgtttctac catcgctcgg ccgatcacaa cccgaccgtg gactggtgaa	
agaaaaacga ccgtttctac catcgctcgg ccgatcacaa cccgaccgtg gactggtgaa ttcgtccgtt ggaccgaacc acggttggtg gcatggcct	1539
<pre>ttcgtccgtt ggaccgaacc acggttggtg gcatggcct <210> SEQ ID NO 21 <211> LENGTH: 1449 <212> TYPE: DNA <213> ORGANISM: Artificial <220> FEATURE:</pre>	
<pre>ttcgtccgtt ggaccgaacc acggttggtg gcatggcct <210> SEQ ID NO 21 <211> LENGTH: 1449 <212> TYPE: DNA <213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: sequence encoding 186 chimera</pre>	
<pre>ttcgtccgtt ggaccgaacc acggttggtg gcatggcct <210> SEQ ID NO 21 <211> LENGTH: 1449 <212> TYPE: DNA <213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: sequence encoding 186 chimera <400> SEQUENCE: 21</pre>	1539
<pre>ttcgtccgtt ggaccgaacc acggttggtg gcatggcct </pre> <pre><210> SEQ ID NO 21 </pre> <pre><211> LENGTH: 1449 </pre> <pre><212> TYPE: DNA </pre> <pre><213> ORGANISM: Artificial </pre> <pre><223> OTHER INFORMATION: sequence encoding 186 chimera </pre> <400> SEQUENCE: 21 acaaatctta atgggacgct gatgcagtat tttgaatggt acacgcccaa tgacggccaa	60
<pre>ttcgtccgtt ggaccgaacc acggttggtg gcatggcct <210> SEQ ID NO 21 <211> LENGTH: 1449 <212> TYPE: DNA <213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: sequence encoding 186 chimera <400> SEQUENCE: 21 acaaatctta atgggacgct gatgcagtat tttgaatggt acacggccaa tgacggccaa cattggaagc gtctgcaaaa cgactcggca tatttggctg aacacggtat tactgccgtc</pre>	1539 60 120
<pre>ttcgtccgtt ggaccgaacc acggttggtg gcatggcct <210> SEQ ID NO 21 <211> LENGTH: 1449 <212> TYPE: DNA <213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: sequence encoding 186 chimera <400> SEQUENCE: 21 acaaatctta atgggacgct gatgcagtat tttgaatggt acacgcccaa tgacggccaa cattggaagc gtctgcaaaa cgactcggca tatttggctg aacacggtat tactgccgtc tggattcccc cggcatataa gggaacgagc caagcggatg tgggctacgg tgcttacgac</pre>	1539 60 120 180
<pre>ttcgtccgtt ggaccgaacc acggttggtg gcatggcct <210> SEQ ID NO 21 <211> LENGTH: 1449 <212> TYPE: DNA <213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: sequence encoding 186 chimera <400> SEQUENCE: 21 acaaatctta atgggacgct gatgcagtat tttgaatggt acacggccaa tgacggccaa cattggaagc gtctgcaaaa cgactcggca tatttggctg aacacggtat tactgccgtc tggattcccc cggcatataa gggaacgagc caagcggatg tgggctacgg tgcttacgac ctttatgatt taggggagtt tcatcaaaaa gggacggttc ggacaaagta cggcacaaaa</pre>	1539 60 120 180 240
<pre>ttcgtccgtt ggaccgaacc acggttggtg gcatggcct <210> SEQ ID NO 21 <211> LENGTH: 1449 <212> TYPE: DNA 213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: sequence encoding 186 chimera <400> SEQUENCE: 21 acaaatctta atgggacgct gatgcagtat tttgaatggt acacgcccaa tgacggccaa cattggaagc gtctgcaaaa cgactcggca tatttggctg aacacggtat tactgccgtc tggattcccc cggcatataa gggaacgagc caagcggatg tgggctacgg tgcttacgac ctttatgatt taggggagtt tcatcaaaaa gggacggttc ggacaaagta cggcacaaaa ggagagctgc aatctgcgat caaaagtctt cattcccgcg acattaacgt ttacgggat</pre>	1539 60 120 180 240 300
<pre>ttcgtccgtt ggaccgaacc acggttggtg gcatggcct <210> SEQ ID NO 21 <211> LENGTH: 1449 <212> TYPE: DNA <213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: sequence encoding 186 chimera <400> SEQUENCE: 21 acaaatctta atgggacgct gatgcagtat tttgaatggt acacggccaa tgacggccaa cattggaagc gtctgcaaaa cgactcggca tatttggctg aacacggtat tactgccgtc tggattcccc cggcatataa gggaacgagc caagcggatg tgggctacgg tgcttacgac ctttatgatt taggggagtt tcatcaaaaa gggacggttc ggacaaagta cggcacaaaa ggagagctgc aatctgcgat caaaagtctt cattcccgcg acattaacgt ttacggggat gtggtcatca accacaaagg cggcgctgat gcgaccgaag atgtaaccgc ggttgaagtc</pre>	60 120 180 240 300 360
<pre>ttcgtccgtt ggaccgaacc acggttggtg gcatggcct <210> SEQ ID NO 21 <211> LENGTH: 1449 <212> TYPE: DNA <213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: sequence encoding 186 chimera <400> SEQUENCE: 21 acaaatctta atgggacgct gatgcagtat tttgaatggt acacgcccaa tgacggccaa cattggaagc gtctgcaaaa cgactcggca tattggctg aacacggtat tactgccgtc tggattcccc cggcatataa gggaacgagc caagcggatg tgggctacgg tgcttacgac ctttatgatt taggggagtt tcatcaaaaa gggacggtt ggacaaagta cggcacaaa ggagagctgc aatctgcgat caaaagtctt cattcccgcg acattaacgt ttacgggat gtggtcatca accacaaagg cggcgctgat gcgaccgaag atgtaaccg ggttgaagtc gatcccgctg accgcaaccg cgtaattcc ggagaatacc taattaaagc ctggacacat</pre>	1539 60 120 180 240 300 360 420
<pre>ttcgtccgtt ggaccgaacc acggttggtg gcatggcct <210> SEQ ID NO 21 <211> LENGTH: 1449 <212> TYPE: DNA <213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: sequence encoding 186 chimera <400> SEQUENCE: 21 acaaatctta atgggacgct gatgcagtat tttgaatggt acacgcccaa tgacggccaa cattggaagc gtctgcaaaa cgactcggca tatttggctg aacacggtat tactgccgtc tggattcccc cggcatataa gggaacgagc caagcggatg tgggctacgg tgcttacgac ctttatgatt taggggagtt tcatcaaaaa gggacggttc ggacaaagta cggccaaaaa ggagagctgc aatctgcgat caaaagtctt cattcccgcg acattaacgt ttacgggaa gtggtcatca accacaaagg cggcgctgat gcgaccgaag atgtaaccgc ggttgaagtc gatcccgctg accgcaaccg cgtaattcc ggagaatacc taattaaagc ctggacacat tttcattttc cggggcgcgg cagcacatac agcgattta aatggcattg gtaccattt</pre>	1539 60 120 180 240 300 360 420 480
<pre>ttcgtccgtt ggaccgaacc acggttggtg gcatggct <210> SEQ ID NO 21 <211> LENGTH: 1449 <212> TYPE: DNA <213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: sequence encoding 186 chimera <400> SEQUENCE: 21 acaaatctta atgggacgct gatgcagtat tttgaatggt acacgcccaa tgacggccaa cattggaagc gtctgcaaaa cgactcggca tattggctg aacacggtat tactgccgtc tggattcccc cggcatataa gggaacgagc caagcggatg tgggctacgg tgcttacgac ctttatgatt taggggagtt tcatcaaaaa gggacggtt ggacaaagta cggcacaaaa ggagagctgc aatctgcgat caaaagtctt cattcccgcg acattaacgt ttacgggaat gtggtcatca accacaaagg cggcgctgat gcgaccgaag atgtaaccg ggttgaagtc gatcccgctg accgcaaccg cgtaattcc ggagaatacc taattaaagc ctggacacat tttcattttc cggggcgcgg cagcacatac agcgattta aatggcattg gtaccatttt gacggaaccg attgggacga gtcccgaaag ctgaaccgca tctataagtt tcaaggaaaga</pre>	1539 60 120 180 240 360 420 480 540
<pre>ttcgtccgtt ggaccgaacc acggttggtg gcatggcct <210> SEQ ID NO 21 <211> LENGTH: 1449 <212> TYPE: DNA <213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: sequence encoding 186 chimera <400> SEQUENCE: 21 acaaatctta atgggacgct gatgcagtat tttgaatggt acacggccaa tgacggccaa cattggaagc gtctgcaaaa cgactcggca tattggctg aacacggtat tactgccgtc tggattcccc cggcatataa gggaacgagc caagcggatg tgggctacgg tgcttacgac ctttatgatt taggggagtt tcatcaaaaa gggacggttc ggacaaagta cggcacaaaa ggagagctgc aatctgcgat caaaagtctt cattcccgcg acattaacgt ttacgggat gtggtcatca accacaaagg cggcgctgat gcgaccgaag atgtaaccgc ggttgaagtc tttcattttc cggggcgcgg cagcacatac agcgattta aatggcattg gtaccattt gacggaaccg attgggacga gtcccgaaag ctgaaccgca tcataagt tcaagaaag gctgggaccg attgggacga gtcccgaaag cgaactata atggcattg accagta ttcaatttc cggggcggg cagcacatac agcgattta aatggcattg gtaccatttt gacggaaccg attgggacga gtcccgaaag ctgaaccgca tcataagt tcaaggaaa gctgggatt gggaagttga cacagaaaac ggaaactatg actacttaat gtatgccgac</pre>	1539 60 120 180 240 300 360 420 480 540 600

gaatattgga getatgacat caacaagttg cacaattaca ttacgaaaac aaacggaacg 840 atgtctttgt ttgatgcccc gttacacaac aaattttata ccgcttccaa atcagggggc 900 gcatttgata tgcgcacgtt aatgaccaat actctcatga aagatcaacc gacattggcc 960 gtcaccttcg ttgataatca tgacaccgag cccggccaag cgcttcagtc atgggtcgac 1020 ccatggttca aaccgttggc ttacgccttt attctaactc ggcaggaagg atacccgtgc 1080 1140 gtottttatg gtgactatta tggcattcca caatataaca ttoottogot gaaaagcaaa 1200 atcgatccgc tcctcatcgc gcgcagggat tatgcttacg gaacgcaaca tgattatctt gatcactccg acatcatcgg gtggacaagg gaaggggtca ctgaaaaacc aggatccggg 1260 ctggccgcac tgatcaccga tgggccggga ggaagcaaat ggatgtacgt tggcaaacaa 1320 cacgetggaa aagtgtteta tgaeettaee ggeaaeegga gtgaeaeegt caceateaae 1380 agtgatggat ggggggaatt caaagtcaat ggcggttcgg tttcggtttg ggttcctaga 1440 1449 aaaacgacc <210> SEQ ID NO 22 <211> LENGTH: 1449 <212> TYPE: DNA <213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: sequence encoding 187 chimera <400> SEQUENCE: 22 acaaatetta atgggacget gatgcagtat tttgaatggt acaegeecaa tgacggeeaa 60 120 cattggaagc gtctgcaaaa cgactcggca tatttggctg aacacggtat tactgccgtc tqqattcccc cqqcatataa qqqaacqaqc caaqcqqatq tqqqctacqq tqcttacqac 180 ctttatgatt taggggagtt tcatcaaaaa gggacggttc ggacaaagta cggcacaaaa 240 ggagagetge aatetgegat caaaagtett catteeegg acattaacgt ttaeggggat 300 360 gtggtcatca accacaaagg cggcgctgat gcgaccgaag atgtaaccgc ggttgaagtc gatecegetg acegeaaceg egtaatttee ggagaataee taattaaage etggacaeat 420 tttcattttc cggggcgcgg cagcacatac agcgatttta aatggcattg gtaccatttt 480 gacggaaccg attgggacga gtcccgaaag ctgaaccgca tctataagtt tcaaggaaag 540 gcttgggatt gggaagtttc cacagaaaac ggaaactatg actacttaat gtatgccgac 600 cttgatatgg atcatcccga agtcgtgacc gagctgaaaa actgggggaa atggtatgtc 660 aacaaaacga acattgatgg gttccggctt gatgccgtca agcatattaa gttcagtttt 720 tttcctgatt ggttgtcgta tgtgcgttct cagactggca agccgctatt taccgtcggg 780 gaatattgga gctatgacat caacaagttg cacaattaca ttacgaaaac aaacggaacg 840 atgtetttgt ttgatgeece gttacacaac aaattttata eegetteeaa ateaggggge 900 gcatttgata tgcgcacgtt aatgaccaat actctcatga aagatcaacc gacattggcc 960 gtcaccttcg ttgataatca tgacaccgag cccggccaag cgcttcagtc atgggtcgac 1020 ccatggttca aaccgttggc ttacgccttt attctaactc ggcaggaagg atacccgtgc 1080 gtottttatg gtgactatta tggcattcca caatataaca ttoottogot gaaaagcaaa 1140 atcgatccgc tcctcatcgc gcgcagggat tatgcttacg gaacgcaaca tgattatctt 1200 1260 gatcactccq acatcatcqq qtqqacaaqq qaaqqqqtca ctqaaaaaacc aqqatccqqq

ctggccgcac tgatcaccga tgggccggga ggaagcaaat ggatgtacgt tggcaaacaa	1320
cacgctggaa aagtgttcta tgaccttacc ggcaaccgga gtgacaccgt caccatcaac	1380
agtgatggat ggggggaatt caaagtcaat ggcggttcgg tttcggtttg ggttcctaga	1440
aaaacgacc	1449
<210> SEQ ID NO 23 <211> LENGTH: 1449 <212> TYPE: DNA <213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: sequence encoding 200 chimera	
<400> SEQUENCE: 23	
acaaatctta atgggacgct gatgcagtat tttgaatggt acacgcccaa tgacggccaa	60
cattggaagc gtctgcaaaa cgactcggca tatttggctg aacacggtat tactgccgtc	120
tggattcccc cggcatataa gggaacgagc caagcggatg tgggctacgg tgcttacgac	180
ctttatgatt taggggagtt tcatcaaaaa gggacggttc ggacaaagta cggcacaaaa	240
ggagagctgc aatctgcgat caaaagtctt cattcccgcg acattaacgt ttacggggat	300
gtggtcatca accacaaagg cggcgctgat gcgaccgaag atgtaaccgc ggttgaagtc	360
gatecegetg acegeaaceg egtaatttee ggagaataee taattaaage etggacacat	420
tttcattttc cggggcgcggg cagcacatac agcgatttta aatggcattg gtaccatttt	480
gacggaaccg attgggacga gtcccgaaag ctgaaccgca tctataagtt tcaaggaaag	540
gcttgggatt gggaagtttc cagtgaaaac ggcaactatg attatttgat gtatgccgac	600
cttgatatgg atcatecega agtegtgaee gagetgaaaa aetgggggaa atggtatgte	660
aacacaacga acattgatgg gttccggctt gatgccgtca agcatattaa gttcagtttt	720
tttcctgatt ggttgtcgta tgtgcgttct cagactggca agccgctatt taccgtcggg	780
gaatattgga gctatgacat caacaagttg cacaattaca ttacgaaaac aaacggaacg	840
atgtetttgt ttgatgeece gttacacaae aaattttata eegetteeaa ateaggggge	900
gcatttgata tgcgcacgtt aatgaccaat actctcatga aagatcaacc gacattggcc	960
gtcaccttcg ttgataatca tgacaccgag cccggccaag cgcttcagtc atgggtcgac	1020
ccatggttca aaccgttggc ttacgccttt attctaactc ggcaggaagg atacccgtgc	1080
gtettttatg gtgactatta tggcatteca caatataaca tteetteget gaaaageaaa	1140
atcgatccgc tcctcatcgc gcgcagggat tatgcttacg gaacgcaaca tgattatctt	1200
gatcactoog acatoatogg gtggacaagg gaaggggtca otgaaaaaaco aggatooggg	1260
ctggccgcac tgatcaccga tgggccggga ggaagcaaat ggatgtacgt tggcaaacaa	1320
cacgctggaa aagtgttcta tgaccttacc ggcaaccgga gtgacaccgt caccatcaac	1380
agtgatggat ggggggaatt caaagtcaat ggcggttcgg tttcggtttg ggttcctaga	1440
aaaacgacc	1449
<210> SEQ ID NO 24 <211> LENGTH: 1449 <212> TYPE: DNA	

<211> LENGH: 1449
<212> TYPE: DNA
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: sequence encoding 200SB chimera

<400> SEQUE	ENCE: 25					
acaaatctta	atgggacgct	gatgcagtat	tttgaatggt	acacgcccaa	tgacggccaa	60
cattggaagc	gtctgcaaaa	cgactcggca	tatttggctg	aacacggtat	tactgccgtc	120
tggattcccc	cggcatataa	gggaacgagc	caagcggatg	tgggctacgg	tgcttacgac	180
ctttatgatt	taggggagtt	tcatcaaaaa	gggacggttc	ggacaaagta	cggcacaaaa	240
ggagagctgc	aatctgcgat	caaaagtctt	cattcccgcg	acattaacgt	ttacggggat	300
gtggtcatca	accacaaagg	cggcgctgat	gcgaccgaag	atgtaaccgc	ggttgaagtc	360
gatcccgctg	accgcaaccg	cgtaatttcc	ggagaatacc	taattaaagc	ctggacacat	420

<210> SEQ ID NO 25 <211> LENGTH: 1449 <212> TYPE: DNA <213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: sequence encoding 202 chimera

aaaacgacc

acaaatctta atgggacgct gatgcagtat tttgaatggt acacgcccaa tgacggccaa 60 cattggaage gtetgeaaaa egacteggea tatttggetg aacaeggtat taetgeegte 120 tggattcccc cggcatataa gggaacgagc caagcggatg tgggctacgg tgcttacgac 180 ctttatgatt taggggagtt tcatcaaaaa gggacggttc ggacaaagta cggcacaaaa 240 ggagagetge aatetgegat caaaagtett catteeegeg acattaaegt ttaeggggat 300 gtggtcatca accacaaagg cggcgctgat gcgaccgaag atgtaaccgc ggttgaagtc 360 gatcccgctg accgcaaccg cgtaatttcc ggagaatacc taattaaagc ctggacacat 420 tttcattttc cggggcgcgg cagcacatac agcgatttta aatggcattg gtaccatttt 480 gacggaaccg attgggacga gtcccgaaag ctgaaccgca tctataagtt tcaaggaaag 540 gcttgggatt gggaagttga cacagaaaac ggcaactatg attatttgat gtatgccgac 600 cttgatatgg atcatcccga agtcgtgacc gagctgaaaa actgggggaa atggtatgtc 660 aacacaacga acattgatgg gttccggctt gatgccgtca agcatattaa gttcagtttt 720 tttcctgatt ggttgtcgta tgtgcgttct cagactggca agccgctatt taccgtcggg 780 gaatattgga gctatgacat caacaagttg cacaattaca ttacgaaaac aaacggaacg 840 atgtetttgt ttgatgeece gttacacaac aaattttata eegetteeaa ateaggggge 900 gcatttgata tgcgcacgtt aatgaccaat actctcatga aagatcaacc gacattggcc 960 1020 gtcaccttcg ttgataatca tgacaccgag cccggccaag cgcttcagtc atgggtcgac 1080 ccatggttca aaccgttggc ttacgccttt attctaactc ggcaggaagg atacccgtgc gtottttatg gtgactatta tggcattcca caatataaca ttoottogot gaaaagcaaa 1140 ategateege teeteatege gegeagggat tatgettaeg gaaegeaaca tgattatett 1200 gatcactccg acatcatcgg gtggacaagg gaaggggtca ctgaaaaaacc aggatccggg 1260 ctggccgcac tgatcaccga tgggccggga ggaagcaaat ggatgtacgt tggcaaacaa 1320 cacgetggaa aagtgtteta tgaeettaee ggeaacegga gtgaeacegt caceateaae 1380 agtgatggat ggggggaatt caaagtcaat ggcggttcgg tttcggtttg ggttcctaga 1440 1449

-continued

<400> SEOUENCE: 24

		-	
-cont	זוכ	nued	

+								
	ttcattttc	cggggcgcgg	cagcacatac	agcgatttta	aatggcattg	gtaccatttt	480	
		attgggacga	-			_	540	
ç	gcttgggatt	gggaagtttc	cagtgaaaac	ggcaactatg	attatttgat	gtatgccgac	600	
ē	atcgatatgg	atcatcccga	agtcgtgacc	gagctgaaaa	actgggggaa	atggtatgtc	660	
ē	acacaacga	acattgatgg	gttccggctt	gatgccgtca	agcatattaa	gttcagtttt	720	
t	tteetgatt	ggttgtcgta	tgtgcgttct	cagactggca	agccgctatt	taccgtcggg	780	
ç	jaatattgga	gctatgacat	caacaagttg	cacaattaca	ttacgaaaac	aaacggaacg	840	
ŧ	atgtetttgt	ttgatgcccc	gttacacaac	aaattttata	ccgcttccaa	atcaggggggc	900	
ç	gcatttgata	tgcgcacgtt	aatgaccaat	actctcatga	aagatcaacc	gacattggcc	960	
ç	Jtcaccttcg	ttgataatca	tgacaccgag	cccggccaag	cgcttcagtc	atgggtcgac	1020	
c	catggttca	aaccgttggc	ttacgccttt	attctaactc	ggcaggaagg	atacccgtgc	1080	
ç	jtcttttatg	gtgactatta	tggcattcca	caatataaca	tteetteget	gaaaagcaaa	1140	
ā	atcgatccgc	tcctcatcgc	gcgcagggat	tatgcttacg	gaacgcaaca	tgattatctt	1200	
ç	jatcactccg	acatcatcgg	gtggacaagg	gaaggggtca	ctgaaaaacc	aggatccggg	1260	
c	tggccgcac	tgatcaccga	tgggccggga	ggaagcaaat	ggatgtacgt	tggcaaacaa	1320	
c	acgctggaa	aagtgttcta	tgacettace	ggcaaccgga	gtgacaccgt	caccatcaac	1380	
a	igtgatggat	ggggggaatt	caaagtcaat	ggcggttcgg	tttcggtttg	ggttcctaga	1440	
ā	aaaacgacc						1449	
	<220> FEATU	TH: 1449 : DNA NISM: Artifi		e encoding 2	202SB chime	ra		
<	. 400							
	(400> SEQUE	ENCE: 26						
ē		ENCE: 26 atgggacgct	gatgcagtat	tttgaatggt	acacgcccaa	tgacggccaa	60	
	acaaatctta						60 120	
c	acaaatctta cattggaagc	atgggacgct	cgactcggca	tatttggctg	aacacggtat	tactgccgtc		
c t	acaaatetta cattggaage cggatteece	atgggacgct gtctgcaaaa	cgactcggca gggaacgagc	tatttggctg caagcggatg	aacacggtat tgggctacgg	tactgccgtc tgcttacgac	120	
c t	acaaatctta cattggaagc cggattcccc ctttatgatt	atgggacgct gtctgcaaaa cggcatataa	cgactcggca gggaacgagc tcatcaaaaa	tatttggctg caagcggatg gggacggttc	aacacggtat tgggctacgg ggacaaagta	tactgccgtc tgcttacgac cggcacaaaa	120 180	
t c	acaaatetta cattggaage cggatteece etttatgatt ggagagetge	atgggacgct gtctgcaaaa cggcatataa taggggagtt	cgactcggca gggaacgagc tcatcaaaaa caaaagtctt	tatttggctg caagcggatg gggacggttc cattcccgcg	aacacggtat tgggctacgg ggacaaagta acattaacgt	tactgccgtc tgcttacgac cggcacaaaa ttacggggat	120 180 240	
c t c c	acaaatctta cattggaagc cggattcccc ctttatgatt ggagagctgc gtggtcatca	atgggacgct gtctgcaaaa cggcatataa taggggagtt aatctgcgat	cgactcggca gggaacgagc tcatcaaaaa caaaagtctt cggcgctgat	tatttggctg caagcggatg gggacggttc cattcccgcg gcgaccgaag	aacacggtat tgggctacgg ggacaaagta acattaacgt atgtaaccgc	tactgccgtc tgcttacgac cggcacaaaa ttacggggat ggttgaagtc	120 180 240 300	
c t c c c c c c c c c c c	acaaatctta cattggaagc cggattcccc ctttatgatt ggagagctgc gtggtcatca gatcccgctg	atgggacgct gtctgcaaaa cggcatataa taggggagtt aatctgcgat accacaaagg	cgactcggca gggaacgagc tcatcaaaaa caaaagtctt cggcgctgat cgtaatttcc	tatttggctg caagcggatg gggacggttc cattcccgcg gcgaccgaag ggagaatacc	aacacggtat tgggctacgg ggacaaagta acattaacgt atgtaaccgc taattaaagc	tactgccgtc tgcttacgac cggcacaaaa ttacggggat ggttgaagtc ctggacacat	120 180 240 300 360	
t c c c c c t	acaaatctta cattggaagc cggattcccc ctttatgatt ggagagctgc gtggtcatca gatcccgctg cttcattttc	atgggacgct gtctgcaaaa cggcatataa taggggagtt aatctgcgat accacaaagg accgcaaccg	cgactcggca gggaacgagc tcatcaaaaa caaaagtctt cggcgctgat cgtaatttcc cagcacatac	tatttggctg caagcggatg gggacggttc cattcccgcg gcgaccgaag ggagaatacc agcgatttta	aacacggtat tgggctacgg ggacaaagta acattaacgt atgtaaccgc taattaaagc aatggcattg	tactgccgtc tgcttacgac cggcacaaaa ttacggggat ggttgaagtc ctggacacat gtaccatttt	120 180 240 300 360 420	
t c c c c c c t t	acaaatctta cattggaagc cggattcccc ctttatgatt ggagagctgc gtggtcatca gatcccgctg cttcattttc gacggaaccg	atgggacgct gtctgcaaaa cggcatataa tagggggggtt aatctgcgat accacaaagg accgcaaccg cggggcgcgg	cgactcggca gggaacgagc tcatcaaaaa caaaagtctt cggcgctgat cgtaatttcc cagcacatac gtcccgaaag	tatttggctg caagcggatg gggacggttc cattcccgcg gcgaccgaag ggagaatacc agcgatttta ctgaaccgca	aacacggtat tgggctacgg ggacaaagta acattaacgt atgtaaccgc taattaaagc aatggcattg tctataagtt	tactgccgtc tgcttacgac cggcacaaaa ttacggggat ggttgaagtc ctggacacat gtaccatttt tcaaggaaag	120 180 240 300 360 420 480	
د ب و و و و ر و ر و ر و ر و ر و ر و ر و	acaaatctta cattggaagc cggattcccc ctttatgatt ggagagctgc gtggtcatca gatcccgctg cttcattttc gacggaaccg gcttgggatt	atgggacgct gtctgcaaaa cggcatataa taggggagtt aatctgcgat accacaaagg accgcaaccg cggggcgcgg attgggacga	cgactcggca gggaacgagc tcatcaaaaa caaaagtctt cggcgctgat cgtaatttcc cagcacatac gtcccgaaag cacagaaaac	tatttggctg caagcggatg gggacggttc cattcccgcg gcgaccgaag ggagaatacc agcgatttta ctgaaccgca ggcaactatg	aacacggtat tgggctacgg ggacaaagta acattaacgt atgtaaccgc taattaaagc aatggcattg tctataagtt attattgat	tactgccgtc tgcttacgac cggcacaaaa ttacggggat ggttgaagtc ctggacacat gtaccatttt tcaaggaaag gtatgccgac	120 180 240 300 360 420 480 540	
t c c c c c c c t t c c c c c c c c c c	acaaatctta cattggaagc cggattcccc ctttatgatt ggagagctgc gtggtcatca gatcccgctg cttcattttc gacggaaccg gcttgggatt atcgatatgg aacacaacga	atgggacgct gtctgcaaaa cggcatataa taggggagtt aatctgcgat accacaaagg accgcaaccg cgggggcgcgg attgggacga gggaagttga atcatcccga acattgatgg	cgactcggca gggaacgagc tcatcaaaaa caaaagtctt cggcgctgat cgtaatttcc cagcacatac gtcccgaaag cacagaaaac agtcgtgacc gttccggctt	tatttggctg caagcggatg gggacggttc cattcccgcg gcgaccgaag ggagaatacc agcgatttta ctgaaccgca ggcaactatg gagctgaaaa gatgccgtca	aacacggtat tgggctacgg ggacaaagta acattaacgt atgtaaccgc taattaaagc aatggcattg tctataagtt attatttgat actgggggaa agcatattaa	tactgccgtc tgcttacgac cggcacaaaa ttacggggat ggttgaagtc ctggacacat gtaccatttt tcaaggaaag gtatgccgac atggtatgtc gttcagtttt	120 180 240 300 420 480 540 600 660 720	
t c c c c c c c c t t t	acaaatctta cattggaagc cggattcccc ctttatgatt ggagagctgc gtggtcatca gatcccgctg cttcattttc gacggaaccg gcttgggatt atcgatatgg aacacaacga cttcctgatt	atgggacgct gtctgcaaaa cggcatataa taggggagtt aatctgcgat accacaaagg accgcaaccg cggggcgcgg attgggacga gggaagttga atcatcccga acattgatgg ggttgtcgta	cgactcggca gggaacgagc tcatcaaaaa caaaagtctt cggcgctgat cgtaatttcc cagcacatac gtcccgaaag cacagaaaac agtcgtgacc gttccggctt tgtgcgttct	tatttggctg caagcggatg gggacggttc cattcccgcg gcgaccgaag ggagaatacc agcgatttta ctgaaccgca ggcaactatg gagctgaaaa gatgccgtca cagactggca	aacacggtat tgggctacgg ggacaaagta acattaacgt atgtaaccgc taattaaagc aatggcattg tctataagtt attatttgat actgggggaa agcatattaa agccgctatt	tactgccgtc tgcttacgac cggcacaaaa ttacggggat ggttgaagtc ctggacacat gtaccatttt tcaaggaaag gtatgccgac atggtatgtc gttcagtttt taccgtcggg	120 180 240 300 420 480 540 600 660 720 780	
د ب د د د د د د د د د د د د د د د د د د	acaaatctta cattggaagc cggattcccc ctttatgatt ggagagctgc gtggtcatca gatcccgctg cttcattttc gacggaaccg gcttgggatt atcgatatgg aacacaacga cttcctgatt gaatattgga	atgggacgct gtctgcaaaa cggcatataa taggggagtt aatctgcgat accacaaagg accgcaaccg cgggggcgcgg attgggacga gggaagttga atcatcccga acattgatgg	cgactcggca gggaacgagc tcatcaaaaa caaaagtctt cggcgctgat cgtaatttcc cagcacatac gtcccgaaag cacagaaaac agtcgtgacc gttccggctt tgtgcgttct caacaagttg	tatttggctg caagcggatg gggacggttc cattcccgcg gcgaccgaag ggagaatacc agcgatttta ctgaaccgca ggcaactatg gagctgaaaa gatgccgtca cagactggca cacaattaca	aacacggtat tgggctacgg ggacaaagta acattaacgt atgtaaccgc taattaaagc aatggcattg tctataagtt actgggggaa agcatattaa agccgctatt ttacgaaaac	tactgccgtc tgcttacgac cggcacaaaa ttacggggat ggttgaagtc ctggacacat gtaccattt tcaaggaaag gtatgccgac atggtatgtc gttcagtttt taccgtcggg aaacggaacg	120 180 240 300 420 480 540 600 660 720	

51

gcatttgata tgcgcacgtt aatgaccaat actetcatga aagatcaacc gacattggcc 960 gtcaccttcg ttgataatca tgacaccgag cccggccaag cgcttcagtc atgggtcgac 1020 ccatggttca aaccgttggc ttacgccttt attctaactc ggcaggaagg atacccgtgc 1080 gtettttatg gtgaetatta tggeatteea caatataaca tteetteget gaaaageaaa 1140 atcgatccgc tcctcatcgc gcgcagggat tatgcttacg gaacgcaaca tgattatctt 1200 gatcactccg acatcatcgg gtggacaagg gaaggggtca ctgaaaaacc aggatccggg 1260 ctggccgcac tgatcaccga tgggccggga ggaagcaaat ggatgtacgt tggcaaacaa 1320 cacgetggaa aagtgtteta tgaeettaee ggeaaeegga gtgaeaeegt eaceateaae 1380 agtgatggat gggggggaatt caaagtcaat ggcggttcgg tttcggtttg ggttcctaga 1440 aaaacgacc 1449 <210> SEQ ID NO 27 <211> LENGTH: 1449 <212> TYPE: DNA <213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: sequence encoding 228 chimera <400> SEOUENCE: 27 acaaatetta atgggaeget gatgeagtat tttgaatggt acaegeeeaa tgaeggeeaa 60 cattggaage gtetgeaaaa egacteggea tatttggetg aacaeggtat tactgeegte 120 tggattcccc cggcatataa gggaacgagc caagcggatg tgggctacgg tgcttacgac 180 ctttatgatt taggggagtt tcatcaaaaa gggacggttc ggacaaagta cggcacaaaa 240 qqaqaqctqc aatctqcqat caaaaqtctt cattcccqcq acattaacqt ttacqqqqat 300 gtgqtcatca accacaaaqq cgqcqctqat qcqaccqaaq atqtaaccqc qqttqaaqtc 360 gatecegetg acegeaaceg egtaatttee ggagaataee taattaaage etggaeacat 420 tttcattttc cggggcgcgg cagcacatac agcgatttta aatggcattg gtaccatttt 480 gacggaaccg attgggacga gtcccgaaag ctgaaccgca tctataagtt tcaaggaaag 540 gcttgggatt gggaagtttc cagtgaaaac ggcaactatg attatttgat gtatgccgac 600 atcgattatg accateetga tgtegtagea gaaattaaga gatggggeae ttggtatgee 660 aatgagetee aattggaegg ttteeggett gatgeegtea ageatattaa gtteagtttt 720 tttcctgatt ggttgtcgta tgtgcgttct cagactggca agccgctatt taccgtcggg 780 gaatattgga gctatgacat caacaagttg cacaattaca ttacgaaaac aaacggaacg 840 atgtctttgt ttgatgcccc gttacacaac aaattttata ccgcttccaa atcagggggc 900 gcatttgata tgcgcacgtt aatgaccaat actctcatga aagatcaacc gacattggcc 960 gtcaccttcg ttgataatca tgacaccgag cccggccaag cgcttcagtc atgggtcgac 1020 1080 ccatggttca aaccgttggc ttacgccttt attctaactc ggcaggaagg atacccgtgc gtcttttatg gtgactatta tggcattcca caatataaca ttccttcgct gaaaagcaaa 1140 atcgatccgc tcctcatcgc gcgcagggat tatgcttacg gaacgcaaca tgattatctt 1200 gatcactccg acatcatcgg gtggacaagg gaaggggtca ctgaaaaacc aggatccggg 1260 ctggccgcac tgatcaccga tgggccggga ggaagcaaat ggatgtacgt tggcaaacaa 1320 cacgetggaa aagtgtteta tgaeettaee ggeaaeegga gtgaeaeegt eaeeateaae 1380

agtgatggat ggggggaatt caaagtcaat ggcggttcgg tttcggtttg ggtt	cctaga 1440
aaaacgacc	1449
<210> SEQ ID NO 28 <211> LENGTH: 1449 <212> TYPE: DNA <213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: sequence encoding 228SB chimera	
<400> SEQUENCE: 28	
gcgaatetta atgggaeget gatgeagtat tttgaatggt acaegeeeaa tgae	ggccaa 60
cattggaagc gtctgcaaaa cgactcggca tatttggctg aacacggtat tact	gccgtc 120
tggattcccc cggcatataa gggaacgagc caagcggatg tgggctacgg tgct	tacgac 180
ctttatgatt taggggagtt tcatcaaaaa gggacggttc ggacaaagta cggo	acaaaa 240
ggagagetge aatetgegat caaaagtett catteeegeg acattaaegt ttae	ggggat 300
gtggtcatca accacaaagg cggcgctgat gcgaccgaag atgtaaccgc ggtt	gaagte 360
gatecegetg acegeaaceg egtaatttee ggagaataee taattaaage etge	acacat 420
tttcattttc cggggcgcgg cagcacatac agcgatttta aatggcattg gtac	cattt 480
gacggaaccg attgggacga gtcccgaaag ctgaaccgca tctataagtt tcaa	ggaaag 540
gettgggatt gggaagttga cacagaaaac ggcaactatg attatttgat gtat	gccgac 600
atcgattatg accateetga tgtegtagea gaaattaaga gatggggeae ttge	tatgcc 660
aatgagetee aattggaegg ttteeggett gatgeegtea ageatattaa gtte	agtttt 720
ttteetgatt ggttgtegta tgtgegttet eagaetggea ageegetatt taee	gteggg 780
gaatattgga gctatgacat caacaagttg cacaattaca ttacgaaaac aaac	ggaacg 840
atgtetttgt ttgatgeece gttacacaae aaattttata eegetteeaa atea	gggggc 900
gcatttgata tgcgcacgtt aatgaccaat actctcatga aagatcaacc gaca	
gtcaccttcg ttgataatca tgacaccgag cccggccaag cgcttcagtc atgo	
ccatggttca aaccgttggc ttacgccttt attctaactc ggcaggaagg atac	
gtottttatg gtgactatta tggcattoca caatataaca ttoottogot gaaa	
atcgatccgc tecteatege gegeagggat tatgettaeg gaaegeaaca tgat	
gatcacteeg acateategg gtggacaagg gaaggggtea etgaaaaaee agga	
ctggccgcac tgatcaccga tgggccggga ggaagcaaat ggatgtacgt tgg	
cacgetggaa aagtgtteta tgaeettaee ggeaaeegga gtgaeaeegt eae agtgatggat ggggggaatt eaaagteaat ggeggttegg ttteggtttg ggtt	
agugauggau gygygyaatt taaagttaat gytygttugg titteggtug gytt	1449

<210> SEQ ID NO 29 <211> LENGTH: 1449 <212> TYPE: DNA <213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: sequence encoding 249 chimera	
<400> SEQUENCE: 29	
acaaatctta atgggacgct gatgcagtat tttgaatggt acacgcccaa tgac	ggccaa 60

cattggaage gtetgeaaaa egaeteggea tatttggetg aacaeggtat taetgeegte	120			
tggatteece eggeatataa gggaaegage caageggatg tgggetaegg tgettaegae	180			
ctttatgatt taggggagtt tcatcaaaaa gggacggttc ggacaaagta cggcacaaaa	240			
ggagagetge aatetgegat caaaagtett catteeegeg acattaaegt ttaeggggat	300			
gtggtcatca accacaaagg cggcgctgat gcgaccgaag atgtaaccgc ggttgaagtc	360			
gatecegetg acegeaaceg egtaatttee ggagaataee taattaaage etggacaeat	420			
tttcattttc cggggcgcgg cagcacatac agcgatttta aatggcattg gtaccatttt	480			
gacggaaccg attgggacga gtcccgaaag ctgaaccgca tctataagtt tcaaggaaag	540			
gcttgggatt gggaagtttc cagtgaaaac ggcaactatg attatttgat gtatgccgac	600			
atcgattatg accateetga tgtegtagea gaaattaaga gatgggggeae ttggtatgee	660			
aatgagetee aattggaegg ttteegtett gatgetgtea aacaeattaa atttettt	720			
ttgcgggatt gggttaatca tgtcaggtct cagactggca agccgctatt taccgtcggg	780			
gaatattgga gctatgacat caacaagttg cacaattaca ttacgaaaac aaacggaacg	840			
atgtetttgt ttgatgeece gttacacaae aaattttata eegetteeaa ateaggggge	900			
gcatttgata tgcgcacgtt aatgaccaat actctcatga aagatcaacc gacattggcc	960			
gtcaccttcg ttgataatca tgacaccgag cccggccaag cgcttcagtc atgggtcgac	1020			
ccatggttca aaccgttggc ttacgccttt attctaactc ggcaggaagg atacccgtgc	1080			
gtettttatg gtgaetatta tggeatteea caatataaca tteetteget gaaaageaaa	1140			
atcgatccgc tcctcatcgc gcgcagggat tatgcttacg gaacgcaaca tgattatctt	1200			
gatcactccg acatcatcgg gtggacaagg gaaggggtca ctgaaaaacc aggatccggg	1260			
ctggccgcac tgatcaccga tgggccggga ggaagcaaat ggatgtacgt tggcaaacaa	1320			
cacgetggaa aagtgtteta tgaeettaee ggeaaeegga gtgaeaeegt eaeeateaae	1380			
agtgatggat ggggggaatt caaagtcaat ggcggttcgg tttcggtttg ggttcctaga	1440			
aaaacgacc	1449			
<210> SEQ ID NO 30 <211> LENGTH: 1449 <212> TYPE: DNA <213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: sequence encoding 249SB chimera				
<400> SEQUENCE: 30				
acaaatetta atgggaeget gatgeagtat tttgaatggt acaegeeeaa tgaeggeeaa	60			
cattggaage gtetgeaaaa egaeteggea tatttggetg aacaeggtat taetgeegte	120			
tggattcccc cggcatataa gggaacgagc caagcggatg tgggctacgg tgcttacgac	180			
ctttatgatt taggggagtt tcatcaaaaa gggacggttc ggacaaagta cggcacaaaa	240			
ggagagctgc aatctgcgat caaaagtctt cattcccgcg acattaacgt ttacggggat	300			
gtggtcatca accacaaagg cggcgctgat gcgaccgaag atgtaaccgc ggttgaagtc	360			
gatecegetg acegeaaceg egtaatttee ggagaataee taattaaage etggacaeat	420			
tttcattttc cggggcgcgg cagcacatac agcgatttta aatggcattg gtaccatttt	480			
gacggaaccg attgggacga gtcccgaaag ctgaaccgca tctataagtt tcaaggaaag	540			

gettgggatt gggaagttga cacagaaaac ggcaactatg attatttgat gtatgeegac 600 atcgattatg accateetga tgtegtagea gaaattaaga gatggggeae ttggtatgee 660 aatgagetee aattggaegg ttteegtett gatgetgtea aacacattaa attttettt 720 ttgegggatt gggttaatca tgtcaggtet cagactggca ageegetatt tacegteggg 780 gaatattgga gctatgacat caacaagttg cacaattaca ttacgaaaac aaacggaacg 840 atgtetttgt ttgatgeece gttacacaac aaattttata eegetteeaa ateaggggge 900 gcatttgata tgcgcacgtt aatgaccaat actctcatga aagatcaacc gacattggcc 960 gtcaccttcg ttgataatca tgacaccgag cccggccaag cgcttcagtc atgggtcgac 1020 ccatggttca aaccgttggc ttacgccttt attctaactc ggcaggaagg atacccgtgc 1080 1140 gtottttatg gtgactatta tggcattcca caatataaca ttoottogot gaaaagcaaa atcgatccgc tcctcatcgc gcgcagggat tatgcttacg gaacgcaaca tgattatctt 1200 1260 gatcactccg acatcatcgg gtggacaagg gaaggggtca ctgaaaaaacc aggatccggg ctggccgcac tgatcaccga tgggccggga ggaagcaaat ggatgtacgt tggcaaacaa 1320 cacgetggaa aagtgtteta tgacettace ggeaacegga gtgacacegt caceateaac 1380 agtgatggat ggggggaatt caaagtcaat ggcggttcgg tttcggtttg ggttcctaga 1440 aaaacgacc 1449 <210> SEQ ID NO 31 <211> LENGTH: 1449 <212> TYPE: DNA <213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: sequence encoding 254 chimera <400> SEOUENCE: 31 acaaatetta atgogacget gatgeagtat tttgaatggt acaegeeeaa tgaeggeeaa 60 120 cattqqaaqc qtctqcaaaa cqactcqqca tatttqqctq aacacqqtat tactqccqtc tggattcccc cggcatataa gggaacgagc caagcggatg tgggctacgg tgcttacgac 180 ctttatgatt taggggagtt tcatcaaaaa gggacggttc ggacaaagta cggcacaaaa 240 ggagagctgc aatctgcgat caaaagtctt cattcccgcg acattaacgt ttacggggat 300 gtggtcatca accacaaagg cggcgctgat gcgaccgaag atgtaaccgc ggttgaagtc 360 gatecegetg acegeaaceg egtaatttee ggagaataee taattaaage etggacaeat 420 tttcattttc cggggcgcgg cagcacatac agcgatttta aatggcattg gtaccatttt 480 gacggaaccg attgggacga gtcccgaaag ctgaaccgca tctataagtt tcaaggaaag 540 gcttgggatt gggaagtttc cagtgaaaac ggcaactatg attatttgat gtatgccgac 600 atcgattatg accateetga tgtegtagea gaaattaaga gatggggeae ttggtatgee 660 aatgagetee aattggaegg ttteegtett gatgetgtea aacaeattaa attteettt 720 ttgcgggatt gggttaatca tgtcagggaa aaaacgggga agccgctatt taccgtcggg 780 gaatattgga gctatgacat caacaagttg cacaattaca ttacgaaaac aaacggaacg 840 atgtetttgt ttgatgeece gttacacaac aaattttata eegetteeaa ateaggggge 900 960 qcatttqata tqcqcacqtt aatqaccaat actctcatqa aaqatcaacc qacattqqcc

gtcaccttcg ttgataatca tgacaccgag cccggccaag cgcttcagtc atgggtcgac

55

ccatggttca aaccgttggc ttacgccttt attctaactc ggcaggaagg atacccgtgc 1080 gtettttatg gtgaetatta tggeatteea caatataaca tteetteget gaaaageaaa 1140 ategateege teeteatege gegeagggat tatgettaeg gaaegeaaea tgattatett 1200 gatcactccg acatcatcgg gtggacaagg gaaggggtca ctgaaaaaacc aggatccggg 1260 ctggccgcac tgatcaccga tgggccggga ggaagcaaat ggatgtacgt tggcaaacaa 1320 cacgetggaa aagtgtteta tgaeettaee ggeaaeegga gtgaeaeegt caceateaae 1380 agtgatggat ggggggaatt caaagtcaat ggcggttcgg tttcggtttg ggttcctaga 1440 aaaacgacc 1449 <210> SEQ ID NO 32 <211> LENGTH: 1449 <212> TYPE: DNA <213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: sequence encoding 254SB chimera <400> SEQUENCE: 32 acaaatotta atgggacgot gatgcagtat tttgaatggt acacgoocaa tgacggocaa 60 cattggaagc gtctgcaaaa cgactcggca tatttggctg aacacggtat tactgccgtc 120 180 tqqattcccc cqqcatataa qqqaacqaqc caaqcqqatq tqqqctacqq tqcttacqac 240 ctttatqatt taqqqqaqtt tcatcaaaaa qqqacqqttc qqacaaaqta cqqcacaaaa ggagagetge aatetgegat caaaagtett catteeegeg acattaacgt ttacggggat 300 gtggtcatca accacaaagg cggcgctgat gcgaccgaag atgtaaccgc ggttgaagtc 360 gatecceptg acceptaacce cetaatttec gegagaatace taattaaage cteggacacat 420 tttcattttc cqqqqcqcqq caqcacatac aqcqatttta aatqqcattq qtaccatttt 480 gacggaaccg attgggacga gtcccgaaag ctgaaccgca tctataagtt tcaaggaaag 540 gcttgggatt gggaagttga cacagaaaac ggcaactatg attatttgat gtatgccgac 600 atcgattatg accatectga tgtegtagea gaaattaaga gatggggeae ttggtatgee 660 aatgagetee aattggaegg ttteegtett gatgetgtea aacacattaa attttettt 720 ttgcgggatt gggttaatca tgtcagggaa aaaacgggga agccgctatt taccgtcggg 780 gaatattgga gctatgacat caacaagttg cacaattaca ttacgaaaac aaacggaacg 840 atgtetttgt ttgatgeece gttacacaac aaattttata eegetteeaa ateaggggge 900 gcatttgata tgcgcacgtt aatgaccaat actctcatga aagatcaacc gacattggcc 960 gtcaccttcg ttgataatca tgacaccgag cccggccaag cgcttcagtc atgggtcgac 1020 ccatggttca aaccgttggc ttacgccttt attctaactc ggcaggaagg atacccgtgc 1080 gtottttatg gtgactatta tggcattcca caatataaca ttoottogot gaaaagcaaa 1140 1200 atcgatccgc tectcatege gegeagggat tatgettaeg gaacgeaaca tgattatett gatcactccg acatcatcgg gtggacaagg gaaggggtca ctgaaaaaacc aggatccggg 1260 ctggccgcac tgatcaccga tgggccggga ggaagcaaat ggatgtacgt tggcaaacaa 1320 cacgetggaa aagtgtteta tgaeettaee ggeaaeegga gtgaeaeegt eaceateaae 1380 1440 aqtqatqqat qqqqqqaatt caaaqtcaat qqcqqttcqq tttcqqtttq qqttcctaqa 1449 aaaacqacc

<210> SEQ ID NO 33 <211> LENGTH: 1449 <212> TYPE: DNA <213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: sequence encoding 259 chimera <400> SEOUENCE: 33 acaaatctta atgggacgct gatgcagtat tttgaatggt acacgcccaa tgacggccaa 60 cattggaagc gtctgcaaaa cgactcggca tatttggctg aacacggtat tactgccgtc 120 tggattcccc cggcatataa gggaacgagc caagcggatg tgggctacgg tgcttacgac 180 ctttatgatt taggggagtt tcatcaaaaa gggacggttc ggacaaagta cggcacaaaa 240 ggagagetge aatetgegat caaaagtett catteeegeg acattaaegt ttaeggggat 300 gtggtcatca accacaaagg cggcgctgat gcgaccgaag atgtaaccgc ggttgaagtc 360 420 gatecegetg accgeaaceg egtaatttee ggagaataee taattaaage etggaeacat tttcattttc cggggcgcgg cagcacatac agcgatttta aatggcattg gtaccatttt 480 gacggaaccg attgggacga gtcccgaaag ctgaaccgca tctataagtt tcaaggaaag 540 gcttgggatt gggaagtttc cagtgaaaac ggcaactatg attatttgat gtatgccgac 600 660 atcqattatq accatectqa tqtcqtaqea qaaattaaqa qatqqqqeae ttqqtatqee aatgagetee aattggaegg ttteegtett gatgetgtea aacaeattaa attteettt 720 780 ttgcgggatt gggttaatca tgtcagggaa aaaacgggga aggaaatgtt tacggtaggg gaatattgga gctatgacat caacaagttg cacaattaca ttacgaaaac aaacggaacg 840 atqtctttqt ttqatqcccc qttacacaac aaattttata ccqcttccaa atcaqqqqqc 900 gcatttgata tgcgcacgtt aatgaccaat actctcatga aagatcaacc gacattggcc 960 gtcaccttcg ttgataatca tgacaccgag cccggccaag cgcttcagtc atgggtcgac 1020 ccatggttca aaccgttggc ttacgccttt attctaactc ggcaggaagg atacccgtgc 1080 gtettttatg gtgaetatta tggeatteea caatataaca tteetteget gaaaageaaa 1140 atcgatccgc tectcatege gegeagggat tatgettaeg gaacgeaaca tgattatett 1200 gatcactccg acatcatcgg gtggacaagg gaaggggtca ctgaaaaacc aggatccggg 1260 ctggccgcac tgatcaccga tgggccggga ggaagcaaat ggatgtacgt tggcaaacaa 1320 cacgetggaa aagtgtteta tgaeettaee ggeaaeegga gtgaeaeegt eaceateaae 1380 agtgatggat ggggggaatt caaagtcaat ggcggttcgg tttcggtttg ggttcctaga 1440 aaaacgacc 1449 <210> SEQ ID NO 34 <211> LENGTH: 1449 <212> TYPE: DNA <213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: sequence encoding 259SB chimera <400> SEQUENCE: 34 acaaatctta atgggacgct gatgcagtat tttgaatggt acacgcccaa tgacggccaa 60 120 cattqqaaqc qtctqcaaaa cqactcqqca tatttqqctq aacacqqtat tactqccqtc 180 tqqattcccc cqqcatataa qqqaacqaqc caaqcqqatq tqqqctacqq tqcttacqac

ctttatgatt taggggagtt toatcaaaa gggacggtt ggacaagta cggacaaaa 240 gggagactge aatctgogat caaagtett cattcocge gacattaacgt ttacgggagat 300 gtggtoatca accacaaagg cggogctgat gcgaccgaag atgtaacce ggttgaagte 360 gatcocgett accegcaacce cgtaattee gggaataee taattaaage etggacaeat 420 tttaattte cgggggegg cagcacaae acggaattaa atggaattet taatgge ttggacaettt 480 gaeggaaceg attgggacga gtoccgaag etgaacaea gggaattaa aggggaatt gacaatae gattatg acactoetga tgegtagea gaaattaag gatggggace ttggtatgee 660 aatggatta gggtaattaa tgegagga taacacgggaa gagaaatgtt tacggtagg 780 gaatattgg accatgacat atgacagga aaaacgggga aggaaatgtt tacggtagg 900 getttgtat tgggtoce gttaccacae aaatttata ccgetteea atcagggacg 900 gettettgt ttgatgoee gtacacaea aaatttata ccgetteea atcagggge 900 gatacttgg getatgaea taacacaag accegge aggaataea tacggaaga 1020 gtcactteg tggacatta tggcacega ccggacaag cgettaagt atgggtacge 1020 gtcactteg tggacatta tggcacega gaaggggaata tacgaacaaggaa 1200 gtcactceg acacacag gggegggagagaaggaaggaatgt tggcaacaa 1200 gtcactteg tgacacacag gggeggggagaggaaggaaggaatgt gggacacag 1200 gtcactteg gacacag gggegggaggaggaggaaggaaggagaatggggaggacactggaacagaacaa 1300 <		
<pre>gtggtoatca accacaagg cggcgtgat gcgaccgaag atgtaaccgc ggttgaatc gatcccyctg accgcaccg cgtaattec ggagaatacc taattaage ctggaccat tuttatte cggggcogg cagcactac acgcgattta atgggattg dacattt ad gacggaaccg attgggacg gtcccgaaag ctgaaccgca tetataagt teaaggaag futggtat gggaagtga cacagaaaac ggcaactag attattgat gtatgccgac atcgattatg accatctga tgccqaaag cgaactag attattgat gtatgccgac tutcggggatt gggaagtga cacagaaaac ggcaactag attattgat gtatgccgac atcgattatg accatctga tgccqagaa gagaattaag gatggggca ttggtatgc tutcggggatt gggtaatca tgccaggaa aaacagggaa ggaaatgt tacggtagg gaatattga getatgaca tacgacaga aaacaggag aggaaatgt tacggtagg gaatattga ggtatgaca cacacaatg cacaatata atttettt ticggggatt gggtaatca tgccaggaa aaacaggga aggaaatgt tacggtag ggatattga getatgacat cacaaagtg cacaattaa tacgaaca aacggaag b00 gcattgat tgggcagt aatgaccaa aattetaa tccgaaca acagggag b00 gcattgat tgggcacgt atgacat atcccatga aagtecaac gacattggc b00 gcattgata tgcgcacgt atgaccat actectag aggacaac gacatggc b00 gcattgata gggacatta tggcacgg ccggcaag cgctcagt atgggtcga b00 gcattgga aacgtgg taagactaa ggacacag ggaaggag ataccgtg b00 gcattgga aacgtgg taagactaa ggacagga ggagagaa atccgtg b00 gcattgg ggacatata tggcacgg ggaaggagt atggaagga ataccgg b00 gcattgga aacgtgg taggacaag ggaaggagt atggatacg tggaaagaa b1140 atcgatcog acatcatcg ggggagag ggaagcaat ggatgacgt tggcaacaa b320 cacgctgga aagtgttat gaccttac ggcaacgg gtgacacg cacaataaca b220 Februme: c220 F</pre>	ctttatgatt taggggagtt tcatcaaaaa gggacggttc ggacaaagta cggcacaaaa	240
<pre>gatcccyctg accgcaccg cgtaattee ggagataee taataage etggacaet 420 tttoatttee eggggeegg eggeeatae agegattta aatggeatg gtaceattt 480 gaeggaaceg atggggaeg gteeegaaae ggeaactag attattgat gtaceatttt 480 geetgggatt gggaagttga eacagaaae ggeaactag attattgat gtatgeegae 600 ategattag aceateetga tgeegtagea gaaataaga gatggggee ttggtatgee 660 aatggetee aattggaegg ttteegtett gatgetgtea aaeaeataa attteettt 720 ttgeeggatt gggtaatea tgeeggagaa eaaaegggga aggaaatgtt taeggtaggg 780 gaatattgg getatgaet eacaagtg cacaataea ttaegaaae gaagggge 900 geattgata tgeegeegt aatgaeeaa aaetettata cegeteeaa acaaeggaaeg 840 atgeettgat tgeegeegt aatgaeeaa aaetettata cegeteeaa acaaeggaeg 900 geattgata tgeegeegt aatgaeeaa acetetaaga agateaae gaeatggee 960 gteaeettgat tgeegeegt aatgaeeaa acetetaga aagateaae gaeatggee 960 gteaeettgat tgeegeegt aatgaeeaa acetetaga aagateaee gaeattggee 1020 ceatggtea aaeegttge ttaegeett atteeaet ggeeggaag ataeeegtge 1080 gteetttatg gtgaeatta tgeeatee gaeageaag egeteagaaa 1140 ategateege teeteateg egegaggga taegetaeg gaaggaagaa 1140 ategateeg teeteateg gegegggg gaageaaat ggatgaeet gaaaageaa 1140 aaggatggat ggggggaat caaagteag ggaagegaaat ggatgaeet tgeeaaaaa 1320 caegetggaa aagtgteta tgeeetae ggeaacegga gtgaeeegt caecataea 1380 agtgatggat ggggggaat caaagteag gegggteeg ttteggttg ggteeaaea 1320 caegetggaa aagtgtteta tgaeetae ggeaacegga gtgaeeegt caecataea 1380 agtgatggat ggggggaat caaagteag gegggteeg ttteggttg ggteeaaea 1320 c220> FEV INA c220> FEV INA c220> FEV INA c220> FEV INA c220> FEV INA c220> FEV INA c220> FEV INA 26 c220> FEV INA c220> FEV INA c</pre>	ggagagctgc aatctgcgat caaaagtctt cattcccgcg acattaacgt ttacggggat	300
The arrow of th	gtggtcatca accacaaagg cggcgctgat gcgaccgaag atgtaaccgc ggttgaagtc	360
gacggaaccg attgggacga gtocogaaag ofgaacogca totataagtt toaaggaaag gottgggatt gggaagttg ocacagaaac gscaactatg attattgat gtatgoogac atcgattatg accatoodg ttoogtott gatgotgta aacaattaa atttotttt 720 ttgooggatt gggtaatca tgtoggaga gaaattaag gatggggac ttggtatgoo gaatattgga gottagacat caacaagttg cacaattaa ttaogaaac aaaggaag 940 atgtottgt tigatgooco gtacacaac aaattaa ttoogaaac aaaggagg 940 atgtottgt tigatgooco gtacacaac aaattaa ttoogaaac aaaggagg 940 goatattgga gottagacat caacaagttg cacaattaa ttaogaaac aaaggggg 940 goatattga tgoocoo gtacacaac aaattaa toogotoo aatoaggggg 940 goatattga tgoocoo gtacacaac aaattaa coortoo aatoagggge 940 gtocottg tigataatca tgacacoga coogocaag coottoagto atgoggoog gottgata tgoogaagt taogoot attoo aagagaag ataccoof 940 gtocactoo tigataata tgacacoga coogocaag coottoagto atgogtogo 1020 coatggtoo aacogtiggo ttaogoott attotaacto ggcaggaag ataccoof 1020 gatcactoog tootcatogo gocgaggat tatgottaag taocoof 1020 gatcactoog acatactogg gtggacaagg gaaggagada too tgaaaaaca aggatcoog 1200 ctggocgac tgatcaccga tgggocogga ggaagcaat ggatgacac tgaaaaca 1320 cacgotggaa aagtgttota tgacctaco ggcaacogga ggagacaca tgattatot 1200 cacgotggaa aagtgttot tgacctaco ggcaacogga ggaagacaat ggatgaca 1320 cacgotggaa aagtgttot tgacctaco ggcaacogga gtgacacogt caccatcaac 1380 agtgatggat ggggggaatt caaagtcaat ggcoggtog tttoggttig ggttootaga 1440 aaaacgaco 1449 <2210 > SEQ ID NO 35 <2210 > EQ ID NO 35 <2210 > EQ ID NO 36 <2210 > EQ ID NO 36 <2210 > EQ ID NO 36 <2210 > FEATURE: 22 <2220 > TIPE: DNA <2230 > OHER INFORMATION: primer Pred550-F <400 > SEQUENCE: 35 aaccogggtt gaagtogato co 22 <210 > SEQ ID NO 37 <211 > LENGTH: 22 <223 > OTHER INFORMATION: primer Pred610-R <400 > SEQUENCE: 36 cocgaaaat gaaaatgtgt co 22 <210 > SEQ ID NO 37 <211 > LENGTH: 22 <212 > TIPE: DNA <220 > FEATURE: 22 <212 > TIPE: NA <220 > FEATURE: 22 <213 > TIPE: NA <220 > FEATURE: 22 <214 > TIPE: NA <220 > FEATURE: 22 <215 > TIPE: NA <220 > FEATURE: 22 <216 > SEQ ID NO 37 <211 > LENGTH: 22 <217 > TIPE: NA <220 > FEATURE: 22 <210 > SEQ ID NO 37 <211 > SEQ ID NO	gatecegetg acegeaaceg egtaatttee ggagaataee taattaaage etggacaeat	420
<pre>gcttgggatt gggaagttga cacagaaaac ggcaactatg attattgat gtatgccgac 600 atcgattatg accatcctga tgtcgtagca gaaattaaga gatggggcac ttggtatgcc 660 aatgagctcc aattggacgg tttccgtctt gatgctgtca aaccattaa atttctttt 720 ttgcgggatt gggtaatca tgtcagtgga aaaacgggga aggaagatgtt tacggtaggg 780 gaatattgga gctatgacat caacaagttg cacaattaa ttacgaaaac aaacggaacg 840 atgtctttgt ttgatgcccc gttacacaac aatttata ccgcttccaa atcaggggc 960 gcatttgata tgcgcacgtt aatgaccaat actccatga aagatcaacc gacattggc 960 gtcaccttog ttgataatca tgacacgag ccggccaag cgettcagtc atgggtcgac 1020 ccatggttca aaccgttggc ttacgcctt attctaact ggcaggaag atacceqtg 1020 ccatggtca aaccgtgg ctacgcct attggacag ccggccaag cgettcagt atggtcgac 1020 ccatggtca aaccgtgg ttacgcctt attctaact ggcaggaag atacceqtg 1020 gtctttatg gtgactatt tggcacag ccggcagg gaaggaga taccceqt 1220 gatcactccg actatcgg gtggacaagg gaaggggtca ctgaaaacc aggatccgg 1260 ctggccgcac tgatcaccga tgggccggg ggaagcaat ggatgacgt tggcaacaa 1320 cacgctggaa aagtgttct tgacttac ggcaggag gaagcaat ggatgacgt tggcaacaa 1320 cacgctggaa aagtgttct tgactacca ggcacgga ggagcaccg caccatcaa 1380 agtgatggat ggggggaatt caaagtcaat ggcggttcgg tttcggtttg ggttcctag 1449 <210> SEQ ID NO 35 <211> LENOTH: 22 <222> TYPE: DNA <223> OTHER INFORMATION: primer Fred550-F <400> SEQUENCE: 35 aaccgcggtt gaagtcgatc cc <22 <210> SEQ ID NO 36 <211> LENOTH: 22 <222> TYPE: DNA <203> OTHER INFORMATION: primer Fred510-R <400> SEQUENCE: 36 cccggaaaat gaaaatgtgtc <22 <</pre>	tttcattttc cggggcgcggg cagcacatac agcgatttta aatggcattg gtaccatttt	480
atcgattatg accatcctga tgtcgtagca gaattaaga gatggggcac ttggtatgcc figcgggat gggttaatca tgtcgtgtag aaatgag aggaaatgt tacggtaggg gaatatgga getagacat caacaagtg cacaattaca ttacgaaaac aaacggaag gaatatgga getagacat caacaagtg cacaattaca ttacgaaaac aaacggaag go gcatttgat tggcacgtt aatgaccaa aattttata ccgcttccaa atcagggggc go gcatttgat tggcacgt aatgaccaa actotcatga aagatcaacc gacattggcc figcaccttcg ttgataatca tgacaccgag cccggccaag cgettcagtc atgggtcgac gtcatttatg gtgactatta tggcatcca caatataca ttactgaaaacc aggatcggc gccatggttca aaccgttggc ttacgcctt attctaact ggcaggaag atacccgtg gtcatttatg gtgactatta tggcatcca caatataca ttecttogt gaaaagcaaa 1140 atggatcgc tectcatcgc gcgcaggga tatgettag gaacgaaac tgattatett 1200 gatcactccg acatcatcgg gtggacaagg gaaggagtca etgaaaacc aggatceggg 1260 etggcegcac tgatcaccga tgggccggga ggaagcaaat ggatgaccgt caccatcaac 1380 agtgatggat ggggggaatt caaagtcaat ggcggttcg tteggettag 1440 aaaacgacc 1449 <210> SEQ ID NO 35 <211> LENGTH: 22 <222> OTHER INFORMATION: primer Fred550-F <400> SEQUENCE: 35 aaccgcggtt gaagtcgatc cc 220 <210> SEQ ID NO 36 <211> LENGTH: 22 <222> TYPE: DNA <213> ORGNISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: primer Fred510-R <400> SEQUENCE: 36 cccggaaaat gaaatgtgt cc 221 <210> SEQ ID NO 37 <211> LENGTH: 22 <221> TYPE: DNA <210> SEQ ID NO 37 <211> LENGTH: 22 <221> TYPE: DNA <210> SEQ ID NO 37 <211> LENGTH: 22 <221> TYPE: DNA <211> CACGTI NO 37 <211> CACG	gacggaaccg attgggacga gtcccgaaag ctgaaccgca tctataagtt tcaaggaaag	540
aatgagotoc aattggacgg tttocgtott gatgotgtoa aacacattaa atttotttt 720 ttgogggatt gggttaatca tgtoagggaa aaaacgggga aggaaatgtt taoggtaggg 780 gaatattgga gotatgacat caacaagttg cacaattaca ttaogaaac aacggaacg 840 Atgtotttgt ttgatgococ gttacacaac aaatttata cogotocaa atcaggggo 900 goattgata tgogcacgt aatgaccaat actotcatga aagatcaaco gacattggoo 960 gtcacottog ttgataatca tgacacaga cooggocaag cgottcagto atgggtogao 1020 coatggttoa aacogttggo ttacgoott attotaact ggoaggaagg ataccogtgo 1020 coatggttoa aacogttggo ttacgoott attotaact ggoaggaagg ataccogtgo 1080 gtottttatg gtgactatta tggoatcoc caatataaca ttoottogot gaaaagcaaa 1140 atogatcogo tootcatogo gogcagggat tatgottacg gaacgcaaca tgattatot 1200 gataattogg acatoatogg gtggacaagg gaaggagtac ttgaaaacc aggatcoggg 1260 ctggocgoca tgatcaccga tgggocggag ggaagcaat ggatgtacgt tggoaaacaa 1320 cacgotggaa aagtgttota tgacottaco ggcaacogga gtgacacogt caccatcaac 1380 agtgatggat ggggggaatt caaagtoaat ggcggttogg tttoggtttg ggttoctaga 1440 aaaacgacc 1449 <210> SEQ ID NO 35 <211> LENGTH: 22 <221> TYPE: DNA <213> ORAMISM: Artificial <220> FEATURE: <222> OTHER INFORMATION: primer Fred550-F <400> SEQUENCE: 35 aaccgoggtt gaagtogato co 22 <210> SEQ ID NO 36 <211> LENGTH: 22 <220> FEATURE: <222> OTHER INFORMATION: primer Fred510-R <400> SEQUENCE: 36 cocggaaaat gaaaatgtgt co 22 <210> SEQ ID NO 37 <211> LENGTH: 22 <221> TYPE: DNA <212> TYPE: DNA <213> ORCAMISM: Artificial <220> FEATURE: <221> TYPE: DNA <213> ORCAMISM: Artificial <220> FEATURE: <221> TYPE: DNA <213> ORCAMISM: Artificial <220> TEATURE: <221> TYPE: DNA <221> TYPE:	gcttgggatt gggaagttga cacagaaaac ggcaactatg attatttgat gtatgccgac	600
ttgegggatt gggttaatca tgtcagggaa aaaacgggga aggaaatgtt tacggtagg 780 gaatattgga getatgacat caacaagttg cacaattaca ttacgaaaac aaacggaacg 840 atgtetttgt ttgatgeee gttaacaaa aatttata cegetteeaa ateaggggge 900 geattgata tgegeaegtt aatgaeeaat acteeatga aagateaace gaeattggee 960 gteaeetteg ttgataatea tgaeeeaga eeeggeeaag egetteagte atgggtegae 1020 ceatggttea aacegttgge ttacgeett attetaate egeeaggaagg ataceegge 1020 ceatggttea aacegttgge ttacgeett attetaate ggeaggaagg ataceegge 1020 gteaetttag gtgaetatta tggeatee aatataaa atteettee ggeaggaagg ataceegge 1080 gteetttatg gtgaetatta tggeatee caaataaaa tteetteeg gaaageaaa 1140 ategateege teeteateg gegeagggat tatgettaeg gaaegeaaa tgattaett 1200 gateaeteeg acateategg gtggaeaagg gaaggagtea etgaaaaee aggateeggg 1260 etggeegeae tgateaeega tggeeggga ggaageaaat ggatgtaegt tggeaaaeaa 1320 caegetggaa aagtgtteta tgaeettaee ggeaaeegg gtggeaeegg ataceegt eaceateaa agtgatggat ggggggaatt caaagteaat ggeggttegg ttteggtttg ggtteetaga 1440 aaaacgaee 1449 <210> SEQ ID NO 35 <211> LENGTH: 22 <222> OTHER INFORMATION: primer Fred550-F <400> SEQUENCE: 35 aacegeggtt gaagtegate ce 22 <210> SEQ ID NO 36 <211> LENGTH: 22 <222> TIPE: DNA <213> ORGANISM: Artificial <220> FEATURE: <222> OTHER INFORMATION: primer Fred610-R <400> SEQUENCE: 36 ceeggaaaat gaaatgtgt ce 22 <210> SEQ ID NO 37 <211> LENGTH: 22 <221> TIPE: DNA <212> TIPE: DNA <213> ORGANISM: Artificial <220> FEATURE: <221> TIPE: DNA <213> ORGANISM: Artificial <220> FEATURE: <222> TIPE: DNA <214> TIPE: DNA <215> SEQ ID NO 37 <211> LENGTH: 22 <212> TIPE: DNA <213> ORGANISM: Artificial <220> FEATURE: <221> TIPE: DNA <214> TIPE: DNA <215> ORGANISM: Artificial <220> TIPE: DNA <214> TIPE: DNA <215> ORGANISM: Artificial <220> FEATURE: <221> TIPE: DNA <221> TIPE: DNA	atcgattatg accateetga tgtegtagea gaaattaaga gatggggeae ttggtatgee	660
<pre>gaatattgga gctatgacat caacaagttg cacaattaca ttacgaaaac aaacggaacg 840 atgtetttgt ttgatgecee gttacacaae aaatttata cogettecaa ateaggggge 900 geatttgata tgegeaegtt aatgaceaat acteetatga aagateaace gacattggee 960 gteacetteg ttgataatea tgaceegag eeeggeeag gegettegg eagaaggagg ataceegte 1020 ceatggttea aacegttgge ttacgeettt attetaaete ggeaggaagg ataceegte 1020 ceatggttea aacegttgge ttacgeettt attetaaete ggeaggagg ataceegte 1080 gtetttatg gtgaetatta tggeatece caatataaea tteetteg gaaageaaa 1140 ategateege teeteatege gegeagggat tatgettaeg gaaegeaaea tgattatett 1200 gateaeteeg acateategg gtggaeaagg gaaggagaaat ggatgaeaet ggateegg 1260 ctggeegeae tgateaeega tggeegggag ggaageaaat ggatgaeegt tggeaaeaa 1320 caegetggaa aagtgttet tgaeettee ggeaaeegga gtgaeaeegt caceateaae 1380 agtgatggat ggggggaatt caaagteaat ggeggtegg tteeggtttg ggtteetaga 1440 aaaaegaee 1449 </pre>	aatgagetee aattggaegg ttteegtett gatgetgtea aacacattaa attttettt	720
atgetttgt tigatgede gitaeacaae aaatttaa cegetteaa ateagggge 900 geattigat igegeaegit aatgeeeaa acteteaiga aagateaaee gaeatiggee 960 gicaeetteg tigataatea tgeeeegit aatgeeeag eeeggeeaag egetteagte atgggtegae 1020 eeatggttea aaeegitgge tiaegeetti attetaaete ggeaggaagg ataeeegige 1080 gicettitatg gigaetatta tggeatteea eaatataaea tieetteget gaaaageaaa 1140 ategateege teeteatege gegeagggat taigettaeg gaaegeaaea tgattaett 1200 gateaeteeg acateategg giggaeaagg gaaggggtee eigaaaaee aggateeggg 1260 etggeegeae tgateaeegg atggeeggga ggaageaaat ggatgtaegt tggeaaaeaa 1320 eaegetggaa aagtgiteta tgaeettaee ggeaaeegga gigaeeegg teeetaae 1380 agtgatggat ggggggaatt eaageteae ggeageggg gigaeeegg eaecegi eaeeaae 1380 agtgatggat ggggggaatt eaagteaae ggeggteeg titeeggttig ggiteetaga 1440 aaaaegaee 1449 <210> SEQ ID NO 35 <211> LENKOTH: 22 <212> TTPE: DNA <223> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: primer Fred550-F <400> SEQUENCE: 35 aaeegeggit gaagtegate ce 22 <210> SEQ ID NO 36 <211> LENKOTH: 22 <223> OTHER INFORMATION: primer Fred610-R <400> SEQUENCE: 36 ceeggaaaat gaaaatgtgt ce 22 <210> SEQ ID NO 37 <211> LENKOTH: 22 <223> OTHER INFORMATION: primer Fred610-R <400> SEQUENCE: 36 ceeggaaat gaaaatgtgt ce 22 <210> SEQ ID NO 37 <211> LENKOTH: 22 <212> TTPE: DNA <213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: primer Fred610-R	ttgcgggatt gggttaatca tgtcagggaa aaaacgggga aggaaatgtt tacggtaggg	780
gcatttgata tgcgcacgtt aatgaccaat actctcatga aagatcaacc gacattggcc960gtcaccttcg ttgataatca tgcacacgag cccggccaag cgcttcagtc atgggtcgac1020ccatggttca aaccgttggc ttacgccttt attctaactc ggcaggaagg atacccgtgc1080gtcttttatg gtgactatta tggcattca caatataca ttocttcget gaaaagcaaa1140atcgatccgc tcctcatcge gcgcagggat tatgettacg gaacgcaaca tgattatt1200gatcactccg acatcatcgg gtggacaagg gaaggggtca ctgaaaaacc aggatccggg1260ctggccgcac tgatcaccga tgggccggga ggaagcaaat ggatgtacgt tggcaacaa1320cacgetggaa aagtgtteta tgacettace ggcaaccgga gtgacaccgt caccatcaac1380agtgatggat ggggggaatt caaagtcaat ggcggttegg tttcggtttg ggttcetaga1449<210> SEQ ID NO 351449<210> SEQ UD NO 3522<212> TYPE: DNA22<212> TYPE: DNA22<213> CGANISM: Artificial<224	gaatattgga gctatgacat caacaagttg cacaattaca ttacgaaaac aaacggaacg	840
gtcaccttcg ttgataatca tgacaccgag cccggccaag cgcttcagtc atgggtcgac1020ccatggttca aaccgttggc ttacgccttt attctaactc ggcaggaagg atacccgtgc1080gtcatttatg gtgactatta tggcattcca caatataaca ttocttcgct gaaaagcaaa1140atcgatccgc tcctcatcgc gcgcagggat tatgettacg gaacgcaaca tgattatctt1200gatcactccg acatcatcgg gtggacaagg gaaggagta ctgaaaaacc aggatccggg1260ctggccgcac tgatcaccga tgggccggga ggaagcaaat ggatgtacgt tggcaaacaa1320cacgctggaa aagtgttcta tgaccttacc ggcaaccgga gtgacaccgt caccatcaac1380agtgatggat ggggggaatt caaagtcaat ggcggttcgg tttcggtttg ggttcctaga1440aaaacgacc1449<210> SEQ ID NO 351449<211> ENGTH: 22222<212> TYPE: DNA220<210> SEQ ID NO 3622<211> LENGTH: 2222<212> TYPE: DNA222<212> TYPE: DNA222<2	atgtetttgt ttgatgeece gttacacaae aaattttata eegetteeaa ateaggggge	900
ccatggttca aaccgttggc ttacgccttt attctaactc ggcaggaagg atacccgtgc 1080 gtcttttatg gtgactatta tggcattca caatataaca ttccttcgct gaaaagcaaa 1140 atcgatccgc tcctcatcgc gcgcagggat tatgcttacg gaacgcaaca tgattatctt 1200 gatcactccg acatcatcgg gtggacaagg gaaggggtca ctgaaaaacc aggatccggg 1260 ctggccgcac tgatcaccga tgggccggga ggaagcaaat ggatgtacgt tggcaaacaa 1320 cacgctggaa aagtgttcta tgaccttacc ggcaaccgga gtgacaccgt caccatcaac 1380 agtgatggat ggggggaatt caaagtcaat ggcggttcgg tttcggtttg ggttcctaga 1440 aaaacgacc 1449 <210> SEQ ID NO 35 <211> LENGTH: 22 <212> TYPE: DNA <213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: primer Fred550-F <400> SEQUENCE: 35 aaccgcggtt gaagtcgatc cc 22 <210> SEQ ID NO 36 <211> LENGTH: 22 <212> TYPE: DNA <213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: primer Fred610-R <400> SEQUENCE: 36 cccggaaaat gaaaatgtgt cc 22 <210> SEQ ID NO 37 <311> LENGTH: 22 <212> TYPE: DNA <213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: primer Fred610-R <400> SEQUENCE: 36 cccggaaaat gaaaatgtgt cc 22 <210> SEQ ID NO 37 <311> LENGTH: 22 <312> TYPE: DNA <213> ORGANISM: Artificial <220> FEATURE: <221> TYPE: DNA	gcatttgata tgcgcacgtt aatgaccaat actctcatga aagatcaacc gacattggcc	960
<pre>gtcttttatg gtgactatta tggcattcCa Caatataaca ttccttcgct gaaaagcaaa 1140 atcgatccgc tcctcatcgc gcgcagggat tatgcttacg gaacgcaaca tgattattt 1200 gatcactccg acatcatcgg gtggacaagg gaaggggtca ctgaaaaacc aggatccgg 1260 ctggccgcac tgatcaccga tgggccggga ggaagcaaat ggatgtacgt tggcaaacaa 1320 cacgctggaa aagtgttcta tgaccttacc ggcaaccgga gtgacaccgt caccatcaac 1380 agtgatggat ggggggaatt caaagtcaat ggcggttcgg tttcggttg ggttcctaga 1440 aaaacgacc 1449 </pre>	gtcaccttcg ttgataatca tgacaccgag cccggccaag cgcttcagtc atgggtcgac	1020
atcgatccgc tootcatogc gogcagggat tatgottacg gaacgcaaca tgattatott 1200 gatcactoog acatcatogg gtggacaagg gaaggggtca otgaaaaacc aggatcoggg 1260 otggoogcac tgatcacoga tgggooggga ggaagcaaat ggatgtacgt tggcaaacaa 1320 cacgooggaa aagtgttota tgacottaco ggcaacogga gtgacacogt caccatcaac 1380 agtgatggat gggggggaatt caaagtcaat ggoggtcogg tttoggtttg ggttootaga 1440 aaaacgaco 1449 <210> SEQ ID NO 35 <211> LENGTH: 22 <212> TYPE: DNA <213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: primer Fred550-F <400> SEQUENCE: 35 aaccgcggtt gaagtcgato co 22 <210> SEQ ID NO 36 <211> LENGTH: 22 <122> TYPE: DNA <213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: primer Fred610-R <400> SEQUENCE: 36 cccggaaaat gaaaatggt cc 22 <210> SEQ ID NO 37 <211> LENGTH: 22 <212> TYPE: DNA <213> ORGANISM: Artificial <220> FEATURE: <223> THER INFORMATION: primer Fred610-R <400> SEQUENCE: 36 cccggaaaat gaaaatgtgt cc 22 <210> SEQ ID NO 37 <211> LENGTH: 22 <212> TYPE: DNA <213> ORGANISM: Artificial <220> FEATURE: <221> TYPE: DNA	ccatggttca aaccgttggc ttacgccttt attctaactc ggcaggaagg atacccgtgc	1080
<pre>gatcactccg acatcatcgg gtggacaagg gaaggggtca ctgaaaaacc aggatccggg 1260 ctggccgcac tgatcaccga tgggccggga ggaagcaaat ggatgtacgt tggcaaacaa 1320 cacgctggaa aagtgttcta tgaccttacc ggcaaccgga gtgacaccgt caccatcaac 1380 agtgatggat ggggggaatt caaagtcaat ggcggttcgg tttcggtttg ggttcctaga 1440 aaaacgacc 1449 <210> SEQ ID NO 35 <211> LENGTH: 22 <212> TYPE: DNA <213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: primer Fred550-F <400> SEQUENCE: 35 aaccgcggtt gaagtcgatc cc 22 <212> TYPE: DNA <213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: primer Fred610-R <400> SEQUENCE: 36 cccggaaaat gaaaatgtgt cc 22 <210> SEQ ID NO 37 <211> LENGTH: 22 <212> TYPE: DNA <213> ORGANISM: Artificial <220 FEATURE: <223> OTHER INFORMATION: primer Fred610-R <400> SEQUENCE: 36 cccggaaaat gaaaatgtgt cc 22 <212> TYPE: DNA <213> ORGANISM: Artificial <220 FEATURE: <223> OTHER INFORMATION: primer Fred610-R <400> SEQUENCE: 36 cccggaaaat gaaaatgtgt cc 22 </pre>	gtettttatg gtgaetatta tggeatteea eaatataaea tteetteget gaaaageaaa	1140
ctggccgcac tgatcaccga tgggccggga ggaagcaaat ggatgtacgt tggcaaccaa1320cacgctggaa aagtgttcta tgaccttacc ggcaaccgga gtgacaccgt caccatcaac1380aqtgatggat ggggggaatt caaagtcaat ggcggttcgg tttcggtttg ggttcctaga1440aaaacgacc1449<210> SEQ ID NO 35<211> LENGTH: 22<212> TYPE: DNA<213> ORGANISM: Artificial<220> FEATURE:<223> OTHER INFORMATION: primer Fred550-F<400> SEQUENCE: 35aaccgcggtt gaagtcgatc cc22<212> TYPE: DNA<213> ORGANISM: Artificial<220> FEATURE:<221> SEQ ID NO 36<211> LENGTH: 22<212> TYPE: DNA<213> ORGANISM: Artificial<220> SEQ UENCE: 35aaccgcggtt gaagtcgatc cc22<212> TYPE: DNA<213> ORGANISM: Artificial<220> SEQ UENCE: 36cccggaaaat gaaaatgtgt cc22<210> SEQ ID NO 37<211> LENGTH: 22<212> TYPE: DNA<213> ORGANISM: Artificial<220> FEATURE:<210> SEQ ID NO 37<211> LENGTH: 22<212> TYPE: DNA<213> ORGANISM: Artificial<220> FEATURE:<214	ategateege teeteatege gegeagggat tatgettaeg gaaegeaaca tgattatett	1200
cacgotggaa aagtgttota tgacottaco ggoaacogga gtgacacogt caccatcaac 1380 agtgatggat ggggggaatt caaagtcaat ggoggttogg tttoggtttg ggttoctaga 1440 aaaacgaco 1449 <210> SEQ ID NO 35 <211> LENGTH: 22 <212> TYPE: DNA <213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: primer Fred550-F <400> SEQUENCE: 35 aaccgoggtt gaagtogato co 22 <210> SEQ ID NO 36 <211> LENGTH: 22 <212> TYPE: DNA <213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: primer Fred610-R <400> SEQUENCE: 36 ccoggaaaat gaaaatgtgt cc 22 <210> SEQ ID NO 37 <211> LENGTH: 22 <212> TYPE: DNA <213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: primer Fred610-R <400> SEQUENCE: 36 ccoggaaaat gaaaatgtgt cc 22	gatcactccg acatcatcgg gtggacaagg gaaggggtca ctgaaaaacc aggatccggg	1260
agtgatggat ggggggaatt caaagtcaat ggcggttcgg tttcggtttg ggttcctaga 1440 aaaacgacc 1449 <210> SEQ ID NO 35 <211> LENGTH: 22 <212> TYPE: DNA <213> OGGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: primer Fred550-F <400> SEQUENCE: 35 aaccgcggtt gaagtcgatc cc 22 <210> SEQ ID NO 36 <211> LENGTH: 22 <212> TYPE: DNA <213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: primer Fred610-R <400> SEQUENCE: 36 cccggaaaat gaaaatgtgt cc 22 <210> SEQ ID NO 37 <211> LENGTH: 22 <221> TYPE: DNA <220> FEATURE: <220> FEATURE:	ctggccgcac tgatcaccga tgggccggga ggaagcaaat ggatgtacgt tggcaaacaa	1320
aaaacgacc1449<210> SEQ ID NO 35<211> LENGTH: 22<212> TYPE: DNA<223> OTHER INFORMATION: primer Fred550-F<400> SEQUENCE: 35aaccgcggtt gaagtcgatc cc22<210> SEQ ID NO 36<211> LENGTH: 22<212> TYPE: DNA<213> ORGANISM: Artificial<220> FEATURE:<210> SEQ UD NO 36<211> LENGTH: 22<212> TYPE: DNA<213> ORGANISM: Artificial<220> FEATURE:<223> OTHER INFORMATION: primer Fred610-R<400> SEQUENCE: 36cccggaaaat gaaaatggt cc22<210> SEQ ID NO 37<211> LENGTH: 22<212 TYPE: DNA	cacgctggaa aagtgttcta tgaccttacc ggcaaccgga gtgacaccgt caccatcaac	1380
<pre></pre> <pre></pre> <pre></pre> <pre><210> SEQ ID NO 35 <211> LENGTH: 22 <212> TYPE: DNA <213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: primer Fred550-F <400> SEQUENCE: 35 aaccgcggtt gaagtcgatc cc 22 <210> SEQ ID NO 36 <211> LENGTH: 22 <212> TYPE: DNA <213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: primer Fred610-R <400> SEQUENCE: 36 cccggaaaat gaaaatgtgt cc 22 <210> SEQ ID NO 37 <211> LENGTH: 22 <212> TYPE: DNA <213> ORGANISM: Artificial <220> FEATURE: <220> SEQ ID NO 37 <211> LENGTH: 22 <212> TYPE: DNA <213> ORGANISM: Artificial <220> FEATURE:</pre>	agtgatggat ggggggaatt caaagtcaat ggcggttcgg tttcggtttg ggttcctaga	1440
<pre><211> LENGTH: 22 <212> TYPE: DNA <213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: primer Fred550-F <400> SEQUENCE: 35 aaccgcggtt gaagtcgatc cc 22 </pre>	aaaacgacc	1449
aaccgcggtt gaagtcgatc cc 22 <210> SEQ ID NO 36 <211> LENGTH: 22 <212> TYPE: DNA <213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: primer Fred610-R <400> SEQUENCE: 36 cccggaaaat gaaaatgtgt cc 22 <210> SEQ ID NO 37 <211> LENGTH: 22 <212> TYPE: DNA <213> ORGANISM: Artificial <220> FEATURE:	<211> LENGTH: 22 <212> TYPE: DNA <213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: primer Fred550-F	
<pre><210> SEQ ID NO 36 <211> LENGTH: 22 <212> TYPE: DNA <213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: primer Fred610-R <400> SEQUENCE: 36 cccggaaaat gaaaatgtgt cc 22 <210> SEQ ID NO 37 <211> LENGTH: 22 <212> TYPE: DNA <213> ORGANISM: Artificial <220> FEATURE:</pre>	~	
<pre><211> LENGTH: 22 <212> TYPE: DNA <213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: primer Fred610-R <400> SEQUENCE: 36 cccggaaaat gaaaatgtgt cc 22 <210> SEQ ID NO 37 <211> LENGTH: 22 <212> TYPE: DNA <213> ORGANISM: Artificial <220> FEATURE:</pre>	aaccgcggtt gaagtcgatc cc	22
<pre><210> SEQ ID NO 37 <211> LENGTH: 22 <212> TYPE: DNA <213> ORGANISM: Artificial <220> FEATURE:</pre>	<211> LENGTH: 22 <212> TYPE: DNA <213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: primer Fred610-R	
<211> LENGTH: 22 <212> TYPE: DNA <213> ORGANISM: Artificial <220> FEATURE:	cccggaaaat gaaaatgtgt cc	22
	<211> LENGTH: 22 <212> TYPE: DNA <213> ORGANISM: Artificial <220> FEATURE:	

58

-concinded	
<400> SEQUENCE: 37	
cgcacgttaa tgaccaatac tc	22
<210> SEQ ID NO 38 <211> LENGTH: 22 <212> TYPE: DNA <213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: primer Ethyl 1190-R	
<400> SEQUENCE: 38	
gettggeegg geteggtgte at	22
<210> SEQ ID NO 39 <211> LENGTH: 40 <212> TYPE: DNA <213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: primer SS187DT-200etc fwd <400> SEQUENCE: 39 gcttgggatt gggaagttga cacagaaaac ggcaactatg	40
<210> SEQ ID NO 40 <211> LENGTH: 40 <212> TYPE: DNA <213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: primer SS187DT-200etc rev <400> SEQUENCE: 40	
catagttgcc gttttctgtg tcaacttccc aatcccaagc	40

What is claimed is:

1. A chimeric polypeptide having a length of about 480-515 amino acid residues, the chimeric polypeptide having (a) an amino-terminal domain comprising 180 or more contiguous amino acid residues of an N-terminal portion of an AmyL amylase, and (b) a carboxy-terminal domain comprising a carboxy-terminal portion of an AmyS amylase; with the proviso that the chimeric polypeptide is not a wild-type AmyL amylase or AmyS amylase, and wherein said chimeric polypeptide has enhanced thermostability relative at least to the AmyS amylase.

2. The chimeric polypeptide of claim 1 comprising at least one substituted amino acid residue in the amino-terminal domain, relative to the AmyL amylase, so as to provide at least a part of a stabilizing structure that enhances thermostability of the polypeptide.

3. The chimeric polypeptide of claim **2**, wherein the stabilizing structure is a salt bridge formed, at least in part, by the substituted amino acid residue.

4. The chimeric polypeptide of claim **2**, wherein the substituted amino acid residue corresponds to position 187 or 188, or both, in the AmyL or AmyS amylase.

5. The chimeric polypeptide of claim **4**, wherein an Asp residue and a Thr residue are substituted in the chimeric polypeptide for two consecutive Ser residues in the AmyL amylase.

6. The chimeric polypeptide of claim **1**, wherein the AmyL amylase has the amino acid sequence of SEQ ID NO: 1.

7. The chimeric polypeptide of claim 1, wherein the AmyS amylase has the amino acid sequence of SEQ ID NO: 2.

8. The chimeric polypeptide of claim **1** having at least about 95% sequence identity to any of SEQ ID NOS: 1-17, with the proviso that the chimeric polypeptide is not SEQ ID NOS: 1 or 2.

9. The chimeric polypeptide of claim **8** wherein an Asp residue and a Thr residue are substituted in the chimeric polypeptide for two consecutive Ser residues at position 187 in the AmyL amylase.

10. The chimeric polypeptide of claim 1 comprising a catalytic activity of an α -amylase that retains at least 50% of its activity after incubation at 95° C. for 30 minutes.

11. The chimeric polypeptide of claim 10 that retains at least about 60% of its catalytic activity after incubation at 95° C. for 60 minutes.

12. The chimeric polypeptide of claim 11 which retains at least about 80% of its catalytic activity after incubation at 95° C. for 60 minutes.

13. The chimeric polypeptide of claim 1 comprising a catalytic activity of an α -amylase that has greater specific activity than the AmyL amylase.

14. A thermostable chimeric α -amylase comprising an N-terminal portion and a C-terminal portion; the N-terminal portion comprising a contiguous amino acid sequence from

an N-terminal portion of an AmyL amylase, and the C-terminal portion comprising a contiguous amino acid sequence from a C-terminal portion of an AmyS amylase; wherein the chimeric α -amylase has a specific activity greater than the AmyL amylase, and greater thermostability at 95° C. than the AmyS amylase, and having a primary amino acid sequence that is about 475-520 residues long.

15. The chimeric amylase of claim 14 which, when used in a liquefaction process for a starch slurry, has about equivalent peak viscosity reduction of the starch slurry as AmyS amylase in a comparable liquefaction process, and reduces final viscosity of the starch slurry as well as the AmyL amylase in a comparable liquefaction process.

16. The chimeric amylase of claim 15 that retains at least 50% of its specific activity after incubation at 95° C. for 30 minutes.

17. The chimeric amylase of claim 16 that retains at least 80% of it specific activity after incubation at 95° C. for 60 minutes.

18. The chimeric amylase of claim **15**, wherein the AmyL amylase has the sequence of SEQ ID NO: 1 and the AmyS amylase has the sequence of SEQ ID NO: 2.

19. The chimeric amylase of claim **17** having at least about 95% sequence identity to any of SEQ ID NOS: 1-17, with the proviso that the chimeric amylase is not SEQ ID NO: 1 or 2.

20. The chimeric amylase of claim **19** further comprising at least one substituted amino acid residue in the N-terminal domain, relative to the AmyL amylase, so as to provide at least a part of a stabilizing structure that enhances thermostability of the polypeptide.

21. The chimeric polypeptide of claim **20**, wherein the stabilizing structure is a salt bridge formed, at least in part, by the substituted amino acid residue.

22. The chimeric polypeptide of claim **21**, wherein the substituted amino acid residue corresponds to position 187 or 188 or both in the AmyL or AmyS amylase.

23. The chimeric polypeptide of claim **22**, wherein an Asp residue and a Thr residue are substituted in the chimeric polypeptide for two consecutive Ser residues in the AmyL amylase.

24. A composition comprising one or more of:

- a chimeric polypeptide having a length of about 480-515 amino acid residues, having an amino-terminal domain comprising about 180 or more contiguous amino acid residues of an N-terminal portion of an AmyL amylase, and a carboxy-terminal domain comprising a carboxyterminal portion of an AmyS amylase; said chimeric polypeptide having enhanced thermostability relative at least to the AmyS amylase; or
- a thermostable chimeric α -amylase about 475-520 amino acid residues long, having an N-terminal portion comprising a contiguous amino acid sequence from an N-terminal portion of an AmyL amylase, and a C-terminal portion comprising a contiguous amino acid sequence from a C-terminal portion of an AmyS amylase, said chimeric α -amylase having a specific activity greater than the AmyL amylase and greater thermostability at 95° C. than the AmyS amylase; or

a combination thereof.

25. The composition of claim **24** further comprising one or more additional polypeptides.

26. The composition of claim **25**, wherein the one or more additional polypeptides is an enzyme.

27. The composition of claim 24 that includes one or more detergents or cleaning agents.

28. The composition of claim **24** that is formulated for use in food or food processes.

29. A food-grade lyophilized composition comprising the composition of claim **24**.

30. A polynucleotide encoding:

- a chimeric polypeptide having a length of about 480-515 amino acid residues, and having an amino-terminal domain comprising about 180 or more contiguous amino acid residues of an N-terminal portion of an AmyL amylase, and a carboxy-terminal domain comprising a carboxy-terminal portion of an AmyS amylase; said chimeric polypeptide having enhanced thermostability relative at least to the AmyS amylase; or
- a thermostable chimeric α -amylase about 475-520 amino acid residues long, and having an N-terminal portion comprising a contiguous amino acid sequence from an N-terminal portion of an AmyL amylase, and a C-terminal portion comprising a contiguous amino acid sequence from a C-terminal portion of an AmyS amylase, said chimeric α -amylase having a specific activity greater than the AmyL amylase, and greater thermostability at 95° C. than the AmyS amylase.

31. The polynucleotide of claim **30** that encodes a polypeptide having at least about 95% sequence identity to any of SEQ ID NOS: 1-17, with the proviso that said polypeptide is not SEQ ID NO: 1 or 2.

32. The polynucleotide of claim **31**, wherein the codon usage is optimized for expression of the chimeric polypeptide in a microorganism or a plant.

33. A vector comprising the polynucleotide of claim 32.

34. A bacterial cell comprising the vector of claim **33**, wherein the vector is an expression vector.

35. A host cell that expresses the polynucleotide of claim **30**.

36. The host cell of claim **35**, wherein the host cell is a bacteria or a plant.

37. The host cell of claim **36** that is from an organism acceptable for the production of food processing aids.

38. The host cell of claim **35** that is a *Bacillus licheniformis*, *Bacillus subtilis*, or *Bacillus stearothermophilus*.

39. The host cell of claim **36**, wherein the host cell is a plant and the plant is used for ethanol production.

40. A method of producing a composition comprising a chimeric polypeptide or a thermostable α -amylase the method comprising:

- utilizing a host cell selected from the group consisting of *Bacillus licheniformis, B. subtilis,* and *B. stearothermophilus,* for a fermentation process wherein a protein is expressed, said protein comprising:
 - (a) a chimeric polypeptide having a length of about 480-515 amino acid residues, having an amino-terminal domain comprising about 180 or more contiguous amino acid residues of an N-terminal portion of an AmyL amylase, and a carboxy-terminal domain comprising a carboxy-terminal portion of an AmyS amylase; said chimeric polypeptide having enhanced thermostability relative at least to the AmyS amylase; or
 - (b) a thermostable chimeric α-amylase about 475-520 amino acid residues long, having an N-terminal portion comprising a contiguous amino acid sequence from an N-terminal portion of an AmyL amylase, and a C-terminal portion comprising a contiguous amino

acid sequence from a C-terminal portion of an AmyS amylase, said chimeric α -amylase having a specific activity greater than the AmyL amylase and greater thermostability at 95° C. than the AmyS amylase, and

at least partially purifying the expressed polypeptide, thereby producing the composition.

41. The method of claim **40**, wherein the fermentation process is a fed-batch fermentation process.

42. The method of claim 40 further comprising the step of further purifying the polypeptide expressed to make a purified composition having no genotoxic potential in in vitro assays; and no toxic effects in acute and sub-chronic dosing studies in animals.

43. The method of claim **42**, wherein the purified composition comprises not more than 40 ppm total heavy metals, not more than 5 ppm arsenic, not more than 10 ppm lead, not more than 5×104 total viable organisms (CFU/g), not more than 30 coliforms (CFU/g), and no detectable *Salmonella*, mycotoxins or antibacterial activity by standard tests.

44. The method of claim 40, wherein the composition comprises more than one α -amylase activity.

45. A method of liquefying a starch slurry comprising: making a slurry comprising a starch,

heating the slurry to an acceptable temperature for liquefaction,

adding to the slurry, a composition comprising one or more of:

- a chimeric polypeptide having a length of about 480-515 amino acid residues, having an amino-terminal domain comprising about 180 or more contiguous amino acid residues of an N-terminal portion of an AmyL amylase, and a carboxy-terminal domain comprising a carboxy-terminal portion of an AmyS amylase; said chimeric polypeptide having enhanced thermostability relative at least to the AmyS amylase; or
- a thermostable chimeric α -amylase about 475-520 amino acid residues long, having an N-terminal portion comprising a contiguous amino acid sequence from an N-terminal portion of an AmyL amylase, and a C-terminal portion comprising a contiguous amino acid sequence from a C-terminal portion of an AmyS amylase, said chimeric α -amylase having a specific activity greater than the AmyL amylase, and greater thermostability at 95° C. than the AmyS amylase, or a combination thereof, and
- incubating the slurry with the composition for a time and at a temperature sufficient to liquefy the starch slurry.

46. The method of claim **26**, wherein the addition of the composition

- reduces the peak viscosity of the slurry as well as the addition of an AmyS amylase used in a comparable liquefaction, and
- reduces the final viscosity of the slurry as well as the addition of an AmyL amylase used in a comparable liquefaction.

47. The method of claim 46, wherein the temperature is at least about 80° C. to about 100° C.

Apr. 28, 2011

48. The method of claim **45**, wherein the slurry comprises about 15-40% starch on a dry-weight basis.

49. The method of claim **48**, wherein the liquefaction is part of a fermentation.

50. The method of claim **49**, wherein the fermentation is used to produce a food product, a food additive, a fuel, or a fuel additive.

51. The method of claim **50**, wherein the fuel or fuel additive is an alcohol.

52. The method of claim **51**, wherein the alcohol is ethanol. **53**. A method of cleaning a surface to remove starch residue comprising the steps of providing a surface that has starch residue to be removed, contacting the surface with a composition of claim **24**, for a time and at a temperature sufficient to result in removal of the starch residue.

54. The method of claim **53**, wherein the composition comprises one or more of a protease, a lipase, an additional amylase, or a combination thereof.

55. The method of claim **54** further comprising a step of rinsing or bulk removal of residue prior to the contacting step.

56. The method of claim 53, wherein the temperature during the contacting step reaches at least $50-100^{\circ}$ C.

57. A method of treating a woven material that has been previously subjected to contact with a coating comprising starch or a starch-derivative, the method comprising contacting the woven material with a solution comprising a composition according to claim **24** for a time and under conditions sufficient to substantially remove the coating from the woven material.

58. The method of claim **57**, wherein the woven material is a fabric.

59. The method of claim **57**, wherein the contacting step is performed at a pressure that is greater then ambient atmospheric pressure.

60. A kit for facilitating liquefaction of starch slurry, said kit comprising at least one of:

- a chimeric polypeptide having a length of about 480-515 amino acid residues, and comprising an amino-terminal domain comprising about 180 or more contiguous amino acid residues of an N-terminal portion of an AmyL amylase, and a carboxy-terminal domain comprising a carboxy-terminal portion of an AmyS amylase; said chimeric polypeptide having enhanced thermostability relative at least to the AmyS amylase; or
- a thermostable chimeric α -amylase about 475-520 amino acid residues long, and comprising an N-terminal portion comprising a contiguous amino acid sequence from an N-terminal portion of an AmyL amylase, and a C-terminal portion comprising a contiguous amino acid sequence from a C-terminal portion of an AmyS amylase, said chimeric α -amylase having a specific activity greater than the AmyL amylase and greater thermostability at 95° C. than the AmyS amylase, and

instructions for use of the kit in the liquefaction of a starch slurry.

* * * * *